




DRUG FORMULARY VERSION 02/2023

**PHARMACY DEPARTMENT
HOSPITAL DUCHESS OF KENT
SANDAKAN, SABAH**



Disediakan oleh	MOHD RIDZUAN BIN ZAKARIA PEGAWAI FARMASI Y/M DIS	 MOHD RIDZUAN BIN ZAKARIA PEGAWAI FARMASI UF52 RPH : 9440 HOSPITAL DUCHESS OF KENT
Disahkan oleh	THAM YAP YUAN KETUA PEGAWAI FARMASI	 THAM YAP YUAN KETUA PEGAWAI FARMASI HOSPITAL DUCHESS OF KENT NO. PENDAFTARAN: 5301
Diluluskan oleh	DR.MOHD FAHMIE BIN OTHMAN PENGARAH HOSPITAL	 DR. MOHD FAHMIE BIN OTHMAN MHA, MBBS, Bmed. Sc No. NPM 50418 PENGARAH HOSPITAL HOSPITAL DUCHESS OF KENT SANDAKAN, SABAH

Disclaimer:

Drug Formulary HDOK publication for internal circulation and use by clinicians in Hospital Duchess of Kent Sandakan only. These formulary are intended as a guide only, and not as a replacement for clinical expertise. The authors of these formulary have made considerable efforts to ensure the information upon which they are based is accurate and up to date at the time of publication. User of these formulary are strongly recommended to confirm that the information contained within them, especially drug doses, is correct by way of independent sources. The authors and publishers accept no responsibility for any inaccuracies, information perceived as misleading, or the success or failure of any treatment regimen detailed in the formulary.

Editorial Board

Advisors

Dr. Mohd Fahmie Bin Othman, Hospital Director
Ms. Tham Yap Yuan, Chief Pharmacist

Editor

Mr. Mohd Ridzuan Bin Zakaria, Head of Pharmacy Drug Information Service Unit

Contributors

Mr. James Voo Yau Hon, Head of Clinical Pharmacy Unit
Mr. Ahmad Ashraf bin Lukman, Head of Manufacturing Pharmacy Unit
Mr. Omar Haireza Bin Kamaruzaman, AMS Pharmacist

Category of Prescribers

Category	Prescribers
A*	Consultant/Specialists for specific indications only
A	Consultant/Specialists
A/KK	Consultant/Specialists/Family Physician Specialists
B	Consultant/Specialists/Family Physician Specialists /Medical Officers
C	Consultant/Specialists/Family Physician Specialists /Medical Officers/Paramedical staffs
C+	Consultant/Specialists/Family Physician Specialists/Medical Officers/Paramedical staffs/Paramedical staffs doing Midwifery

The category of prescriber authorized to initiate the prescription for the drug is listed above. Dental consultant, Dental specialist and Dental officers are also included in this category but for the drugs used in dental treatment only.

Hospital Formulary Version 01/2023
Hospital Duchess of Kent, Sandakan

No.	Generic Name	MDC	Indications	Dosage	Category
1.	Acetazolamide 250 mg Tablet	S01EC0100 OT1001XX	Reduction of intraocular pressure in open-angle glaucoma, secondary glaucoma and peri-operatively in angle-closure glaucoma	250 mg 1-4 times a day, the dosage being titrated according to patient response	B
2.	Acetazolamide 500 mg Injection	S01EC0100 OP4001XX	Reduction of intra-ocular pressure in open-angle glaucoma, secondary glaucoma and peri-operatively in angle-closure glaucoma	Adult : 250-1000 mg per 24hours, usually in divided doses for amounts over 250mg daily	B (SRQ OPHTH)
3.	Acetylcysteine 200 mg / ml Injection	V03AB2352 OP3001XX	Antidote for paracetamol poisoning (Off-label indication with one-off UKK approval: Non-PCM-induced acute liver failure)	Diluted with dextrose 5% and infused IV. Initial, 150 mg/kg IV in 200 ml over 60 minutes, then 50 mg/kg IV in 500 ml over 4 hours, followed by 100 mg/kg IV in 1000 ml over 16 hours. Total dose: 300mg/kg in 20 hour	A* (SRQ GENERAL)
4.	Acetylsalicylic Acid 100 mg, Glycine 45 mg Tablet	B01AC0625 9T1001XX	i) Prevention of myocardial infarct, stroke, vascular occlusion and deep vein thrombosis. ii) Transient ischaemic attacks	1 tablet daily	B (SRQ MED)
5.	Acetylsalicylic Acid 300 mg Soluble Tablet	N02BA0100 OT4001XX	Initial treatment of cardiovascular disorders such as angina pectoris and myocardial infarction and for the prevention of cardiovascular events in patients at risk. Other such uses include the treatment and prevention of cerebrovascular disorders such as stroke.	150mg to be taken daily. Use in children under 16 years old is not recommended	C
6.	Acriflavine 0.1 % Lotion	D08AA0300 OL6001XX	Infected skin, lesions, cuts, abrasions, wounds and burns.	Apply undiluted three times daily to the affected part.	C+
7.	Acyclovir 200 mg Tablet	J05AB01- 000-T10- 01-XXX	i) Treatment of Herpes simplex & Varicella zoster infections ii) Prophylaxis of Herpes simplex infections in immune-compromised patients	Indication (i) Treatment for Herpes Simplex: ADULT - 200mg 5 times daily; In severely immune-compromised patients: dose can be doubled to 400 mg. CHILD - two years and above should be given adult dosages, infants and children below two years old should be given half the adult dose. Treatment for Varicella Zoster: ADULT - 800mg 5 times daily; CHILD - 6 years and over: 800 mg four times daily, 2 - < 6 years: 400 mg four times daily, Under 2 years: 200 mg four times daily. Indication (ii) ADULT - Immune-compromised patients: 200 mg four times daily. Severely immune-compromised patients: dose can be doubled to 400 mg. CHILD - two years and above should	A/KK

No.	Generic Name	MDC	Indications	Dosage	Category
				be given adult dosages, infants and children below two years old should be given half the adult dose. Dosing is according to Product Information Leaflet.	
8.	Acyclovir 250 mg Injection	J05AB01-000-P4-001-XXX	i)Treatment of Herpes simplex & Varicella zoster infections ii)Prophylaxis of Herpes simplex infections in immune-compromised patients	ADULT: 5 mg/kg by IV infusion 8 hourly for 5 days, doubled to 10mg/kg every 8 hourly in varicella-zoster in the immunocompromised and in simplex encephalitis (usually given for at least 10 days in encephalitis; possibly for 14 - 21 days). NEONATE & INFANT up to 3 months with disseminated herpes simplex: 20mg/kg every 8 hourly for 14 days (21 days in CNS involvement), varicella-zoster 10-20mg/kg every 8 hourly usually for 7 days. CHILD, 3 months - 12 years: Herpes simplex or Varicella Zoster: 250 mg/m ² 8 hourly for 5 days, doubled to 500 mg/m ² 8 hourly for varicella-zoster in the immunocompromised and in simplex encephalitis (usually given for 10 days in encephalitis)	A*
9.	Acyclovir 3% Eye Ointment	S01AD0300 0G5101XX	Only for the treatment of herpes simplex keratitis	Apply 1 cm 5 times daily. Continue for at least 3 days after healing	A* (UKK CFLN) (SRQ OPHTH)

No.	Generic Name	MDC	Indications	Dosage	Category
10.	Acyclovir 800 mg Tablet	J05AB01-000-T10-02-XXX	i) Treatment of Herpes simplex & Varicella zoster infections ii) Prophylaxis of Herpes simplex infections in immune-compromised patients	Indication (i) Treatment for Herpes Simplex: ADULT - 200mg 5 times daily; In severely immune-compromised patients: dose can be doubled to 400 mg. CHILD - two years and above should be given adult dosages, infants and children below two years old should be given half the adult dose. Treatment for Varicella Zoster: ADULT - 800mg 5 times daily; CHILD - 6 years and over: 800 mg four times daily, 2 - < 6 years: 400 mg four times daily, Under 2 years: 200 mg four times daily. Indication (ii) ADULT - Immune-compromised patients: 200 mg four times daily. Severely immune-compromised patients: dose can be doubled to 400 mg. CHILD - two years and above should be given adult dosages, infants and children below two years old should be given half the adult dose. Dosing is according to Product Information Leaflet.	A/KK (SRQ A&E)
11.	Adenosine 3 mg / ml Injection	C01EB1000 OP3001XX	Rapid conversion of paroxysmal supraventricular tachycardia to sinus rhythm	ADULT: Initially: 3 mg given as a rapid IV bolus (over 2 seconds). Second dose: If the first dose does not result in elimination of the supraventricular tachycardia with in 1 or 2 minutes, 6 mg should be given also as a rapid IV bolus. Third dose: If the second dose does not result in elimination of the supraventricular tachycardia with in 1-2 minutes, 12 mg should be given also as a rapid IV bolus	B
12.	Adrenaline Acid (Epinephrine) Tartrate 1 mg / ml Injection	C01CA2412 3P3001XX	Cardiopulmonary resuscitation (Off-label indication with one-off UKK approval: Septic shock)	1mg by intravenous injection repeated every 3-5 minutes according to response	B
13.	Agomelatine 25 mg Tablet	N06AX2200 OT1001XX	Major depression	The recommended dose is 25mg once daily at bedtime, maybe increased to 50mg once daily at bedtime.	A* (SRQ PSY)
14.	Albendazole 200 mg Tablet	P02CA0300 OT1001XX	i) Single or mixed infestations of intestinal parasites ii) Strongyloides infection	i) Child 12-24months: 200mg as a single dose ii) Adult & Child above 2 years: 400mg as a single dose for 3 consecutive days; Child 12 – 24 months: 200mg as a single dose for 3 consecutive days	C+

No.	Generic Name	MDC	Indications	Dosage	Category
15.	Albendazole 200 mg /5ml Suspension	P02CA0300 0L8001XX	i) Single or mixed infestations of intestinal parasites ii) Strongyloides infection	i) Child 12-24 months: 200mg as a single dose ii) Adult & Child above 2 years: 400mg as a single dose for 3 consecutive days; Child 12 – 24 months: 200mg as a single dose for 3 consecutive days	C+
16.	Alcohol 70 % Solution	D08AX0800 0L9901XX	Use as antiseptic and disinfectant	Apply to the skin undiluted or when needed	C+
17.	Alendronate Sodium 70 mg Tablet	M05BA0452 0T1001XX	i) Osteoporosis in postmenopausal women with a history of vertebral fracture and whom oestrogen replacement therapy is contraindicated. ii) Osteoporosis (Male)	70 mg once weekly. Swallow the tablet whole with a full glass of plain water only on an empty stomach at least 30 minutes before breakfast (and any other oral medication); stand or sit upright for at least 30 minutes and do not lie down until after eating breakfast	A* (SRQ MED) (SRQ O&G) (SRQ ORTHO)
18.	Alfacalcidol 1 mcg Capsule	A11CC0300 0C1002XX	i) Chronic kidney disease mineral bone disorder ii) Osteoporosis iii) Hypoparathyroidism and pseudohypoparathyroidism iv) Rickets and osteomalacia	Initial dose ADULT and CHILD above 20kg body weight : 1 mcg daily; CHILD under 20kg body weight : 0.05 mcg/kg/day. Maintenance dose : 0.25 mcg to 2 mcg daily Dosing is individualised based on serum calcium level and according to product insert/protocol	A/KK (SRQ MED)
19.	Alfacalcidol 2 mcg / ml Injection	A11CC0300 0P3001XX	i) Chronic kidney disease mineral bone disorder ii) Osteoporosis iii) Hypoparathyroidism and pseudohypoparathyroidism iv) Rickets and osteomalacia	Initial dose ADULT and CHILD above 20kg body weight : 1 mcg daily; CHILD under 20kg body weight : 0.05 mcg/kg/day. Maintenance dose : 0.25 mcg to 2 mcg daily Dosing is individualised based on serum calcium level and according to product insert/protocol	A* (SRQ MED)
20.	Alfuzosin HCl 10 mg Tablet	G04CA0111 0T1001XX	Treatment of functional symptoms related with benign prostatic hypertrophy (BPH)	10mg once a day pre bed	A* (SRQ SURG)
21.	Alkaline Nasal Douche	R01A00099 9L5001XX	To remove nasal plug	To be diluted with an equal volume of warm water before use	B
22.	Allopurinol 100 mg Tablet	M04AA0100 0T1002XX	i) Frequent and disabling attacks of gouty arthritis (2 or more attacks/year). ii) Clinical or radiographic signs of erosive gouty arthritis. iii) The presence of tophaceous deposits. iv) Urate nephropathy. v) Urate nephrolithiasis. vi) Impending cytotoxic chemotherapy or radiotherapy for lymphoma or leukaemia	Initial dose: 50-100 mg daily. Maintenance: 300-900mg daily (depending on renal function).	A/KK

No.	Generic Name	MDC	Indications	Dosage	Category
23.	Allopurinol 300 mg Tablet	M04AA0100 OT1001XX	i) Frequent and disabling attacks of gouty arthritis (2 or more attacks/year). ii) Clinical or radiographic signs of erosive gouty arthritis. iii) The presence of tophaceous deposits. iv) Urate nephropathy. v) Urate nephrolithiasis. vi) Impending cytotoxic chemotherapy or radiotherapy for lymphoma or leukaemia	Initial dose: 50-100 mg daily. Maintenance: 300-900mg daily (depending on renal function).	A/KK
24.	Alprazolam 0.5 mg Tablet	N05BA1200 OT1002XX	Anxiety disorders	0.25-0.5 mg 3 times daily (elderly or debilitated 0.25 mg 2-3 times daily), increased if necessary to a total dose of 3mg/day. Not recommended for children	A/KK (SRQ MED) (SRQ PSY) (SRQ ANAES)
25.	Alprostadi 500 mcg/ml Injection	C01EA0100 OP3001XX	For treatment of congenital heart diseases which are ductus arteriosus dependent	0.05 - 0.1 mcg/kg/min by continuous IV infusion, then decreased to lowest effective dose	A* (SRQ PAED)
26.	Alteplase 50mg per Vial Injection	B01AD02- 000-P40-01- XXX	Thrombolytic treatment of acute ischaemic stroke.	0.9 mg/kg (maximum of 90 mg) infused over 60 minutes with 10% of the total dose administered as an initial intravenous bolus. Treatment must be started as early as possible within 4.5 hours after onset of stroke symptoms and after exclusion of intracranial haemorrhage by appropriate imaging technique.	A* (SRQ A&E) (SRQ MED)
27.	Amantadine HCl 100 mg Capsule	N04BB0111 OC1001XX	Parkinson's disease	Initial dose: 100 mg daily and is increased to 100 mg twice daily (not later than 4 p.m.) after a week. Elderly over 65 years: less than 100 mg or 100 mg at intervals of more than 1 day	B (SRQ MED) (SRQ REHAB)
28.	Amikacin 125 mg/ml Injection	J01GB06183 P3003XX	Infections due to susceptible organisms	ADULT: (IM or IV): 15 mg/kg/day 8 - 12 hourly for 7 - 10 days. Maximum: 1.5 g/day. CHILD: 15 mg/kg/day 8 - 12 hourly. Maximum: 1.5 g/day. Neonates: Initial loading dose of 10 mg/kg followed by 7.5 mg/kg/day 12 hourly. Maximum 15mg/kg/day	A
29.	Amikacin 250 mg/ml Injection	J01GB06183 P3002XX	Infections due to susceptible organisms	ADULT: (IM or IV): 15 mg/kg/day 8 - 12 hourly for 7 - 10 days. Maximum: 1.5 g/day. CHILD: 15 mg/kg/day 8 - 12 hourly. Maximum: 1.5 g/day. Neonates: Initial loading dose of 10 mg/kg followed by 7.5 mg/kg/day 12 hourly. Maximum 15mg/kg/day	A

No.	Generic Name	MDC	Indications	Dosage	Category
30.	Amiloride HCl 5 mg & Hydrochlorothiazide 50 mg Tablet	C03EA0190 OT1001XX	i) Diuretic as an adjunct to the management of oedematous states ii) Hypertension	i) Initially 1 - 2 tab daily adjusted according to response. Max : 4 tabs daily. ii) 1 -2 tabs daily as a single or divided dose	B
31.	Amino Acids Injection (Vaminolact - PAED Dipeptiven (with glutamine) - SURG)	B05BA0191 OP3001XX	Source of amino acids in patients needing IV nutrition	Dose to be individualised. ADULT usually 500-2000 ml by IV. ADULT usual requirement for amino acid: 1-2g/kg/day	A (SRQ PAED) (SRQ SURG)
32.	Amino Acids, Glucose and Lipid with Electrolytes Injection (SMOFKabiven, Peripheral, 1.5 L)	B05BA1091 OP3001XX	Source of amino acids, carbohydrate, lipid and electrolytes in patients needing IV nutrition	Dose to be individualised. ADULT: 500 - 2000 ml daily given by IV. ADULT usual requirement for amino acid 1-2 g/kg/day, carbohydrate 4-6 g/kg/day, lipid 2-3 g/kg/day	A (SRQ SURG)
33.	Amino Acids, Glucose and Lipid with Electrolytes Injection (SMOFKabiven, Central, 1.5 L)	B05BA1091 OP3001XX	Source of amino acids, carbohydrate, lipid and electrolytes in patients needing IV nutrition	Dose to be individualised. ADULT: 500 - 2000 ml daily given by IV. ADULT usual requirement for amino acid 1-2 g/kg/day, carbohydrate 4-6 g/kg/day, lipid 2-3 g/kg/day	A (SRQ ANAES) (SRQ SURG)
34.	Aminophylline 25 mg / ml Injection	R03DA0500 OP3001XX	Reversible airways obstruction, acute severe bronchospasm	Adult: Loading dose: 6 mg/kg (ideal body weight) or 250-500 mg (25 mg/ml) by slow inj or infusion over 20-30 min. Maintenance infusion dose: 0.5 mg/kg/hr. Max rate: 25 mg/min. Children: 6 months and over (if not previously on theophylline): Loading dose: 6mg/kg. Maintenance dose: 6 mth-9 yr: 1 mg/kg/hr and 10-16 yr: 0.8 mg/kg/hr. Dosing is individualised and according to product insert/protocol.	B
35.	Amiodarone 200 mg Tablet	C01BD0111 OT1001XX	Arrhythmias	200 mg 3 times daily for 1 week, then reduced to 200 mg twice daily for another week. Maintenance dose, usually 200 mg daily or the minimum required to control the arrhythmia. Dosing is according to product insert / protocol.	A* (SRQ MED) (SRQ PAED)
36.	Amiodarone 50 mg / ml Injection	C01BD0111 OP3001XX	i) Arrhythmias ii) Cardiopulmonary resuscitation of shock-resistant ventricular fibrillation in cardiac arrest	i) Initial: 5mg/kg over 20-120minutes Maintenance: 10-20mg/kg/24hr Max. dose: 1.2g/24hr. ii) Initial: 300mg or 5mg/kg rapid Additional 150mg if condition persists. Dosing is according to product insert / protocol.	A* (SRQ GENERAL)

No.	Generic Name	MDC	Indications	Dosage	Category
37.	Amisulpride 400 mg Tablet	N05AL0500 OT1001XX	Treatment of psychoses, particularly acute or chronic schizophrenia disorders characterized by positive symptoms(e.g. delusion, hallucinations, thought disorders) and/or negative symptoms(e.g. blunted emotions, emotional and social withdrawal) including when the negative symptoms predominate	Predominantly negative episodes: 50-300 mg once daily adjusted according to the patient's response. Mixed episodes with positive and negative symptoms: 400-800 mg/day in 2 divided doses adjusted according to the patient's response. Should be taken on an empty stomach (Preferably taken before meals)	A* (SRQ PSY)
38.	Amitriptyline HCl 25 mg Tablet	N06AA0911 OT1001XX	Depression (Off-label indication with one-off UKK approval: Neuropathic pain)	Initially 25 mg 3 times a day. Maintenance: 25-100 mg daily in divided doses. Hospitalized patient: 100 mg/day & gradually increase to 200-300 mg/day. ADOLESCENT and ELDERLY: initially 20-30 mg/day in divided doses w/ gradual increments. CHILD under 16 years are not recommended	B
39.	Amlodipine 10 mg & Valsartan 160 mg Tablet	C09DB0193 5T1003XX	Essential hypertension in patients whose blood pressure is not adequately controlled by monotherapy	Doses range from amlodipine besylate 5 mg/valsartan 160 mg to amlodipine besylate 10 mg/valsartan 320 mg ORALLY once daily, with dose titration occurring every 1 to 2 weeks if necessary. MAX amlodipine besylate 10 mg/valsartan 320 mg	A/KK (SRQ MED)
40.	Amlodipine 5 mg Tablet	C08CA0100 OT1001XX	Hypertension	5 mg once daily. Max: 10 mg	B
41.	Amlodipine 10 mg Tablet	C08CA0100 OT1002XX	Hypertension	5 mg once daily. Max: 10 mg	B
42.	Amoxicillin & Clavulanate 228 mg/5 ml Syrup	J01CR02961 F2102XX	Infections caused by susceptible organisms	Mild to Moderate infection: 25 mg/kg/day (based on Amoxicillin dose) in 2 divided dose. Severe infection: 45 mg/kg/day (based on Amoxicillin dose) in 2 divided dose	A/KK (SRQ GENERAL)
43.	Amoxicillin 1 g & Clavulanate 200 mg Injection	J01CR02961 P4002XX	Infections caused by susceptible organisms. Respiratory tract, skin, soft tissue, GUT infection, septicaemia, peritonitis, post-operative infection and osteomyelitis	CHILD less than 3 months: 30 mg/kg 12 hourly. 3 months - 12 years: 30 mg/kg 6 - 8 hourly. ADULT: 1.2 g by IV or intermittent infusion 6 - 8 hourly	A (SRQ GENERAL)
44.	Amoxicillin 500 mg Capsule	J01CA04012 C1002XX	Infections caused by susceptible strains of gram positive and gram negative organisms	ADULT: 250 - 500 mg 3 times daily. CHILD: 20 - 40 mg/kg/day in divided doses 8 hourly	B
45.	Amoxicillin 500 mg & Clavulanate 125 mg Tablet	J01CR02961 T1002XX	Infections due to beta-lactamase producing strain where amoxicillin alone is not appropriate. Respiratory tract, skin, soft tissue, GUT infection, septicaemia, peritonitis, post-operative infection & osteomyelitis	ADULT & CHILD more than 12 years: Mild to moderate infections: 625 mg twice daily.	A/KK

No.	Generic Name	MDC	Indications	Dosage	Category
46.	Amoxicillin Trihydrate 125 mg / 5ml Syrup	J01CA04012 F1001XX	Infections caused by susceptible strains of gram positive and gram negative organisms	CHILD less than 10 years: 125 - 250 mg 8 hourly. CHILD less than 20 kg: 20 - 40 mg/kg/day in 3 - 4 divided doses	B
47.	Amphotericin B 50 mg Injection (Conventional)	J02AA01801 P4001XX	Systemic fungal infections	ADULT: 0.25 mg/kg/day by IV infusion, gradually increase if tolerated to 1 mg/kg/day. Maximum in severe cases: 1.5 mg/kg daily or on alternate days. For neonates, lower doses are recommended	A
48.	Ampicillin Sodium & Sulbactam Sodium 250 mg / 5 ml Suspension	J01CR01-961-F21-01-XXX	Treatment of susceptible bacterial infections	ADULT: 375-750mg twice daily. CHILDREN (weight < 30kg): 25-50mg/kg/day in two divided doses. For children weighing 30kg and more, follow usual adult dose.	B (SRQ PEAD)
49.	Ampicillin Sodium & Sulbactam Sodium 375 mg Tablet	J01CR01961 T1001XX	Treatment of susceptible bacterial infections	ADULT: 375-750 mg twice daily CHILDREN AND INFANTS: 25-50 mg/kg/day in 2 divided doses, if ≥ 30kg use an adult dose	A/KK (SRQ GENERAL)
50.	Ampicillin Sodium 1 g & Sulbactam Sodium 500 mg Injection	J01CR01961 P4002XX	Treatment of susceptible bacterial infections	ADULT: 1.5 - 12 g/day in divided doses 6 - 8 hourly. Maximum: 4 g Sulbactam. CHILD: 150-300 mg/kg/day 6 - 8 hourly. Prophylaxis of surgical infections: 1.5 - 3 g at induction of anaesthesia. May be repeated 6 - 8 hourly. NEONATES: First week of life, 75 mg/kg/day in divided doses every 12 hour	A (SRQ GENERAL)
51.	Ampicillin Sodium 500 mg Injection	J01CA01520 P4001XX	Treatment of susceptible bacterial infections (non beta-lactamase producing organisms); meningitis	250 - 500 mg IM/IV every 4 - 6 hours. Maximum: 400 mg/kg/day. Meningitis: 2 g 6 hourly. CHILD: 150 mg/kg/daily IV in divided doses. Usual children dose less than 10 years, half adult dose	B
52.	Ampicillin Trihydrate 125 mg / 5 ml Suspension	J01CA01012 F2101XX	Treatment of susceptible bacterial infections (non beta-lactamase producing organisms)	CHILD: 50 - 100 mg/kg/day 4 times daily. Under 1 year: 62.5 - 125 mg 4 times daily, 1 - 10 years: 125 - 250 mg 4 times daily	B
53.	Anastrozole 1 mg Tablet	L02BG0300 OT1001XX	Hormonal therapy in breast cancer in post-menopausal women if failed/ contraindicated with Tamoxifen	1 mg daily	A* (SRQ SURG)
54.	Anidulafungin 100 mg Injection	J02AX06000 P3001XX	Treatment of invasive candidiasis, including candidemia in adults when intolerance or resistance to Amphotericin B or Fluconazole	Loading dose of 200 mg on day 1, then 100 mg once daily thereafter for at least 14 days after the last positive culture.	A* (SRQ ANAES)

No.	Generic Name	MDC	Indications	Dosage	Category
55.	Anti Rhd Immunoglobulin Injection 300 mcg / 2 ml (150 mcg = 750 IU) (Rhogam)	J06BB01000 P3001XX	Prevention of Rh(D) sensitisation to Rh(D)-negative woman: i) Pregnancy/delivery of Rh(D)-positive infant ii) Abortion/threatened abortion, ectopic pregnancy or hydatidiform mole iii) Transplacental haemorrhage resulting from antepartum haemorrhage, amniocentesis, chorionic biopsy or obstetric manipulative procedures e.g. external version or abdominal trauma	i) Antenatal prophylaxis: According to general recommendations, currently administered doses range from 50 – 330 micrograms or 250 - 1650 IU. For specific details, please refer to product's package insert. ii) Postnatal prophylaxis: According to general recommendations, currently administered doses range from 100 – 300 micrograms or 500 – 1500 IU. For specific details, please refer to product's package insert.	B
56.	Antirabies Immunoglobulin (equine) 300IU/ ml Injection (Not kept in HDOK; only to obtain from HQE if there is any cases)	J06BB05000 P3001XX	Treatment of rabies, post-exposure	Human rabies immunoglobulin: 20 iu/kg; half by IM and half by infiltration around the wound. Equine rabies immunoglobulin: 40iu/kg of body weight in adults and children. Note: Please refer to package insert for recommendations by the manufacturer	B (UKK CFLN)
57.	Antivenene Cobra Injection	J06AA03000 P3002XX	Treatment of patients who exhibit manifestations of systemic envenoming following a bite by Cobra (Naja kaouthia).	Initial dose of 100 ml of reconstituted antivenene given by slow intravenous infusion (2 ml/min). Subsequent dose can be given every 12 hours according to the clinical symptoms. As product may differ from batches and manufacturer, it is strongly recommended to refer to the product insert on dosing recommendation.	B (SRQ A&E)
58.	Antivenene Serum (Sea snake) 1000 units Injection	J06AA03000 P3003XX	Treatment of patients who exhibit manifestations of systemic envenoming following a bite by sea snake.	1000 units by IV infusion over 1/2 to 1 hour. In severe cases 3000-10000 units may be required	B (SRQ A&E)
59.	Aqueous Cream	D02AX0000 OG1001XX	As an emollient for dry skin. Can be used as soap substitute for bathing.	As a soap or apply to the skin as an emollient	C+
60.	Aripiprazole 10 mg Tablet	N05AX1200 OT1002XX	i) Treatment of acute episodes of schizophrenia and for maintenance of clinical improvement during continuation therapy. ii) Treatment of acute manic episodes associated with bipolar I disorder	Schizophrenia: 10 or 15 mg/day. Maintenance dose: 15 mg/day. Bipolar mania: Starting dose: 15 or 30 mg/day. Dose adjustment should occur at intervals of not less than 24 hour	A* (SRQ PSY)

No.	Generic Name	MDC	Indications	Dosage	Category
61.	Aripiprazole 400 mg Powder and Solvent for Prolonged-release Suspension for Injection	N05AX12-010-P20-01-XXX	Maintenance treatment of schizophrenia in adult patients stabilized with oral aripiprazole	Recommended starting and maintenance dose is 400 mg to be administered once monthly as a single injection (no sooner than 26 days after the previous injection). After the first injection, treatment with 10 mg to 20 mg oral aripiprazole should be continued for 14 consecutive days to maintain therapeutic aripiprazole concentrations during initiation of therapy.	A* (SRQ PSY)
62.	Artemether 20 mg + Lumefantrine 120mg Tablet	P01BE52981 T1001XX	Acute uncomplicated falciparum malaria	ADULT and CHILD over 12 years weighing over 35 kg : 4 tablets as a single dose at the time of initial diagnosis, again 4 tablets after 8 hours and then 4 tablets twice daily (morning and evening) on each of the following two days (total course comprises 24 tablets). INFANT and CHILD weighing 5 kg to less than 35 kg : A 6 dose regimen with 1 to 3 tablets per dose, depending on bodyweight	B (SRQ MED)
63.	Artesunate 60 mg Injection	P01BE03000 P3001XXX	Treatment of severe malaria in adults and children	2.4 mg of artesunate/kg body weight, by intravenous (IV) or intramuscular (IM) injection, at 0, 12 and 24 hours, then once daily until oral treatment can be substituted. For adults and children with severe malaria or who are unable to tolerate oral medicines, artesunate 2.4 mg/kg body weight IV or IM given on admission (time = 0), then at 12 hrs and 24 hrs, then once a day for 5-7 days is the recommended treatment.	B (SRQ MED)
64.	Artificial tears / eye lubricant ophthalmic gel	S01KA0200 0G32XXXX	Symptomatic relief of severe dry eye conditions and as lens lubricant during ophthalmic diagnostic procedures	Instill 1-2 drops in affected eye(s) as needed. Refer to product information leaflet.	B (SRQ OPHTH)
65.	Artificial tears / eye lubricant ophthalmic solution (with preservative)	S01XA2000 0D20XXXX	Tear deficiency, ophthalmic lubricant; for relief of dry eyes and eye irritation	1 - 2 drops several times a day. Refer to product information leaflet	B
66.	Artificial tears / eye lubricant ophthalmic solution (preservative free)	S01XA2000 0D20XXXX	Tear deficiency, ophthalmic lubricant; for relief of dry eyes and eye irritation	1 - 2 drops several times a day. Refer to product information leaflet	B (SRQ OPHTH)

No.	Generic Name	MDC	Indications	Dosage	Category
67.	Ascorbic Acid 100 mg Tablet	A11GA0100 OT1002XX	Vitamin C deficiency	ADULT: 100-250 mg once or twice daily. CHILD: 100mg three times daily for one week followed by 100mg daily until symptoms abate.	C+
68.	Ascorbic Acid 500 mg Tablet	A11GA0100 OT1003XX	Vitamin C deficiency	ADULT: 100-250 mg once or twice daily. CHILD: 100mg three times daily for one week followed by 100mg daily until symptoms abate.	C+
69.	Atenolol 100 mg Tablet	C07AB0300 OT1002XX	Hypertension, angina pectoris, myocardial infarction and arrhythmias	Hypertension and arrhythmias; 50 - 100 mg daily, Angina; 100 mg daily, Myocardial infarction; individualised	B
70.	Atomoxetine HCl 10 mg Capsule	N06BA0911 OC1001XX	Attention deficit hyperactivity disorder (ADHD) in children 6 years and older who do not respond to methylphenidate or who have intolerable effects or have tics. Diagnosis should be made according to DSM IV criteria or the guidelines in ICD-10	CHILD and ADOLESCENTS up to 70 kg: Initially 0.5 mg/kg/day for at least 7 days, then increased according to response. Maintenance: 1.2 mg/kg/day. ADULTS and ADOLESCENTS more than 70 kg: Initially 40 mg/day for at least 7 days then increased according to response. Maintenance: 80 mg/day. Max 100 mg/day	A* (UKK PSY)
71.	Atomoxetine HCl 25 mg Capsule	N06BA0911 OC1003XX	Attention deficit hyperactivity disorder (ADHD) in children 6 years and older who do not respond to methylphenidate or who have intolerable effects or have tics. Diagnosis should be made according to DSM IV criteria or the guidelines in ICD-10	CHILD and ADOLESCENTS up to 70 kg: Initially 0.5 mg/kg/day for at least 7 days, then increased according to response. Maintenance: 1.2 mg/kg/day. ADULTS and ADOLESCENTS more than 70 kg: Initially 40 mg/day for at least 7 days then increased according to response. Maintenance: 80 mg/day. Max 100 mg/day	A* (UKK PSY)
72.	Atomoxetine HCl 40 mg Capsule	N06BA0911 OC1004XX	Attention deficit hyperactivity disorder (ADHD) in children 6 years and older who do not respond to methylphenidate or who have intolerable effects or have tics. Diagnosis should be made according to DSM IV criteria or the guidelines in ICD-10	CHILD and ADOLESCENTS up to 70 kg: Initially 0.5 mg/kg/day for at least 7 days, then increased according to response. Maintenance: 1.2 mg/kg/day. ADULTS and ADOLESCENTS more than 70 kg: Initially 40 mg/day for at least 7 days then increased according to response. Maintenance: 80 mg/day. Max 100 mg/day	A* (UKK PSY)
73.	Atorvastatin 20mg Tablet	C10AA05-000-T10-02-XXX	i) Hypercholesterolaemia ii) Prevention of cardiovascular disease	i) & ii) 10 mg once daily. Maximum: 80 mg daily	B (SRQ PAED)
74.	Atorvastatin 40 mg Tablet	C10AA0500 OT1001XX	i) Hypercholesterolaemia ii) Prevention of cardiovascular disease	i) & ii) 10 mg once daily. Maximum: 80 mg daily	B (SRQ MED)

No.	Generic Name	MDC	Indications	Dosage	Category
75.	Atracurium Besylate 10 mg / ml in 2.5 ml Injection	M03AC0419 7P3001XX	Muscle relaxant in general anaesthesia, Endotracheal intubation, Aid controlled ventilation.	Adult & childn >2 mth 0.3-0.6 mg/kg IV. Endotracheal intubation dose: 0.5-0.6 mg/kg. Supplementary dose: 0.1-0.2 mg/kg as required. Continuous infusion rates of 0.3-0.6 mg/kg/hr to maintain neuromuscular block during long surgical procedure.	A* (SRQ ANAES)
76.	Atropine Sulphate 1 % Eye Drops	S01FA01183 D2001XX	Determination of refraction, strabismus, iritis and iridocyclitis, after extra or intracapsular extraction of lens	Use in adults - For uveitis: 1 drop in the eye(s), 3 times daily. - For refraction: 1 drop in the eye(s), repeated 1 hour before the examination	B (UKK PAED)
77.	Atropine Sulphate 1 mg / ml Injection	A03BA0118 3P3001XX	i) Reduce vagal inhibition, salivary and bronchial secretion in anaesthesia ii) Reversal of excessive bradycardia iii) Reversal of effect of competitive muscle relaxants iv) Overdosage with other compounds having muscarinic action v) Organophosphate poisoning	i) Adult: 300-600 mcg IM/SC 30-60 minutes before anaesthesia. Alternatively, 300-600 mcg IV immediately before induction of anaesthesia. Child: >20 kg: 300-600 mcg; 12-16 kg: 300 mcg; 7-9 kg: 200 mcg; >3 kg: 100 mcg. Doses to be given via IM/SC admin 30-60 minutes before anaesthesia. ii) Adult: 500 mcg every 3-5 minutes. Total: 3 mg. Max Dosage: 0.04 mg/kg body weight. iii) Adult 0.6-1.2 mg before or with anticholinesterase iv) Adult: 0.6-1 mg IV/IM/SC, repeated every 2 hr. v) Adult: 2 mg IV/IM, every 10-30 minutes until muscarinic effects disappear or atropine toxicity appears. In severe cases, dose can be given as often as every 5 minutes. In moderate to severe poisoning, a state of atropinisation is maintained for at least 2 days and continued for as long as symptoms are present. Child: 20 mcg/kg given every 5-10 minutes.	B

No.	Generic Name	MDC	Indications	Dosage	Category
78.	Azathioprine 50 mg Tablet	L04AX01000 T1001XX	i) Prophylaxis of rejection in organ and tissue transplant ii) Auto-immune diseases iii) Rheumatoid arthritis	i) Adult: 1-5 mg/kg/day. Adjust dose according to clinical response and haematological tolerance. Dose may also be given via IV administration. ii) Adult: 1-3 mg/kg/day. Discontinue treatment if there is no improvement after 12 week. iii) Adult: Initially, 1 mg/kg/day given in 1-2 divided doses for 6-8 week, may increase by 0.5 mg/kg every 4 week until response or up to 2.5 mg/kg/day. Maintenance: Reduce dose gradually to achieve the lowest effective dose.	A
79.	Azithromycin 200 mg / 5 ml Granules	J01FA10011 F1001XX	PRESCRIBER CATEGORY A*: Treatment of complicated respiratory tract infections. PRESCRIBER CATEGORY A/K: Treatment of pertussis	CHILD 36 - 45 kg: 400 mg, 26 - 35 kg: 300 mg, 15 - 25 kg 200 mg, less than 15 kg: 10 mg/kg. To be taken daily for 3 days or to be taken as a single dose on day 1, then half the daily dose on days 2 - 5	A*, A/KK (SRQ PAED)
80.	Azithromycin 250 mg Tablet	J01FA10011 T1001XX	Category of prescriber A/KK is only approved for indications: (i) Adult treatment of uncomplicated genital infections due to Chlamydia trichomatis or susceptible Neisseria gonorrhoea. (ii) Treatment of pertussis The following indications are still under the category of prescriber A*: (iii) Treatment of complicated respiratory tract infections; (iv) Prophylaxis against Mycobacterium avium complex in patients with advanced HIV.	i) 1 g as a single dose; ii) 500 mg in a single dose on day 1 then 250mg per day on days 2-5 iii) 500 mg daily for 3 days; iv) 1 g weekly	A*, A/KK (SRQ GENERAL)
81.	Azithromycin 500 mg Injection	J01FA10011 P4001XX	i. Severe atypical pneumonia ii. Treatment of pelvic inflammatory diseases (PID) caused by susceptible organism in patients who require initial IV therapy	i. 500 mg IV as a single daily dose for a minimum of two days followed by 500 mg oral dose as a single daily dose to complete a 7 - 10 days course ii. 500mg as a single dose by the IV route for 1 or 2 days followed by oral azithromycin at a single daily dose of 250mg to complete a 7-day course of therapy.	A* (SRQ GENERAL)

No.	Generic Name	MDC	Indications	Dosage	Category
82.	Baclofen 10 mg Tablet	M03BX0100 OT1001XX	Spasticity of the skeletal muscle	ADULT: 5 mg 3 times daily. Max: 80 mg daily (20mg 4 times a day). CHILD: starting dose: 0.3mg/kg/day in divided dose, titrate up cautiously in 1 -2 weeks interval. Usual maintenance dose: 0.75 - 2 mg/kg daily (age more than 10 years, maximum: 2.5 mg/kg daily). The dose should not exceed 40 mg/day in children below 8 years of age, but a maximum dose of 60 mg/day may be given in children over 8 years of age. Dosing is individualised and according to product insert/protocol	B
83.	Balanced Salt Solution (Centurion 500 ml Bag, Occusol 500 ml Bottle)	B05CB1090 7L5001XX	For irrigation during ocular surgery	Irrigate as directed	A (SRQ OPHTH)
84.	Barium Suphate Suspension	V08BA0118 3L8001XX	For x-ray examination of the alimentary tract: i) Oesophagus ii) Stomach and duodenum iii) Colon	i) Up to 150 ml of a 50% - 200% suspension orally ii) Up to 300 ml of a 30% - 200% suspension orally iii) Up to 2 litre of a 30% - 200% suspension orally	B (SRQ RADIO) (UKK)
85.	BCG Vaccine Freeze-Dried Injection	J07AN01000 P4001XX	For the prevention of tuberculosis	0.05 to 0.1 ml by intradermal. Dosing is according to Immunisation Schedule under NIP.	C+
86.	Beclomethasone Dipropionate 100 mcg/dose Inhaler	R03BA0113 3A2101XX	Prophylaxis of asthma especially if not fully controlled by bronchodilators	Adults: The usual maintenance dose is one to two inhalations (200-400 mcg) twice daily. If needed, the dose can be increased up to 1600 mcg/day divided in two to four doses : Children 6-12 years old: One inhalation (200 mcg) two times daily and dose may be increased up to 800 mcg/day in divided two to four doses if necessary.	B

No.	Generic Name	MDC	Indications	Dosage	Category
87.	Beclomethasone dipropionate 100mcg and formoterol fumarate dihydrate 6mcg pressurized inhalation solution	R03AK07-986-A21-01-XXX	i) Regular treatment of asthma where use of a combination product (inhaled corticosteroid and long-acting beta2 agonist) is appropriate in: a) Patients not adequately controlled with inhaled corticosteroids and "as needed" inhaled short-acting beta2 agonist, or b) Patients already adequately controlled on both inhaled corticosteroids and long-acting beta2-agonists. The following indication (COPD) is categorised as A* - To be initiated by Consultant/ Specialists from disciplines related to the listed indication only: ii) Treatment of COPD patients with a blood eosinophil count of 300 cells/microliter and more iii) Treatment of COPD patients with blood eosinophil count of 100 cells/microliter and more with history of repeated exacerbation despite regular treatment with long-acting bronchodilators.	For asthma, the dosage is based on treatment approach: i) Maintenance therapy (taken as regular maintenance treatment with a separate as needed rapid-acting bronchodilator): Dose recommendations for adults 18 years and above: One or two inhalations twice daily. The maximum daily dose is 4 inhalations. ii) Maintenance and reliever therapy (taken as regular maintenance treatment and as needed in response to asthma symptoms): Dose recommendations for adults 18 years and above: The recommended maintenance dose is 1 inhalation twice daily (one inhalation in the morning and one inhalation in the evening). Patients should take 1 additional inhalation as needed in response to symptoms. If symptoms persist after a few minutes, an additional inhalation should be taken. The maximum daily dose is 8 inhalations. For COPD: 2 puffs two times a day.	A/KK (SRQ MED)
88.	Benzalkonium 0.01% - 0.02% Cream	D08AJ01000 G1001XX	Prevention and treatment of nappy rash	Wash and dry baby's bottom. Apply by spreading the cream evenly paying particular attention to the fold of the skin, after every nappy change	B
89.	Benzathine Penicillin 2.4 MIU (1.8 g) Injection	J01CE08702 P4001XX	i) Treatment of mild to moderately severe infections due to Penicillin G-sensitive organisms ii) Treatment of syphilis	i) ADULT: 1.2 mega units IM ii) For syphilis: 2.4 mega units weekly for 1 - 3 weeks	B
90.	Benzhexol 2 mg Tablet	N04AA0111 OT1001XX	i) Symptomatic treatment of paralysis agitans and of parkinsonism, arteriosclerotic, idiopathic, or post-encephalitic origin ii) Alleviate extrapyramidal syndrome induced by phenothiazine derivatives or reserpine iii) Spasmodic torticollis, facial spasms and other dyskinesia	i) & iii) Initial: 1-2mg daily Maintenance: Gradual increment to 6-10mg daily according to response ii) 5-15mg daily Dosing is individualised and according to product insert / protocol	B
91.	Benzoic Acid Compound Ointment	D01AE1295 2G5002XX	Tinea infections of thickened skin of palms and soles	Apply sparingly to affected area once or twice daily	C

No.	Generic Name	MDC	Indications	Dosage	Category
92.	Benzydamine HCl 0.15 % Solution	A01AD0211 0M2001XX	For relief of painful condition of the oral cavity	Used as a 30 seconds gargle or rinse, undiluted. ADULT 15 ml. CHILD less 12 years 5-15 ml. Uninterrupted treatment should not be more than 7 days	B (SRQ ENT)
93.	Benzydamine Hydrochloride 3.0 mg / ml throat spray	A01AD0211 0A4201X X	Temporary relief of painful conditions of the mouth and throat including tonsillitis, sore throat, radiation mucositis, aphthous ulcers, pharyngitis, swelling, redness, inflammatory conditions, post-rosurgical and periodontal procedures. (For pediatric and otorhinolaryngology use. Restrict to patients who are not able to gargle)	ADULTS and CHILDREN OVER 12 YEARS: 2-4 sprays (1-2mg) directly onto the sore/inflamed area and swallow gently. Repeat every 1 1/2 to 3 hours as necessary. CHILDREN 6-12 YEARS: 2 sprays (1mg) directly onto sore/ inflamed area and swallow gently. Repeat every 11/2 to 3 hours as necessary. CHILDREN UNDER 6 YEARS: Not recommended. Uninterrupted treatment should not exceed seven days, unless under medical supervision	A* (SRQ ENT)
94.	Benzyl Benzoate 12.5 % Emulsion (Child)	P03AX0125 2L2001XX	Scabies - for child 2-12 years old	After bath, apply over the whole body, neck down and leave on for 24 hours then wash off. Reapply for another 24 hours, the first repeat application should be within 5 days of the initial application, a third application may be required in some cases	C
95.	Benzyl Benzoate 25 % Emulsion (Adult)	P03AX0100 0L2002XX	Scabies, for adult and children more than 12 years old	After bath, apply over the whole body, neck down and leave on for 24 hours then wash off. Reapply for another 24 hours, the first repeat application should be within 5 days of the initial application, a third application may be required in some cases.	C+
96.	Benzylpenicillin 1 mega unit (600 mg) Injection	J01CE01702 P4001XX	i) Infections caused by susceptible organisms ii) Infective endocarditis	i) Adult: 600mg - 3600mg (1 - 6 mega units) daily, divided into 4 to 6 doses. Higher doses (24 mega units) in divided doses may be given in serious infections such as meningitis. Child 1 month to 12 years old: 100mg/kg/day in 4 divided doses, not exceeding 4g/day; Infants 1 -4 weeks: 75mg/kg/day in 3 divided doses; Newborn Infants: 50mg/kg/day in 2 divided doses ii) 7.2 to 12g (12 - 20 mega units) maybe given daily in divided doses	B

No.	Generic Name	MDC	Indications	Dosage	Category
97.	Benzylpenicillin 5 mega unit (3g) Injection	J01CE01702 P4002XX	i) Infections caused by susceptible organisms ii) Infective endocarditis	i) ADULT: 600 - 1200 mg IM 4 times daily, increased if necessary in more serious infections. CHILD: 50 - 100 mg/kg body weight daily IV in 2 - 4 divided doses ii) ADULT: 7.2 g daily by slow IV infusion in 6 divided doses	B
98.	Beractant Intratracheal Suspension (200 mg phospholipids in 8 ml vial)	R07AA0200 OL8001XX	Treatment of newborn baby with birth weight of 700 g or greater undergoing mechanical ventilation for respiratory distress syndrome, whose heart rate and arterial oxygenation are continuously monitored	100 mg/kg (4 ml/kg) body weight intratracheally up to 4 doses in 1st 48 hr. Doses should not be given more frequently than 6 hrly. To be administered as soon as possible.	A* (SRQ PAED)
99.	Betahistine Dihydrochloride 24 mg Tablet	N07CA0111 OT1003XX	i) Meniere's Syndrome as defined by the following core symptoms: - Vertigo (with nausea/vomiting). - Hearing loss (Hardness of hearing). - Tinnitus (ringing in the ears) ii) Symptomatic treatment of vestibular vertigo	24-48 mg in divided doses daily	A/KK (SRQ ENT)
100.	Betamethasone 17-Valerate 0.01-0.05% Cream (0.01%, 0.0125%, 0.025% & 0.05%)	D07AC0125 6G1001XX	Topical corticosteroid indicated for the relief of inflammatory and pruritic manifestation of steroid-responsive dermatoses.	Apply sparingly to affected area 2 times daily then reduced to once daily when improvement occurs	B
101.	Betamethasone 17-Valerate 0.1% Cream	D07AC0125 6G1002XX	Potent topical corticosteroid indicated for adults, elderly and child over 1 year for relief of inflammatory and pruritic manifestation of steroid-responsive dermatoses.	Apply sparingly to affected area 2 times daily then reduced to once daily when improvement occurs	A (SRQ GENERAL)
102.	Betamethasone Disodium Phosphate and Neomycin Sulphate 0.5% Ear/Eye Drops	S01CA0599 1D2001XX	Eye: Infected inflammatory conditions of the eyes. Ear: Allergic dermatosis in the ear	Eye: 1 drops 3-4 times daily. Ear: 4 drops 3-4 times daily	A
103.	Bicalutamide 50 mg Tablet	L02BB0300 OT1001XX	Androgen deprivation therapy in advanced prostate cancer in combination with luteinising hormone-releasing hormone (LHRH) analogue therapy or surgical castration.	50 mg once daily (morning or evening), with or without food. Take on the same time each day. Adult: When used with gonadorelin analogue: Usual dose: 50 mg once daily. May be started with or at least 3 days before starting gonadorelin analogue therapy.	A* (SRQ SURG)
104.	Bimatoprost 0.01% Ophthalmic Solution	S01EE03000 D2002XXX	Reduction of elevated intraocular pressure in chronic open-angle glaucoma and ocular hypertension in adults (as monotherapy or as adjunctive therapy to beta blockers). Prescribing Restrictions: To be used as 2nd line	One drop in the affected eye(s) once daily, administered in the evening.	A* (SRQ OPHTH)

No.	Generic Name	MDC	Indications	Dosage	Category
105.	Bisacodyl 10 mg Suppository	A06AB0200 0S2002XX	i) Constipation ii) Bowel preparation for radiological procedures and surgery	i) ADULT and CHILD (over 10 years): 10 mg per rectal CHILD (4 to 10 years): 5 mg per rectal ii) ADULT and CHILD (over 10 years:)10 to 20 mg, CHILD (4 to 10 years): 5 mg the following morning before procedures insert rectally	C
106.	Bisacodyl 5 mg Suppository	A06AB0200 0S2001XX	i) Constipation ii) Bowel preparation for radiological procedures and surgery	i) ADULT and CHILD (over 10 years): 10 mg per rectal CHILD (4 to 10 years): 5 mg per rectal ii) ADULT and CHILD (over 10 years:)10 to 20 mg, CHILD (4 to 10 years): 5 mg the following morning before procedures insert rectally	C
107.	Bisacodyl 5 mg Tablet	A06AB0200 0T1001XX	i) Constipation ii) Bowel preparation for radiological procedures and surgery	i) ADULT and CHILD (over 10 years): 5 to 10 mg, CHILD (4 to 10 years): 5 mg. To be taken at night for effect on the following morning ii) ADULT and CHILD (over 10 years): 10 mg in the morning and 10 mg in the evening the day before procedures. CHILD (4 to 10 years): 5 mg the night before procedures	C
108.	Bisoprolol Fumarate 2.5 mg Tablet	C07AB07- 000-T10- 01-XXX	i) Hypertension ii) Coronary heart disease (angina pectoris) iii) Treatment of stable congestive cardiac failure in addition to ACEI's and diuretics	1.25 mg once daily, gradually titrate to maximum tolerable dose (i) & (ii): Max: 20mg/ day (iii): Max 10mg/ day	B (SRQ ANAES) (SRQ MED) (SRQ PAED)
109.	Bisoprolol Fumarate 5 mg Tablet	C07AB07- 000-T10- 02-XXX	i) Hypertension ii) Coronary heart disease (angina pectoris) iii) Treatment of stable congestive cardiac failure in addition to ACEI's and diuretics	1.25 mg once daily, gradually titrate to maximum tolerable dose (i) & (ii): Max: 20mg/ day (iii): Max 10mg/ day	B (SRQ MED) (SRQ PAED)
110.	Bleomycin 15 mg Injection	L01DC0111 0P4001XX	Solid tumours; Lymphomas	15 - 30 mg weekly in divided doses or 10 - 20 mg/m ² once or twice weekly or 10 mg/m ² slow bolus in 15 minutes D1 and D15. Total dosage: should not exceed 300 mg. CHILD: 10 - 15 mg/m ² over 6 hours every 3 - 4 weeks (Routes: SC, IM, IV (either as bolus or as infusion over 24 hours), intra-arterial, intra-pleural)	A (SRQ ONCO)
111.	Brimonidine Tartrate 0.15 % Ophthalmic	S01EA0512 3D2001XX	Lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension	1 drop in the affected eye(s) 3 times daily	A* (SRQ OPHTH)

No.	Generic Name	MDC	Indications	Dosage	Category
112.	Bromhexine HCl 4 mg / 2 ml Injection	R05CB0211 0P3001XX	Secretolytic therapy in acute and chronic bronchopulmonary diseases associated with abnormal mucous secretion and impaired mucous transport	4mg IM or IV 2 - 3 times daily (maximum 12mg/day)	A (SRQ GENERAL)
113.	Bromhexine HCl 4 mg / 5 ml Oral Solution	R05CB0211 0L1001XX	Secretolytic therapy in acute and chronic bronchopulmonary diseases associated with abnormal mucous secretion and impaired mucous transport	Adult: 8-16 mg three times daily. Children: By body weight: 0.3 mg/kg/day 8 hourly for 7 days, then 0.15 mg/kg/day 8 hourly; or Based on age: 6-12 years – 4mg three times daily; 2-6 years – 2mg three times daily; Less than 2 years – 1mg three times daily.	B
114.	Bromhexine HCl 8 mg Tablet	R05CB0211 0T1001XX	Secretolytic therapy in acute and chronic bronchopulmonary diseases associated with abnormal mucous secretion and impaired mucous transport. Prescribing Restriction(s): Medical Assistant in health settings without Medical Officer is allowed to prescribe this medicine for adult use only.	Adult: 8-16 mg three times daily. Children: By body weight: 0.3 mg/kg/day 8 hourly for 7 days, then 0.15 mg/kg/day 8 hourly; or Based on age: 6-12 years – 4 mg three times daily; 2-6 years – 2 mg three times daily	C
115.	Bromocriptine Mesilate 2.5 mg Tablet	G02CB0119 6T1001XX	i) Hypogonadism, galactorrhoea, infertility in men and women, cyclical benign breast and menstrual disorders ii) Acromegaly iii) Hyperprolactinaemia, prolactinomas iv) Parkinson's disease	i) Initial dose of 1.25-2.5mg once daily at bedtime. Dose may be increased by 2.5mg/day every 3 to 7 days as tolerated to a total of 5 to 7.5mg daily in divided doses ii) 1.25 - 2.5 mg at bedtime for 3 days and may be increased by 1.25 - 2.5 mg every 3 to 7 days up to 30 mg a day in divided doses iii) Initial dose of 1.25mg, two or three times a day. Increase dosage gradually over several weeks to 10 - 20mg a day in divided doses. Higher doses may be required iv) Initial dose of 1.25 mg one or two times a day. Dose may be increased by 2.5mg/day increments in 2 -to 4-week intervals as needed. Maintenance dose ranges from 10 to 30mg daily in divided doses. Dosing is individualised and according to product insert/protocol	A/KK
116.	Budesonide 1 mg / 2 ml Nebuliser Solution	R03BA0200 0A3002XX	Treatment of asthma in patients where use of a pressurized inhaler or dry powder formulation is unsatisfactory or inappropriate.	ADULT : Initially 1 - 2 mg twice daily. CHILD 3 months - 12 years of age : 500 mcg - 1 mg. Maintenance dose : half of the above doses	B

No.	Generic Name	MDC	Indications	Dosage	Category
117.	Budesonide 160 mcg and Formoterol 4.5 mcg Inhalation	R03AKO7-989-A21-01-XXX	Category of prescriber A/KK: i) Regular treatment of asthma where use of a combination (inhaled corticosteroid and long-acting beta2-agonist) is appropriate: - Patients not adequately controlled with inhaled corticosteroids and "as needed" inhaled short-acting beta2-agonists. or - Patients already adequately controlled on both inhaled corticosteroids and long-acting beta2-agonists. ii) As a reliever treatment for mild asthma patients who do not adhere to regular inhaled corticosteroid Category of prescriber A*: iii) Treatment of COPD patients with a blood eosinophil count of 300 cells/microliter and more iv) Treatment of COPD patients with blood eosinophil count of 100 cells/microliter and more with history of repeated exacerbation despite regular treatment with long-acting bronchodilators.	i) Asthma Maintenance therapy: Adult ≥ 18 yr 160 mcg to 320 mcg bd. Some patients may require up to a max of 640 mcg bd. Adolescent 12-17 yr 160 mcg to 320 mcg bd. Childn 6-11 yr 160 mcg bd, <6 yr Not recommended. Maintenance & relief Adult and adolescent ≥ 12 yr 320 mcg/day either as 160 mcg bd or 320 mcg od either morning or evening. For some patients a maintenance dose of 320 mcg bd may be appropriate. Patients should take 160 mcg additional inhalation as needed in response to symptoms. If symptoms persist after a few minutes, an additional inhalation should be taken. Not more than 960 mcg should be taken on any single occasion. A total daily dose of more than 1280 mcg is not normally needed, however a total daily dose of up to 1920 mcg could be used for a limited period. Patients using more than 1280 mcg daily should seek medical advice, should be reassessed & their maintenance therapy reconsidered. ii) Asthma reliever-only therapy: 160 mcg as needed, but no more than 960 mcg to be taken on any single occasion. Children & adolescent <12 yr: Not recommended iii & iv) COPD: Adult ≥ 18 yr 320 mcg bd.	A/KK (SRQ MED)
118.	Budesonide 200 mcg /dose Inhalation	R03BA0200 0A2102XX	Maintenance treatment of asthma as prophylactic therapy especially if not fully controlled by bronchodilators	ADULT: 200-1600 mcg daily in 2-4 divided doses. Maintenance with twice daily dosing. CHILD more than 7 years: 200-800 mcg, 2 - 7 years: 200-400 mcg. To be inhaled in 2-4 divided doses.	B
119.	Budesonide 500 mcg / 2 ml Nebuliser Solution	R03BA0200 0A3001XX	Treatment of asthma in patients where use of a pressurized inhaler or dry powder formulation is unsatisfactory or inappropriate.	ADULT : Initially 1 - 2 mg twice daily. CHILD 3 months - 12 years of age : 500 mcg - 1 mg. Maintenance dose : half of the above doses	B

No.	Generic Name	MDC	Indications	Dosage	Category
120.	Budesonide 64 mcg Nasal Spray	R01AD0500 0A4103XX	Seasonal allergic, perennial rhinitis and nasal polyposis	ADULT and CHILD 6 years and older. Rhinitis: 2 spray into each nostril once daily in the morning or 1 spray into each nostril twice daily. Nasal polyps : 2 spray twice daily	A/KK (SRQ ENT)
121.	Bumetanide 0.5 mg /ml Injection	C03CA0200 0P3001XX	Oedema used in furosemide allergic patient	IV injection: 1 - 2 mg repeated after 20 mins. IV infusion: 2 - 5 mg over 30 - 60 mins	A* (SRQ MED)
122.	Bupivacaine 0.5 % Heavy Injection	N01BB0111 0P3003XX	Used for spinal anaesthesia	ADULT: 2 - 4 ml. Not to exceed 2 mg/kg in a single dose	A (SRQ ANAES)
123.	Bupivacaine 0.5 % Injection (plain)	N01BB0111 0P3002XX	For peripheral sympathetic nerve and epidural (excluding caudal) anaesthesia and obstetrics anaesthesia	Regional nerve block or epidural block: 15 - 30 ml. Nerve block of finger or toe: 2 - 6 ml. Maximum: 2 mg/kg body weight in any 4 hours period, equivalent to 25 - 30 ml in adults of average weight	B
124.	Bupivacaine 0.5 % with Adrenaline 1:200,000 Injection	N01BB5197 5P3001XX	Regional nerve block or epidural block	10 - 40 ml (0.25 %) or maximum : 2 mg/kg body weight in any 4 hours period, equivalent to 25 - 30 ml of 0.5% solution	B
125.	Cabergoline 0.5 mg Tablet	G02CB0300 0T1001XX	i) Inhibition of physiological lactation soon after parturition ii) Suppression of established lactation iii) Treatment of hyperprolactinaemic disorders	i) 1 mg as a single dose during the first post-partum day ii) 0.25 mg every 12 hours for 2 days iii) Initial: 0.5 mg/week given in one or two divided weekly doses. May gradually increase dose by 0.5 mg/week no sooner than every 4 weeks until an optimal therapeutic response is achieved. Usual dose range: 0.25 mg to 2 mg/week (higher doses >1 mg /week may be divided in as many as 3 to 4 divided doses	A* (SRQ MED)
126.	Calamine Cream	D04AX0000 0G1001XX	Soothes and relieves nappy rashes, prickly heat, minor skin irritations, insect bites and sunburn, Pruritic skin conditions.	Apply to the affected area as required, 1-3 times daily	C+
127.	Calamine Lotion	D04AX0000 0L8001XX	Soothes and relieves nappy rashes, prickly heat, minor skin irritations, insect bites and sunburn, Pruritic skin conditions.	Apply to the skin as required and allow to dry, 1-3 times daily	C+

No.	Generic Name	MDC	Indications	Dosage	Category
128.	Calcipotriol 50 mcg/g Ointment	D05AX0200 0G5001XX	Psoriasis vulgaris.	ADULT Apply to the affected skin lesions twice daily. Maintenance therapy may be achieved with less frequent application. The weekly dose should not exceed 100 g. CHILD over 6 years, apply twice daily. 6-12 years maximum 50gm weekly, over 12 years maximum 75gm weekly. The dosing is individualized according to product insert / protocol	A* (SRQ GENERAL)
129.	Calcitriol 0.25 mcg Capsule	A11CC0400 0C1001XX	i) Osteoporosis ii) Chronic kidney disease-mineral bone disorder iii) Hypoparathyroidism and pseudohypoparathyroidism iv) Rickets and osteomalacia	i) 0.25 mcg 2 times daily ii) ADULT and CHILD 3 years and older: Initial dose: 0.25 mcg. In patients with normal or only slightly reduced serum calcium levels, doses of 0.25 mcg every other day is sufficient. Dosage may be increased if necessary to 0.5 mcg/day. Maintenance dose: 0.5-1mcg daily CHILD less than 3 years: 10 to 15 ng/kg/day iii) and iv) 0.25 mcg/day given in the morning	A/KK
130.	Calcium Carbonate 500 mg Tablet	A12AA0412 1T1001XX	i) Hyperphosphatemia (phosphate binder) in chronic kidney disease patients ii) Calcium supplementation	i) Total dose of elemental calcium from calcium-based phosphate binder not to exceed 1,500 mg/day. Dosing is individualised based on serum phosphate level and according to product insert/protocol ii) 500 mg to 4g per day as calcium carbonate in 1-3 divided doses (500mg capsule contains 200mg elemental calcium) Dosing is individualised based on serum calcium level and according to product insert/protocol	B
131.	Calcium Chloride Dihydrate, Sodium Chloride, Magnesium Chloride Hexahydrate, Sodium Acetate Trihydrate, Potassium Chloride, and Malic Acid Solution (Sterofundin)	B05BB0190 5P6002XX	Replacement of extracellular fluid losses in the case of isotonic dehydration, where acidosis is present or imminent.	The maximum infusion rate depends on the needs of the patient in fluid replacement and electrolytes, patient's weight, clinical condition, and biological status. Adults, elderly, adolescents: 500ml-3L/24hr. Babies, children: 20ml to 100ml/kg/24 hr.	A (SRQ ANAES) (SRQ MED)

No.	Generic Name	MDC	Indications	Dosage	Category
132.	Calcium Gluconate 10 % Injection	A12AA0300 0P3001XX	i) Acute hypocalcaemia ii) Hypocalcaemic tetany iii) Cardiac resuscitation	Dos: i) ADULT: 1 to 2 g (2.2 to 4.4 mmol). CHILD: 50mg/kg/dose (0.5ml/kg/dose) IV short infusion over at least 10 to 20 minutes, per dose. Max: 20ml per dose. ii) ADULT: 1g (2.2 mmol) by slow IV injection followed by continuous infusion of 4 g (8.8 mmol) daily iii) IV or intracardiac injection, 1g (2.2mmol) Dosing is individualised and according to product insert/protocol	B
133.	Calcium Lactate 300 mg Tablet	A12AA0512 5T1001XX	For prophylaxis of calcium deficiency and treatment of chronic hypocalcaemia	ADULT: 300mg - 600mg (as elemental Ca) daily in divided doses Dosing is individualised and according to product insert/protocol	C
134.	Calcium Polystyrene Sulphonate Powder	V03AE0199 9F2101XX	Hyperkalemia resulting from acute or chronic renal failure	ADULT: 15 – 30g daily in 2-3 divided doses. Each dose should be suspended in 30 – 50ml of water and administered orally at least 3 hours before or 3 hours after other oral medications. CHILD: 0.125-0.25g/kg orally or rectally 4 times per day (max: 10g/dose). NEONATE: 0.125-0.25g/kg rectally 4 times/day. Evacuate the resin 8-12 hours after the last dose with glycerine enema. (Oral route is CONTRAINDICATED in neonates) Dosing is individualised and according to product insert/protocol	A/KK (SRQ GENERAL)
135.	Captopril 25 mg Tablet	C09AA0100 0T1002XX	i) Hypertension ii) Congestive heart failure iii) Post-myocardial infarction iv) Diabetic kidney disease	i) Initial: 25-75mg in 2-3 divided doses Maintenance: 100-150mg in 2-3 divided doses ii) Initial: 6.25-12.5mg 2-3 times daily Maintenance: 75-150mg daily in divided doses iii) Initial: 6.25mg followed by 12.5mg and then 25mg Maintenance: 75-150mg daily in 2-3 divided doses iv) 75-100 mg in divided doses Dosing is individualised and according to product insert / protocol.	B

No.	Generic Name	MDC	Indications	Dosage	Category
136.	Carbachol 0.01 % Intraocular Solution	S01EB0210 0D2001XX	For intraocular use for miosis during surgery	Instill no more than 0.5 ml gently into the anterior chamber	A (SRQ OPHTH)
137.	Carbamazepine 100 mg/5 ml (2% w/v) Syrup	N03AF0100 0L9001XX	Epilepsy	ADULT: Initially, 100-200 mg once or twice daily gradually increased by increments of 100-200 mg every 2 week. Maintenance: 0.8-1.2 g daily in divided doses. CHILD: 10-15 years: 0.6-1 g daily; 5-10 years: 400-600 mg daily; 1-5 years: 200-400 mg daily; less than or equal to 1 year: 100-200 mg daily. Alternatively, 10-20 mg/kg body weight daily in divided doses. Max: Adult: 1.6 g daily	A (SRQ PAED)
138.	Carbamazepine 200 mg CR Tablet	N03AF01-000-T50-01-XXX	i) Epilepsy ii) Trigeminal Neuralgia iii) Idiopathic glossopharyngeal neuralgia iv) Acute mania and maintenance of bipolar affective disorder to prevent or attenuate recurrence	ADULT: Initial, 200 mg twice daily for the first week, may increase dosage by 200 mg/day at weekly intervals until optimal response is obtained. Maximum 1.6 g/day. CHILD: usual maximum dosage 1000 mg/day in children 12-15 years of age, 1200 mg/day in patients above 15 years of age	A (SRQ MED) (SRQ PAED)
139.	Carbamazepine 200 mg Tablet	N03AF0100 0T1001XX	i) Epilepsy ii) Trigeminal neuralgia (Off-label indication with one-off UKK approval: Aggression and associated impulsivity)	i) ADULT: 100 - 200 mg 1 - 3 times daily increased gradually to usual dose of 0.8 - 1.2 g daily in divided doses. CHILD: Up to 1 year: 100 - 200 mg daily; 1 - 5 yrs: 200 - 400 mg daily; 5 - 10 years: 400 - 600 mg daily; 10 - 15 years: 0.6 - 1 g daily ii) The initial dosage of 200 to 400mg should be slowly raised daily until freedom from pain is achieved (normally at 200mg 3 to 4 times daily). The dosage should then be gradually reduced to the lowest possible maintenance level. In elderly patients, an initial dose of 100mg twice daily is recommended.	B
140.	Carbimazole 5 mg Tablet	H03BB0100 0T1001XX	Hyperthyroidism	ADULT: Initially, 10-60mg daily in divided doses given 8 hourly. Maintenance: 5 to 20mg daily. CHILDREN > 6 years: Initially 15mg daily in divided doses. CHILDREN 1-6 years: Initially 7.5mg daily in divided doses	B
141.	Carboprost Tromethamine 250 mcg Injection	G02AD0499 9P3001XX	Treatment of refractory postpartum haemorrhage unresponsive to conventional methods of management.	Initially 250 mcg deep IM inj. The dose may be repeated at intervals of 15-90 min if necessary. Max total dose: 2000 mcg (8 doses).	A* (SRQ O&G)

No.	Generic Name	MDC	Indications	Dosage	Category
142.	Carvedilol 25 mg Tablet	C07AG0200 OT1002XX	i) Treatment of all patients with stable and symptomatic, mild, moderate and severe chronic heart failure in combination with ACEis and diuretics ii) Hypertension iii) Angina pectoris	i) Initial: 3.125mg twice daily for 2 weeks Maintenance: Titrate up to as tolerated Max: <85 kg: 25 mg twice daily >85 kg: 50 mg twice daily ii) Initial: 12.5mg once daily Maintenance: 25mg once daily Max. 50mg daily in 1 or 2 divided doses iii) Initial: 12.5mg once daily Maintenance: 25mg once daily Max. 100mg daily in 1 or 2 divided doses Dosing is individualised and according to product insert / protocol.	A/KK (SRQ MED)
143.	Carvedilol 6.25 mg Tablet	C07AG0200 OT1001XX	i) Treatment of all patients with stable and symptomatic, mild, moderate and severe chronic heart failure in combination with ACEis and diuretics ii) Hypertension iii) Angina pectoris	i) Initial: 3.125mg twice daily for 2 weeks Maintenance: Titrate up to as tolerated Max: <85 kg: 25 mg twice daily >85 kg: 50 mg twice daily ii) Initial: 12.5mg once daily Maintenance: 25mg once daily Max. 50mg daily in 1 or 2 divided doses iii) Initial: 12.5mg once daily Maintenance: 25mg once daily Max. 100mg daily in 1 or 2 divided doses Dosing is individualised and according to product insert / protocol.	A/KK (SRQ MED) (SRQ PAED)
144.	Cefazolin Sodium 1 g Injection	J01DB04520 P3001XX	Infection caused by cefazolin-sensitive microorganism, infection of the respiratory tract, urogenital tract, skin and soft tissue, bile duct, bones and joint, endocarditis, systemic septic infection, peri-operative/ surgical prophylaxis	ADULT: Uncomplicated infections: 500 - 1000 mg 2 - 3 times daily. Moderately severe and severe infections: 500 - 1000 mg 3 - 4 times daily. Severe life-threatening infections: 1 - 1.5 g 4 times daily. Rarely, dose up to 12 g daily. CHILDREN >1 month: 25-50 mg/kg/day in 3-4 divided dose	A (SRQ ORTHO) (SRQ SURG) (SRQ MED) (SRQ PAED) (SRQ O&G)

No.	Generic Name	MDC	Indications	Dosage	Category
145.	Cefepime 1 g Injection	J01DE01110 P4002XX	Febrile neutropenia, septicaemia, lower respiratory tract infection, urinary tract infection, skin and skin structure infections, gynaecologic and intra-abdominal infections	ADULT: 1 - 2 g twice daily for most infections. For severe infections including febrile neutropenia: 2 g 3 times daily. CHILD: 2 mth - 16 yr: ≤40 kg: 50 mg/kg every 8-12 hr for 7-10 days	A* (SRQ GENERAL)
146.	Cefoperazone Sodium 1g Injection	J01DD1252 OP4002XX	Infections due to gram-negative bacteria	ADULT: 1 - 2 g twice daily IM or IV. By IV, adult dose may be doubled. Maximum: 16 g daily in divided doses. CHILD & INFANT: 50 - 200 mg/kg/day in 2 - 4 divided doses. NEONATE less than 8 days: 50 - 200 mg/kg/day 12 hourly	A (SRQ GENERAL)
147.	Cefoperazone Sodium 500 mg & Sulbactam Sodium 500 mg Injection	J01DD6200 OP4001XX	i) Treatment of infections due to multi-drug resistance pathogens producing B-lactamase ii) Treatment of infections caused by Acinetobacter species	ADULT: 1 - 2 g twice daily. In severe or refractory infections the daily dosage of sulbactam/cefoperazone may be increased up to 8g (4g cefoperazone activity) CHILD: 40 - 80 mg/kg/day in 2 to 4 equally divided doses; in serious or refractory infections, may increase to 160mg/kg/d in 2 - 4 equally divided doses.	A (SRQ GENERAL)
148.	Cefotaxime 1 g Injection	J01DD0152 OP4002XX	Infections due to gram-negative bacteria	ADULT: 1 g 12 hourly (up to 12 g/day in severe cases). CHILD: 50 - 180 mg/kg/day in 4 - 6 divided doses	A
149.	Cefotaxime 500 mg Injection	J01DD0152 OP4001XX	Infections due to gram-negative bacteria	ADULT: 1 g 12 hourly (up to 12 g/day in severe cases). CHILD: 50 - 180 mg/kg/day in 4 - 6 divided doses	A
150.	Ceftazidime 2g Injection	J01DD0252 OP4004XX	Severe gram negative bacterial infections	ADULT: 1 g 8 hourly or 2 g 12 hourly. In severe infections: 2 g 8 hourly. CHILD: 25 - 150 mg/kg/day in 2 - 3 divided doses	A (SRQ GENERAL)

No.	Generic Name	MDC	Indications	Dosage	Category
151.	Ceftazidime 2g / Avibactam 0.5g Injection	J01DD52-961-P41-01-001	Approved Indication(s): i. Complicated intra-abdominal infection, in combination with metronidazole ii. Complicated urinary tract infection, including pyelonephritis ii. Hospital-acquired pneumonia, including ventilator-associated pneumonia Prescribing restriction(s): i. To be restricted to carbapenem-resistant Enterobacteriaceae (CRE) as an alternative to polymyxin. ii. Treatment initiated after proven susceptibility to ceftazidime/avibactam via C&S testing. iii. To be prescribed by Infectious Disease Specialist only	Ceftazidime 2g / Avibactam 0.5g vial three times daily by intravenous infusion over 2 hours in patients 18 years or older for 5 to 14 days	A* (SRQ ANAES)
152.	Ceftriaxone 0.25 g Injection	J01DD0452 0P4001XX	i) Gonorrhoea ii) Chancroid	i) 250 mg by deep IM injection ii) single IM injection 250 mg only. For severe infection up to 100 mg/kg/day	A/KK (SRQ GENERAL)
153.	Ceftriaxone 0.5 g Injection	J01DD0452 0P4002XX	Infections caused by susceptible organisms	ADULT: 1 - 2 g once daily. Severe infection: 4 g daily at 12 hour intervals. NEONATE up to 2 weeks: 20 - 50 mg/kg body weight daily, not to exceed 50 mg/kg INFANT & CHILD, 3 weeks - 12 years: 20 - 80 mg/kg body weight daily. CHILD with body weight 50 kg or more: adult dose.	A/KK (SRQ GENERAL)
154.	Ceftriaxone 1 g Injection	J01DD0452 0P4003XX	Infections caused by susceptible organisms	ADULT: 1 - 2 g once daily. Severe infection: 4 g daily at 12 hour intervals. NEONATE up to 2 weeks: 20 - 50 mg/kg body weight daily, not to exceed 50 mg/kg INFANT & CHILD, 3 weeks - 12 years: 20 - 80 mg/kg body weight daily. CHILD with body weight 50 kg or more: adult dose.	A (SRQ GENERAL)
155.	Cefuroxime Axetil 125 mg Tablet	J01DC02233 T1001XX	Upper and lower respiratory tract, genito-urinary tract, skin & soft tissue and urinary tract infections (UTI)	ADULT: 250 mg twice daily; UTI: 125 mg twice daily. CHILD: 30 mg/kg/day in 2 divided doses, up to 500 mg daily	A/KK (SRQ GENERAL)
156.	Cefuroxime Axetil 125 mg / 5 ml Suspension	J01DC02233 F2101XX	Infections caused by susceptible organisms	30 mg/kg/day in 2 divided doses, up to 500 mg daily.	A (SRQ GENERAL)

No.	Generic Name	MDC	Indications	Dosage	Category
157.	Cefuroxime Sodium 1.5 g Injection	J01DC02520 P4003XX	Infections caused by susceptible organisms, surgical prophylaxis	ADULT: 750 mg every 6 - 8 hours as IM or IV. Severe infections: 1.5 g every 6 - 8 hours as IV. CHILD: 30 - 100 mg/kg/day in 3 - 4 divided doses or 2-3 divided doses in neonates. Surgical prophylaxis: 1.5 g IV	A
158.	Cefuroxime Sodium 750 mg Injection	J01DC02520 P4002XX	Infections caused by susceptible organisms, surgical prophylaxis	ADULT: 750 mg every 6 - 8 hours as IM or IV. Severe infections: 1.5 g every 6 - 8 hours as IV. CHILD: 30 - 100 mg/kg/day in 3 - 4 divided doses or 2-3 divided doses in neonates. Surgical prophylaxis: 1.5 g IV	A
159.	Celecoxib 200 mg Capsule	M01AH0100 OC1001XX	i) Osteoarthritis ii) Rheumatoid Arthritis iii) Acute pain iv) Ankylosing Spondylitis	i) ADULTS: 200 mg once daily. May increase to 200 mg bid, if necessary. CHILD not recommended ii) 100 mg twice daily, increased if necessary to 200 mg 2 times daily; CHILD not recommended iii) 400 mg as a single dose on first day followed by 200mg once daily on subsequent days iv) Initial, 200 mg once daily or 100 mg twice daily; if no effect after 6 weeks, may increase to max. 400 mg daily in 1-2 divided doses. If no response following 2 weeks of treatment with 400 mg/day, consider discontinuation and alternative treatment	A/KK (SRQ GENERAL)
160.	Cephalexin Monohydrate 125 mg/5 ml Syrup	J01DB01010 F2101XX	Respiratory tract infections, ear, nose and throat infections, urinary tract infections, obstetric and gynaecologic infections	CHILD: 25 - 100 mg/kg/day every 6 hourly. Maximum: 4 g daily	B
161.	Cephalexin Monohydrate 250 mg Capsule	J01DB01010 C1001XX	i) Respiratory tract infection, urinary tract infection ii) Complicated, recurrent or chronic infections, bronchitis iii) Pneumonia	i) 250 mg 6 hourly ii) 250 - 500 mg 6 hourly iii) 1 - 1.5 g 3 times daily or 4 times daily. Maximum: 6 g/day Child: 25-100 mg/kg daily in divided doses. Max: 4 g daily.	B
162.	Cetirizine HCl 10 mg Tablet	R06AE0711 OT1001XX	Urticaria, allergic dermatoses (insect bites, atopic eczema), perennial rhinitis, allergic rhinitis	ADULT and CHILD over 6 years: 10 mg daily or 5 mg twice daily. Child 2-6 years: 5 mg once daily or 2.5 mg twice daily	B
163.	Cetrimide 1-2 % Lotion	D08AJ04000 L6001XX	As shampoo and cleansing Agent	Apply to affected area	C+

No.	Generic Name	MDC	Indications	Dosage	Category
164.	Charcoal, Activated 250 mg Tablet	A07BA0100 OT1001XX	i) Diarrhoea and food poisoning ii) Reduce absorption of drugs, plant, inorganic poison and chemicals in poisoning cases	i) ADULT: 500mg - 1000mg given 3-4 times daily. CHILD (up to 12 years): 250-500mg 3-4 times daily. ii) ADULT and CHILD over 12 years: initial 25-100 g or 1-2g/kg; repeat initial dose as soon as possible or 25-50 g every 4-6 hours. CHILD (up to 12 years): 0.5 to 1 g/kg/dose (Maximum: 50 g/dose). Dose may be repeated every 2-6 hours as needed.	C
165.	Charcoal, Activated 50 g Granules	A07BA0100 OF1001XX	Emergency treatment of acute oral poisoning and drug overdose	ADULT and CHILD 12 years and above: Acute poisoning: 50 to 100g in suspension. Severe poisoning: 50 to 100g as an initial dose followed by 20g every 4 to 6 hours. CHILD up to 12 years: 1 g/kg/dose (Maximum: 50 g/dose). Dose may be repeated every 4 to 6 hours as needed. Dosing is individualised and according to product insert/protocol.	A
166.	Chlorambucil 2 mg Tablet	L01AA02000 T1001XX	Low grade lymphoma, chronic lymphocytic leukaemia. Ovarian cancer	General: Initial: 0.1 - 0.2 mg/kg body weight daily for 4 - 8 weeks maintenance: given either by reduced daily dosage or intermittent course of treatment. Chronic Lymphocytic Leukaemia: initial: 0.15 mg/kg/day until total leukocyte count has fallen to 10,000 per uL, then resumed treatment until 4 weeks after the end of the first course then continued at a dosage 0.1 mg/kg/day.	A (SRQ MED)
167.	Chloramphenicol 0.5 % Eye Drops	S01AA0100 OD2001XX	Ophthalmic infections	Instill 1 drop of a 0.5% solution every 2 hr. Increase dosage interval upon improvement.	C
168.	Chloramphenicol 1 % Eye Ointment	S01AA0100 OG5101XX	Treatment of ocular infections involving the conjunctiva and/or cornea caused by chloramphenicol susceptible organisms	ADULT and CHILD : Apply to the conjunctiva, a thin strip (approximately 1 cm) of ointment every 3 hours or more frequently	C
169.	Chloramphenicol 5 % w/v Ear Drops	S02AA0100 OD1001XX	Acute otitis media, otitis externa with perforation	Apply 2-3 drops into the ear 2-3 times daily. Not to be used for long term	C
170.	Chlorhexidine Gluconate 0.2 % Mouthwash	R02AA0512 7M2001XX	As a gargle	Rinse mouth with 10 ml for about 1 minute twice daily	C

No.	Generic Name	MDC	Indications	Dosage	Category
171.	Chlorhexidine 1:200 (0.5%) in Alcohol (Hand Disinfectant).	D08AC5213 7L9901XX	Use as hand disinfectant for pre-surgical operation and skin disinfectant.	Pre-op surgical hand disinfection: Spread 5ml thoroughly over both hands and forearms, rubbing vigorously. When dry apply a further 5ml and repeat procedure. Antiseptic hand disinfection on the ward: Spread 3ml thoroughly over the hands and wrist rubbing vigorously until dry. Disinfection of patient's skin: Prior to surgery, apply to a sterile swab and rub thoroughly over the operation site for a minimum of 2 mins	C+
172.	Chlorhexidine Gluconate 1% cream	D08AC0213 7G1001XX	For disinfection or lubricating during gynaecological and obstetric procedures or childbirth.	Apply as required on affected area after cleaning	C+
173.	Chlorhexidine Gluconate 2% in Alcohol 70% Solution	D08AC5213 7L9902XX	Use as disinfectant in central venous catheter care bundle	Skin Preparation: Use Chlorhexidine Gluconate 2% in Isopropyl Alcohol 70% and allow to dry. Catheter access: Apply to catheter ports or hubs prior to accessing the line for administering fluids or injections	C
174.	Chlorhexidine Gluconate 4% Scrub	D08AC0213 7M9901XX	Surgical hand scrub/disinfection, pre-op skin preparation	Surgical hand disinfection: Apply 5ml to clean hands and forearms for 1 min. Rinse and repeat with another 5ml for a further 2 mins and then rinse and dry. General skin disinfection: Apply appropriate quantity to wet area and scrub for 1 min. Rinse thoroughly & dry	C+
175.	Chlorhexidine Gluconate 5% Solution	D08AC0213 7L9901XX	Use as antiseptic and disinfectant in: i) Preoperative skin disinfection ii) Emergency disinfection of instruments iii) Wounds or burns	To be used as diluted solution: (i) 0.5 % w/v Aqueous solution : Dilute 10 ml of solution with 70% alcohol up to 100ml. (ii) 0.5 % w/v Aqueous solution : Dilute 10 ml of solution with 70% alcohol up to 100ml. Immerse for 2 minutes (iii) 0.05 % w/v aqueous solution : Dilute 1 ml of solution with 100 ml of sterile water.	C+
176.	Chloroquine Phosphate 250 mg Tablet (150 mg Chloroquine base)	P01BA0116 2T1001XX	Treatment of malaria - acute attack	ADULT 600 mg base stat, 300 mg 6 - 8 hours later and a further 300 mg on each of 2 following days. CHILD 3 - 4 years : 150 mg base stat, 75 mg 6 hours later, then 75 mg daily for 2 days. CHILD 5 - 8 years : 300 mg stat, 150 mg 6 hours later, then 150 mg daily for 2 days	C (UKK CFLN)

No.	Generic Name	MDC	Indications	Dosage	Category
177.	Chlorpheniramine Maleate 10 mg / ml Injection	R06AB0425 3P3001XX	Allergic conditions	10-20mg IM or SC, repeated if required. Not to exceed 40mg in 24 hours. 10-20mg over 1 minute by slow IV	B
178.	Chlorpheniramine Maleate 2 mg / 5ml Syrup	R06AB0425 3L9001XX	Symptomatic treatment of allergic conditions responsive to antihistamine	CHILD 2 - 5 years : 1 mg every 4 - 6 hours (maximum 6 mg daily) 6 - 12 years : 2 mg every 4 - 6 hours (maximum 12 mg daily)	C
179.	Chlorpheniramine Maleate 4 mg Tablet	R06AB0425 3T1001XX	Symptomatic treatment of allergic conditions responsive to antihistamine	ADULT : 4 mg every 4 - 6 hours. Maximum 24 mg daily. CHILD 2 - 5 years : 1 mg every 4 - 6 hours (maximum 6 mg daily) 6 - 12 years : 2 mg every 4 - 6 hours (maximum 12 mg daily)	C
180.	Chlorpromazine HCl 100 mg Tablet	N05AA0111 0T1002XX	i) Psychotic conditions ii) Anti-emetic	ADULT: Initial: 25-50mg two-three times daily Maintenance: 25-100mg two- three times daily CHILD: Not recommended Dosing is according to product insert / protocol.	B
181.	Choline Salicylate 8.7 %, Cetylkonium Chloride 0.01 % Dental Gel	N02BA0390 0G3001XX	For relief of the pain and discomfort in mouth ulcers and sores, infant teething and denture irritation	Apply to area 4 times daily	B
182.	Ciclosporin 100 mg Capsule	L04AD0100 0C1002XX	i) Patients in whom donor specific transplantation cannot be carried out and in young children to minimise side-effects of steroids ii) Follow-up cases of bone marrow transplant iii) Patients with severe rheumatoid arthritis not responding to other second line drugs iv) Patients with idiopathic nephrotic syndrome who are steroid toxic or poor response to cyclophosphamide v) Severe aplastic anemia, pure red cell aplasia vi) Cases of recalcitrant psoriasis and atopic eczema vii) Treatment of chronic ocular inflammatory disorders/uveitis	i & ii) Initially 12.5 - 15 mg/kg/day, beginning on the day before transplant. Maintenance approx 12.5 mg/kg/day for 3 - 6 months before being tapered off to zero by 1 year of transplantation iii) 3 mg/kg/day in 2 divided doses for first 6 weeks. May increased gradually to maximum 5 mg/kg. Treatment withdrawn if no response after 3 months iv) ADULT: 5 mg/kg/day in 2 divided doses. CHILD: 6 mg/kg/day in 2 divided doses. Patients with permitted levels of kidney failure, the starting dose must not more than 2.5 mg/kg/day v) 12 mg/kg/day vi) 2.5 mg/kg/day in 2 divided doses increasing if there is no improvement after 4 weeks by 0.5 -1 mg/kg/month up to maximum 5 mg/kg/day vii) 5 mg/kg/day in 2 divided doses, may increase to 7 mg/kg/day in resistant cases. Maintenance: Less than 5 mg/kg/day especially during remission	A*

No.	Generic Name	MDC	Indications	Dosage	Category
183.	Ciclosporin 100 mg/ml Drink Solution	L04AD0100 OL5002XX	i) Patients in whom donor specific transplantation cannot be carried out and in young children to minimise side-effects of steroids ii) Follow-up cases of bone marrow transplant iii) Patients with severe Rheumatoid arthritis not responding to other second line drugs iv) Patients with idiopathic nephrotic syndrome who are steroid toxic or poor response to cyclophosphamide v) Severe aplastic anaemia, pure red cell aplasia vi) Cases of recalcitrant psoriasis and atopic eczema	i & ii) Initially 12.5 - 15 mg/kg/day, beginning on the day before transplant. Maintenance approx 12.5 mg/kg/day for 3 - 6 months before being tapered off to zero by 1 year of transplantation iii) 3 mg/kg/day in 2 divided doses for first 6 weeks. May increased gradually to maximum 5 mg/kg. Treatment withdrawn if no response after 3 months iv) ADULT: 5 mg/kg/day in 2 divided doses. CHILD: 6 mg/kg/day in 2 divided doses. Patients with permitted levels of kidney failure, the starting dose must not more than 2.5 mg/kg/day v) 12 mg/kg/day vi) 2.5 mg/kg/day in 2 divided doses increasing if there is no improvement after 4 weeks by 0.5 -1 mg/kg/month up to maximum 5 mg/kg/day	A* (SRQ PAED)
184.	Ciclosporin 25mg Capsule	L04AD0100 OC1001XX	i) Patients in whom donor specific transplantation cannot be carried out and in young children to minimise side-effects of steroids ii) Follow-up cases of bone marrow transplant iii) Patients with severe rheumatoid arthritis not responding to other second line drugs iv) Patients with idiopathic nephrotic syndrome who are steroid toxic or poor response to cyclophosphamide v) Severe aplastic anemia, pure red cell aplasia vi) Cases of recalcitrant psoriasis and atopic eczema vii) Treatment of chronic ocular inflammatory disorders/uveitis	i & ii) Initially 12.5 - 15 mg/kg/day, beginning on the day before transplant. Maintenance approx 12.5 mg/kg/day for 3 - 6 months before being tapered off to zero by 1 year of transplantation iii) 3 mg/kg/day in 2 divided doses for first 6 weeks. May increased gradually to maximum 5 mg/kg. Treatment withdrawn if no response after 3 months iv) ADULT: 5 mg/kg/day in 2 divided doses. CHILD: 6 mg/kg/day in 2 divided doses. Patients with permitted levels of kidney failure, the starting dose must not more than 2.5 mg/kg/day v) 12 mg/kg/day vi) 2.5 mg/kg/day in 2 divided doses increasing if there is no improvement after 4 weeks by 0.5 -1 mg/kg/month up to maximum 5 mg/kg/day vii) 5 mg/kg/day in 2 divided doses, may increase to 7 mg/kg/day in resistant cases. Maintenance: Less than 5 mg/kg/day especially during remission	A*

No.	Generic Name	MDC	Indications	Dosage	Category
185.	Ciclosporine Ophthalmic Emulsion 0.05 %	S01XA1800 0D2001XX	To increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. Increased tear production was not seen in patients currently taking anti inflammatory drugs or using punctal plugs.	1 drop twice a day in each eye approximately 12 hours apart.	A* (SRQ OPHTH)
186.	Cinnarizine 25 mg Tablet	N07CA0200 0T1001XX	i) Vestibular disorders ii) Motion sickness	i) ADULT and CHILD > 12years: 25mg three times a day ii) 25mg 2 hours before travel and 12.5mg every 8 hours during journey CHILD 5-12 years: Half the adult dose Dosing is according to product insert.	B
187.	Ciprofloxacin 200 mg/100 ml Injection	J01MA0212 5P3002XX	Treatment of infections due to susceptible bacterial strains	Suggest to rephrase ADULT: the dosage range is 100-400 mg twice daily Gonorrhoea: 100mg single dose Upper and Lower Urinary Tract Infection: 100 mg bd Upper and Lower Respiratory Tract Infection: 200 mg bd-400 mg twice daily Cystic Fibrosis with psuedomonal Lower RTI: 400 mg bd Others: 200-400 mg bd inhalation Anthrax: 400 mg bd	A (SRQ GENERAL)
188.	Ciprofloxacin 250 mg Tablet	J01MA0211 0T1001XX	Treatment of infections due to susceptible bacterial strains	ADULT: 125-750 mg twice daily. Acute gonorrhoea: a single dose of 250 mg	A (SRQ GENERAL)
189.	Ciprofloxacin HCl 0.3 % Ophthalmic Solution	S01AX1311 0D2001XX	Treatment of bacterial infections caused by susceptible strains in i) corneal ulcers ii) bacterial conjunctivitis	i) 2 drops every 15 minutes for the first 6 hours, then 2 drops every 30 minutes for the rest of the first day. Second day: 2 drops every hour. Subsequent days (3rd - 14th day): 2 drops every 4 hours. Treatment may be continued after 14 days if corneal re-epithelialization has not occurred ii) 1 - 2 drops every 2 hours into the conjunctival sac while awake for 2 days and 1-2 drops every 4 hours while awake for the next 5 days	A* (SRQ OPHTH)
190.	Clarithromycin 250 mg Tablet	J01FA09000 T1001XX	Only for i) treatment of complicated respiratory tract infection not responding to standard macrolides ii) eradication of Helicobacter pylori infection	i) 250 - 500 mg twice daily. Up to 6 - 14 days ii) 500 mg twice daily with omeprazole & amoxicillin. Up to 2 weeks	A* (SRQ GENERAL)

No.	Generic Name	MDC	Indications	Dosage	Category
191.	Clindamycin HCl 300 mg Capsule	J01FF01110 C1001XX	i) Skin and soft tissue infections, bone & joint infections ii) Cerebral toxoplasmosis iii) Children less than 8 years old: Treatment and prophylaxis of malaria in combination with quinine, as an alternative to doxycycline	i) ADULT: 150 - 300 mg every 6 hours; up to 450 mg every 6 hours in severe infections; Max: 1.8g/day CHILD: 3 - 6 mg/kg every 6 hours. Children weighing <10 kg should receive at least 37.5 mg every 8 hr. ii) 600 mg 6 hourly for 6 weeks iii) 10mg/kg twice a day, in combination with quinine. The combination to be given for 7 days	A* (SRQ GENERAL)
192.	Clindamycin Phosphate 150 mg/ml Injection	J01FF01162 P3001XX	i) Skin and soft tissue infections, bone & joint infections ii) Cerebral toxoplasmosis	i) ADULT: 0.6 - 2.7 g daily (in 2 - 4 divided doses); up to 4.8 g daily; CHILD over 1 month, 20 - 40 mg/kg/day or 350 mg/m ² /day in 3 - 4 divided doses ii) 1200 mg every 6 hours for 3 weeks followed by 300 mg orally every 6 hours for another 3 weeks	A* (SRQ GENERAL)
193.	Clobazam 10 mg tablet	N05BA0900 OT1001XX	As adjunctive therapy in patients with epilepsy not adequately stabilised with their basic medication.	The initial dose in adults and adolescents >15 yr should be low (5 to 15 mg daily), if necessary, increased gradually to a maximum daily dose of about 80mg. Doses of up to 30mg may be taken as a single dose in the evening. The initial dose in children from 3 to 15 yr is normally 5 mg. A maintenance dose of 0.3 to 1.0mg/kg body weight daily is usually sufficient.	A* (SRQ PEAD)
194.	Clobetasol Propionate 0.05 % Cream	D07AD0113 3G1001XX	Short term treatment only of more resistant dermatoses eg. psoriasis, recalcitrant eczemas, lichen planus, discoid lupus erythematosus and other conditions which do not respond satisfactorily to less potent steroids	Apply sparingly once or twice daily, changing to lower potency therapy as soon as condition is controlled. For mild to moderate use maximum for 2 weeks. For moderate to severe maximum duration 4 consecutive weeks. Max: 50 g/week	A (SRQ GENERAL)
195.	Clobetasone Butyrate 0.05 % Cream	D07AB0125 5G1001XX	For the relief of the inflammatory and pruritic manifestations of steroid responsive dermatoses.	Apply to 1-2 times a day	A/KK (SRQ GENERAL)
196.	Clomiphene Citrate 50 mg Tablet	G03GB0213 6T1001XX	Treatment of ovulatory failure in women desiring pregnancy	Initial: 50 mg once daily for 5 days. Increase to 100mg OD for 5 days if there is no response (commence as early as 30 days after the previous course).	A (SRQ O&G)

No.	Generic Name	MDC	Indications	Dosage	Category
197.	Clomipramine HCl 25 mg Tablet	N06AA0411 OT1001XX	Depression, obsessive-compulsive disorder.	Initially 10 mg daily, increased gradually as necessary to 30 - 150 mg daily in divided doses or as a single dose at bedtime; max 250 mg daily. ELDERLY initially 10 mg daily increased carefully over approximately 10 days to 30 - 75 mg daily; Child: ≥10 yr: Initially, 25 mg daily, increased gradually over 2 wk. Max: 3 mg/kg/day or 100 mg daily, whichever is smaller. Give in divided doses. Once titrated, dose may be given as a single dose at bedtime.	A (SRQ PSY)
198.	Clonazepam 0.5 mg Tablet	N03AE0100 OT1001XX	i) Epilepsy ii) Non-epileptic myoclonus	i) & ii) ADULT: Initial dose should not exceed 1.5mg/day divided into 3 doses, may be increased in increments of 0.5mg every 3 days until seizures are controlled. Maintenance dose: 3-6mg/day. Maximum: 20mg/day. CHILD up to 10 years: initial dose 0.01-0.03 mg/kg/day in 2-3 divided doses, increased by no more than 0.25-0.5mg every third day, maximum 0.2mg/kg/day. CHILD 10-16 years: initial dose 1-1.5mg/day in 2-3 divided doses, may be increased by 0.25-0.5mg every third day until individual maintenance dose of 3-6mg/day is reached.	B (SRQ REHAB)
199.	Clonazepam 2 mg Tablet	N03AE0100 OT1002XX	i) Epilepsy ii) Non-epileptic myoclonus	i) & ii) ADULT: Initial dose should not exceed 1.5mg/day divided into 3 doses, may be increased in increments of 0.5mg every 3 days until seizures are controlled. Maintenance dose: 3-6mg/day. Maximum: 20mg/day. CHILD up to 10 years: initial dose 0.01-0.03 mg/kg/day in 2-3 divided doses, increased by no more than 0.25-0.5mg every third day, maximum 0.2 mg/kg/day. CHILD 10-16 years: initial dose 1-1.5mg/day in 2-3 divided doses, may be increased by 0.25-0.5mg every third day until individual maintenance dose of 3-6mg/day is reached.	B

No.	Generic Name	MDC	Indications	Dosage	Category
200.	Clopidogrel 75 mg Tablet	B01AC0419 2T1001XX	Secondary prevention of atherothrombotic events in: i) Adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. Prescribing restriction: as second/third line treatment in patients who are sensitive or intolerant to acetylsalicylic acid and/or ticlopidine). ii) Adult patients suffering from acute coronary syndrome: • Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention. • ST segment elevation acute myocardial infarction, in combination with acetylsalicylate acid (ASA) in medically treated patients eligible for thrombolytic therapy.	75 mg once daily	A/KK (SRQ MED)
201.	Clostridium Botulinum Toxin Type A 100 units Injection	M03AX01-000-P40-01-XXX	i) Focal dystonias ii) Hemifacial spasm iii) Spasticity including cerebral palsy iv) Neurogenic bladder	20 - 200 units 3 months once	A* (SRQ REHAB)
202.	Clostridium Botulinum Type A toxin haemagglutinin complex 500 units/vial powder for injection	M03AX0100 0P4002XX	i) Focal dystonias ii) Hemifacial spasm iii) Spasticity including cerebral palsy	Initially 20 U/kg divided between both calf muscles. May be titrated 10-30 U/kg up to max of not >1000 U/patient. Should only be used in children > 2 years of age. Repeat injections given not less than 3 months from previous injection.	A* (SRQ REHAB)
203.	Clotrimazole 1 % Cream	D01AC0100 0G1001XX	For treatment of fungal infection (eg: cutaneous candidiasis, tinea corporis, tinea cruris, tinea pedis and tinea versicolor).	Apply on affected area twice daily, optimally for 4 weeks including 2 weeks after lesions have cleared.	B
204.	Clotrimazole 1 % Ear Drop	S02AA0000 0D1002XX	Otomycosis; concomitant therapy with antibiotics and corticosteroid ear drops	4 to 5 drops 3 to 4 times daily	B (SRQ ENT)
205.	Clotrimazole 500 mg Vaginal Tablet	G01AF0200 0S1003XX	Vaginal candidiasis	500 mg as a single one-time dose	B
206.	Cloxacillin Sodium 125 mg / 5 ml Suspension	J01CF02520 L8001XX	Treatment of susceptible bacterial infections, notably penicillinase-producing staphylococci	Child: 50-100 mg/kg in divided doses every 6 hr	B
207.	Cloxacillin Sodium 500 mg Capsule	J01CF02520 C1002XX	Treatment of susceptible bacterial infections, notably penicillinase	ADULT: 250 - 500 mg every 6 hours. Child: 50-100 mg/kg in divided doses every 6 hr.	B

No.	Generic Name	MDC	Indications	Dosage	Category
208.	Cloxacillin Sodium 250 mg Injection	J01CF02520 P4001XX	Treatment of susceptible bacterial infections, notably penicillinase	ADULT: 250 to 500 mg every 6 hours depending on type and severity of infection. CHILD less than 20 kg: 25 to 50 mg/kg/day in equally divided doses every 6 hours	B
209.	Cloxacillin Sodium 500 mg Injection	J01CF02520 P4002XX	Treatment of susceptible bacterial infections, notably penicillinase	ADULT: 250 to 500 mg every 6 hours depending on type and severity of infection. CHILD less than 20 kg: 25 to 50 mg/kg/day in equally divided doses every 6 hours	B
210.	Clozapine 100 mg Tablet	N05AH0200 OT1002XX	Treatment of resistant schizophrenia	Initial dose : 12.5 mg (once or twice) daily, increase slowly in steps of 25	A (SRQ PSY)
211.	Clozapine 25 mg Tablet	N05AH0200 OT1001XX	Treatment of resistant schizophrenia	Initial dose : 12.5 mg (once or twice) daily, increase slowly in steps of 25	A (SRQ PSY)
212.	Coal Tar 1-9 % Ointment	D05AA0000 05001XX	Dandruff, seborrheic dermatitis, atopic dermatitis, eczema and psoriasis. Used as a mild astringent for the skin, as a soothing and protective application in eczema and as a protective to slight excoriation	Apply sparingly to the affected area 1-3 times daily starting with low strength preparations	B
213.	Coal Tar 20 % Solution	D05AA0000 0L5201XX	Dandruff, seborrheic dermatitis, atopic dermatitis, eczema and psoriasis	To dilute 1 cap (15 ml) into 10L of water and soak for 20 minutes.	B
214.	Colchicine 0.5 mg Tablet	M04AC0100 OT1001XX	i) Acute gout and prophylaxis of recurrent gout. ii) Leucocytoclastic Vasculitis either cutaneous or systemic involvement, Behcet's syndrome, Urticarial vasculitis, Systemic sclerosis, Sweet's syndrome and severe recalcitrant aphthous stomatitis	i) Acute gout: Initial dose, 1 mg, then 0.5 mg after 1 hour. No further tablets should be taken for 12 hours. After 12 hours, treatment can resume if necessary with a maximum dose of 500 micrograms (1 tablet) every 8 hours until symptoms are relieved. The course of treatment should end when symptoms are relieved or when a total of 6 mg (12 tablets) has been taken. No more than 6 mg (12 tablets) should be taken as a course of treatment. After completion of a course, another course should not be started for at least 3 days (72 hours). Prophylaxis of recurrent gout: 0.5 mg bd ii) 0.5 mg 1-3 times daily depends on disease and severity, up to a maximum of 3 mg/day	B

No.	Generic Name	MDC	Indications	Dosage	Category
215.	Colistimethate Sodium 1 million IU per vial (Polymyxin E)	J01XB01520 P4001xxx	Intravenous administration for the treatment of serious infections caused by Gram negative bacteria, when more commonly used systemic antibacterial agents may be contraindicated or may be ineffective because of bacterial resistance.	A minimum of 5 days treatment is generally recommended. For the treatment of respiratory exacerbations in cystic fibrosis patients, treatment should be continued up to 12 days. Children and adults (including elderly): Up to 60kg: 50,000 units/kg/day to a maximum of 75,000 units/kg/day. The total daily dose should be divided into three doses given at approximately 8-hour intervals. Over 60kg: 1-2 million units three times a day. The maximum dose is 6 million units in 24 hours. Renal impairment: In moderate to severe renal impairment, excretion of colistimethate sodium is delayed. Dosage in Renal Impairment (for over 60 kg body weight): - Mild (CrCl 20-50 ml/min): 1-2 million units every 8 hr. - Moderate (CrCl 10-20 ml/min): 1 million units every 12-18 hr. - Severe (CrCl <10 ml/min): 1 million units every 18-24 hr.	A* (SRQ ANAES) (SRQ MED)
216.	Compound Sodium Lactate (Hartmanns Solution)	B05XA3012 5P6001XX	Replacement of extracellular losses of fluid and electrolytes, as an alkaliniser agent	100-1000 ml by IV or according to the needs of the patient	C
217.	Conjugated Oestrogens 0.625 mg Tablet	G03CA5700 0T1001XX	i. Prevention and management of osteoporosis associated with estrogen deficiency. ii. Female hypoeestrogenism. iii. Moderate to severe vasomotor symptoms associated with estrogen deficiency. iv. Atrophic vaginitis and atrophic urethritis.	i) 0.3 - 0.625 mg daily ii) 0.3- 1.25mg daily for 3weeks, then off for 1 week iii) & iv) 0.3mg-1.25mg daily	A (SRQ MED) (SRQ PAED)
218.	Conjugated Oestrogens 0.625 mg / g Cream	G03CA5700 0G1001XX	Treatment of atrophic vaginitis, dyspareunia and kraurosis vulvae	i. Atrophic Vaginitis and Kraurosis Vulvae: Initial dose: Intravaginal 0.5g daily for 21 days and then off for 7 days (cyclical regimen). Dose range: 0.5- 2g daily based on individual response. ii. Dyspareunia: 0.5g intravaginally twice weekly continuous regimen or in a cyclic regimen of 21 days of therapy followed by 7 days off of therapy.	A (SRQ O&G)

No.	Generic Name	MDC	Indications	Dosage	Category
219.	Copper 375mm² Intrauterine Device	G02BA02-000-M90-02-XXX	Intrauterine contraception.	Intrauterine insertion: 1 unit to be replaced within 5 years from the date of insertion.	B (SRQ O&G)
220.	Crotamiton 10 % Cream	P03A000000 G1001XX	i) Pruritus ii) Scabies iii) Insect bite reactions	i) and iii) Massage into affected area until the medication is completely absorbed. Repeat as needed. Apply 2 or 3 times daily ii) Apply to the whole body from below the chin. 2nd application is applied 24 hr later. May need to use once daily for up to 5 days.	B
221.	Cyanocobalamin 1 mg / ml Injection	B03BA0100 OP3002XX	i) Prophylaxis of anaemia associated with Vitamin B12 deficiency ii) Uncomplicated pernicious anaemia or Vitamin B12 malabsorption	i) Prophylaxis of anaemia: 250-1000 mcg IM every month ii) Uncomplicated pernicious anaemia or Vitamin B12 malabsorption: Initial 100 mcg daily for 5-10 days followed by 100-200 mcg monthly until complete remission is achieved. Maintenance: up to 1000 mcg monthly. CHILD 30-50 mcg daily for 2 or more weeks (to a total dose of 1-5mg). OR AS PRESCRIBED.	B
222.	Cyclophosphamide 50 mg Tablet	L01AA0100 OT1001XX	i) Solid tumours, leukaemia, lymphoma, autoimmune disorders, autoimmune bullous diseases, connective tissue disease, pyoderma gangrenosum ii) For severe lupus nephritis (Class III & IV), systemic vasculitis and steroid resistant/dependent nephrotic syndrome iii) Systemic lupus erythematosus (SLE), rheumatoid arthritis, polyarteritis nodosa, Wegener granulomatosis	i) ADULT: 50 - 100 mg/day. Monitor full blood count (FBC), liver function, urine microscopy and renal function. CHILD, up to 1 year: 10 - 20 mg daily, 1 - 5 years: 30 - 50 mg daily, 6 - 12 years: 50 - 100 mg daily ii) 2 mg/kg/day for 3 - 4 months iii) 1 - 1.5 mg/kg/day orally in divided doses	A (SRQ MED) (SRQ PAED) (UKK MED)
223.	Cyclopentolate 0.2 % with Phenylephrine 1 % Eye Drops	S01GA5599 OD2001XX	Dilating agent for premature babies	1 drop every 5 - 10 minutes; not exceeding three times to produce rapid mydriasis. Observe infants closely for at least 30 minutes	A (SRQ OPHTH)
224.	Cyclopentolate 1 % Eye Drops	S01FA04000 D2002XX	Mydriasis and cycloplegia	ADULT: 1 drop of solution in eye(s); may repeat after 5-10 minutes if needed. CHILD: 1 drop of solution in eye(s); may repeat after 5-10 minutes if needed. Pre-treatment on the day prior to examination is usually not necessary. If desirable, 1 or 2 drops may be instilled the evening prior to examination.	A (SRQ OPHTH)

No.	Generic Name	MDC	Indications	Dosage	Category
225.	Cycloserine 250 mg Capsule	J04AB01000 C1001XX	Multi-Drug Resistance Tuberculosis treatment failure. (For respiratory physicians)	ADULT: Initial: 250 mg every 12 hours for 14 days, then administer 0.5 - 1 g daily in 2 divided doses for 18 - 24 months (maximum daily dose: 1 g). CHILD: 2-12 yr: 5 mg/kg bid; 12-18 yr: 250 mg bid for 2 wk then adjusted to a max dose of 1 g daily	A* (SRQ MED)
226.	Dabigatran Etexilate 110 mg Capsule	B01AE0799 9C1002XX	i) Prevention of venous thromboembolic events in patients who have undergone total knee replacement or total hip replacement surgery. ii) Reduction of the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF). iii) Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and prevention of recurrent DVT and PE in adults.	i) Following total knee replacement: Initially ADULT 110mg (ELDERLY, 75 mg) within 1- 4 hours after surgery, then 220 mg (ELDERLY, 150 mg) once daily thereafter for 6-10 days Following total hip replacement: Initially ADULT 110 mg (ELDERLY, 75 mg) within 1- 4 hours after surgery, then 220 mg (ELDERLY, 150 mg) once daily thereafter for 28-35 days ii) Recommended daily dose is 300mg taken orally as 150mg hard capsule twice daily. Therapy should be continued lifelong. iii) Recommended daily dose is 300mg taken as one 150mg capsule BD following treatment with a parenteral anticoagulant for at least 5 days. The duration of therapy should be individualized after careful assessment of the treatment benefit against the risk for bleeding. ii) & iii) For the following groups, the recommended daily dose is 220 mg taken as one 110mg capsule twice daily: - Patients aged 80 years or above -Patients who receive concomitant verapamil Special patient population for renal impairment : Renal function should be assessed by calculating the creatinine clearance (CrCl) prior to initiation of treatment with Dabigatran to exclude patients for treatment with severe renal impairment (i.e. CrCl < 30 ml/min).	A* (SRQ MED)

No.	Generic Name	MDC	Indications	Dosage	Category
227.	Danazol 100 mg Capsule	G03XA0100 OC1001XX	i) Endometriosis ii) Benign breast disorders including gynaecomastia fibrocystic breast disease and pubertal breast hypertrophy iii) Menorrhagia iv) Prophylaxis of hereditary angioedema	i. 400mg daily in 2 to 4 divided doses, starting on the 1st day of the menstrual cycle; daily doses of 800mg are also employed. ii. 100mg to 400mg daily in divided dose. iii. 200 mg BD iv. 400 mg daily. Reduce to 200 mg daily after 2 months attack free period. General dosing range: 200-800mg daily in 2 or 4 divided doses. Dosing is individualised and according to product insert/protocol	A/KK
228.	Danazol 200 mg Capsule	G03XA0100 OC1002XX	i) Endometriosis ii) Benign breast disorders including gynaecomastia fibrocystic breast disease and pubertal breast hypertrophy iii) Menorrhagia iv) Prophylaxis of hereditary angioedema	i. 400mg daily in 2 to 4 divided doses, starting on the 1st day of the menstrual cycle; daily doses of 800mg are also employed. ii. 100mg to 400mg daily in divided dose. iii. 200 mg BD iv. 400 mg daily. Reduce to 200 mg daily after 2 months attack free period. General dosing range: 200-800mg daily in 2 or 4 divided doses. Dosing is individualised and according to product insert/protocol	A/KK
229.	Dapsone 100 mg Tablet	J04BA02000 T1001XX	i) Leprosy ii) Dermatitis herpetiformis	i) ADULT: 6 - 10 mg/kg weekly/ 1.4mg/kg daily (around 50 - 100 mg daily). CHILD: 1 - 2 mg/kg/day. Maximum: 100 mg/day ii) ADULT: 50 - 300 mg daily	B (UKK MED – Off-label use)

No.	Generic Name	MDC	Indications	Dosage	Category
230.	Darbepoetin alfa 20mcg / 0.5ml injection	B03XA02- 000-P50-01- XXX	i. Treatment of anaemia associated with chronic renal failure, including patients on dialysis and patients not on dialysis. ii. Anemia with myelodysplastic syndrome	Indication (i): Haemodialysis patients: Initial dose: 20mcg IV once weekly Initial dose for switched ESA-treated patient: 15 – 60mcg IV once weekly Maintenance dose: 15 – 60mcg IV once weekly, then 30 – 120mcg IV biweekly. Peritoneal dialysis patients and patients with chronic kidney disease not on dialysis: Initial dose: 30mcg IV or SC biweekly Initial dose for switched ESA-treated patient: 30 – 120mcg IV or SC biweekly Maintenance dose: 30 – 120mcg IV or SC biweekly, then 60 – 180mcg IV or SC once every four weeks. Indication (ii): Adults: 240mcg administered as a single subcutaneous injection once weekly. The dose should be decreased in view of the degree of anemic symptoms and the patient's age.	A* (SRQ PAED)

231.	Dapagliflozin 10mg Tablet	A10BX09-999-T32-01-XXX	Indication 1: Dapagliflozin is indicated for use as an add-on combination therapy in combination with other glucose-lowering medicinal products including insulin, to improve glycemic control in adult patients with type 2 diabetes mellitus when these, together with diet and exercise, do not provide adequate glycaemic control. Indication 2: Dapagliflozin is indicated to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and established cardiovascular disease (CVD). Indication 3: To reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure (NYHA class II-IV) with reduced ejection fraction. Indication 4: For cardiorenal protection in adult patients with chronic kidney disease, with or without Type 2 Diabetes Mellitus, with eGFR$\geq$25mL/min/1.73m² and urine albumin creatinine ratio (UACR) $\geq$200-5,000mg/m² (or the equivalent in uPRC/u-dipstick) receiving stable treatment with ACEi or ARB (unless they are contraindicated or not tolerated). Pres. Restrictions Indication 1: Patients with HbA1c between 6.5%-10.0% while on single / combination anti-diabetic therapy. Indication 2: Patients with HbA1c not more than 10.0% while on adequate trial of metformin. Indication 3: Treatment to be initiated in hospital setting before continuation of treatment for stable patients by Family Medicine Specialist (FMS) in the primary care setting; All patients must be counselled regarding risk of euglycemic ketoacidosis before initiation of treatment. Indication 4: In adult patients with underlying Type 2 Diabetes Mellitus, to be used only if HbA1c level <10%.	10 mg once daily	A/KK (SRQ MED)
------	----------------------------------	------------------------	---	------------------	-------------------

No.	Generic Name	MDC	Indications	Dosage	Category
			All patients must be counselled regarding risk of euglycemic ketoacidosis before initiation of treatment.		
232.	Deferasirox 90 mg Film Coated Tablet	V03AC03-000-T32-01-XXX	Treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adult and pediatric patients aged 2 years and above	• Recommended initial dose is 14 mg/kg body weight. • An initial dose of 21 mg/kg may be considered for patients receiving more than 14 ml/kg/month of packed red blood cells, and for whom the objective is maintenance of the body iron level. • An initial dose of 7 mg/kg may be considered for patients receiving less than 7 ml/kg/month of packed red blood cells, and for whom the objective is maintenance of the body iron level. • For patients already well-managed on treatment with Deferoxamine, a starting dose of Deferasirox film-coated tablets that is numerically one third of the Deferoxamine dose could be considered. In patients not adequately controlled with doses of 21 mg/kg (e.g. serum ferritin levels persistently above 2,500 mcg/L and not showing a decreasing trend over time), doses of up to 28 mg/kg may be considered. Doses above 28 mg/kg are not recommended because there is only limited experience with doses above this level.	A* (SRQ PAED)

No.	Generic Name	MDC	Indications	Dosage	Category
233.	Deferasirox 360 mg Film Coated Tablet	V03AC03-000-T32-03-XXX	Treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adult and pediatric patients aged 2 years and above	• Recommended initial dose is 14 mg/kg body weight. • An initial dose of 21 mg/kg may be considered for patients receiving more than 14 ml/kg/month of packed red blood cells, and for whom the objective is maintenance of the body iron level. • An initial dose of 7 mg/kg may be considered for patients receiving less than 7 ml/kg/month of packed red blood cells, and for whom the objective is maintenance of the body iron level. • For patients already well-managed on treatment with Deferoxamine, a starting dose of Deferasirox film-coated tablets that is numerically one third of the Deferoxamine dose could be considered. In patients not adequately controlled with doses of 21 mg/kg (e.g. serum ferritin levels persistently above 2,500 mcg/L and not showing a decreasing trend over time), doses of up to 28 mg/kg may be considered. Doses above 28 mg/kg are not recommended because there is only limited experience with doses above this level.	A* (SRQ MED) (SRQ PAED)
234.	Deferiprone 500 mg Tablet	V03AC0200T1001XX	Treatment of iron overload in patients with thalassemia major for whom desferrioxamine therapy is contraindicated or inadequate. Add on therapy to desferrioxamine for thalassemia patients with cardiac complication	25 mg/kg 3 times a day for total daily dose of 75 mg/kg. Doses greater 100 mg/kg are not recommended	A* (SRQ MED) (SRQ PAED)
235.	Denosumab in 1.0 mL solution (60 mg / mL) Pre-filled syringe (subcutaneous injection)	M05BX04000P4001XX	Post-Menopausal Osteoporosis. Prescribing Restrictions: To be used by Orthopaedic Specialist, Rheumatologist, Endocrinologist and Geriatricians	A single subcutaneous injection of 60 mg administered once every 6 months. Patients should receive calcium and vitamin D supplements whilst undergoing treatment.	A* (SRQ ORTHO)
236.	Desferrioxamine B Methanesulphonate 0.5 g Injection	V03AC01196P3001XX	i) Acute iron poisoning in children ii) Investigation and treatment of haemochromatosis iii) Diagnosis and treatment of aluminium toxicity in patients with renal failure and dialysis iv) Chronic iron toxicity or overload	i) 2 g by IM immediately and 5 g by mouth after gastric lavage ii) 0.5 - 1.5 g by IM injection daily iii) Diagnosis: 5 mg per kg by slow intravenous infusion during the last hour of haemodialysis. Treatment: 5 mg per kg once a week by slow intravenous infusion during the last hour of dialysis iv) 30 - 50 mg/kg	A (SRQ MED) (SRQ PAED)

No.	Generic Name	MDC	Indications	Dosage	Category
237.	Desflurane Liquid	N01AB0700 OL5001XX	i) Induction and maintenance of anaesthesia in adult ii) Maintenance of anaesthesia in infants & children	ADULT: Induction, initially 3% in oxygen or nitrous oxide/oxygen and increased by 0.5%-1% every 2-3 breaths or as tolerated (up to 11%), until loss of consciousness. Maintenance: 2.5%-8.5% with or without concomitant nitrous oxide CHILD: maintenance, inhaled in concentrations of 5.2%-10% with or without concomitant nitrous oxide	A (SRQ ANAES)
238.	Desloratadine 5 mg Tablet	R06AX2700 OL9001XX	Allergic rhinitis and chronic idiopathic urticaria.	Adults and Adolescents (12 years of age and older): 5mg once a day regardless of mealtime.	A* (SRQ ENT)
239.	Desloratadine 2.5mg/5ml syrup	R06AX2700 OL9001XX	Allergic rhinitis and chronic idiopathic urticaria.	For use in children 1-2 years old only. For children only: 1-5 yrs: 2.5ml once a day (with or without meal) 6-11 yrs: 5ml once a day (with or without meal)	A* (SRQ ENT)
240.	Desmopressin 60mcg Sublingual Tablet	H01BA02-122-T70-01-001	i) Central diabetes insipidus ii) Primary nocturnal enuresis iii) Treatment of nocturia associated with nocturnal polyuria in adults	i) 60mcg 3 times daily sublingually (daily dose range from 120mcg to 720mcg); ii) 120mcg once daily at bedtime, sublingually (maximum dose 240mcg); iii) 60mcg once daily at bedtime (dose range from 120mcg to 240mcg).	A (SRQ PAED) (SRQ MED)
241.	Desmopressin Acetate 4 mcg / ml Injection	H01BA0212 2P3001XX	Central Diabetes Insipidus.	Adults 1-4 mcg 1-2 times daily. Children above the age of 1 year 0.4-1 mcg 1-2 times daily. Children below the age of 1 year 0.2-0.4 mcg 1-2 times daily.	A
242.	Desogestrel 150 mcg & Ethinylestradiol 30 mcg Tablet	G03AB0595 4T1001XX	Contraception	1 tablet daily for 21 days, subsequent courses repeated after 7 day interval (during which withdrawal bleeding occurs)	C+ (SRQ O&G)
243.	Desvenlafaxine Succinate 50 mg Extended Release Tablet	N06AX2399 9T5002XX	Major depression	Recommended dose is 50mg once daily, with or without food.	A* (SRQ PSY)
244.	Dexamethasone 0.5 mg Tablet	H02AB0200 OT1001XX	i) Prophylaxis and management of nausea and vomiting in cancer chemotherapy, post-operation and palliative care ii) Treatment of adrenocortical function abnormalities iii) Any other treatment requiring corticosteroid therapy.	0.5mg to 10mg daily is given for oral administration. Dose can be titrated up to 20mg daily in severe disease depending on the condition being treated. The dosing is individualized according to product insert / protocol	A (SRQ GENERAL)

No.	Generic Name	MDC	Indications	Dosage	Category
245.	Dexamethasone 4 mg Tablet	H02AB0200 OT1003XX	i) Prophylaxis and management of nausea and vomiting in cancer chemotherapy, post-operation and palliative care ii) Treatment of adrenocortical function abnormalities iii) Any other treatment requiring corticosteroid therapy.	0.5mg to 10mg daily is given for oral administration. Dose can be titrated up to 20mg daily in severe disease depending on the condition being treated. The dosing is individualized according to product insert / protocol	A (SRQ GENERAL)
246.	Dexamethasone Sodium Phosphate 0.1 % Eye Drops	S01BA0116 2D2001XX	Acute steroid responsive inflammatory abd allergic conditions	Instil 1 drop 4-6 times daily. Severe conditions: Instil 1 drop hourly, then reduced to 1 drop 4 hourly as the inflammation subsides.	A (SRQ OPHTH)
247.	Dexamethasone Sodium Phosphate 4 mg / ml Injection	H02AB0216 2P3001XX	i) Prophylaxis and management of nausea and vomiting in cancer chemotherapy, post-operation and palliative care ii) Treatment of adrenocortical function abnormalities iii) Any other treatment requiring corticosteroid therapy.	i-iii) Initial dosage: 0.5 mg to 20 mg per day depending on the specific disease entity being treated. The total daily dosage should not exceed 80 mg. The dosing is individualized according to product insert / protocol	B
248.	Dexamethasone and Neomycin Sulphate and Polymyxin B Eye Ointment	S01CA0199 0G5101XX	Treatment of ocular inflammation when concurrent use of an antimicrobial is judged necessary	Apply a small amount into the conjunctival sac(s) 3 – 4 times daily, may be used adjunctively with drops at bedtime	A (SRQ OPHTH)
249.	Dexamethasone and Neomycin Sulphate and Polymyxin B Sulphate Ophthalmic Suspension	S01CA0199 0D2001XX	Treatment of ocular inflammation when concurrent use of an antimicrobial is judged necessary	1 - 2 drops hourly for severe cases and 4 - 6 hourly for mild infection	A (SRQ OPHTH)
250.	Dexmedetomidine HCl 100mcg / ml Injection	N05CM1811 0P4001XX	i) Sedation of intubated and mechanically ventilated ICU patients. For use only by specialist anaesthetist ii) For sedation of non-intubated patients prior to and/or during surgical and other procedures	i) Not to be infused for more than 24 hours, 1 mcg/kg over 10 minutes as loading dose. Maintenance dose: 0.2 - 0.7 mcg/kg/hr ii) Not to be infused for more than 24 hours, 1 mcg/kg over 10 minutes as loading dose. Maintenance dose: 0.2 - 0.7 mcg/kg/hr	A* (SRQ ANAES)
251.	Dextrose 5% Injection	B05BA0300 0P6001XX	For parenteral replenishment of fluid and minimal carbohydrate calories as required by the clinical condition of the patient	According to the needs of the patient	B
252.	Dextrose 10% Injection	B05BA0300 0P6002XX	For parenteral replenishment of fluid and minimal carbohydrate calories as required by the clinical condition of the patient	According to the needs of the patient	B
253.	Dextrose 20% Injection	B05BA0300 0P6003XX	For parenteral replenishment of fluid and minimal carbohydrate calories as required by the clinical condition of the patient	According to the needs of the patient	B

No.	Generic Name	MDC	Indications	Dosage	Category
254.	Dextrose 50 % Injection	B05BA0300 OP6005XX	For parenteral replenishment of fluid and minimal carbohydrate calories as required by the clinical condition of the patient	According to the needs of the patient	B
255.	Diazepam 5 mg / ml Injection	N05BA0100 OP3001XX	i) Status epilepticus ii) Skeletal muscle spasm iii) Anxiety disorders	i) ADULT: initial dose 10-20mg IV, in the following hours 20mg IM or by intravenous drip infusion as necessary. CHILD 2 to 5 years of age: slow IV 0.2 - 0.5mg every two to five minutes up to a maximum of 5mg. If necessary, dose can be repeated in two to four hours. CHILD 5 years and older: slow IV 1mg every two to five minutes up to a maximum of 10mg. If necessary, dose can be repeated in two to four hours. ii) ADULT: 10mg once or twice IV. CHILD 2 to 5 years of age: IM or IV, 1 to 2mg the dosage being repeated every three to four hours as needed. CHILD 5 years and older: IM or IV, 5 to 10mg, the the dosage being repeated every three to four hours as needed. iii) ADULT: 10-20mg three times daily IM or IV until acute symptoms subside.	B
256.	Diazepam 5 mg Tablet	N05BA0100 OT1002XX	i) Muscle spasm of varied aetiology, including tetanus ii) Anxiety disorders	i) ADULT: 2-10 mg 3-4 times daily. CHILD 6 months and older: 0.12 - 0.8 mg/kg daily in divided doses, every 6-8 hours ii) ADULT: 2 mg 3 times daily, increased in severe anxiety to 15 - 30 mg daily in divided doses. ELDERLY (or debilitated) half adult dose. CHILD (night terrors), 1 - 5 mg at bedtime	B
257.	Diazepam 5 mg Rectal Solution	N05BA0100 OG2001XX	Status epilepticus, skeletal muscle spasm	Status epilepticus - ADULT: 0.5 mg/kg repeated after 12 hours if necessary. CHILD (febrile convulsions, prolonged or recurrent): 0.5 mg/kg (maximum 10 mg), repeated if necessary. Not recommended for children below 2 years	B
258.	Diclofenac 1 % Gel	M02AA1552 OG3001XX	i) Post-traumatic inflammation of the tendons, ligaments & joints. ii) Localised forms of soft tissue rheumatism and degenerative rheumatism	Apply 3 - 4 times daily and gently rubbed in	A (SRQ GENERAL)

No.	Generic Name	MDC	Indications	Dosage	Category
259.	Diclofenac Sodium 12.5 mg Suppository	M01AB0552 OS2001XX	Pain and inflammation in rheumatic disease and juvenile arthritis	ADULT: 100 mg usually at night, max total daily dose 150 mg. CHILD ABOVE 1 YEAR AND ADOLESCENT: 0.5-2mg/kg daily divided to 2-3 doses. Maximum dose for juvenile RA is 3mg/kg/day in divided doses	A (SRQ GENERAL)
260.	Diclofenac Sodium 50 mg Suppository	M01AB0552 OS2003XX	Pain and inflammation in rheumatic disease and juvenile arthritis	ADULT: 100 mg usually at night, max total daily dose 150 mg. CHILD ABOVE 1 YEAR AND ADOLESCENT: 0.5-2mg/kg daily divided to 2-3 doses. Maximum dose for juvenile RA is 3mg/kg/day in divided doses	A (SRQ ANAES)
261.	Diclofenac Sodium 50 mg Tablet	M01AB0552 OT1001XX	Pain and inflammation in rheumatic disease and of non-rheumatic origin	ADULTS: Initial dose of 150 mg daily. Mild or long term: 75 - 150 mg daily in 2 to 3 divided doses after food. Maximum: 200mg/day. CHILD more than 6 months : 1 - 3 mg/kg body weight daily in divided doses. Maximum: 3mg/kg/day (150mg/day).	B
262.	Diclofenac Sodium 75 mg / 3 ml Injection	M01AB0552 OP3001XX	Pain and inflammation in rheumatic disease and of non-rheumatic origin	IM 75 mg once daily (2 times daily in severe cases) for not more than 2 days. Max 150mg/day. Not suitable for children.	A/KK (SRQ GENERAL)
263.	Dienogest 2 mg tablet	G03DB0800 OT1001XX	Treatment of endometriosis	One tablet daily. Treatment can be started on any day of menstrual cycle. Tablets must be taken continuously without regard to vaginal bleeding.	A/KK (SRQ O&G)
264.	Digoxin 0.25 mg Tablet	C01AA0500 OT1001XX	Heart failure, with atrial fibrillation, supraventricular arrhythmias (particularly, atrial fibrillation)	Rapid digitalisation: 0.75 -1.5 mg in divided doses over 24 hours; less urgent digitalisation, 250 mcg-500 mcg daily (higher dose may be divided). Maintenance : 62.5mg -500 mcg daily (higher dose may be divided) according to renal function and , in atrial fibrillation, on heart rate response; usual range, 125-250 mcg daily (lower dose may be appropriate in elderly)	B
265.	Digoxin 250 mcg / ml Injection	C01AA0500 OP3001XX	Heart failure , with atrial fibrillation, supraventricular arrhythmias (particularly, atrial fibrillation)	Rapid digitilisation: ADULT & CHILD over 10 years, initially 0.75 - 1.5 mg, followed by 250 mcg 6 hourly until digitilisation is complete	A (SRQ GENERAL)

No.	Generic Name	MDC	Indications	Dosage	Category
266.	Digoxin 50 mcg / ml Elixir	C01AA0500 0L1001XX	Heart failure, with atrial fibrillation, supraventricular arrhythmias (particularly, atrial fibrillation)	Rapid digitalization, give in divided doses; PREMATURE: 20-30 mcg/kg; FULLTERM: 25-35 mcg/kg; CHILD 1-2 years : 35 to 60 mcg/kg; CHILD 2-5 years: 30-40 mcg/kg; CHILD 5-10 years: 20-35 mcg/kg; CHILD over 10 years: 10-15 mcg/kg. For daily maintenance doses or for gradual digitalization, give 20% to 30% of oral digitalizing dose for premature infants or 25% to 35% of oral digitalizing dose for all other pediatric patients	B
267.	Dihydrocodeine Tartrate 30 mg Tablet	N02AA0812 3T1001XX	For the control of moderate to severe chronic pain	ADULT: 30 - 60 mg every 4 - 6 hours. PAED, over 4 yrs: 0.5 - 1 mg/kg body weight every 4-6 hours	B
268.	Diltiazem HCl 30 mg Tablet	C08DB0111 0T1001XX	i) Treatment of angina ii) Hypertension	Initially 30mg tds, may increase to 60mg tds (elderly initially twice daily; increased if necessary to 360 mg daily.	B
269.	Dinoprostone (Prostaglandin E2) 3 mg Vaginal Tablet	G02AD0200 0S1001XX	Induction of labour	3 mg vaginal tablet to be inserted high into the posterior fornix. A second 3 mg tablet may be inserted after 6-8 hours if labour is not established. Max 6 mg	A (SRQ O&G)
270.	Diosmin 450 mg and Hesperidin 50 mg Tablet	C05CA5393 1T1001XX	i) Haemorrhoids ii) Chronic venous insufficiency	i) Acute attack: 6 tablets daily for the first 4 days, then 4 tablets daily in 2 divided doses for 3 days and 2 tablets thereafter. Chronic: 2 tablets daily ii) 2 tab daily with meals	B
271.	Diphenhydramine HCl 14 mg / 5 ml Expectorant	R06AA52- 110-L21-01- XXX	Cough	ADULT: 5 - 10 ml 2 - 3 times daily.	C
272.	Diphenhydramine HCl 7 mg / 5 ml Expectorant	R06AA52- 110-L90-03- XXX	Cough	CHILD 6-12 years: 2.5 to 5 ml 2-3 times daily CHILD 2-5 years: 2.5 ml 2-3 times daily NOT to be used in children less than 2 years in age	C
273.	Diphenoxylate HCl 2.5 mg with Atropine Sulphate 0.025 mg Tablet	A07DA0192 2T1001XX	Symptomatic treatment of acute and chronic diarrhoea	ADULT: 2 tablets 4 times daily, later reduced when diarrhoea is controlled. Maintenance: 2 tablets once daily as needed (Max: 8 tablets daily)	B
274.	Diphtheria antitoxin 100,000 IU Injection	J07AF01000 P3001XX	Diphtheria	Therapeutic: 10,000 - 30,000 units by IM or IV. Increase to 40,000 - 100,000 units in severe cases. Doses up to 30,000 units may be given IM	B (UKK CFLN)

No.	Generic Name	MDC	Indications	Dosage	Category
275.	Dobutamine HCl 12.5 mg / ml Injection	C01CA0711 OP3001XX	Hypotension and heart failure	Initial 0.5-1 mcg/kg/min by IV, maintenance 2.5-10mcg/kg/min. Frequently, doses up to 20mcg/kg/min are required for adequate hemodynamic improvement. On rare occasions, infusion rates up to 40mcg/kg/min	A
276.	Dolutegravir 50mg Tablet	J05AX12000 T3201XX	Dolutegravir is indicated in combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected adults and adolescents above 12 years of age.	i) HIV-1 patients without documented or clinically suspected resistance to the integrase class: 50 mg (one tablet), once daily, orally. ii) HIV-1 patients with resistance to the integrase class: 50 mg (one tablet), twice daily, orally.	A* (SRQ PAED)
277.	Domperidone 1 mg / ml Suspension	A03FA03000 L8001XX	Nausea, vomiting, dyspepsia, gastro-esophageal reflux	Adults and adolescents ≥ 12 years of age and weighing ≥ 35 kg & children < 12 years of age and weighing ≥ 35 kg: 10ml three to four times per day. Maximum dose: 40mg/day. Adults and adolescents (≥ 12 years of age) weighing < 35 kg: 0.25mg/kg three to four times per day. Maximum dose: 35mg/day.	B
278.	Domperidone 10 mg Tablet	A03FA03253 T1001XX	Nausea, vomiting, dyspepsia, gastro-esophageal reflux	Adults and adolescents ≥ 12 years of age and weighing ≥ 35 kg & children < 12 years of age and weighing ≥ 35 kg: 10mg three to four times per day. Maximum dose: 40mg/day	B
279.	Donepezil HCl 10 mg Tablet	N06DA0211 OT1002XX	Treatment of mild, moderate and severe dementia in Alzheimer's disease. [psychiatrists, neurologists and geriatricians only]	5 - 10 mg once daily at bedtime. Maximum 10 mg daily	A (SRQ PSY)
280.	Donepezil HCl 5 mg Tablet	N06DA02-110-T10-01-XXX	Treatment of mild, moderate and severe dementia in Alzheimer's disease. Psychiatrists, neurologists and geriatricians only	5 - 10 mg once daily at bedtime. Maximum 10 mg daily	A (SRQ PSY)
281.	Donepezil HCl 5mg Orodispersible Tablet	N06DA02-110-T40-01-XXX	Treatment of mild to moderate dementia in Alzheimer's disease, as well as in patients with severe Alzheimer's disease Psychiatrists, neurologists and geriatricians only	Initiated at 5mg/day (one a day dosing), should be maintained for at least 1 month in order to allow the earliest clinical responses and to allow steady state concentration to be achieved. The maximum recommended daily dose is 10 mg.	A* (SRQ PSY)

No.	Generic Name	MDC	Indications	Dosage	Category
282.	Dopamine HCl 40 mg / ml Injection	C01CA0411 0P3001XX	Non-hypovolemic hypotension	Initial dose 2-5 mcg/kg/min with incremental changes of 5-10 mcg/kg/min at 10-15 minutes intervals until adequate response is noted. Most patients are maintained at less than 20 mcg/kg/min. If dosage exceeds 50 mcg/kg/min, assess renal function frequently	B
283.	Dorzolamide HCl 2 % Ophthalmic Solution	S01EC0311 0D2001XX	All glaucoma patients where beta blockers are contraindicated and when intraocular pressure is not well controlled by other drugs	Monotherapy: 1 drop 3 times daily. Adjunctive therapy with an ophthalmic beta-blocker: 1 drop 2 times daily. When substituting for another ophthalmic antiglaucoma agent with this product, discontinue the other agent after proper dosing on one day and start Trusopt on the next day. If more than 1 topical ophthalmic drug is used, the drugs should be administered at least 10 mins apart	A* (SRQ OPHTH)
284.	Doxazosin Mesilate 4 mg CR Tablet	C02CA0419 6T5001XX	Benign Prostatic Hyperplasia	4 mg once daily to maximum 8 mg/day	A* (SRQ SURG)
285.	Doxorubicin HCl 2 mg / ml Injection	L01DB0111 0P4002XX	i) Solid tumours, leukaemia, non-Hodgkin's lymphoma ii) Leukaemia (ALL induction) iii) Multiple myeloma	i) 30 - 75 mg/m ² IV as a single dose at 21 day intervals ii) 25 - 45 mg/m ² once a week for the first 4 weeks during induction or re-induction phase (refer to specific protocol. Caution: Total cumulative dose of doxorubicin must not exceed 550 mg/m ² due to risk of cardiotoxicity. CHILD: 30 mg/m ² /dose over 6 - 24 hours for 1 - 2 days. Need to check cardiac function closely by echocardiography every cumulative dose of 100 mg/m ² to maximum 360 mg/m ² iii) 9 mg/m ² over 24 hours infusion for 4 days at monthly intervals	A (SRQ ONCO)
286.	Doxycycline 100 mg Capsule	J01AA02000 C1001XX	Prophylaxis and treatment for infections due to susceptible organisms	Prophylaxis : 100-200mg daily or weekly Treatment : 100-300mg daily Dosing is individualised based on type of infections and according to product insert/protocol	B

No.	Generic Name	MDC	Indications	Dosage	Category
287.	Duloxetine 30 mg Capsule	N06AX2111 0C1001XX	i) Major depressive disorder ii) Diabetic peripheral neuropathic pain iii) Generalised Anxiety Disorder	i) & ii) ADULT: 60 mg once daily up to a maximum dose of 120mg/day (in divided doses) CHILD and ADOLESCENT under 18 years not recommended iii) Generalised Anxiety: Initial dose: 30 mg OD with or without food Maintenance dose: 60 mg OD	A* (SRQ PSY)
288.	Duloxetine 60 mg Capsule	N06AX2111 0C1002XX	i) Major depressive disorder ii) Diabetic peripheral neuropathic pain iii) Generalised Anxiety Disorder	i) & ii) ADULT: 60 mg once daily up to a maximum dose of 120mg/day (in divided doses) CHILD and ADOLESCENT under 18 years not recommended iii) Generalised Anxiety: Initial dose: 30 mg OD with or without food Maintenance dose: 60 mg OD	A* (SRQ PSY)
289.	Dutasteride 0.5 mg Capsule	G04CB0200 0C1001XX	Benign prostatic hyperplasia in men with an enlarged prostate gland	0.5 mg daily	A* (SRQ SURG)
290.	Dutasteride 0.5 mg and Tamsulosin 0.4 mg Capsule	G04CA5295 3C1001XX	Combination therapy for the treatment of moderate to severe symptoms of BPH with: i) Large prostate (>30g) ii) Poor risk or not fit for surgery iii) Those who are awaiting their turn for surgery	One capsule daily	A* (SRQ SURG)
291.	Dydrogesterone 10 mg Tablet	G03DB0111 0T1001XX	i) Dysmenorrhoea ii) Endometriosis iii) Dysfunctional uterine bleeding (to arrest and to prevent bleeding) iv) Threatened abortion v) Habitual abortion vi) Post menopausal complaints (hormone replacement therapy in combination with oestrogen)	i) 10 mg bd from day 5 - 25 of cycle ii) 10 mg bd - tds from day 5 - 25 of the cycle or continuously iii) To arrest bleeding :10 mg bd with an oestrogen once daily for 5 - 7 days, To prevent bleeding : 10 mg bd with an oestrogen once daily from day 11 - 25 of the cycle iv) 40 mg at once, then 10mg 8hrly until symptoms remit v) 10 mg bd until 20th week of pregnancy vi) 10-20 mg daily during last 12-14 days of each cycle	A/KK (SRQ O&G)
292.	Ear Wax Softener	S02DA3090 0D10XXXX	Occlusion or partial occlusion of the external auditory meatus by soft wax or wax plug	Instill 5 drops into the ears. Refer product information leaflet	B

No.	Generic Name	MDC	Indications	Dosage	Category
293.	Efavirenz 600 mg Tablet	J05AG03000 T1001XX	Combination therapy for HIV infections with a protease inhibitor and/or Nucleoside Reverse Transcriptase Inhibitors (NRTIs)	ADULT: 600 mg once daily. ADOLESCENT & CHILD less than 17 years, more than 40 kg: 600 mg once daily, 32.5 - less than 40 kg: 400 mg once daily, 25 - less than 32.5 kg: 350 mg once daily, 20 - less than 25 kg: 300 mg once daily, 15 - less than 20 kg: 250 mg once daily, 13 - less than 15 kg: 200 mg once daily. No studies in children less than 3 years or less than 13 kg. Formulation unsuitable for children less than 40 kg	A/KK (SRQ MED) (SRQ PAED)
294.	Efavirenz 200 mg Capsule	J05AG03-000-C10-03-XXX	Combination therapy for HIV infections with a protease inhibitor and or Nucleoside Reverse Transcriptase Inhibitors (NRTIs)	ADULT: 600 mg once daily. ADOLESCENT & CHILD less than 17 years, more than 40 kg: 600 mg once daily, 32.5 - less than 40 kg: 400 mg once daily, 25 - less than 32.5 kg: 350 mg once daily, 20 - less than 25 kg: 300 mg once daily, 15 - less than 20 kg: 250 mg once daily, 13 - less than 15 kg: 200 mg once daily. No studies in children less than 3 years or less than 13 kg. Formulation unsuitable for children less than 40 kg	A/KK (SRQ PAED)
295.	Efavirenz 200 mg Tablet	J05AG03-000-T10-03-XXX	Combination therapy for HIV infections with a protease inhibitor and or Nucleoside Reverse Transcriptase Inhibitors (NRTIs)	ADULT: 600 mg once daily. ADOLESCENT & CHILD less than 17 years, more than 40 kg: 600 mg once daily, 32.5 - less than 40 kg: 400 mg once daily, 25 - less than 32.5 kg: 350 mg once daily, 20 - less than 25 kg: 300 mg once daily, 15 - less than 20 kg: 250 mg once daily, 13 - less than 15 kg: 200 mg once daily. No studies in children less than 3 years or less than 13 kg. Formulation unsuitable for children less than 40 kg	A/KK (SRQ PAED)
296.	Eltrombopag Olamine 25 mg Film-coated Tablet	B02BX0599 9T1001XX	Short term use in idiopathic thrombocytopenic purpura patients as bridging therapy for splenectomy or surgery and in cases of severe bleeding. (Off-label indication with UKK approval: Severe aplastic anaemia).	Individualised dosage based on the patient's platelet count. Adult Initially 50 mg once daily. East Asian patient 25 mg once daily. Then, adjust dose to maintain platelet count $\geq 50,000/\text{microliter}$. Max: 75 mg daily.	A* (UKK MED)

No.	Generic Name	MDC	Indications	Dosage	Category
297.	Enalapril 5 mg Tablet	C09AA0225 3T1001XX	i) Hypertension ii) Heart failure iii) Prevention of coronary ischemic events in patients with left ventricular dysfunction	i) Initial: 5mg once daily. Maintenance: 10-20mg once daily Max. 40mg daily in 1-2 divided doses ii) & iii) Initial: 2.5mg once daily Maintenance: 20mg in 1-2 divided doses Max. 40mg daily in 2 divided doses Dosing is individualised and according to product insert / protocol.	B
298.	Enalapril 10 mg Tablet	C09AA0225 3T1002XX	i) Hypertension ii) Heart failure iii) Prevention of coronary ischemic events in patients with left ventricular dysfunction	i) Initial: 5mg once daily. Maintenance: 10-20mg once daily Max. 40mg daily in 1-2 divided doses ii) & iii) Initial: 2.5mg once daily Maintenance: 20mg in 1-2 divided doses Max. 40mg daily in 2 divided doses Dosing is individualised and according to product insert / protocol.	B
299.	Enalapril 20 mg Tablet	C09AA0225 3T1003XX	i) Hypertension ii) Heart failure iii) Prevention of coronary ischemic events in patients with left ventricular dysfunction	i) Initial: 5mg once daily. Maintenance: 10-20mg once daily Max. 40mg daily in 1-2 divided doses ii) & iii) Initial: 2.5mg once daily Maintenance: 20mg in 1-2 divided doses Max. 40mg daily in 2 divided doses Dosing is individualised and according to product insert / protocol.	B

No.	Generic Name	MDC	Indications	Dosage	Category												
300.	Enoxaparin Sodium 40 mg Injection	B01AB0552 OP5002XX	PRESCRIBER CATEGORY A*: i. Prophylaxis of venous thromboembolic diseases (DVT and PE) especially in perioperative, high risk surgical cases and medical patients with acute illness at increased risk of VTE ii. Treatment of venous thromboembolic diseases (DVT and PE). iii. Acute coronary syndrome: a. Treatment of unstable angina and Non-ST-segment elevation myocardial infarction (NSTEMI), in combination with oral acetylsalicylic acid. b. Treatment of acute ST-segment elevation myocardial infarction (STEMI) including patients to be managed medically or with subsequent Percutaneous Coronary Intervention (PCI). PRESCRIBER CATEGORY A/KK: Prevention of DVT in antenatal and/or postnatal women with VTE risk scoring of 3 or more. A written consent form by the patient is necessary prior treatment initiation. Healthcare facilities are advised to refer to “Panduan Penggunaan Ubat- Ubatan yang Mengandung Unsur Tidak Halal”.	PRESCRIBER CATEGORY A*: i. Moderate risk: 20mg SC 2 hours before surgery then 20mg SC once daily High risk: 40mg SC 12 hours before surgery then 40mg SC once daily Medical patients: 40mg once daily ii. 1.5mg/kg once daily or 1mg/kg twice daily iii. 1 mg/kg every 12 hours PRESCRIBER CATEGORY A/KK: <table><tr><th>Weigh</th><th>Dose</th></tr><tr><td><50 kg</td><td>20mg OD</td></tr><tr><td>50-90 kg</td><td>40mg OD</td></tr><tr><td>91-130 kg</td><td>60mg OD</td></tr><tr><td>131-170 kg</td><td>80mg OD</td></tr><tr><td>>170 kg</td><td>0.6mg/kg /day</td></tr></table>	Weigh	Dose	<50 kg	20mg OD	50-90 kg	40mg OD	91-130 kg	60mg OD	131-170 kg	80mg OD	>170 kg	0.6mg/kg /day	A*, A/KK (SRQ GENERAL)
Weigh	Dose																
<50 kg	20mg OD																
50-90 kg	40mg OD																
91-130 kg	60mg OD																
131-170 kg	80mg OD																
>170 kg	0.6mg/kg /day																
301.	Enoxaparin Sodium 60 mg Injection	B01AB0552 OP5003XX	PRESCRIBER CATEGORY A*: i) Prevention of Deep Vein Thrombosis (DVT) especially in perioperative and high risk surgical cases ii) Treatment of DVT iii) Unstable angina and non Q wave Myocardial Infarction. PRESCRIBER CATEGORY A/KK: Prevention of DVT in antenatal and/or postnatal women with VTE risk scoring of 3 or more. A written consent form by the patient is necessary prior treatment initiation. Healthcare facilities are advised to refer to “Panduan Penggunaan Ubat- Ubatan yang Mengandung Unsur Tidak Halal”.	i) Prophylaxis for DVT especially in surgical patients: moderate risk, 20 mg SC approximately 2 hours before surgery then 20 mg every 24 hours for minimum 7 - 10 days, high risk (eg orthopaedic surgery, medical patients, 40mg every 24 hours for at least 6 days until patient ambulant, max 14 days. ii) Treatment of DVT or pulmonary embolism, 1.5 mg/kg every 24 hours, usually for 5 days and until adequate oral anticoagulation established. iii) Unstable angina and non-ST-segment-elevation myocardial infarction 1 mg/kg every 12 hours, usually for 2 - 8 days	A*, A/KK (SRQ GENERAL)												

No.	Generic Name	MDC	Indications	Dosage	Category
302.	Entacapone 200 mg Tablet	N04BX0200 OT1001XX	Parkinson's Disease. An adjunct to standard levodopa/benserazide or levodopa/carbidopa for use in patients with parkinson's disease and end of dose motor fluctuations, who cannot be stabilised on those combinations	200 mg to be taken with each daily dose of levodopa/dopa-decarboxylase inhibitor. Max 2g daily. May be taken with or without food	A (SRQ MED)
303.	Entecavir 0.5 mg Tablet	J05AF10000 T1001XX	First line treatment of Chronic Hepatitis B in patients who satisfy the criteria for treatment and require long-term therapy or have a very high baseline viral load	0.5-1 mg once daily. Renal Dose Adjustment: 0.5-1 mg every 48 hours (30-49 ml/min); 0.5-1 mg every 72hours (10-29 ml/min); 0.5 mg-1 mg every 5-7 days (<10 ml/min; HD or CAPD).	A* (SRQ MED)
304.	Eperisone HCl 50 mg Tablet	M03BX0911 OT1001XX	Myotonic symptoms associated with cervical syndrome, periartthritis of shoulder and lumbago spastic paralysis	50 mg 3 times daily	A (SRQ ORTHO) (SRQ REHAB) (SRQ ANAES)
305.	Ephedrine HCl 30 mg / ml Injection	R03CA0211 OP3001XX	Treatment of bronchial spasm in asthma, adjunct to correct haemodynamic imbalances and treat hypotension in epidural and spinal anaesthesia	By IM, SC or IV. Severe, acute bronchospasm: 12.5-25 mg. Further dosage should be determined by patient response. When used as a pressor agent: ADULT 25 - 50 mg SC/IM. If necessary, a second IM dose of 50 mg or an IV dose of 25 mg may be given. Direct IV injection, 10 - 25 mg may be given slowly. Maximum parenteral ADULT dose: 150 mg in 24 hours. CHILD : 3 mg/kg or 100 mg/m2 SC or IV daily, in 4 - 6 divided doses	B
306.	Epirubicin 2 mg / ml Injection	L01DB0311 OP4002XX	i. Solid tumour ii. Non-Hodgkin's lymphoma iii. Leukaemia (ALL induction) iv. Lymphoma	75 - 90mg/m2 body area injected IV in 3 - 5 min, repeated at 21 day intervals. Higher doses up to 135mg/m2 as single agent and 120mg/m2 as combination (effective in treatment of breast cancer) CHILD: 50 mg/m2 over 6 hours. Schedule depends on protocol. Refer to specific product for dosing information	A* (SRQ ONCO)
307.	Erythromycin Ethylsuccinate 200 mg/5 ml Suspension	J01FA01238 F2101XX	Treatment of susceptible bacterial infections	Child: 30-50 mg/kg daily, increased to twice the usual dose in severe cases. 2-8 yr: 1 g daily in divided doses; <2 yr: 500 mg daily in divided doses.	B
308.	Erythromycin Ethylsuccinate 400 mg Tablet	J01FA01238 T1001XX	Treatment of susceptible bacterial infections	Adult 400 mg 6 hrly or 800 mg 12 hrly. Max: 4 g/day. Childn 30-50 mg/kg in divided doses. Childn 2-8 yr 1 g/day in divided doses in severe cases. Infant & childn ≤2 yr 500 mg/day in divided doses.	B

No.	Generic Name	MDC	Indications	Dosage	Category
309.	Erythromycin Lactobionate 500 mg Injection	J01FA01129 P3001XX	Only for treatment of i) certain forms of meningitis ii) septicaemia not responding to usual antibiotics iii) mycoplasma pneumonia iv) infection with gram-positive organisms (e.g. tetanus, streptococcal infection) associated with Penicillin allergy, only when oral erythromycin cannot be given (Off-label indication with one-off UKK approval: Prokinetic)	Adult & Child: 25 – 50 mg/kg /day infusion every 6 hours. Maximum: 4 g/day.	A* (SRQ GENERAL)
310.	Erythropoietin Human Recombinant 2000 IU Injection	B03XA01-000-P50-02-XXX	i) Treatment of anaemia associated with chronic renal failure. Dialysis patients who have haemoglobin less than 10 g/dL or are exhibiting symptoms of anaemia although haemoglobin more than 10 g/dL and pre-transplant cases ii) Anaemia in cancer (non-myeloid malignancies) with concomitant chemotherapy	a) EPO Alfa: 150IU/kg three times weekly or 40,000IU once weekly b) EPO Beta: 450IU/kg once weekly or 30,000 IU once weekly Dosing is according to product insert.	A (SRQ MED)
311.	Escitalopram 10 mg Tablet	N06AB1012 4T1001XX	i) Major depression ii) Treatment of panic disorder with or without agoraphobia	i) 10 mg once daily; may be increased to max 20 mg daily. ii) Panic disorder with or without agoraphobia: Initially 5 mg for the first week, thereafter increased to 10 mg daily. Max 20 mg daily, ELDERLY initially half the adult dose, lower maintenance dose may be sufficient. CHILD and ADOLESCENT under 18 years not recommended	B (SRQ PSY)
312.	Esmolol HCl 10 mg / ml Injection	C07AB0911 0P3001XX	i) Supraventricular tachycardia ii) Intraoperative and postoperative tachycardia and/or hypertension	i) & ii) 50-200 mcg/kg/min Dosing is individualised and according to product insert/protocol.	A* (SRQ A&E) (SRQ MED) (SRQ ANAES)
313.	Esomeprazole 40 mg Injection	A02BC0500 0P3001XX	i) Acute erosive/ulcerative oesophagitis ii) Non -variceal upper gastrointestinal bleed	i) 20- 40 mg once daily for 2-5 days ii) 80 mg by IV bolus followed by 8mg/hour infusion for 72 hours	A* (SRQ MED) (SRQ SURG)
314.	Esomeprazole 40 mg Capsule	A02BC0500 T1001XX	i) Gastro-oesophageal reflux disease ii) H. pylori eradication	i) 20mg daily for 4-8 weeks ii) 40mg daily for 10 days in combination with amoxicillin 1g twice daily or clarithromycin 500mg twice daily	A (SRQ MED) (SRQ SURG)
315.	Essential Phospholipids, nicotinamide, cyanocobalamin, tocopheryl, pyridoxine, thiamine, riboflavin capsule	A05BA0092 4C1001XX	Nutritional support in the management of damaged liver (due to chronic liver disease, liver cirrhosis, fatty liver & intoxication by hepatotoxic substances).	1-2 capsules 3 times a day	A/KK

No.	Generic Name	MDC	Indications	Dosage	Category
316.	Estradiol Valerate 1 mg Tablet	G03CA0325 6T1002XX	i. Hormone replacement therapy (HRT) for the treatment of signs and symptoms of estrogen deficiency due to natural menopause or castration. ii. Prevention of postmenopausal osteoporosis.	1-2 mg daily continuously. Titrate to the minimum effective dose necessary to control symptoms.	A* (SRQ O&G)
317.	Estradiol Valerate 2 mg and Norgestrel 500 mcg with Estradiol Valerate 2 mg Tablet	G03FB0195 3T1001XX	i. Hormone replacement therapy (HRT) for the treatment of signs and symptoms of estrogen deficiency due to menopause or hypogonadism, castration or primary ovarian failure in women with an intact uterus. ii. Prevention of postmenopausal osteoporosis. iii. Control of irregular menstrual cycles. iv. Treatment of primary or secondary amenorrhea.	One white tablet daily for the first 11 days, followed by one light brown tablet daily for 10 days then stop for a 7- day tablet-free interval before commencing next pack.	B
318.	Ethambutol HCl 400 mg Tablet	J04AK02110 T1002XX	Tuberculosis	Adult: 15-25 mg/kg daily (max 1200 mg) or 50 mg/kg biweekly (max 2000 mg). Children: 15-25 mg/kg daily or 50 mg/kg twice weekly.	B
319.	Ether Solvent	N01AA0100 0L9901XX	To remove adhesive plaster from the skin	Dose depending on the route and procedure	C
320.	Ethionamide 250 mg Tablet	J04AD03000 T1001XX	As second-line therapy in the treatment of Multi Drug Resistant Tuberculosis only in combination with other efficacious agents and only when therapy with isoniazid, rifampicin, or other first-line agents has failed.	ADULT: 15-20 mg/kg daily, in divided doses if necessary; maximum dose 1g/day. CHILD: 10-20 mg/kg in 2-3 divided doses or 15 mg/kg/24hrs as a single daily dose.	A* (SRQ MED) (SRQ PAED)
321.	Ethyl Chloride 100 ml Spray	N01BX0100 0A4001XX	For minor surgical procedures including lancing boils, incision and drainage of small abscesses, pain due to athletic injuries and pain due to injection administration	Spray to affected area at a distance of about 30cm until a fine white film is produced	C
322.	Etomidate 20 mg / 10 ml Injection	N01AX0700 0P3001XX	Induction of general anaesthesia for haemodynamically unstable patients	Adult: 300 mcg/kg given slowly over 30-60 seconds into a large vein in the arm. Child: Up to 30% more than the standard adult dose. Elderly: 150-200 mcg/kg, subsequently adjusted according to effects.	A* (SRQ A&E-UKK)
323.	Etonogestrel 68 mg Implant	G03AC0800 0P1001XX	Contraception	Subdermal insertion: A single implant is effective for 3 years (to be removed 3 years from the date of insertion)	A/KK (SRQ O&G)

No.	Generic Name	MDC	Indications	Dosage	Category
324.	Etoricoxib 90 mg Tablet	M01AH0500 OT1001XX	i) Acute and chronic treatment of signs and symptoms of osteoarthritis (OA) and rheumatoid arthritis (RA) ii) Acute gouty arthritis iii) Acute pain	i) OA: 60 mg once daily. RA: 60mg once daily and may be increased to 90mg once daily if needed. Once the patient is stabilized, down-titration to 60mg once daily may be appropriate. ii & iii) Acute gouty arthritis and acute pain: 120 mg once daily (Given the exposure to COX-2 inhibitors, doctors are advised to use the lowest effective dose for the shortest possible duration of treatment)	A/KK (SRQ ANAES) (SRQ ORTHO) (SRQ REHAB) (SRQ SURG)
325.	Etoricoxib 120 mg Tablet	M01AH0500 OT1002XX	i) Acute and chronic treatment of signs and symptoms of osteoarthritis (OA) and rheumatoid arthritis (RA) ii) Acute gouty arthritis iii) Acute pain	i) OA: 60 mg once daily. RA: 60mg once daily and may be increased to 90mg once daily if needed. Once the patient is stabilized, down-titration to 60mg once daily may be appropriate. ii & iii) Acute gouty arthritis and acute pain: 120 mg once daily (Given the exposure to COX-2 inhibitors, doctors are advised to use the lowest effective dose for the shortest possible duration of treatment)	A* (SRQ A&E)
326.	Ezetimibe 10 mg Tablet	C10AX0900 OT1001XX	i) Co-administration with statins for patients who have chronic heart disease or are chronic heart disease equivalent or familial hypercholesterolaemia with target LDL-C not achieved by maximum dose of statins ii) Monotherapy in patients with documented biochemical intolerance to statins	10 mg once daily. Not recommended for children less than 10 years old	A* (SRQ MED)

No.	Generic Name	MDC	Indications	Dosage	Category
327.	Factor IX, Factor II, Factor VII and Factor X In Combination Injection	B02BD0100 0P4001XX	i) Treatment and perioperative prophylaxis of bleeding in acquired deficiency of the prothrombin complex coagulation factors, such as deficiency caused by treatment with vitamin K antagonists, or in case of overdose of vitamin K antagonists, when rapid correction of the deficiency is required. ii) Treatment and perioperative prophylaxis of bleeding in congenital deficiency of any of the vitamin K dependent coagulation factors only if purified specific coagulation factor product is not available.	Amount and frequency of administration should be calculated on an individual patient basis. Individual dosage requirements can only be identified on the basis of regular determinations of the individual plasma levels of the coagulation factors of interest or on the global tests of the prothrombin complex levels (INR, Quick's test) and a continuous monitoring of the clinical condition of the patient. An approximate calculation is as follows: Required dose (IU) = body weight (kg) x desired factor rise (IU/dl or % of normal) x reciprocal of the estimated recovery, i.e. Factor II = 53 Factor VII = 59 Factor IX = 77 Factor X = 56 As product may differ from one to another, it is strongly advised to refer to the manufacturer (product insert) in regards to dosing calculation.	A* (SRQ MED) (SRQ ANAES) (SRQ A&E)
328.	Factor VIIa Recombinant eptacog alfa (activated) 50 KIU (1 mg) Injection	B02BD0800 0P4004XX	Treatment of bleeding episodes and prevention of excessive bleeding in connection with surgery in patients with inherited or acquired haemophilia with inhibitors to coagulation factors VIII or IX	Initially 4.5 KIU (90 mcg)/kg body weight IV bolus over 2-5 minutes, followed by 3-6 KIU (60-120 mcg)/kg body weight depending on type & severity of haemorrhage or surgery performed. Dosing interval: initially 2-3 hour to obtain haemostasis and until clinically improved. If continued therapy is needed, dose interval can be increased successively to every 4, 6, 8 or 12 hours	A* (SRQ MED)

No.	Generic Name	MDC	Indications	Dosage	Category
329.	Factor VIII Inhibitor Bypassing Activity Injection	B02BD0300 OP4001XX	i) Treatment and prophylaxis of hemorrhages in hemophilia A and B patients with inhibitors. ii) Treatment and prophylaxis of hemorrhages in non-hemophilic patients who have developed inhibitors to Factors VIII, IX and XI. iii) Treatment of patients with acquired inhibitors to Factors X and XIII. iv) In the combination with Factor VIII concentrate for a long-term therapy to achieve a complete and permanent elimination of the Factor VIII inhibitor so as to allow for regular treatment with Factor VIII concentrate as in patients without inhibitor.	As a general guideline, a dose of 50 to 100 IU/kg body weight is recommended, not exceeding an individual dose of 100IU/kg bw and a maximum daily dose of 200 IU/kg bw.	A (SRQ MED)
330.	Factor VIII (Human blood coagulation factor) & Von Willebrand factor Injection	B02BD0600 OP4002XX	i) The treatment and prophylaxis of haemorrhage or surgical bleeding in Von Willebrand Disease (VWD) when 1-deamino-8-D-arginine vasopressin (desmopressin, DDAVP) treatment alone is ineffective or contraindicated. ii) The treatment and prophylaxis of bleeding associated with factor VIII deficiency due to haemophilia A.	i) Von Willebrand Disease: Spontaneous Bleeding Episodes: Initially, factor VIII 12.5-25 IU/kg and ristocetin cofactor 25-50 IU/kg followed by factor VIII 12.5 IU/kg and ristocetin cofactor 25 IU/kg subsequently every 12-24 hrs. Minor Surgery: Factor VIII 30 IU/kg and ristocetin cofactor 60 IU/kg daily. Major Surgery: Initially, factor VIII 30-40 IU/kg and ristocetin cofactor 60-80 IU/kg followed by factor VIII 15-30 IU/kg and ristocetin cofactor 30-60 IU/kg subsequently every 12-24 hrs. Prophylaxis: Factor VIII 12.5-20 IU/kg and ristocetin cofactor 25-40 IU/kg 3 times weekly. ii) Hemophilia A therapy: Minor haemorrhage: 10-15 IU/kg every 12-24 hours. Moderate to severe haemorrhage: 15-40 IU/kg every 8 to 24 hours. Minor surgery: Loading dose 20-30 IU/kg, maintenance dose 15-30 IU/kg. Major surgery: Loading dose 40-50 IU/kg, maintenance dose 10-40 IU/kg. Prophylaxis: 25-40 IU/kg three times weekly As product may differ from one to another, it is strongly advised to refer to the manufacturer (product insert) in regards to dosing calculation.	A* (SRQ MED)

No.	Generic Name	MDC	Indications	Dosage	Category
331.	Factor IX Injection	B02BD04-000-P99-01-XXX	Prevention and control of bleeding in patients with factor IX deficiency due to haemophilia B	Number of factor IX units required = body weight (kg) x desired factor IX increase (%) x 1.0 IU/kg Dosing is individualised and according to product insert/protocol.	A (SRQ MED)
332.	Fat Emulsion 20 % for IV Infusion (Intralipid)	B05BA0200 0P6002XX	Local anaesthetic toxicity	Dose to be individualised.	A (SRQ ANAES)
333.	Fat Emulsion 20 % for IV Infusion (SMOFlipid)	B05BA0200 0P6002XX	Source of lipid in patients needing IV nutrition	Dose to be individualised. ADULT usual lipid requirement 2-3 g/kg/day. INFANT 0.5-1 g/kg/day	A (SRQ GENERAL)
334.	Felodipine 5 mg Extended Release Tablet	C08CA0200 0T1001XX	Hypertension	Initiate at 5 mg once daily. Usual dose, 5 - 10 mg once daily in the morning	A/KK (SRQ MED)
335.	Felodipine 10 mg Extended Release Tablet	C08CA0200 0T1002XX	Hypertension	Initiate at 5 mg once daily. Usual dose, 5 - 10 mg once daily in the morning	A/KK (SRQ MED)
336.	Fentanyl Citrate 50 mcg / ml Injection	N01AH01-136-P30-01-XXX	Short duration analgesia during pre-medication induction and maintenance of anaesthesia, and in the immediate post-operative period.	Dose should be individualized according to age, body weight, physical status, underlying pathological conditions and type of surgery and anaesthesia. ADULT: Premedication: IM 50 - 100 mcg, 30 - 60 mins prior to surgery. Adjunct to general anaesthesia: Induction IV 50 – 100 mcg, repeat 2 - 3 mins intervals until desired effect is achieved. IV/IM 25 - 50mcg in elderly and poor risk patients. Maintenance: IV/IM 25 – 50 mcg. Adjunct to regional anaesthesia: IM/slow IV 50 - 100mcg when additional analgesia is required. Post-operatively (recovery room): IM 50 - 100mcg for pain control, tachypnoea and emergency delirium. May be repeated in 1- 2 hours as needed. CHILD (2 - 12 years): Induction & maintenance: 2 - 3 mcg/kg.	A
337.	Fentanyl 12mcg / h Transdermal Patch	N02AB03-136-M70-05-XXX	As a second line drug in the management of opioid responsive, moderate to severe chronic cancer pain.	ADULT and CHILD over 2 years previously treated with a strong opioid analgesic, initial dose based on previous 24-hour opioid requirement (consult product literature). If necessary dose should be adjusted at 72-hour intervals in steps of 12-25 mcg/hr	A* (SRQ Palliative)

No.	Generic Name	MDC	Indications	Dosage	Category
338.	Fentanyl 25 mcg /h Transdermal Patch	N02AB03-136-M70-01-XXX	As a second line drug in the management of opioid responsive, moderate to severe chronic cancer pain	Patients who have not previously received a strong opioid analgesic, initial dose , one 25 mcg/hour patch to be replaced after 72 hours. Patients who have received a strong opioid analgesic, initial dose based on previous 24 hours opioid requirement (oral morphine sulphate 90 mg over 24 hours = one 25 mcg/hour patch). Not recommended in children.	A* (SRQ Palliative)
339.	Ferric Ammonium Citrate 800 mg/10 ml Peadiatric Mixture	B03AB0613 6L2101XX	Prevention and treatment of iron-deficiency anaemias	CHILD up to 1 year 5 ml, 1 - 5 years 10 ml, taken well diluted with water	C
340.	Ferrous controlled release 525 mg, Vitamin B1, Vitamin B2, Vitamin B6, Vitamin B12, Vitamin C, Niacinamide, Calcium Pantothenate, Folic Acid 800 mcg Tablet	B03AE1090 3T1001XX	Anemia due to iron deficiency, megaloblastic anemia where there is an associated deficiency of Vitamin C and Vitamin B-complex particularly in pregnancy. In primary health clinic, the indication is restricted to anemia due to iron deficiency in pregnant women ONLY.	One tablet daily	A/KK (SRQ O&G)
341.	Ferrous Fumarate 200 mg Tablet	B03AA0213 8T1001XX	Prevention and treatment of iron deficiency anaemias	Adult: Usual dose range: Up to 600 mg daily. May increase up to 1.2 g daily if necessary. Child: As syrup containing 140 mg(45 mg iron)/5 ml. Preterm neonate: 0.6-2.4 ml/kg daily; up to 6 years old: 2.5-5 ml twice daily	C+
342.	Filgrastim (G-CSF) 30 MU/ ml Injection	L03AA02000 P3001XX	i) Prevention and treatment of febrile neutropenia due to cancer chemotherapy (except chronic myeloid leukaemia and myelodysplastic syndrome) ii) Haemopoietic stem cell transplantation (HSCT)/stem cell harvesting	i) Adult: SC or IV 5 mcg/kg/day. Initiation: 24 - 72 hours after chemotherapy. Duration: Until a clinically adequate neutrophil recovery is achieved (absolute neutrophil count of at least 1 x 10 ⁹ /L on 2 consecutive days) ii) Refer to protocol	A* (SRQ GENERAL)
343.	Finasteride 5 mg Tablet	G04CB0100 0T1001XX	Treatment and control of benign prostatic hyperplasia Prescribing restrictions Consultant/specialists for specific indications only, including geriatricians	5mg once daily	A* (SRQ SURG)

344.	Fluconazole 50 mg Capsule	J02AC01000 C1001XX	i) Cryptococcosis a) cryptococcal meningitis and infections of other sites (e.g., pulmonary, cutaneous) b) Prevention of relapse of cryptococcal meningitis in patients in AIDS after a full course of primary therapy ii) Systemic candidiasis, including candidemia, disseminated candidiasis and other forms of invasive candidal infections. These include infections of the peritoneum, endocardium, eye, and pulmonary and urinary tracts. iii) Mucosal candidiasis. a) Oropharyngeal candidiasis b) Chronic oral atrophic candidiasis (denture sore mouth) c) Oesophageal, non-invasive bronchopulmonary infections, candiduria, mucocutaneous candidiasis d) Prevention of relapse of oropharyngeal candidiasis in patients with AIDS, after a full course of primary therapy iv) Genital candidiasis. a) Vaginal candidiasis (acute or recurrent) b) Prophylaxis of recurrent vaginal candidiasis (three or more episodes a year) c) Candidal balanitis. v) Prevention of fungal infections in patients with malignancy who are predisposed to such infections as a result of cytotoxic chemotherapy or radiotherapy. vi) Dermatomycosis a) Tinea pedis, tinea corporis, tinea cruris and dermal Candida infections b) Tinea versicolor	i) a) 400mg on Day1 followed by 200mg to 400mg once daily usually at least 6 to 8 weeks for cryptococcal meningitis. CHILD $\geq$ 4 weeks-11 years: Treatment: 6-12mg/kg once daily. b) 200 mg once daily indefinitely. CHILD:- Maintenance: 6mg/kg once daily ii) 400 mg on Day 1 followed by 200 mg once daily CHILD $\geq$ 4 weeks-11 years: 6-12mg/kg once daily. iii) a) 50mg to 100mg once daily for 7 to 14 days CHILD:- Loading dose: 6mg/kg on Day 1 followed by 3mg/kg daily. b) 50 mg once daily for 14 days concurrently with local antiseptic measures to the denture c) 50 mg to 100 mg once daily for 14 to 30 days. CHILD:- 0-14 days: Initially, 6mg/kg, followed by 3mg/kg every 72 hours. Max: 12 mg/kg 72 hourly. 15-27 days: Initially, 6mg/kg, followed by 3 mg/kg every 48 hours. Max: 12 mg/kg 48 hourly. 28 days-11 years: Initially, 6 mg/kg, followed by 3 mg/kg once daily. d) 150 mg once weekly. iv) a) 150 mg as a single oral dose. b) 150 mg once-monthly dose may be used for usually 4 to 12 months c) 150 mg as a single oral dose. v) 50 mg to 400 mg once daily vi) a) 150 mg once weekly or 50 mg once daily for normally 2 to 6 weeks b) 300mg once weekly for 2 weeks; a third weekly dose of 300-400mg. An alternate dosing regimen is 50mg once daily for 2 to 4 weeks. Dosing is individualised and according to product insert/protocol.	A (SRQ GENERAL)
------	----------------------------------	-----------------------	--	--	--------------------

345.	Fluconazole 100 mg Capsule	J02AC01000 C1002XX	i) Cryptococcosis a) cryptococcal meningitis and infections of other sites (e.g., pulmonary, cutaneous) b) Prevention of relapse of cryptococcal meningitis in patients in AIDS after a full course of primary therapy ii) Systemic candidiasis, including candidemia, disseminated candidiasis and other forms of invasive candidal infections. These include infections of the peritoneum, endocardium, eye, and pulmonary and urinary tracts. iii) Mucosal candidiasis. a) Oropharyngeal candidiasis b) Chronic oral atrophic candidiasis (denture sore mouth) c) Oesophageal, non-invasive bronchopulmonary infections, candiduria, mucocutaneous candidiasis d) Prevention of relapse of oropharyngeal candidiasis in patients with AIDS, after a full course of primary therapy iv) Genital candidiasis. a) Vaginal candidiasis (acute or recurrent) b) Prophylaxis of recurrent vaginal candidiasis (three or more episodes a year) c) Candidal balanitis. v) Prevention of fungal infections in patients with malignancy who are predisposed to such infections as a result of cytotoxic chemotherapy or radiotherapy. vi) Dermatomycosis a) Tinea pedis, tinea corporis, tinea cruris and dermal Candida infections b) Tinea versicolor	i) a) 400mg on Day1 followed by 200mg to 400mg once daily usually at least 6 to 8 weeks for cryptococcal meningitis. CHILD $\geq$ 4 weeks-11 years: Treatment: 6-12mg/kg once daily. b) 200 mg once daily indefinitely. CHILD:- Maintenance: 6mg/kg once daily ii) 400 mg on Day 1 followed by 200 mg once daily CHILD $\geq$ 4 weeks-11 years: 6-12mg/kg once daily. iii) a) 50mg to 100mg once daily for 7 to 14 days CHILD:- Loading dose: 6mg/kg on Day 1 followed by 3mg/kg daily. b) 50 mg once daily for 14 days concurrently with local antiseptic measures to the denture c) 50 mg to 100 mg once daily for 14 to 30 days. CHILD:- 0-14 days: Initially, 6mg/kg, followed by 3mg/kg every 72 hours. Max: 12 mg/kg 72 hourly. 15-27 days: Initially, 6mg/kg, followed by 3 mg/kg every 48 hours. Max: 12 mg/kg 48 hourly. 28 days-11 years: Initially, 6 mg/kg, followed by 3 mg/kg once daily. d) 150 mg once weekly. iv) a) 150 mg as a single oral dose. b) 150 mg once-monthly dose may be used for usually 4 to 12 months c) 150 mg as a single oral dose. v) 50 mg to 400 mg once daily vi) a) 150 mg once weekly or 50 mg once daily for normally 2 to 6 weeks b) 300mg once weekly for 2 weeks; a third weekly dose of 300-400mg. An alternate dosing regimen is 50mg once daily for 2 to 4 weeks. Dosing is individualised and according to product insert/protocol.	A
------	-----------------------------------	-----------------------	--	--	---

346.	Fluconazole 2 mg / ml Injection	J02AC01000 P9901XX	i) Cryptococcosis a) cryptococcal meningitis and infections of other sites (e.g., pulmonary, cutaneous) b) Prevention of relapse of cryptococcal meningitis in patients in AIDS after a full course of primary therapy ii) Systemic candidiasis, including candidemia, disseminated candidiasis and other forms of invasive candidal infections. These include infections of the peritoneum, endocardium, eye, and pulmonary and urinary tracts. iii) Mucosal candidiasis. a) Oropharyngeal candidiasis b) Chronic oral atrophic candidiasis (denture sore mouth) c) Oesophageal, non-invasive bronchopulmonary infections, candiduria, mucocutaneous candidiasis d) Prevention of relapse of oropharyngeal candidiasis in patients with AIDS, after a full course of primary therapy iv) Genital candidiasis. a) Vaginal candidiasis (acute or recurrent) b) Prophylaxis of recurrent vaginal candidiasis (three or more episodes a year) c) Candidal balanitis. v) Prevention of fungal infections in patients with malignancy who are predisposed to such infections as a result of cytotoxic chemotherapy or radiotherapy. vi) Dermatomycosis a) Tinea pedis, tinea corporis, tinea cruris and dermal Candida infections b) Tinea versicolor	i) a) 400mg on Day1 followed by 200mg to 400mg once daily usually at least 6 to 8 weeks for cryptococcal meningitis. CHILD $\geq$ 4 weeks-11 years: Treatment: 6-12mg/kg once daily. b) 200 mg once daily indefinitely. CHILD:- Maintenance: 6mg/kg once daily ii) 400 mg on Day 1 followed by 200 mg once daily CHILD $\geq$ 4 weeks-11 years: 6-12mg/kg once daily. iii) a) 50mg to 100mg once daily for 7 to 14 days CHILD:- Loading dose: 6mg/kg on Day 1 followed by 3mg/kg daily. b) 50 mg once daily for 14 days concurrently with local antiseptic measures to the denture c) 50 mg to 100 mg once daily for 14 to 30 days. CHILD:- 0-14 days: Initially, 6mg/kg, followed by 3mg/kg every 72 hours. Max: 12 mg/kg 72 hourly. 15-27 days: Initially, 6mg/kg, followed by 3 mg/kg every 48 hours. Max: 12 mg/kg 48 hourly. 28 days-11 years: Initially, 6 mg/kg, followed by 3 mg/kg once daily. d) 150 mg once weekly. iv) a) 150 mg as a single oral dose. b) 150 mg once-monthly dose may be used for usually 4 to 12 months c) 150 mg as a single oral dose. v) 50 mg to 400 mg once daily vi) a) 150 mg once weekly or 50 mg once daily for normally 2 to 6 weeks b) 300mg once weekly for 2 weeks; a third weekly dose of 300-400mg. An alternate dosing regimen is 50mg once daily for 2 to 4 weeks.	A (SRQ GENERAL)
------	--	-----------------------	--	---	--------------------

No.	Generic Name	MDC	Indications	Dosage	Category
				Dosing is individualised and according to product insert/protocol.	
347.	Flucytosine 500 mg Tablet	J02AX01000 T1001XX	Only for the treatment of fungal meningitis	ADULT: 50 - 150 mg/kg/day in 4 divided doses	A* (UKK MED)
348.	Fludrocortisone Acetate 0.1 mg Tablet	H02AA0212 2T1001XX	As an adjunct to glucocorticoids in the management of primary adrenocortical insufficiency in Addison's disease and treatment of salt-losing adrenogenital syndrome	Adrenocorticoid insufficiency (chronic): ADULT 1 tablet daily. Salt-losing adrenogenital syndrome: ADULT 1 - 2 tablets daily. CHILD and INFANT 0.5 - 1 tablet daily	A (UKK CFLN) (SRQ MED) (SRQ PAED)
349.	Flumazenil 0.1 mg / ml Injection	V03AB2500 OP3001XX	i) Diagnosis and/or management of benzodiazepine overdose due to self-poisoning or accidental overdose ii) Reversal of sedation following anaesthesia with benzodiazepine	i) Initial, 0.2 mg IV over 30 seconds; if desired level of consciousness not obtained after an additional 30 seconds, give dose of 0.3 mg IV over 30 seconds; further doses of 0.5 mg IV over 30 seconds may be given at 1-minutes intervals if needed to maximum total dose of 3 mg; patients with only partial response to 3 mg may require additional slow titration to a total dose of 5 mg; if no response 5 minutes after receiving total dose of 5 mg, overdose is unlikely to be benzodiazepine and further treatment with flumazenil will not help ii) 0.2 mg IV over 15 seconds; if desired level of consciousness is not obtained after waiting 45 seconds, a second dose of 0.2 mg IV may be given and repeated at 60-seconds intervals as needed (up to a maximum of 4 additional times) to a maximum total dose of 1 mg; most patients respond to doses of 0.6 to 1 mg; in the event of re-sedation, repeated doses may be given at 20-minutes intervals if needed; for repeat treatment, no more than 1 mg (given as 0.5 mg/minute) should be given at any one time and no more than 3 mg should be given in any one hour	B
350.	Flunarizine HCl 5 mg Capsule	N07CA0311 OC1001XX	i) Migraine prophylaxis ii) Maintenance treatment of vestibular disturbances and of cerebral and peripheral disorders	i) ADULT: 5 - 10 mg daily preferably at night. ELDERLY more than 65 years: 5 mg at night. Maintenance 5-day treatment at the same daily dose ii) 5 - 10 mg at night. If no improvement after 1 month, discontinue treatment	B

No.	Generic Name	MDC	Indications	Dosage	Category
351.	Fluorescein 1 mg Ophthalmic Strip	S01JA01520 M9901XX	Used in diagnostic examinations	Moisten tip with tear fluid from lower fornix, sterile water or ophthalmic solution and gently stroke across the conjunctiva	B
352.	Fluorescein Sodium 10 % Injection	S01JA01520 P3001XX	Diagnostic fluorescein angiography or angioscopy of the fundus and of the iris vasculature	ADULT: Inject 5 mL of Fluorescein 10% solution for injection rapidly into the antecubital vein after taking precautions to avoid extravasation. Dosing is individualised and according to product insert/protocol	A (SRQ OPHTH)
353.	Fluorometholone 0.1 % Ophthalmic Suspension	S01BA0700 0D2001XX	Treatment of steroid responsive ocular inflammation	1-2 drops 2 to 4 times daily. During the initial 24-48 hr, dose may be increased to 2 drops 2 hourly.	A* (SRQ OPHTH)
354.	Fluoxetine HCl 20mg Tablet	N06AB0311 0C1001XX	i) Depressive illness ii) Obsessive compulsive disorder	i) 20 mg once daily increased after 3 weeks if necessary, usual dose 20 - 60 mg (ELDERLY 20 - 40 mg) once daily max 80 mg once daily (ELDERLY max 60 mg once daily). ii) Initially 20 mg once daily increased after 2 weeks if necessary, usual dose 20 - 60 mg (ELDERLY 20 - 40 mg) once daily, max 80 mg (ELDERLY max 60 mg) once daily, discontinue if no improvement within 10 weeks. CHILD and ADOLESCENT under 18 years are not recommended	A/KK (SRQ PSY)
355.	Flupenthixol Decanoate Depot 20 mg / ml Injection	N05AF0113 5P2001XX	Chronic psychoses	By deep IM, initial test dose of 5-20 mg, then after at least 7 days. 20 - 40 mg repeated at intervals of 2 - 4 weeks. Maximum 400 mg weekly. Usual maintenance dose 50 mg every 4 weeks to 300 mg every 2 weeks. ELDERLY, initially quarter to half adult dose. CHILD not recommended. Deep IM recommended. Not for IV use	B
356.	Fluphenazine Decanoate 25 mg / ml Injection	N05AB0213 5P3001XX	Long term management of psychotic disorders	By deep IM : Test dose 12.5 mg (6.25 mg in ELDERLY), then after 4-7 days 12.5 mg-100 mg repeated at intervals of 14-35 days, adjusted according to response. CHILD not recommended	B
357.	Fluticasone Furoate 27.5 mcg / dose Nasal Spray	R01AD0813 9A4101XX	Treatment of nasal symptoms (rhinorrhea, nasal congestion, nasal itching and sneezing) and ocular symptoms (itching/burning, tearing/watering, and redness of the eye) of seasonal and perennial allergic rhinitis	Adults/Adolescents (≥12years): 1-2 sprays(27.5 mcg/spray) in each nostril once daily. Children (2-11 years): 1-2 sprays (27.5 mcg/spray) in each nostril once daily	A* (SRQ ENT)

No.	Generic Name	MDC	Indications	Dosage	Category
358.	Fluticasone Propionate 125 mcg/dose Inhaler	R03BA0513 3A2101XX	Prophylactic treatment for asthma	ADULT and CHILD more than 16 years i) Mild asthma: 100 mcg - 250 mcg twice daily ii) Moderate asthma: 250 - 500 mcg twice daily iii) Severe asthma: 500 mcg - 1000 mcg twice daily. Alternatively, the starting dose of fluticasone dipropionate may be gauged at half the total daily dose of beclomethasone dipropionate or equivalent administered by inhalation.	B (SRQ PAED)
359.	Fluvoxamine 50 mg Tablet	N06AB0825 3T1001XX	i) Depression ii) Obsessive Compulsive Disorder	i) Initial: 50 - 100 mg daily in the evening, increased if necessary to 300 mg daily (over 150 mg in divided doses); usual maintenance dose 100 mg daily. CHILD and ADOLESCENT under 18 years not recommended ii) Starting dose is 50 mg per day for 3 – 4 days.(The effective dosage is 100-300 mg). The starting dose for children from 8 years on and adolescents is 25mg per day, preferably at bedtime. (Max: 200 mg) (>50mg divided dose)	B
360.	Folic Acid 5 mg Tablet	B03BB0100 0T1001XX	i) For the prevention and treatment of folate deficiency states ii) For the prevention of neural tube defect in the foetus	i) ADULT initially 10-20mg mg daily for 14 days or until haematopoietic response obtained. Daily maintenance: 2.5 mg-10mg .CHILD up to 1 year:250 mcg/kg daily; 1 to 5 years:2.5mg/day;6-12 years: 5mg/day ii) 5 mg daily starting before pregnancy and continued through the first trimester	C+

No.	Generic Name	MDC	Indications	Dosage	Category
361.	Fondaparinux Sodium 2.5 mg / 0.5 ml Injection	B01AX0552 0P5001XX	i) Prevention of venous thromboembolic events (VTE) in orthopedic surgery (e.g. hip fracture, major knee or hip replacement surgery), abdominal surgery in patients at risk of thromboembolic complication. ii) Treatment of unstable angina or non-ST segment elevation myocardial infarction [UA/NSTEMI] in patients for whom urgent invasive management (PCI) is not indicated. iii) Treatment of ST segment elevation myocardial infarction (STEMI) in patients managed with thrombolytics or are not receiving other forms of reperfusion therapy	i) 2.5 mg once daily given by SC, administered 6 hr following surgical closure provided homeostasis has been established. Usual duration of therapy is 5 to 9 days; for hip fracture patients, an extended course of up to 24 days is recommended. ii) ADULT more than 18 years: 2.5 mg once daily given by SC, initiated as soon as possible after diagnosis and continued for up to 8 days or until hospital discharge. If patient needs to undergo PCI, unfractionated heparin to be admin as per local practice protocol, taking into account the patient's bleeding risk and time of last dose of fondaparinux. Fondaparinux may be restarted no earlier than 2 hr after sheath removal. iii) ADULT more than 18 years: 2.5 mg once daily; first dose to be given IV (directly through an existing IV line or as infusion in 25 or 50 ml of 0.9% saline over 1-2 min), subsequent doses to be given SC. Treatment to be initiated as soon as diagnosis is made and continued up to a max of 8 days or until hospital discharge, whichever comes earlier. If patient needs to undergo non-primary PCI, unfractionated heparin to be admin as per local practice protocol, taking into account the patient's bleeding risk and time of last dose of fondaparinux. Fondaparinux may be restarted no earlier than 3 hr after sheath removal	A* (SRQ GENERAL)
362.	Frusemide 10 mg / ml Injection	C03CA0100 0P3001XX	Oedema	Initial: 20-50mg once via slow IV or IM Maintenance: Increase by 20mg every 2 hours and titrate to an effective dose if necessary. CHILD: 0.5 - 1.5 mg/kg 6-24hourly. Dosing is individualised and according to product insert / protocol.	B

No.	Generic Name	MDC	Indications	Dosage	Category
363.	Frusemide 40 mg Tablet	C03CA0100 OT1001XX	Oedema	ADULT: Initial: 20-80mg daily Max. 600mg/day CHILD: 1-3mg/kg daily Max. 40mg/day Dosing is individualised and according to product insert / protocol.	B
364.	Frusemide 10mg/ml Oral Solution	C03CA01- 000-L90-01- XXX	Oedema	ADULT: Initial: 20-80mg daily. Max. 600mg/day. CHILD: 1-3mg/kg daily. Max. 40mg/day. Dosing is individualised and according to product insert / protocol.	B (SRQ/UKK PAED)
365.	Fuller's Earth Powder	V03AB0000 0F2101XX	Adsorbent in pesticide poisoning	Adult: 100-150 g every 2-4 hours. Child: 1-2 g/kg. (100 g of Fuller's Earth is mixed with 200 ml water. Repeat until Fuller's Earth is seen in stool (normally between 4-6 hours)	C
366.	Fusidic Acid 1 % Eye Drops	S01AA1300 0D2001XX	Bacterial eye infections caused by susceptible organisms	1 drop in conjunctival sac 12 hourly. To be continued for 2 days after the eye appears normal. On the first day of treatment, may be applied more frequently : 1 drop 4 hourly. Surgical prophylaxis : 1 drop every 12 hours, 24 - 48 hours before operation	A (SRQ OPHTH)
367.	Gabapentin 100 mg Tablet	N03AX1200 OT1002X X	i) Add-on therapy for intractable partial epilepsy, refractory to standard anti-epileptic drugs ii) Treatment of various types of neuropathic pain, both peripheral (which includes diabetic neuropathy, post-herpetic neuralgia, trigeminal neuralgia) in adult more than 18 years	ADULT & CHILD > 12 yrs: 900-3600 mg/day. Therapy may be initiated by administering 300 mg TDS on day 1, or by titrating the dose as: 300 mg once on day 1, 300 mg BD on day 2, 300 mg TDS on day 3. Thereafter, then dose may be increased in 3 equally divided doses up to max 3600 mg/day. CHILD 3-12 yr: Initially 10-15 mg/kg/day in 3 divided dose. Effective dose: CHILD 3 to less than 5 yrs: 40 mg/kg/day in 3 divided doses, CHILD 5-12 yrs: 25-35 mg/kg/day in 3 divided doses ii) ADULT: 900 mg/day in 3 equally divided doses. Max 3600 mg/day	A* (SRQ ANAES) (SRQ REHAB) (SRQ Palliative)

No.	Generic Name	MDC	Indications	Dosage	Category
368.	Gabapentin 300 mg Capsule	N03AX1200 0C1001XX	PRESCRIBER CATEGORY A*: Add-on therapy for intractable partial epilepsy, refractory to standard anti-epileptic drugs. PRESCRIBER CATEGORY A/KK: Treatment of various types of neuropathic pain, both peripheral (which includes diabetic neuropathy, post-herpetic neuralgia, trigeminal neuralgia) in adult more than 18 years.	ADULT & CHILD > 12 yrs: 900-3600 mg/day. Therapy may be initiated by administering 300 mg TDS on day 1, or by titrating the dose as: 300 mg once on day 1, 300 mg BD on day 2, 300 mg TDS on day 3. Thereafter, then dose may be increased in 3 equally divided doses up to max 3600 mg/day. CHILD 3-12 yr: Initially 10-15 mg/kg/day in 3 divided dose. Effective dose: CHILD 3 to less than 5 yrs: 40 mg/kg/day in 3 divided doses, CHILD 5-12 yrs: 25-35 mg/kg/day in 3 divided doses ii) ADULT: 900 mg/day in 3 equally divided doses. Max 3600 mg/day	A*, A/KK (SRQ GENERAL)
369.	Gemfibrozil 300 mg Capsule	C10AB0400 0C1001XX	Treatment of hyperlipoproteinaemias (TYPES IIA, IIB, III, IV, V)	ADULT: 1200 mg/day in 2 divided doses, 30 minutes before breakfast and dinner. Dose range from 0.9 - 1.5 g daily	A/KK (SRQ MED)
370.	Gentamicin 0.1% Cream	D06AX0718 3G1001XX	For the treatment of primary and secondary skin infections caused by susceptible bacteria.	Apply 2 - 3 times daily	A* (SRQ MED)
371.	Gentamicin 0.3% Eye Drops	S01AA1118 3D2001XX	Bacterial eye infections caused by susceptible organisms	1 drops every 4 hours, in severe infection dosage may be increased up to 1 drops every hour Dosing is individualised and according to product insert/protocol	A/KK (SRQ GENERAL)
372.	Gentamicin 0.3% Eye Ointment	S01AA1118 3G5101XX	Bacterial eye infections caused by susceptible organisms	Apply a small amount (approx. 1/2-inch ribbon) into affected eye(s) 2-3 times daily.	A/KK (SRQ GENERAL)
373.	Gentamicin Sulphate 40 mg/ml Injection	J01GB03183 P3003XX	Infections due to susceptible organisms	ADULT: 3 - 5 mg/kg/day 8 hourly IM or IV. CHILD up to 2 weeks: 3 mg/kg every 12 hours; 2 weeks - 12 years: 2 mg/kg 8 hourly	B
374.	Gliclazide 30 mg Modified Release Tablet	A10BB0900 0T5002XX	Diabetes mellitus type 2	Initially, 30 mg daily at breakfast time, may increase in successive steps to 60, 90 or 120mg daily at 1 month intervals. Max daily dose: 120mg	B (SRQ MED)
375.	Gliclazide 80 mg Tablet	A10BB0900 0T1001XX	Diabetes mellitus type 2	Initially 40-80 mg daily. A single dose should not exceed 160 mg and when higher doses are required, a twice daily split dosage is advised and should be divided. Maximum daily dose: 320 mg. For elderly, starting dose should be 40 mg twice daily.	B

No.	Generic Name	MDC	Indications	Dosage	Category
376.	Glucagon (Lyophilised) 1 mg / ml Injection	H04AA0100 0P4001XX	Management of hypoglycaemia	Adult, children > 20 kg: 1 mg by SC, IM or IV. Children < 20 kg : 0.5 mg. If patient does not respond within 10 minutes, administer IV glucose. Repeat in 20 minutes if necessary.	B
377.	Glutaraldehyde Solution 2 %	V07AV0000 0L9905XX	High level disinfection for heat sensitive equipments such as endoscopes	20 minutes or more immersion is recommended for endoscopes before the session and between patients after thorough cleaning based on manufacturer recommendation	A
378.	Glycerin 25 % and Sodium Chloride 15 % Enema (Ravin Enema)	A06AG2092 1G2001XX	Constipation	1 enema as required	C+
379.	Glycerine 25 % w / w in aqueous cream	D02AX000G 1001XX	As an emollient for the symptomatic relief of dry skin conditions and as soap substitute for skin-bathing.	Apply to the affected area as required	C (SRQ PAED)
380.	Glyceryl Trinitrate 0.5 mg Sublingual Tablet	C01DA0222 1T1001XX	Prophylaxis and treatment of angina and left ventricular failure	0.5-1 mg sublingually may be repeated every 5 minutes until relief is obtained. Seek physician if the pain persists after a total of 3 tablets in a 15 minutes period.	C
381.	Glyceryl Trinitrate 5 mg / ml Injection	C01DA0222 1P3001XX	i) Angina pectoris. ii) Congestive heart failure. ii) Control of hypertensive episodes. iv) Production of controlled hypotension during surgery.	Initial: 5-25mcg/min Dosing is individualised and according to product insert or protocol.	A
382.	Glycine 1.5 % Irrigation Solution	B05CX0300 0H3001XX	Bladder irrigation during genitourinary surgery	The dosage depends on the extent of the procedure and its duration	A (SRQ SURG)
383.	Glycopyrrolate 200 mcg / ml Injection	A03AB0232 0P3001XX	i) To reduce secretions (respiratory tract) for certain types of surgery ii) Reversal of neuromuscular block in patients where atropine is contraindicated	i) ADULT: Pre-op: 4 mcg/kg via IM administration 30-60 mins before procedure. Intraoperative: 100 mcg via IV administration, repeat at 2-3 min intervals when needed. Max: 400 mcg/dose. CHILD: 4 to 8 mcg/kg IM or IV (maximum 200mcg), may be repeated if necessary, during operation. ii) ADULT: 200 mcg by IV for each 1 mg of neostigmine or 5 mg pyridostigmine CHILD: 10 mcg/kg IV for each 50 mcg/kg neostigmine or equivalent dose of pyridostigmine. Dosing is individualised and according to product insert/protocol	A* (SRQ ANAES) (SRQ PAED)

No.	Generic Name	MDC	Indications	Dosage	Category
384.	Goserelin 10.8 mg Depot Injection	L02AE0300 0P2002XX	Androgen deprivation therapy in prostate cancer.	One 10.8 mg depot injected subcutaneously into the anterior abdominal wall, every 12 weeks.	A (SRQ SURG)
385.	Granisetron HCl 1 mg / ml Injection	A04AA0211 0P3001XX	i) Prevention and treatment of nausea and vomiting associated with chemotherapy and radiotherapy ii) Post-operative nausea and vomiting	i) ADULT 1-3 mg as an IV bolus not less than 30 seconds; maximum 9 mg/day. CHILD over 2 years; single dose of 10-40 mcg/kg as an IV infusion; maximum 3 mg/day ii) ADULT 1 mg by slow IV injection over 30 seconds prior to induction of anaesthesia	A (SRQ GENERAL)
386.	Griseofulvin 125mg Tablet	D01BA0100 0T1001XX	Dermatophyte infections of the skin, scalp, hair and nails, where topical therapy has failed or inappropriate	Adults: 500mg-1000mg daily, taken as a single dose or in divided; Children: 10mg-20mg/kg daily in divided doses. The dosing is individualized according to product insert / protocol	B
387.	Haemodialysis Concentrate with Bicarbonate	B05ZA0090 8H1002XX	For acute renal failure, chronic renal failure, overhydration, intoxication, adjustment of acid-base and electrolyte balance	Dose depending on clinical cases	A (SRQ GENERAL)
388.	Haemophilus Influenza Type B Conjugate Vaccine Injection	J07AG01000 P4001XX	Immunisation of infants against Haemophilus Influenza Type B	0.5 ml IM. In patients with thrombocytopenia or bleeding disorders, vaccine can be administered by SC.	C+
389.	Haloperidol 1.5 mg Tablet	N05AD01-000-T10-01-XXX	i) Psychotic disorder – management of acute and chronic psychotic disorders including schizophrenia, manic states and drug-induced psychoses ii) Management of aggressive and agitated patients, including patients with chronic brain syndrome or mental retardation. iii) Gilles de la Tourette's syndrome - for the control of tics and vocalisations of Tourette's syndrome in children and adults. (Off-label indication with one-off UKK approval: Opioid-induced nausea and vomiting)	ADULT: moderate symptoms: 0.5 mg to 2.0 mg bid/tid; severe symptoms, chronic or resistant: 3.0 mg to 5.0 mg bid/ tid Geriatric / debilitated: 0.5 mg to 2.0 mg bid/tid maximum up to 100 mg daily CHILD: 3-13 years old (15 to 40 kg): 0.5 mg/day increase by 0.5 mg at 5 to 7 days in bid/tid, dosing range 0.05 mg/kg/day to 0.15 mg/kg/day Dosing is according to product insert.	B

No.	Generic Name	MDC	Indications	Dosage	Category
390.	Haloperidol 5 mg Tablet	N05AD01-000-T10-02-XXX	i) Psychotic disorder – management of acute and chronic psychotic disorders including schizophrenia, manic states and drug-induced psychoses ii) Management of aggressive and agitated patients, including patients with chronic brain syndrome or mental retardation. iii) Gilles de la Tourette's syndrome - for the control of tics and vocalisations of Tourette's syndrome in children and adults. (Off-label indication with one-off UKK approval: Opioid-induced nausea and vomiting)	ADULT: moderate symptoms: 0.5 mg to 2.0 mg bid/tid; severe symptoms, chronic or resistant: 3.0 mg to 5.0 mg bid/ tid Geriatric / debilitated: 0.5 mg to 2.0 mg bid/tid maximum up to 100 mg daily CHILD: 3-13 years old (15 to 40 kg): 0.5 mg/day increase by 0.5 mg at 5 to 7 days in bid/tid, dosing range 0.05 mg/kg/day to 0.15 mg/kg/day Dosing is according to product insert.	B
391.	Haloperidol 5 mg / ml Injection	N05AD01-000-P30-01-XXX	i) Management of acute psychotic disorders including schizophrenia, manic states, and drug-induced psychosis. ii) Management of aggressive and agitated patients, including patients with chronic brain syndrome or mental retardation.	ADULT: IM or IV , 2 mg - 10 mg then every 4 - 8 hours according to response to total maximum 18 mg daily. Use in child is not recommended	B
392.	Heparin 1000 units / ml Injection	B01AB0152 0P3001XX	i) Prophylaxis and treatment of venous thrombosis and pulmonary embolism. ii) Treatment of myocardial infarction and arterial embolism. iii) Prevention of clotting in arterial and heart surgery and for prevention of cerebral thrombosis	i) By IV injection, loading dose of 5000 units (10,000 units in severe pulmonary embolism) followed by continuous infusion of 15-25 units/kg/hr. By SC injection (for DVT) of 15,000 units every 12 hours (laboratory monitoring on daily basis essential to adjust dose). Small adult or child, lower loading dose then, 15-25 units/kg/hr by IV infusion, or 250 units/kg every 12 hours by SC injection. ii) As i), for unstable angina and acute peripheral arterial occlusion. iii) Prophylaxis in general surgery, by SC injection, 5000 units 2 hour before surgery, then every 8-12 hours for 7 days or until patient is ambulant, during pregnancy (with monitoring), 5000-10000 units every 12 hours. An adjusted dose regimen may be used for major orthopaedic surgery or low molecular weight heparin may be selected	B

No.	Generic Name	MDC	Indications	Dosage	Category
393.	Heparin 5000 units / ml Injection	B01AB0152 OP3002XX	i) Prophylaxis and treatment of venous thrombosis and pulmonary embolism. ii) Treatment of myocardial infarction and arterial embolism. iii) Prevention of clotting in arterial and heart surgery and for prevention of cerebral thrombosis	i) By IV injection, loading dose of 5000 units (10,000 units in severe pulmonary embolism) followed by continuous infusion of 15-25 units/kg/hr. By SC injection (for DVT) of 15,000 units every 12 hours (laboratory monitoring on daily basis essential to adjust dose). Small adult or child, lower loading dose then, 15-25 units/kg/hr by IV infusion, or 250 units/kg every 12 hours by SC injection. ii) As i), for unstable angina and acute peripheral arterial occlusion. iii) Prophylaxis in general surgery, by SC injection, 5000 units 2 hour before surgery, then every 8-12 hours for 7 days or until patient is ambulant, during pregnancy (with monitoring), 5000-10000 units every 12 hours. An adjusted dose regimen may be used for major orthopaedic surgery or low molecular weight heparin may be selected	B
394.	Heparin Sodium 50 units in Sodium Chloride Injection	B01AB0193 OP3001XX	To maintain patency of peripheral venous catheters	Flush with 5 ml (50 units) every 4 hours or as required	B (SRQ PAEDS)
395.	Hepatitis B Immunoglobulin (Human) Injection	J06BB04000 P3001XX	i) For post-exposure prophylaxis of hepatitis B ii) Prophylaxis against recurrence of hepatitis B infection in chronic hepatitis B post liver transplantation	i) Adults: Recommended Dose: 1000-2000 IU IM and if necessary, the dose should be increased or repeated. Children: Inject 32-48 IU/kg of body weight, should be administered within 7 days after exposure to HBsAg (preferably within 48 hrs). Neonates: Recommended Initial Dose: 100-200 IU. The 1st dose should be administered within 5 days after birth (preferably within 48 hrs) and booster dose should be 32-48 IU/kg body weight. The booster dose should be administered between 2 and 3 months after the 1st administration. ii) Different regimens depending on hepatitis B virus (HBV) DNA positivity	A (SRQ GENERAL)

No.	Generic Name	MDC	Indications	Dosage	Category
396.	Hepatitis B Vaccine Injection -Hepatitis B 10mcg HbsAg Vaccine (Paediatric) -Hepatitis B 20mcg HbsAg Vaccine (Adult)	J07BC01000 P4001XX	Immunisation against infections caused by Hepatitis B virus	0.5 – 1.0 ml by IM. Dosing is according to Immunisation Schedule under NIP and product insert.	C+
397.	Homatropine 2 % Eye Drops	S01FA05330 D2003XX	i) Mydriasis and cycloplegia for refraction ii) Treatment of anterior segment inflammation	i) Adult: Instill 1 or 2 drops of 2% solution immediately before the procedure, repeat at 5-10-minute intervals if necessary. Child: Instill 1 drop of 2% soln immediately before the procedure, repeat at 10-min intervals if necessary. ii) Adult: Instill 1-2 drops of 2% bd-tds up to every 3-4 hr as needed. Child: 3 mth-2 yr: instill 1 drop of 0.5% soln once daily or on alternate days. >2 yr: instill 1 drop of 1% or 2% soln bd.	B (UKK OPHTH)
398.	Human Albumin Injection	B05AA0100 OP3001XX	i) Acute hypovolemic shock ii) Hypoproteinaemia iii) Restoration and maintenance of circulating blood volume in cases of volume deficiency where the use of a colloid is indicated	Dosing is according to product insert/protocol	B (SRQ GENERAL)
399.	Human Normal Globulin Injection	J06BA02000 P3001XX	i. Replacement therapy such as: a) Primary immunodeficiency syndromes b) Severe secondary hypogammabulinaemia and recurrent infections c) Congenital or acquired immune deficiency syndrome with recurrent infections d) Allogeneic haematopoietic stem cell transplantation (HSCT) ii. Immunomodulation such as: a) Immune thrombocytopenic purpura (ITP) in children or adults at high risk of bleeding or prior to surgical interventions to correct the platelet count b) Guillain-Barre syndrome c) Kawasaki disease (Off-label indication with UKK approval: i) Myasthenia gravis (ANAEs)	0.2-2g/kg as required Dosing and frequency of administration are according to product insert and protocol.	A (SRQ MED) (UKK ANAEs – off label)

No.	Generic Name	MDC	Indications	Dosage	Category
400.	Hydralazine HCl 20 mg Injection	C02DB0211 0P3001XX	Hypertensive crisis in pregnancy	i) Slow IV injection, ADULT: 5-10 mg diluted with 10ml sodium chloride 0.9%. May be repeated after 20-30 minutes if necessary. ii) IV infusion 200-300 mcg/minutes. Maintenance dose 50-150 mcg/minutes	B
401.	Hydrochlorothiazide 25 mg Tablet	C03AA0300 0T1001XX	Diuretic, hypertension	ADULT: Diuretics; 25-200 mg daily. Hypertension 12.5-25 mg daily CHILD: Oedema and hypertension; Adjunct; 1 to 2 mg/kg ORALLY daily in single or two divided doses; Children 2-12 years old MAX dose, not to exceed 100 mg ORALLY daily; Infants less than 6 months old, may require doses up to 3 mg/kg ORALLY daily in two divided doses, Infants up to 2 yrs old: MAX dose, not to exceed 37.5 mg ORALLY daily	B
402.	Hydrocortisone 1% & Neomycin 0.5% Cream	D07CA0195 2G1001XX	Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses	Apply sparingly to the affected area. Adult: 3-4 times daily. Children: 1-2 times daily	B
403.	Hydrocortisone 1% Cream	D07AA0200 0G1001XX	Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses	Apply sparingly to the affected area. Adult: 3-4 times daily. Children: 1-2 times daily	B
404.	Hydrocortisone 10 mg Tablet	H02AB0900 0T1001XX	i) Glucocorticoid replacement therapy in primary or secondary adrenal insufficiencies ii) Congenital adrenal hyperplasia in children	ADULT: 20 - 30 mg daily in divided doses. CHILD: 10-15mg/m2/day in 3 divided dose The dosing is individualized according to product insert / protocol	B
405.	Hydrocortisone Sodium Succinate 100 mg Injection	H02AB0952 0P4001XX	Conditions responsive to systemic or local glucocorticoid injection therapy	Initially 100 - 500 mg IV over 30 seconds to more than 10 minutes. Dose may be repeated at intervals of 2, 4 or 6 hours CHILD: 2-4mg/kg/dose every 6 hourly The dosing is individualized according to product insert / protocol	C

No.	Generic Name	MDC	Indications	Dosage	Category
406.	Hydrogen Peroxide 20 volume Solution	D08AX0124 1L9901XX	Skin disinfection, particularly cleansing and deodorising wounds and ulcers	Hydrogen Peroxide 6% (=approx. 20 vol) shall be dispensed. For cleansing wounds: 1.5% to 6% solution apply 2-3 times daily or when necessary. As a mouthwash: rinse the mouth for 2-3 minutes with 15ml of hydrogen peroxide 6% diluted in half a tumblerful of warm water 2-3 times daily. Disinfecting cleaned equipment: immersion for 30 minutes in 6% solution. As ear drop for removal of wax: hydrogen peroxide 6% diluted with 3 parts of water preferably just before use	C
407.	Hydroxychloroquine Sulphate 200 mg Tablet	P01BA0218 3T1001XX	i) SLE and mixed connective tissue disease for skin, joint and serosa ii) Second line therapy for acute rheumatoid arthritis	i) Initially 400 mg daily in divided dose. Maintenance: 200 - 400 mg daily ii) ADULT: 400 - 600 mg daily. Maintenance: 200 - 400 mg daily. CHILD: up to 6.5 mg/kg daily (maximum 400 mg daily)	A (SRQ MED) (SRQ PAED)
408.	Hydroxyethyl Cellulose Jelly	V07AY0025 0G4001XX	For lubricating purpose	Apply sufficiently for lubricating purpose	B
409.	Hydroxyurea 500 mg Capsule	L01XX0500 0C1001XX	i) Solid tumours ii) Chronic myelocytic leukaemia and myeloproliferative disease	i) Intermittent therapy: 80 mg/kg orally as a single dose every 3rd day. Continuous therapy: 20 - 30 mg/kg orally as a single dose dly. Concomitant therapy with irradiation: 80 mg/kg orally as a single dose every 3rd day. (administration of hydroxyurea should be started at least 7 days before initiation of irradiation and continued during radiotherapy as well). ii) Continuous therapy (20 - 30 mg/kg orally as a single dose daily	A (SRQ MED)
410.	Hyoscine N-Butylbromide 1 mg / ml Liquid	A03BB0132 0L5001XX	Gastrointestinal tract and genitourinary tract spasm, dyskinesia of the biliary system	ADULT 10-20 mg, 3-4 times a day. CHILD 6-12 years old: 10 mg 3 times a day.	B
411.	Hyoscine N-Butylbromide 10 mg Tablet	A03BB0132 0T1001XX	Gastrointestinal tract and genito-urinary tract spasm, dyskinesia of the biliary system. Prescribing Restriction(s): Medical Assistant in health settings without Medical Officer is allowed to prescribe this medicine for adult use only.	ADULT 10-20 mg, 3-4 times a day. CHILD 6-12 years old: 10 mg 3 times a day.	C

No.	Generic Name	MDC	Indications	Dosage	Category
412.	Hyoscine N-Butylbromide 20 mg / ml Injection	A03BB0132 0P3001XX	Gastrointestinal tract and genitourinary tract spasm, dyskinesia of the biliary system	ADULT: 20 mg IM/IV repeated after 30 min if needed. Max: 100 mg daily. Not recommended for CHILD below 12 years Dosing is individualised and according to product insert/protocol	B
413.	Ibandronic Acid 150 mg Tablet	M05BA0600 0T1003XX	Treatment of postmenopausal osteoporosis to reduce the risk of fracture. Review treatment after 2 years and if there is positive response, treatment may be continued up to 5 years and then re-evaluate. Treatment should be stopped if there is no positive response after 5 years. Otherwise, patient needs to be given drug holiday for 1 to 2 years and then continue treatment shall the benefit outweigh the risk.	150 mg once monthly	A* (SRQ ORTHO)
414.	Ibuprofen 100mg / 5ml Suspension	M01AE01-000-L80-01-XXX	i. Anti-inflammatory for rheumatic disease ii. Analgesic for treatment of mild to moderate pain	Children: 5 - 10 mg/kg/dose (max 2.4 gm/day) every 6-8 hourly. Not recommended for <7kg	B (SRQ PAED) (SRQ ORTHO)
415.	Ibuprofen 200 mg Tablet	M01AE0100 0T1001XX	Pain and inflammation in rheumatic disease	Dosage: ADULT: 200 - 400 mg 3 times daily after food, maximum 3.2 g daily. CHILD: 30-50 mg/kg body weight daily in divided doses, maximum 2.4 g daily. Lowest effective dose for the shortest possible duration.	B
416.	Ichthammol Glycerin 10 % Ear Drops	S02AA3000 0D1001XX	Ear wick for otitis externa with oedema	2 - 3 drops 3 - 4 times daily and in ear wick for otitis externa	C (SRQ ENT)
417.	Ifosfamide 1 g Injection	L01AA06000 P4001XX	i) Solid tumours ii) Leukaemia iii) Lymphoma	i) 1.2 - 2.4 g/m ² /day for 3 - 7 days as a 30 - 120 minutes infusion. Alternatively, can also be given as a single high dose, eg. 5 g/m ² in a 24 hour infusion. Cycles may be repeated every 3 - 4 weeks ii) CHILD: 400 - 3000 mg/m ² /day for 3 - 5 days according to protocol iii) Refer to protocols	A* (SRQ ONCO)

No.	Generic Name	MDC	Indications	Dosage	Category
418.	Imipenem 500 mg and Cilastatin 500 mg Injection	J01DH5196 1P4002XX	Severe infections caused by susceptible pathogens especially useful in infections involving ESBL organisms. Not to be used for prophylaxis	Based on type or severity of infection, susceptibility of pathogen(s) and patient condition including body weight and renal function. ADULT: 1 - 2 g/day in 3 - 4 divided doses. Maximum: 4 g/day or 50 mg/kg/day. Infusion rate: less than 500 mg dose: over 20 - 30 minutes, more than 500 mg: dose over 40 - 60 minutes. CHILDREN: ≥ 40kg body weight should receive adult doses. CHILDREN AND INFANTS: <40kg body weight should receive 15mg/kg at six hour intervals. The total daily dose should not exceed 2g.	A* (SRQ GENERAL)
419.	Indacaterol maleate 110 mcg and glycopyrronium bromide 50mcg inhalation powder hard capsules	R03AL04989 C1101XX	As a once-daily maintenance bronchodilator treatment to relieve symptoms and reduce exacerbations in adult patients with chronic obstructive pulmonary disease (COPD). Prescriber restriction: Patients with inhaler coordination problem. (Only applies to Primary Care settings)	One capsule inhalation daily.	A/KK (SRQ MED)
420.	Indomethacin 25 mg Capsule	M01AB0100 0C1001XX	Pain and inflammation in rheumatic disease	50 - 200 mg daily in divided doses, with food. Child not recommended.	B
421.	Insulin Aspart 100 IU/ml Injection	A10AB0500 0P3001XX	Diabetic Type 1 and 2 in patients that still experienced hypoglycaemia with use of human insulin	Dose to be individualised. The average daily insulin requirement is between 0.5 to 1.0 units/kg body weight	A* (SRQ MED) (SRQ PAED)
422.	Insulin Aspart 30 % and Protaminated Insulin Aspart 70 % 100 U/ml Injection	A10AD0500 0P3001XX	Diabetic Type 1 and 2 in patients that still experienced hypoglycaemia with use of human insulin	Dose to be individualised. The average daily insulin requirement is between 0.5 to 1.0 units/kg body weight	A/KK (SRQ MED)
423.	Insulin Glargine 300 IU/ 3 ml Injection (Prefilled Pen)	A10AE04-000-P50-01-XXX	i) Diabetes mellitus type I in adults and child over 6 years ii) Diabetes mellitus type II in adult	ADULT and CHILD over 6 years: individualised dose given by SC, once daily at the same time every day. Adult patients who are insulin naive may be initiated with 10IU daily.	A/KK (SRQ MED) (SRQ PAED)
424.	Insulin Recombinant Neutral Human Short-acting 100IU/ml Penfill and Refill	A10AB0100 0P5001XX	Diabetes mellitus	Dose to be individualised. The average daily insulin requirement is between 0.3-1.0 units/kg body weight/day. Daily insulin requirement may be higher in patients with insulin resistance, and lower in patients with residual, endogenous insulin production.	B

No.	Generic Name	MDC	Indications	Dosage	Category
425.	Insulin Recombinant Synthetic Human, Intermediate-Acting 100 IU/ml Penfill and Refill	A10AC0100 0P5001XX	Insulin dependent diabetes mellitus, non insulin dependent diabetes unresponsive to treatment to diet or oral hypoglycaemics, hyperkalaemia to assure proper utilisation of glucose and reduce glucosuria in non diabetic patients receiving parenteral nutrition	Dose to be individualised. The daily insulin requirement is usually between 0.3 and 1.0 IU/kg /day	B
426.	Insulin Recombinant Synthetic Human, Premixed 100 IU/ml Penfill and Refill	A10AD0100 0P5001XX	Insulin dependent diabetes mellitus, non insulin dependent diabetes unresponsive to treatment to diet or oral hypoglycaemics, hyperkalaemia to assure proper utilisation of glucose and reduce glucosuria in non diabetic patients receiving parenteral nutrition	Dose to be individualised. The average daily insulin requirement is between 0.5-1.0 units/kg body weight	B
427.	Iodine and Potassium Iodide Solution	H03CA0020 0L9901XX	i) Pre-operative treatment of thyrotoxicosis ii) Thyrotoxicosis crisis	i) 1 ml daily in divided doses ii) 2 - 3 ml daily	B (UKK)
428.	Iodixanol 320 mg I/ml Injection	V08AB0900 0P3001XX	X-ray contrast medium for cardioangiography, cerebral angiography, peripheral arteriography, abdominal angiography, urography, venography, CT enhancement, lumbar, thoracic and cervical myelography	Depending on type of examination	A (SRQ RADIO)
429.	Iopromide 370mg injection (769 mg of iopromide with 370 mg of iodine per mL)	V08AB0500 0P3002XX	i) For angiography, urography, aortography and the visualization of body cavities ii) Contrast enhancement during computerized tomography iii) To check functioning of a dialysis shunt	Dose depending on the route and procedure	A (SRQ RADIO)
430.	Iopromide 300mg injection (623 mg of iopromide with 300 mg of iodine per mL)	V08AB0500 0P3001XX	i) For angiography, urography, aortography and the visualization of body cavities ii) Contrast enhancement during computerized tomography iii) To check functioning of a dialysis shunt	Dose depending on the route and procedure	A (SRQ RADIO)

No.	Generic Name	MDC	Indications	Dosage	Category
431.	Ipratropium Bromide 0.025% Inhalation Solution (250 mcg/ml)	R03BB0132 0A3002XX	Maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. Used concomitantly with inhaled beta-agonists in the treatment of acute bronchospasm associated with chronic obstructive pulmonary disease including chronic bronchitis and asthma.	Maintenance treatment: i) Adult and adolescents over 12 years old: 500 mcg per dose, 3 to 4 times daily. ii) Children 6 - 12 years old: 250 mcg per dose, 3 to 4 times daily. iii) Children less than 6 years old: 100 - 250mcg per dose, 3 to 4 times daily. Acute attacks (in combination with beta-agonist): i) Adult and adolescents over 12 years old: 500mcg per dose, time interval between doses may be determined by the physician. ii) Children 6 - 12 years old: 250mcg per dose, time interval between doses may be determined by the physician. iii) Children less than 6 years old: 100 - 250 mcg per dose, time interval between doses may be determined by the physician.	B
432.	Ipratropium Bromide 0.5 mg and Salbutamol 2.5 mg per UDV	R03AK0432 0A3001XX	Management of reversible bronchospasm associated with obstructive airway diseases	Acute attacks: 1 unit dose vial. In severe cases not relieved by 1 unit dose vial, 2-unit dose vials may require. Maintenance: 1 unit dose vial 3 - 4 times daily.	B
433.	Ipratropium Bromide 20 mcg and Fenoterol 50 mcg/dose Inhaler	R03AK0398 6A2101XX	Management of symptoms in chronic obstructive airway disorders with reversible bronchospasm such as bronchial asthma and chronic bronchitis with or without emphysema	ADULT & CHILD more than 6 years; Acute asthma 2 puffs. Severe cases: if breathing has not noticeably improved after 5 mins, 2 further puffs may be taken. Intermittent and long-term treatment 1-2 puffs for each administration, up to max 8 puffs/day (average: 1-2 puffs three times daily)	B
434.	Iron Dextran 50 mg/ml Injection	B03AC0600 0P3001XX	Severe iron deficiency anaemia	An initial test dose of 0.5 ml should be given over the desired route. For severe iron deficiency anaemia, 1-2 ml daily given by deep IM. Dosage is individualized according to total iron deficit	B
435.	Iron (III) hydroxide sucrose complex 20mg/ml solution for injection	B03AC0225 0P3001XX	Treatment of iron deficiency anaemia: a) where there is a clinical need for rapid iron supply b) in patients who cannot tolerate oral iron therapy or who are non-compliant c) in active inflammatory bowel disease where oral iron preparations are ineffective	ADULT and ELDERLY: Cumulative dose is to be administered in single doses of 100 - 200 mg of iron 2 - 3 times weekly depending on Hb level. Total cumulative dose: 1000 mg	B SRQ MED (HEMATO/HDU)

No.	Generic Name	MDC	Indications	Dosage	Category
436.	Isoniazid 100 mg Tablet	J04AC01000 T1001XX	i) Tuberculosis ii) Tuberculous meningitis	i) & ii) ADULT 5-8 mg/kg daily (Max 300 mg) or 15-20 mg/kg biweekly (max 1200 mg)	B
437.	Isoniazid 400 mg Tablet	J04AC01000 T1002XX	i) Tuberculosis ii) Tuberculous meningitis	i) & ii) ADULT 5-8mg/kg daily (Max 300mg) or 15-20mg/kg biweekly (max 1200mg)	B
438.	Isoprenaline HCl 0.2 mg/ml Injection	C01CA0211 OP3001XX	Complete heart block (third-degree atrioventricular block) not responding to atropine, while waiting for cardiac pacing	If given as IM: Initially 0.2 mg (1 ml of 1:5000 solution), followed by 0.02-1 mg depending on clinical response. If given as SC: 0.2 mg (1 ml of 1:5000 solution), followed by 0.15-0.2 mg depending on clinical response. If given as IV: 1-2 mg in 500 ml of dextrose 5%, infused at rate of 0.5-2 ml/min while the patient's EKG is being monitored. The dose should be titrated to produce the desired clinical response	B (UKK CFLN) (SRQ GENERAL)
439.	Isosorbide Dinitrate 10 mg Tablet	C01DA0822 1T1001XX	Prophylaxis and treatment for: i) Angina ii) Left ventricular failure	i) 30 - 120 mg daily in divided doses ii) 40 - 160 mg, up to 240 mg if required	B
440.	Isosorbide-5-Mononitrate 60 mg SR Tablet	C01DA1422 1T5002XX	Angina pectoris	Initial: 30mg daily. Maintenance: 30-60mg once daily. Max. 120mg once daily.	A/KK (SRQ MED)
441.	Itopride HCl 50 mg Tablet	A03FA00110 T1001XX	Treatment of gastrointestinal symptoms of functional, non-ulcer dyspepsia (chronic gastritis) i.e sensation of bloating, early satiety, upper abdominal pain or discomfort, anorexia, heartburn, nausea and vomiting	50 mg 3 times daily before meal	A* (SRQ SURG)
442.	Itraconazole 100 mg Capsule	J02AC02000 C1001XX	i) Dermatomycosis including pityriasis versicolor ii) Oral candidiasis iii) Palmar tinea manus and plantar tinea pedis iv) Finger nail onychomycosis v) Toe nail onychomycosis vi) Vulvovaginal candidiasis	i) 200 mg once daily for 7 days ii) 100 mg daily for 15 days iii) 200 mg twice daily for 7 days iv) 200 mg twice daily for 1 week/month for 2 months v) 200 mg twice daily for 1 week/month for 3 months vi) 200 mg morning and evening for 1 day or 200 mg once daily for 3 days	A/KK (SRQ MED) (SRQ PAED)

No.	Generic Name	MDC	Indications	Dosage	Category
443.	Ivabradine 5 mg Tablet	C01EB1711 OT1001XX	i) Symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate ≥ 70 bpm. Ivabradine is indicated: - in adults unable to tolerate or with a contraindication to the use of beta-blockers - or in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose. ii) Treatment of chronic heart failure NYHA II to IV class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ≥ 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated.	Initial dose 5 mg twice daily. May increase dose after 3-4 weeks to 7.5 mg twice daily depending on response. ELDERLY, initial dose 2.5 mg twice daily and titrate to a maximum of 7.5 mg twice daily	A* (SRQ MED)
444.	Kanamycin 1 g Injection	J01GB04183 P4001XX	i) Treatment of gonorrhoea and neonatal meningitis ii) Treatment of TB patients who require reserved second line drugs but have no pre-existing renal complications	i) ADULT: 1 - 2 g daily IM in 1 - 2 equally divided doses. CHILD: 30 - 50 mg/kg/day in 1 - 2 divided doses ii) ADULT: 2 g daily IM in 2 equally divided doses twice a week or 1 g once daily 3 days a week	A* (SRQ MED)
445.	Ketamine 10 mg/ml Injection	N01AX0311 OP3001XX	Sole anaesthetic for short procedures or induction of anaesthesia in certain types of patients (e.g in shock states) (Off-label indication with one-off UKK approval: Analgesic for severe cancer pain and chronic non-cancer pain not responding to opioid and antineuropathics; Adjuvant analgesic in opioid tolerant patients)	IV Initially, 1-4.5 mg/kg IV, a dose of 2 mg/kg produces anesth for 5-10 mins. IM Initially, 6.5-13 mg/kg IM, a dose of 10 mg/kg produces anesth for 12-25 mins.	B
446.	Ketoconazole 2 % Shampoo	D01AC0800 OL5201XX	Dandruff, seborrhoeic dermatitis and pityriasis versicolor.	Seborrhoeic dermatitis & dandruff: Apply twice weekly for 2 to 4 weeks. Pityriasis versicolor: Apply once daily for up to 5 days. Prophylaxis: Once every 1 or 2 weeks. Both left for 3-5minutes before rinsing.	A/KK (SRQ GENERAL)
447.	Ketoprofen 2.5 % Gel	M02AA1000 OG3001XX	Local treatment of osteoarticular & muscular painful disorders of rheumatic or traumatic origin: Contusions, distortions, muscle strains, stiff neck, lumbago.	Apply onto affected areas 2-4 times daily up to 10 days.	A/KK (SRQ ORTHO)

No.	Generic Name	MDC	Indications	Dosage	Category
448.	Ketoprofen 30 mg Transdermal Plaster	M02AA1000 07001XX	Treatment of signs & symptoms of arthritis deformans, periarthritis humero-scapularis, tendinitis, peritendinitis, sore muscle, swelling, pain resulting from trauma (eg. contusion, distorsion, sprain).	Apply 1 plaster to the affected area twice daily	A (SRQ REHAB) (SRQ Palliative)
449.	Labetalol HCl 100 mg Tablet	C07AG0111 0T1001XX	i) Mild, moderate or severe hypertension ii) Hypertension in pregnancy	i) & ii) Initial: 100mg twice daily Maintenance: 200-400mg twice daily Max. 2400mg daily in 3 or 4 divided doses Dosing is individualised and according to product insert / protocol.	B
450.	Labetalol HCl 5 mg / ml Injection	C07AG0111 0P3001XX	Hypertension crisis	ADULT: 20 mg injected slowly for at least 2 min, followed by 40-80 mg dose every 10 min, if necessary up to 300 mg. Patient should remain supine during and 3 hr after the procedure.	B
451.	Lactulose 3.35 g / 5 ml Liquid	A06AD1100 0L5001XX	i) Constipation ii) Hepatic encephalopathy	i) ADULT 15-45 ml daily in 1-2 divided doses adjusted to patient's need. Maintenance dose: 15-30ml daily in 1-2 divided doses. CHILD 0.5 ml/kg/dose once or twice daily ii) ADULT: 30-45 ml 2-4 times daily, dose adjusted to produce 2-3 soft stools daily. CHILD: 1 ml/kg/dose 3-4 times daily	C+
452.	Lamivudine 10 mg / ml Oral Solution	J05AF05000 L9901XX	HIV infection in combination with other antiretroviral agents	ADULT: 150 mg twice daily or 300 mg once daily. INFANT under 1 month: 2 mg/kg twice daily. CHILD 3 month or over: 4 mg/kg twice daily. Maximum 300 mg daily	A* (SRQ PAED)
453.	Lamotrigine 100 mg Tablet	N03AX0900 0T1002XX	i) Adjunctive or monotherapy for partial seizures and generalised tonic-clonic seizures not satisfactorily controlled with other antiepileptic drugs ii) Prevention of mood episodes in adult 18 years and above with bipolar disorder, predominately by preventing depressive episodes	i) Up to 200 mg daily in single or divided dosage ii) 25- 200 mg daily	A (SRQ MED) (SRQ PAED)
454.	Lamotrigine 25 mg Dispersible / Chewable Tablet	N03AX0900 0T2001XX	Add-on therapy in intractable partial seizures	25 mg daily - 50 mg twice daily	A (SRQ MED) (SRQ PAED)

No.	Generic Name	MDC	Indications	Dosage	Category
455.	Lamotrigine 50mg Tablet	N03AX0900 OT1001XX	i) Adjunctive or monotherapy for partial seizures and generalised tonic-clonic seizures not satisfactorily controlled with other antiepileptic drugs ii) Prevention of mood episodes in adult 18 years and above with bipolar disorder, predominately by preventing depressive episodes	i) Up to 200 mg daily in single or divided dosage ii) 25- 200 mg daily	A (SRQ MED) (SRQ PAED) (SRQ PSY)
456.	Latanoprost 0.005% Eye Drops	S01EE01000 D2001XX	Reduction of elevated intraocular pressure in patients with open-angle glaucoma	1 drop in the affected eye(s) once daily	A* (SRQ OPHTH)
457.	Leflunomide 10 mg Tablet	L04AA13000 T1001XX	i) Persistent active rheumatoid arthritis ii) Active psoriatic arthritis	Loading dose: 100 mg once daily for 3 days. Maintenance: 10-20 mg once daily	A* (SRQ MED)
458.	Letrozole 2.5 mg Tablet	L02BG0400 OT1001XX	Hormonal therapy in breast cancer in post-menopausal women if failed/contraindicated to Tamoxifen	2.5 mg once daily	A* (SRQ SURG) (UKK O&G- Off Label)
459.	Leucovorin Calcium (Calcium Folate) 15 mg Tablet	V03AF03390 T1001XX	i) Treatment of folic acid antagonist overdose; ii) Leucovorin (folinic acid) plus tegafur-uracil combination therapy is indicated for the treatment of colorectal cancer in: a) Metastatic stage, b) Adjuvant setting, c) Concurrent setting.	i) 15 mg every 6 hours for the next 48 – 72 hours; ii) Metastatic stage – Leucovorin Calcium 30 mg TDS, Day 1-28, rest 7 days for 5 cycles Adjuvant setting – Leucovorin Calcium 30 mg TDS, Day 1-28, rest 7 days for 5 cycles; Concurrent setting – Leucovorin Calcium 25 mg /day, D8- D36, for 4 weeks Dosing is individualised and according to product insert/protocol	A (SRQ O&G) (SRQ MED)
460.	Leucovorin Calcium (Calcium Folate) 50 mg Injection	V03AF03237 P3002XX	(i) Biochemical modulator for 5-Fluorouracil in the treatment of solid tumour; (ii) As rescue for high dose methotrexate; (iii) Megaloblastic anaemias due to deficiency of folic acid	i) 200mg/m2 by slow IV injection over a minimum 3 minutes, followed by 5-Fluorouracil or 20mg/m2 IV followed by 5-Fluorouracil. In both cases, treatment is repeated daily for 5 days; may repeat at 4-week intervals for 2 courses then 4- to 5-week intervals ii) 15 mg (approximately 10mg/m2) every 6 hours for 10 doses, starting 24 hours after the beginning of the methotrexate infusion iii) Up to 1 mg daily Dosing is individualised and according to product insert/protocol	A

No.	Generic Name	MDC	Indications	Dosage	Category
461.	Levetiracetam 100 mg/ml Injection	N03AX1400 0P3001XX	i) Monotherapy therapy in the treatment of partial onset seizures with or without secondary generalization in patients from age 16 years of age with newly diagnosed epilepsy ii) Adjunctive treatment in partial onset seizures with or without secondary generalization in adults and children from 4 years of age with epilepsy; juvenile myoclonic epilepsy and idiopathic generalized tonic clonic epilepsy from 12 years of age. To be initiated when conventional IV antiepileptic drugs failed to achieve control, or oral form is temporarily not feasible in seizure emergencies	i) ADULTS and ADOLESCENT (from 16 years): Starting dose: 250 mg twice daily, Increase dose to 500 mg twice daily after 2 week. Dose can be further increased by 250 mg twice daily every 2 weeks depending upon the clinical response. Max: 1500 mg twice daily. ii) ADULT more than 18 years and ADOLESCENT (12 to 17 years) more than or equal to 50 kg: Initially 500 mg twice daily may be increased up to 1500 mg twice daily. Dose changes can be made in 500 mg twice daily increments or decrements 2 to 4 weekly. CHILD (4 to 11 years) and ADOLESCENT (12 to 17 years) less than 50 kg: Initially 10 mg/kg twice daily, may be increased up to 30 mg/kg twice daily. Dose changes should not exceed increments or decrements of 10 mg/kg twice daily every 2 weeks. CHILD > 50 kg: Adult dose	A* (SRQ MED) (SRQ PAED) (SRQ A&E)
462.	Levetiracetam 100 mg/ml Oral Solution	N03AX1400 0L9901XX	As adjunctive therapy in the treatment of partial onset seizures with or without secondary generalization in adults and children from 4 years of age with epilepsy	CHILD: 4-11 years and adolescent (12-17 years) less than 50 kg: Initially 10 mg/kg twice daily, may be increased up to 30 mg/kg twice daily. Dose changes should not exceed increments or decrements of 10 mg/kg two times daily twice weekly	A* (SRQ PAED)

No.	Generic Name	MDC	Indications	Dosage	Category
463.	Levetiracetam 500 mg Tablet	N03AX1400 OT1002XX	i) Monotherapy therapy in the treatment of partial onset seizures with or without secondary generalization in patients from age 16 years of age with newly diagnosed epilepsy ii) Adjunctive treatment in partial onset seizures with or without secondary generalization in adults and children from 4 years of age with epilepsy; juvenile myoclonic epilepsy and idiopathic generalized tonic clonic epilepsy from 12 years of age	i) Monotherapy ADULTS and ADOLESCENT (from 16 years): Starting dose: 250 mg twice daily, Increase dose to 500 mg twice daily after 2 week. Dose can be further increased by 250 mg twice daily every 2 week depending upon the clinical response. Max: 1500 mg twice daily. ii) ADULT more than 18 years and ADOLESCENT (12-17 years) more than or equal to 50 kg: Initially 500 mg twice daily may be increased up to 1500 mg twice daily. Dose changes can be made in 500 mg twice daily increments or decrements 2-4 weekly. CHILD (4-11 years) and ADOLESCENT (12-17 years) less than 50 kg : Initially 10 mg/kg twice daily, may be increased up to 30 mg/kg twice daily. Dose changes should not exceed increments or decrements of 10 mg/kg twice daily every 2 weeks. CHILD more than or equal to 50 kg: Adult dose	A* (SRQ MED) (SRQ PAED) (SRQ SURG)
464.	Levodopa 100 mg and Carbidopa 25 mg Tablet	N04BA0200 OT1001XX	Parkinson's disease	Patients not receiving Levodopa before, initially 100 - 125 mg 3 - 4 times daily adjusted according to response. Maintenance: 0.75 - 2 g in divided doses. In patients previously treated with Levodopa the dose should be about 20 - 25% of the dose previously being taken	B
465.	Levodopa 100 mg, Benserazide 25 mg HBS capsule	N04BA0297 7C1001XX	Parkinson's Disease	Initial: 100/25 mg 1-2 times/day, increase every 3-4 days until therapeutic effect, optimal dosage: 400/100 mg to 800/200 mg/day divided into 4-6 doses. Dose: 200/50 mg used only when maintenance therapy is reached and not to exceed levodopa 1000-1200 mg/benserazide 250-300 mg per day	B

No.	Generic Name	MDC	Indications	Dosage	Category
466.	Levodopa 200 mg, Benserazide 50 mg Tablet	N04BA0297 7T1001XX	Parkinson's Disease	Initial: 100/25 mg 1-2 times/day, increase every 3-4 days until therapeutic effect, optimal dosage: 400/100 mg to 800/200 mg/day divided into 4-6 doses. Dose: 200/50 mg used only when maintenance therapy is reached and not to exceed levodopa 1000-1200 mg/benserazide 250-300 mg per day	B
467.	Levodopa 250 mg and Carbidopa 25 mg Tablet	N04BA0200 0T1002XX	Parkinson's disease	Patients not receiving Levodopa before, initially 100 - 125 mg 3 - 4 times daily adjusted according to response. Maintenance: 0.75 - 2 g in divided doses. In patients previously treated with Levodopa the dose should be about 20 - 25% of the dose previous being taken	B
468.	Levofloxacin 500 mg Tablet	J01MA1200 0T1002XX	Community acquired pneumonia	500 mg daily for 7 - 14 days	A* (SRQ MED-Off Label)
469.	Levonorgestrel 1.5 mg Tablet	G03AC0300 0T1001XX	Emergency contraception within 72 hours of unprotected sexual intercourse for the female victim of sexual violence to prevent unwanted pregnancy	1.5 mg as a single dose as soon as possible, preferably within 12 hours but no later than 72 hours after unprotected sexual intercourse	A* (SRQ A&E)
470.	Levonorgestrel 52 mg Intrauterine System	G02BA0300 0P1001XX	i. Contraception. ii. Idiopathic menorrhagia. iii. Protection from endometrial hyperplasia during oestrogen replacement therapy.	One unit intrauterine device to be inserted into the uterine cavity within 7 days of the onset of menstruation or immediately after first trimester abortion. Postpartum insertion should be postponed until 6 weeks after delivery. Can be inserted at any time of amenorrheic woman. One unit IUD is effective for 5 years	A* (SRQ O&G)

No.	Generic Name	MDC	Indications	Dosage	Category
471.	Levothyroxine 50mcg Tablet	H03AA0152 OT1002XX	Hypothyroidism	Start at low dose and increase at 2-4 weeks interval. Usual recommended dose for i) Treatment of benign euthyroid goitre: 75-200mcg. ii) Prophylaxis of relapse after surgery for euthyroid goitre: 75-200mcg iii) Substitution therapy in hypothyroidism: ADULT Initially, 25-50mcg/day. Maintenance: 100-200mcg/day. CHILDREN Initially 12.5-50mcg/day, Maintenance: 100-150mcg/m ² body surface area iv) Concomitant supplementation during anti-thyroid drug treatment of hyperthyroidism: 50-100mcg v) Suppression therapy in thyroid cancer: 150-300mcg	B (SRQ PAED)
472.	Levothyroxine Sodium 100 mcg Tablet	H03AA0152 OT1001XX	Hypothyroidism	Start at low dose and increase at 2-4 weeks interval. Adult: Initially, 50-100 mcg/day may increase by 25-50 mcg at approximately 3 to 4 weeks intervals until the thyroid deficiency is corrected. Maintenance: 100-200 mcg/day. CHILD; 0 - 3 months: 10 - 15 mcg/kg/day; 3 - 6 months: 8 - 10 mcg/kg/day; 6 - 12 months: 6 - 8 mcg/kg/day; 1 - 5 years: 5 - 6 mcg/kg/day; 6 - 12 years: 4 - 5 mcg/kg/day; more than 12 years: 2 - 3 mcg/kg/day	B
473.	Lidocaine 25 mg and Prilocaine 25 mg Cream	N01BB5297 4G1001XX	Surface anaesthesia of the skin in connection with needle insertion and for superficial surgical procedures	Apply a thick layer under occlusive dressing Dosing is according to product insert	A (SRQ ENT) (SRQ PAED) (SRQ REHAB)
474.	Lignocaine 10 % w/ w Spray	N01BB0211 0A4001XX	For surface anaesthesia in dental practice, in otorhinolaryngology and Paracentesis	Spray to affected part	B (SRQ ANAES) (SRQ SURG) (SRQ ENT)
475.	Lignocaine 2 % Jelly	N01BB0211 0G4001XX	Use for endotracheal tubes and instruments, painful procedures in the ear, nose and throat, burns, wounds, abrasions, lacerations; catheterization of the male and female urethra and for symptomatic treatment of cystitis and urethritis	Apply to affected area 10 mins before catheterization.	B

No.	Generic Name	MDC	Indications	Dosage	Category
476.	Lignocaine 2 % Viscous Solution	N01BB0211 0L5001XX	i) To relief pain associated with irritated mucous membranes of the: a) mouth b) pharynx (post-tonsillectomy) c) upper gastrointestinal tract (eg. Esophagitis) Use for instrumentation of the respiratory and digestive tracts (eg. bronchoscopy, oesophagoscopy)	i) a) For anaesthesia of the mouth: Rinse the mouth with 5-15ml (100-300mg lignocaine), then the solution is spat out. In dental practice, 10ml solution (200mg lidocaine) are used. The solution should be spat out when adequate anaesthesia has been achieved (after approx. 1 minute). b) For anaesthesia of the pharynx: Gargle with 5 – 10ml (100-200mg lignocaine), after which the solution is slowly swallowed. c) Painful conditions in the upper GI tract: 5-15ml (100-300mg lignocaine) are rapidly swallowed all at once. *Daily dose should not exceed 1200mg (Total of 60ml) ii) Instrumentations into the stomach: 10-15ml (200-300mg lignocaine) are swallowed. Indications (i) & (ii): The daily dose should not exceed 1200mg (60mL) If combined with other lignocaine products, the total dose of lignocaine on one dosing occasion should not exceed 400mg.	A (SRQ ENT) (SRQ Palliative)
477.	Lignocaine HCl (Lidocaine) 2 % Intramuscular / Subcutaneous Injection (10 ml) (with preservative)	N01BB0211 0P3001XX	ii) For local or regional anaesthesia and nerve block. Not for IV use.	Local anesthesia: ADULT Maximum: 100 mg; CHILD Maximum: 3 mg/kg	B
478.	Lignocaine HCl (Lidocaine) 20 mg / ml Injection (5 ml) (without preservative)	C01BB0111 0P3001XX	Ventricular tachycardia and ventricular fibrillation. For IV use. To be diluted before use (Off-label indication with one-off UKK approval: Adjuvant treatment of refractory trigeminal neuralgia)	50-100 mg IV as a bolus, repeated after 5 minutes if necessary. Maintenance : 1-4 mg/min by IV infusion under ECG monitoring	B

No.	Generic Name	MDC	Indications	Dosage	Category
479.	Lignocaine HCl 5 % and Phenylephrine HCl 0.5 % Nasal Spray	N01BB0298 4A4101XX	Preparation of nasal mucosa for surgery (eg. Cautery to Little's area), aid the treatment of acute nose bleeds and removal of foreign bodies from the nose, topical anaesthesia of the pharynx prior to direct or indirect laryngoscopy, topical anaesthesia and local vasoconstriction prior to endoscopy of the upper airways	Adults and children over 12 years : 5 squirts per nostril. Children: 8 to 12 years 3 squirts per nostril, 4 to 8 years 2 squirts per nostril, 2 to 4 years 1 squirt per nostril. Doses are to be administered once only.	A* (SRQ ENT)
480.	Liquid Paraffin	A06AA0100 0L5001XX	Constipation	ADULT: 10-30 ml daily at night. CHILD: not recommended	C
481.	Lithium Carbonate 300 mg Tablet	N05AN0112 1T1001XX	i) Prophylaxis and treatment of acute mania and hypomania episodes ii) Prophylaxis of manic depression in bipolar illness or bipolar depression and recurrent depression	Dose depends on the preparation used. Doses should be adjusted to produce a serum-lithium concentration of 0.4-1 mmol/l.	A (SRQ PSY)
482.	Loperamide 2 mg Capsule	A07DA0311 0C1001XX	Adjunct to rehydration in acute diarrhoea in adult also in chronic diarrhoea in adult	Acute diarrhoea: ADULT: 4 mg stat, followed by 2 mg after each unformed stool (up to 5 days). Usual 6- 8 mg daily. Max: 16 mg daily. Chronic diarrhoea: Initially 4-8 mg daily in divided doses, adjust according to response. Max: 16 mg daily	B
483.	Lopinavir 200 mg and Ritonavir 50 mg Tablet	J05AE06964 T1001XX	Second line treatment for HAART regimen in combination with other anti-retroviral agents	Adult: - Therapy-naive patients: 400/100 mg bd or 800/200 mg once daily; - Therapy-experienced patients: 400/100 mg bd. - Concomitant therapy (efavirenz, nevirapine, amprenavir, fosamprenavir or nelfinavir) 400/100 mg bd. Children >40 kg or w/ BSA >1.4 m ² as adult dose.	A (SRQ MED)
484.	Lopinavir 80 mg /Ritonavir 20 mg (per ml) Oral Solution	J05AE06964 L9901XX	Management of patients with asymptomatic and symptomatic (early or advanced) HIV Infection with CD4 cell counts <50 cubic mm	Tab Adult Therapy-naive patients 400/100 mg bd or 800/200 mg once daily. Therapy-experienced patients 400/100 mg bd. Concomitant therapy (efavirenz, nevirapine, amprenavir, fosamprenavir or nelfinavir) 400/100 mg bd. Can be used w/ no dose adjustment. Childn >40 kg or w/ BSA >1.4 m ² Adult dose. Oral Soln Childn 6 mth-12 yr, 15-40 kg 10/2.5 mg/kg bd; 7 to <15 kg 12/3 mg/kg bd. Max: 5 mL bd in childn >40 kg. W/ efavirenz or nevirapine 15-45 kg 11/2.75 mg/kg bd; 7 to <15 kg 13/3.25 mg/kg.	A (SRQ PAED)

No.	Generic Name	MDC	Indications	Dosage	Category
485.	Loratadine 1 mg / ml Syrup	R06AX1300 0L9001XX	Allergic rhinitis, chronic urticaria and other allergic dermatological disorders	ADULT and CHILD over 6 years: 10 mg once daily. CHILD 2 - 6 years: 5 mg once daily	A (SRQ ENT) (SRQ PAED)
486.	Loratadine 10 mg Tablet	R06AX1300 0T1001XX	Allergic rhinitis and allergic dermatoses	ADULT and CHILD over 6 years: 10 mg once daily. CHILD 2 - 6 years: 5 mg once daily	B
487.	Loratadine 5 mg and Pseudoephedrine Sulphate 120 mg Tablet	R01BA5298 8T1001XX	For treatment of allergic rhinitis and allergic dermatoses	ADULT and CHILD over 12 years 1 tablet twice daily	A/KK (SRQ ENT)
488.	Lorazepam 1 mg Tablet	N05BA0600 0T1001XX	i) Severe anxiety ii) Insomnia	i) 1 - 4 mg increase to 10 mg daily in divided doses. ELDERLY (or debilitated) half adult dose ii) 1 - 2 mg at bedtime Not recommended in children	A/KK (SRQ GENERAL)
489.	Losartan 50 mg Tablet	C09CA0150 0T1001XX	Patients intolerant to ACE inhibitors in: i) Hypertensive patient with left ventricular hypertrophy ii) Type 2 Diabetes Mellitus with chronic kidney disease iii) Hypertension	i), ii) & iii) Initial: 50mg once daily Max: 100mg once daily Dosing is individualised and according to product insert / protocol.	B (SRQ MED) (SRQ PAED)
490.	Magnesium Sulphate 45 % Paste	D11AX0518 3G6001XX	Inflammatory skin conditions such as boils and carbuncles	Apply under dressing	C
491.	Magnesium Sulphate 50 % Injection	B05XA0518 3P3001XX	i) Treatment and prophylaxis of acute hypomagnesaemia ii) Prevention and treatment of life-threatening seizures in the treatment of toxemias of pregnancy (pre-eclampsia and eclampsia) (Off-label indication with one-off UKK approval: Acute exacerbation of bronchial asthma)	i) Mild hypomagnesaemia (ADULT): 1gm magnesium sulphate (8mEq) IM every 6 hours for 4 doses. Severe hypomagnesaemia (ADULT): 0.25 g/kg IM over 4 hours. Alternative dose of 5g may be given by slow intravenous infusion over 3 hours ii) Toxemia of pregnancy: An initial intravenous dose of 4gm of magnesium sulphate is recommended. Followed by an intramuscular dose of 4-5gm into each buttock. This may be followed by a dose of 4-5gm into alternate buttocks every 4 hours as needed. Alternatively, the initial dose IV dose may be followed by an infusion of 1-2gm/hr	C
492.	Magnesium Trisilicate Mixture	A02AA1091 2L2101XX	Heartburn, dyspepsia	ADULT children over 12 years: 10-20ml 3 times daily or as required. CHILD: 5-11 years: 5-10 ml three times a day or as required	C
493.	Magnesium Trisilicate Tablet	A02AA1091 2T1001XX	Heartburn, dyspepsia	ADULT 1-2 tablet to be chewed up to 6 times a day before meals. CHILD over 6 years one tablet to be taken 3-4 times a day	C

No.	Generic Name	MDC	Indications	Dosage	Category
494.	Mannitol 10 % Injection (10 g/100 ml)	B05BC0100 0P3001XX	Cerebral oedema	0.25- 2 g/kg IV of a 15% to 25% solution over 30-60 minutes. Safety and efficacy not established in children under 12 years of age	A
495.	Mannitol 20 % Injection (20 g/100 ml)	B05BC0100 0P3002XX	Cerebral oedema	0.25- 2 g/kg IV of a 15% to 25% solution over 30-60 minutes. Safety and efficacy not established in children under 12 years of age	A
496.	Mebeverine HCl 135 mg Tablet	A03AA0411 0T1002XX	i) Irritable bowel syndrome ii) Treatment of gastro-intestinal spasm secondary to organic diseases.	135 mg 3 times daily	B (SRQ MED) (SRQ SURG)
497.	Mecobalamin 500 mcg Tablet	M09AX0000 0T1001XX	Peripheral neuropathies	1 tablet 3 times daily. The dosage should be adjusted according to age of patient and severity of symptoms	B
498.	Medroxyprogesterone Acetate 5 mg Tablet	G03DA0212 2T1001XX	i) Secondary amenorrhoea ii) Abnormal uterine bleeding due to hormonal imbalance	i) 5-10 mg daily for 5-10 days started anytime during cycle ii) 5-10 mg daily for 5-10 days on day 16-21 of menstrual cycle. Optimum secretory transformation 10 mg daily for 10 days from day 16 of the cycle	B
499.	Medroxyprogesterone Acetate 50 mg/ml Injection	G03AC0612 2P3001XX	Prevention of pregnancy and to provide long term contraception	150 mg to be administered once every 3 month	B
500.	Mefenamic Acid 250 mg Capsule	M01AG0100 0C1001XX	Mild to moderate pain	ADULT: 250 - 500 mg 3 times daily after meals.	C
501.	Memantine HCl 10 mg Tablet	N06DX0111 0T1001XX	Treatment of moderate to severe Alzheimer's disease.	Initial Week 1: 5mg daily Week 2: 10mg daily Week 3: 15mg daily Week 4 and subsequent: 20mg daily Maintenance 20mg daily Max. dose: 20mg daily	A* (SRQ PSY) (UKK Rehab – Off Label)
502.	Meningococcal A, C, Y, W-135 Vaccine Injection	J07AH04000 P4001XX	Immunisation against meningococcal diseases caused by Neisseria meningitis Group A, Group C, Group Y or Group W-135	Prophylaxis: 0.5 ml by IM.	B
503.	Mercaptopurine 50 mg Tablet	L01BB0200 0T1001XX	i) Langerhan's cell histiocytosis ii) Acute lymphoblastic leukaemia iii) Acute promyelocytic leukaemia APML (maintenance)	Leukaemia adults: 2.5mg/kg or 80-00mg/m ² p.o per day, given as a single dose. To be increased at the end of 4 weeks, If necessary, up to 5mg/kg p.o per day. Maintenance dosage are 1.5mg/kg -2.5mg/kg p.o per day Children age 5 and older: Induction: 2.5mg/kg/day p.o once daily. Maintenance dose: 1.5mg/kg -2.5mg/kg p.o once daily or 70-100mg/m ² p.o once daily.	A (UKK STANDARD)

No.	Generic Name	MDC	Indications	Dosage	Category
504.	Meropenem 1 g Injection	J01DH0200 OP4002XX	i) Nosocomial pneumonia ii) Bacterial meningitis iii) Empirical treatment for presume infections in patients (adult and children) with febrile neutropenia, used as monotherapy or in combination with anti- virals or antifungal agent iv) Septicaemia v) Urinary tract infections vi) Intra-abdominal infections vii) Gynaecological infections	ADULT: 1-2g 8 hourly (refer to specific indication dosing) CHILD: (aged 3 months and over): 10-40mg/kg 8 hourly, if body weight over 50kg, adult dosage should be used Dosing is according to product insert/protocol.	A* (SRQ GENERAL)
505.	Meropenem 500 mg Injection	J01DH0200 OP4001XX	i) Nosocomial pneumonia ii) Bacterial meningitis iii) Empirical treatment for presume infections in patients (adult and children) with febrile neutropenia, used as monotherapy or in combination with anti- virals or antifungal agent iv) Septicaemia v) Urinary tract infections vi) Intra-abdominal infections vii) Gynaecological infections	ADULT: 1-2g 8 hourly (refer to specific indication dosing) CHILD: (aged 3 months and over): 10-40mg/kg 8 hourly, if body weight over 50kg, adult dosage should be used Dosing is according to product insert/protocol	A* (SRQ GENERAL)
506.	Mesalazine 500 mg MR Tablet	A07EC0225 9T1002XX	Inflammatory bowel disease of ulcerative colitis and Crohn's disease.	Active ADULT: up to 4g given once daily or in divided doses CHILD: starting with 30-50 mg/kg/day in divided doses. Maximum dose: 75 mg/kg/day in divided doses. Total daily dose 4g/day Maintenance ADULT: 1.5g to 2g mesalazine once daily or divided doses CHILD: starting with 30-50 mg/kg/day in divided doses. Maximum dose: 75 mg/kg/day in divided doses. Total daily dose 2g/day Dose is according to product insert and dependent on the product/brand used.	A (SRQ MED)
507.	Metformin HCl 500 mg Extended Release Tablet	A10BA0211 0T5001XX	Diabetes mellitus who experienced gastrointestinal side effects with normal metformin	500 mg once daily. Maximum dose 2000 mg once daily with evening meal	B (SRQ MED)
508.	Metformin HCl 500 mg Tablet	A10BA0211 0T1001XX	Diabetes mellitus	Initial: 500 mg orally twice daily with food. Maintenance: titrate in 500mg increments weekly, doses up to 2000 mg daily may be divided into 2 equal doses	B
509.	Methadone 5 mg / ml Syrup	N07BC0211 0L9001XX	Detoxification treatment of narcotic addiction	Initial 10-20 mg per day, increasing by 10-20 mg per day until there are no signs of withdrawal or intoxication. Usual dose 40-60 mg/day	A/KK

No.	Generic Name	MDC	Indications	Dosage	Category
510.	Methotrexate 2.5 mg Tablet	L01BA01000 T1001XX	i) Solid tumours particularly breast, lung, head and neck, bladder, cervical, ovarian, and testicular carcinoma. ii) Acute lymphoblastic leukaemia and acute promyelocytic leukemia (maintenance) iii) Extensive plaque psoriasis, erythrodermic psoriasis, pustular psoriasis, Reiter's syndrome, connective tissue disease	i) ADULT: 20 mg/m ² weekly. CHILD: 20 - 30 mg/m ² weekly according to protocol ii) Relapsed acute lymphoblastic leukaemia (ALL): 100 mg/m ² /day for 5 days 6 weekly according to protocol iii) Dose used by dermatologist: 5 - 25 mg weekly. Liver biopsy after cumulative dose of 1.5 gram and repeat liver biopsy with additional gram received. Maximum cumulative dose is 4 gram. Monitor full blood count (FBC), renal and liver function iv) Rheumatoid arthritis, psoriatic arthropathy: dose used by rheumatologist: 2.5 mg/week orally starting dose, increasing to 7.5 - 20 mg/weekly	A (SRQ GENERAL)

No.	Generic Name	MDC	Indications	Dosage	Category
511.	Methotrexate 25 mg/ml Injection (50mg / 2ml)	L01BA01520 P3001XX	i) Solid tumours ii) Gestational trophoblastic disease iii) Acute leukaemia/lymphomas iv) Rheumatoid arthritis, psoriatic arthropathy, severe/Erythrodermic psoriasis	i) 50 mg/m ² once every 2 - 3 weeks in combination with other drugs ii) 50 mg IV Day 1, 3, 5, 9 every 3 weeks. For high risk gestational trophoblastic disease, use 100 mg/m ² as part of EMA-CO regime iii) High dose regimes: 500 - 3000 mg/m ² per dose may be used, employing the 500 mg preparations. CHILD: Central nervous system prophylaxis for acute leukaemia 2 gm/m ² over 24 hours with folinic acid rescue, 3 doses for B-cell lineage. 4 doses for T-lineage all every 3 weeks. Relapse acute lymphoblastic leukaemia (ALL): 1 gm/m ² over 36 hours with folinic acid rescue every 3 weeks for 9 doses, maintenance: 50 mg/m ² every 2 weeks. B-cell lymphoma: 3 gm/m ² over 3 hours with folinic acid rescue for three doses. Methotrexate level monitoring recommended when using high dose regimens. The 500 mg strength is not for intrathecal (IT) use. Dosage for intrathecal treatment and prophylaxis in leukaemia: less than 1 year: 5 mg, 1 - 2 years: 7.5 mg, 2 - 3 years: 10 mg, more than 3 years: 12.5 mg. IT preparation must be clearly stated/verified. ENSURE THAT PREPARATION IS SUITABLE FOR INTRATHECAL USE iv) Dose used by rheumatologist: 10 - 15 mg IM injection or oral weekly. Dose used by dermatologist: 10 - 25 mg IM injection weekly	A (SRQ ONCO)
512.	Methyl Salicylate 25 % Ointment	M02AC0026 OG5001XX	Relief of minor aches and pains of muscles and joints associated with simple backache, arthritis and rheumatic conditions.	Apply to the affected area, 3-4 times daily.	C+

No.	Generic Name	MDC	Indications	Dosage	Category
513.	Methyldopa 250 mg Tablet	C02AB0111 OT1001XX	Hypertension	Adult: 250 mg 2 - 3 times daily, gradually increased at intervals of 2 or more days, maximum; 3 g/day. Elderly: initially 125 mg twice daily, increased gradually, maximum; 2 g daily. Child: Initially, 10 mg/kg or 300 mg/m ² daily in 2-4 divided doses; increase as necessary. Max: 65 mg/kg, 2 g/m ² or 3 g daily, whichever is least.	B
514.	Methylene Blue 1% Injection	V03AB1710 OP3001XX	For treatment of idiopathic and drug-induced methaemoglobinemia (Off-label indication with one-off UKK approval: As a dye/visualising agent in procedure)	Adult and children: 1 to 2 mg/kg (0.1 to 0.2 mL/kg of a 1% solution) IV very slowly over 5 minutes. This dosage can be repeated if necessary after one hour.	B (UKK CFLN) (SRQ GENERAL)
515.	Methylphenidate HCl 10 mg Tablet	N06BA0411 OT1001XX	Attention deficit hyperactivity disorder (ADHD)	CHILD over 6 years, initially 5 mg 1 - 2 times daily, increased if necessary at weekly intervals by 5 - 10 mg daily to maximum of 60 mg daily in divided doses; discontinue if no response after 1 month, also suspend periodically to assess child's condition (usually finally discontinued during or after puberty)	A (SRQ PSY) (SRQ REHAB)
516.	Methylphenidate HCl 18 mg Extended-release Tablet	N06BA0411 OT5002XX	Attention deficit hyperactivity disorder (ADHD)	CHILD over 6 years: Individualize dosage, to be taken once daily in the morning. Dose may be adjusted in increments to a maximum of 54 mg/day, at weekly interval. Patient new to methylphenidate: starting dose 18 mg once daily; adults 18mg or 36mg once daily. Patient currently using methylphenidate: 18 - 36 mg. Maximum 54 mg/day. Discontinue if no response after 1 month	A* (SRQ PSY)
517.	Methylprednisolone Sodium Succinate 1 g Injection	H02AB0452 OP4002XX	Suppression of inflammatory and allergic disorders, cerebral oedema, immunosuppression treatment of haematological and oncological disorders, treatment of shock states and endocrine disorders	15 - 30 mg/kg daily. Large doses may be repeated 4 - 6 hourly for up to 48 hours	A (SRQ GENERAL)

No.	Generic Name	MDC	Indications	Dosage	Category
518.	Metoclopramide HCl 10 mg Tablet	A03FA01110 T1001XX	Use in adults for: i) Prevention of delayed chemotherapy induced nausea and vomiting (CINV) ii) Prevention of radiotherapy induced nausea and vomiting (RINV) iii) Symptomatic treatment of nausea and vomiting, including acute migraine induced nausea and vomiting Use in children aged 1-18 years for: i) Prevention of delayed chemotherapy induced nausea and vomiting (CINV) as a second line option (Off-label indication with one-off UKK approval: Induce lactation)	Adult: The recommended single dose is 10mg, repeated up to three times daily. The maximum recommended daily dose is 30mg or 0.5mg/kg body weight. The maximum recommended treatment duration is 5 days. Prevention of delayed CINV (children aged 1-18 years): The recommended dose is 0.1-0.5mg/kg body weight, repeated up to three times daily by oral route. The maximum dose in 24 hours is 0.5mg/kg body weight. Dosing table CHILD age 1-3 years old (body weight 10-14kg): 1mg TDS, 3-5 years old (body weight 15-19kg): 2mg TDS, 5-9 years old (body weight 20-29kg): 2.5mg TDS, 9-18 years old (body weight 30-60kg): 5mg TDS, 15-18 years old (body weight > 60kg): 10mg TDS. Tablets are not suitable for use in children weighing less than 30kg. Other pharmaceutical forms may be more appropriate for administration to this population.	B

No.	Generic Name	MDC	Indications	Dosage	Category
519.	Metoclopramide HCl 5 mg / ml Injection	A03FA01110 P3001XX	Use in adults for: i) Prevention of post-operative nausea and vomiting ii) Symptomatic treatment of nausea and vomiting, including nausea and vomiting induced by migraine attacks iii) Prevention of radiotherapy-induced nausea and vomiting Use in children aged 1 to 18 years for: i) Prevention of delayed chemotherapy-induced nausea and vomiting as a second-line option ii) Prevention of post-operative nausea and vomiting as a second-line option	All indications (adult): A single 10mg dose is recommended for the prevention of post-operative nausea and vomiting. The recommended dose for the symptomatic treatment of nausea and vomiting, including nausea and vomiting induced by migraine attacks and for the prevention of radiotherapy-induced nausea and vomiting is 10mg per dose, 1 to 3 times daily. The maximum recommended daily dose is 30mg or 0.5mg/kg. Treatment duration when administering by injection should be as short as possible and a switch to administration via oral or rectal route should be instituted as quickly as possible. All indications (children aged 1 to 18 years of age) The recommended dosage is 0.1 to 0.15mg/kg, 1 to 3 times daily, by intravenous route. The maximum daily dose is 0.5mg/kg. Dosing table: CHILD age 1-3 years old (body weight 10-14kg): 1mg TDS, 3-5 years old (body weight 15-19kg): 2mg TDS, 5-9 years old (body weight 20-29kg): 2.5mg TDS, 9-18 years old (body weight 30-60kg): 5mg TDS, 15-18 years old (body weight > 60kg): 10mg TDS. For the prevention of delayed CINV, the maximum treatment duration is 5 days. For the prevention of post-operative nausea and vomiting, the maximum treatment duration is 48 hours.	B
520.	Metolazone 2.5 mg Tablet	C03BA0800 OT1002XX	Oedema in congestive cardiac failure, nephrotic syndrome and impaired renal function	Adult: 5-10 mg daily, increased if necessary to 20 mg daily. Max: 80 mg in 24 hr. Elderly: Initially, 2.5 mg/day or every other day. Should be taken with food. Take after breakfast.	A* (UKK MED)

No.	Generic Name	MDC	Indications	Dosage	Category
521.	Metoprolol Tartrate 100 mg Tablet	C07AB0212 3T1002XX	i) Hypertension ii) Angina pectoris iii) Myocardial infarct iv) Cardiac arrhythmias v) Migraine prophylaxis vi) Hyperthyroidism	i) Initial: 100mg daily in 1 or 2 divided doses Maintenance: 200mg daily in divided doses Max. 400mg daily ii) 50-100mg 2-3 times daily Max. 400mg daily iii) Initial: 50mg twice daily Maintenance: 100mg twice daily iv) Initial: 50mg 2-3 times daily Maintenance: 300mg daily in divided doses v) 100-200mg daily in 2 divided doses vi) 150-200mg daily in 3-4 divided doses Dosing is individualised and according to product insert/protocol.	B
522.	Metronidazole 200 mg Tablet	P01AB0100 0T1001XX	Anaerobic infection	Anaerobic bacterial infections Adult: Initially, 800 mg followed by 400 mg 8 hly for about 7 days. Other recommended doses: 500 mg 8 hrly or 7.5 mg/kg 6 hrly (max: 4 g in 24 hr). Child: 7.5 mg/kg 8 hrly. Elderly: Use lower end of adult dose recommendations. Do not admin as a single dose. Prophylaxis of postoperative anaerobic bacterial infections Adult: 400 mg by mouth 8 hrly in the 24 hr prior to surgery followed postoperatively by IV or rectal admin until oral therapy is possible. Other sources recommend that oral doses be initiated only 2 hr prior to surgery and that number of doses for all admin routes be limited to a total of 4. Elderly: Dose reduction may be necessary. Tab: Should be taken with food.	B
523.	Metronidazole 200 mg/5 ml Suspension	P01AB0100 0L8001XX	Anaerobic infection	CHILD: 7.5 mg/kg 3 times daily for 7 days	B
524.	Metronidazole 500 mg/100 ml Injection	J01XD01000 P9901XX	Anaerobic infections	ADULT: 500 mg IV infusion 8 hourly. CHILD: 7.5 mg/kg body weight every 8 hours. Neonates: 15mg/kg LD, followed by 7.5mg/kg every 12 hourly. 1 month to 18 years: 7.5mg/kg (maximum 500mg) every 8 hours.	A

No.	Generic Name	MDC	Indications	Dosage	Category
525.	Micafungin Sodium 50mg Injection	J02AX05520 P4101XX	i) Treatment of invasive candidiasis, including candidemia in adults when intolerance or resistance to Amphotericin B or Fluconazole. ii) Treatment of invasive candidiasis in children.	i) Dosage for adults, adolescents ≥ 16 years of age and the elderly for the treatment of invasive candidiasis: - Body weight $> 40\text{kg}$: 100mg/day* - Body weight $\leq 40\text{kg}$: 2mg/kg/day* *If patient's response is inadequate, e.g. persistence of cultures or if clinical condition does not improve, the dose may be increased to 200 mg/day in patients weighing $> 40\text{kg}$ or 4mg/kg/day in patients weighing $\leq 40\text{kg}$. Treatment duration for invasive candidiasis: should be a minimum of 14 days. The antifungal treatment should continue for at least one week after two sequential negative blood cultures have been obtained and after resolution of clinical signs and symptoms of infection. ii) Dosage for children: - Body weight $\leq 40\text{kg}$: 2mg/kg/day; - Body weight $> 40\text{kg}$: 100mg/day	A* (SRQ MED)
526.	Miconazole 2% Cream	D01AC0222 1G1001XX	i) Fungal infections: Tinea pedis, Tinea corporis, Tinea capitis and other dermatophyte infections caused by Trichophyton and Epidermophyton species; ii) Antifungal agent that has been in various candida infections including vaginal candidiasis. Prescribing Restriction(s): To be used as 2nd line treatment at health facilities without medical officer.	Apply sparingly and rub gently onto affected area 1-2 times daily continuing for 14 days after lesions have healed	C
527.	Midazolam 5 mg / 5 ml Injection	N05CD0811 0P3001XX	Pre-operative sedation, induction of general anaesthesia, premedication and sedation in ICU and sedation for minor procedures	Usual sedative range 2.5 - 7.5 mg (about 70 mcg/kg by IV injection over 30 seconds). Premedication by IM injection 70 - 100 mcg/kg 30 -60 minutes before surgery; ELDERLY: 1 - 1.5 mg/kg. Induction: Induction by slow IV infusion 200 - 300 mcg/kg (ELDERLY 100 - 200 mcg/kg. CHILD over 7 years 150 - 200 mcg/kg); Maximum: 0.35mg/kg. Sedation in ICU 0.03 - 0.2 mg/kg/hour	A (SRQ GENERAL)

No.	Generic Name	MDC	Indications	Dosage	Category
528.	Midazolam 5 mg/ml Injection	N05CD0811 0P3002XX	Pre-operative sedation, induction of general anaesthesia, premedication and sedation in ICU and sedation for minor procedures	Usual sedative range 2.5 - 7.5 mg (about 70 mcg/kg by IV injection over 30 seconds). Premedication by IM injection 70 - 100 mcg/kg 30 -60 minutes before surgery; ELDERLY: 1 - 1.5 mg/kg. Induction: Induction by slow IV infusion 200 - 300 mcg/kg (ELDERLY 100 - 200 mcg/kg. CHILD over 7 years 150 - 200 mcg/kg); Maximum: 0.35mg/kg. Sedation in ICU 0.03 - 0.2 mg/kg/hour	A (SRQ GENERAL)
529.	Midazolam 7.5 mg Tablet	N06AX1100 0T4001XX	Pre and post-operative sedation	ADULT: Usually 7.5 - 15 mg at bedtime; or for premedication, 30 - 60 minutes before the procedure. For ELDERLY, debilitated or impaired liver/kidney function: 7.5 mg	A/KK (SRQ GENERAL)
530.	Mirabegron 50 mg Prolonged Release Tablet	G04BD12-000-T52-01-001	Symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome. Prescribing restrictions: For patients who are not responsive, intolerant or unsuitable to use other existing agents.	50mg once daily. Should be taken once daily, with liquid, swallowed whole and is not to be chewed, divided, or crushed	A* (SRQ REHAB) (SRQ SURG)
531.	Mirtazapine 15 mg Orodispersible Tablet	N06AX1100 0T4001XX	Major depression Prescribing Restrictions Consultant/specialists for specific indications only, including Geriatricians and Neurologists	Initially 15 mg daily at bedtime increased according to response up to 45 mg daily as a single dose at bedtime or in 2 divided doses. CHILD and ADOLESCENT under 18 years not recommended	A* (SRQ PSY)
532.	Mirtazapine 30 mg Tablet	N06AX11-000-T32-01-XXX	Major depression Prescribing Restrictions Consultant/specialists for specific indications only, including Geriatricians and Neurologists	Initial: 15mg daily at bedtime Maintenance: 15-45mg daily	A* (SRQ PSY)
533.	Mitomycin-C 10mg Injection	L01DC0300 0P4001XX	i) Gastrointestinal, lung, breast, cervical cancers ii) Bladder tumours iii) Ophthalmological conditions: conjunctival squamous neoplasia, squamous cell carcinoma of conjunctiva, trabeculectomy chronic lymphocytic leukaemia, chronic myelogenous leukaemia. Gastric, colorectal, lung cancer	i) 10 - 20 mg/m ² body surface area (BSA) given as a single dose through a running IV infusion repeated every 6 - 8 weeks. The whole schedule may be repeated depending on the bone marrow ii) 10 - 40 mg daily or every other day (intravesical) iii) 0.4 mg topically as a single application for ophthalmological conditions, duration: 1 to 3 minutes	A* (SRQ ONCO)

No.	Generic Name	MDC	Indications	Dosage	Category
534.	Modified Fluid Gelatin 4 % Injection	B05AA0690 5P9901XX	For primary volume replacement in hypovolaemia, peri-operative stabilization of the circulation, haemodilution, extracorporeal circulation (haemodialysis and heart-lung machine)	ADULT 500 - 1500 ml given as IV infusion	B
535.	Mometasone Furoate 0.1 % Cream	D07AC1313 9G1001XX	Steroid responsive dermatosis and vitiligo. Used where a potent steroid is required for short duration not more than 6 weeks	Apply thin layer to the affected skin areas once daily until the lesion heals or for a duration of 3 weeks whichever is sooner. Massage gently and thoroughly until the medication disappears.	A* (SRQ PAED)
536.	Mometasone Furoate 50 mcg Aqueous Nasal Spray	R01AD0913 9A4101XX	i) Allergic rhinitis. ii) For the treatment of nasal polyps in patients 18 years of age and older.	ALLERGIC RHINITIS: ADULT and CHILD, 12 years and above: 100 mcg/day (2 sprays) to each nostril once daily. Maximum 200 mcg (4 sprays) once daily. Reduce to 50 mcg (1 spray) once daily when control achieved. CHILD 3 - 11 years old: 50 mcg (1 spray) to each nostril once daily. TREATMENT OF NASAL POLYPS: Two sprays (50 micrograms/spray) in each nostril twice daily (total daily dose of 400 mcg). Once symptoms are adequately controlled, dose reduction to two sprays in each nostril once daily (total daily dose 200 mcg) is recommended.	A* (SRQ ENT)
537.	Monobasic Sodium Phosphate 48 %, Dibasic Sodium Phosphate 18 %	A06AG0116 2L5001XX	Bowel cleansing prior to colonoscopy, radiological examination or bowel surgery	45 ml diluted with half a glass (120 ml) of water, followed by one full glass (240 ml) of water to be taken depending on the time of the procedure. For morning procedure, 45 ml dilute with half glass of water should be taken at 7 am and the second 45 ml at 7 pm on the day before the procedure. For afternoon procedure, the first dose should be taken at 7 pm on the day before and the second dose at 7 am on the day of the procedure. Solid food must not be taken during the preparation period; clear fluids or water can be taken liberally. Not recommended for use in children	A (SRQ SURG)
538.	Montelukast Sodium 4 mg Oral Granules	R03DC0352 0F1001XX	Asthmatics, not controlled on high dose inhaled corticosteroids more than 1600 mcg/day and with co-morbid allergic disorders. Chronic treatment of asthma	12 months - 5 years: 1 packet of 4mg oral granules daily at bedtime	A* (SRQ PAED)

No.	Generic Name	MDC	Indications	Dosage	Category
539.	Montelukast Sodium 5 mg Chewable Tablet	R03DC0352 0T2001XX	Asthmatics, not controlled on high dose inhaled corticosteroids more than 1600 mcg/day and with co-morbid allergic disorders. Chronic treatment of asthma	CHILD 6 - 14 years: One 5 mg chewable tablet daily at bedtime	A* (SRQ ENT) (SRQ PAED)
540.	Montelukast Sodium 10 mg Tablet	R03DC0352 0T1001XX	Chronic treatment of asthma and relief of symptoms of seasonal allergic rhinitis for children more than 15 years and adults	CHILD more than 15 years and ADULT: 10 mg daily at bedtime	A/KK (SRQ ENT) (SRQ MED)
541.	Morphine HCl 10 mg / 5 ml Solution	N02AA0111 0L9901XX	For use in management of moderate to severe pain especially that associated with neoplastic disease	5-20 mg or more regularly every 4 hours as needed in terminal pain	B
542.	Morphine Sulphate 10 mg / ml Injection	N02AA01-183-P30-01-XXX	i) For moderate to severe pain especially that associated with neoplastic disease ii) As an analgesic adjunct in general anaesthesia.	ADULT: 5 to 20 mg every 4 hours, intravenously (IV or IM), 2.5 to 15mg should be given by slow injection. CHILD: - Adjusted according to body weight, 0.1 – 0.2 mg /kg every 4 hours. No dose should exceed 15 mg. - Analgesic Indication (i) Subcutaneous, 100 mg to 200 mg (0.1 to 0.2 mg) per kg of body weight every four hours as needed, not to exceed 15mg per dose. Indication (ii) Intravenous, 50 to 100 mcg (0.05 mg to 0.1 mg) per kg of body weight, administered very slowly.	B
543.	Morphine Sulphate 10 mg Prolonged Release Tablet	N02AA0118 3T5001XX	i) Prolonged relief of severe pain associated with neoplastic disease ii) As a second line treatment of chronic non-cancer pain when treatments with adjuvant analgesics and non-pharmacological approach failed Prescribing Restrictions: <u>Indication (ii)</u> Initiated by Pain or Palliative Specialists only	10 - 60 mg 12 hourly intervals, depend upon the severity of the pain. Children (more than 1 year of age) with severe cancer pain: 0.2 - 0.8mg/kg 12 hourly.	A (SRQ GENERAL) (SRQ Palliative)
544.	Morphine Sulphate 30mg Prolonged Release Tablet	N02AA01-183-T50-02-XXX	i) Prolonged relief of severe pain associated with neoplastic disease ii) As a second line treatment of chronic non-cancer pain when treatments with adjuvant analgesics and non-pharmacological approach failed Prescribing Restrictions: <u>Indication (ii)</u> Initiated by Pain or Palliative Specialists only	10 - 60 mg 12 hourly intervals, depend upon the severity of the pain	A (SRQ Palliative)

No.	Generic Name	MDC	Indications	Dosage	Category
545.	Moxifloxacin 0.5 % Ophthalmic Solution	S01AX2211 0D2001XX	Treatment of conjunctivitis caused by susceptible organism	CHILD more than 1 year and ADULT: 1 drop to affected eye(s) 3 times daily for 7 day	A* (SRQ OPHTH)
546.	Multivitamin Infant Drop (Appeton)	A11BA0090 1D5001XX	For prevention and treatment of vitamin deficiencies	INFANT less than 1 year: 1 ml daily	B (SRQ PAED)
547.	Multivitamin Injection Amp 1 : Vit B1, B2, B6 Amp 2: Vit B3, Panthenol, Vit C	A11BA0090 1P3001XX	For prevention and treatment of vitamin deficiencies	Initially 2 - 4 pairs IV 4 - 8 hourly, reducing to 1 pair IV daily. For less serious cases, 1 pair IV 1 - 2 times daily or based on individual requirements	B
548.	Multivitamin Syrup	A11BA0090 1L9001XX	For prevention and treatment of vitamin deficiencies	CHILD 5 ml daily or based on manufacturer	C+ (SRQ PAED)
549.	Multivitamin Tablet	A11BA0090 1T1001XX	For prevention and treatment of vitamin deficiencies	1 - 2 tablets daily or based on individual requirements	B
550.	Mupirocin 2 % Ointment	D06AX0900 0G5001XX	For MRSA infections only	ADULT and CHILD: Apply up to three times daily for up to 10 days	A (SRQ GENERAL)
551.	Mycophenolate Mofetil 250 mg Capsule	L04AA06236 C1001XX	i) Prophylaxis of acute organ rejection in patients receiving allogenic renal, cardiac and hepatic transplant ii) Used with steroids for induction and maintenance of severe lupus nephritis	i) Renal transplant rejection: ADULT: 1 g twice daily. CHILD (3 months and older): 600 mg/m(2)/dose, twice daily; maximum daily dose, 2 g/10 mL. Cardiac transplant rejection: 1.5 g twice daily. Hepatic transplant rejection: 1.5 g twice daily ii) Induction phase: 2 - 3 g/day for up to 6 months. Maintenance phase: dose gradually tapers to 1 g/day	A* (SRQ MED)
552.	Mycophenolate Mofetil 500 mg Tablet	L04AA06236 T1002XX	i) Prophylaxis of acute organ rejection in patients receiving allogenic renal, cardiac and hepatic transplant ii) Used with steroids for induction and maintenance of severe lupus nephritis	i) Renal transplant rejection: ADULT: 1 g twice daily. CHILD (3 months and older): 600 mg/m(2)/dose, twice daily; maximum daily dose, 2 g/10 mL. Cardiac transplant rejection: 1.5 g twice daily. Hepatic transplant rejection: 1.5 g twice daily ii) Induction phase: 2 - 3 g/day for up to 6 months. Maintenance phase: dose gradually tapers to 1 g/day	A* (SRQ MED) (UKK MED – off-label) (SRQ PAED)
553.	Naloxone HCl 0.4 mg / ml Injection	V03AB1511 0P3002XX	For the complete/partial reversal of narcotic depression including respiratory depression induced by opioids such as natural and synthetic narcotics. Diagnosis of suspected acute opioids overdose	Initially 0.4 - 2 mg IV repeated at intervals of 2 - 3 minutes according to patient's needs	B
554.	Naproxen Sodium 275 mg Tablet	M01AE0252 0T1001XX	i) Rheumatic arthritis, osteoarthritis and ankylosing spondylitis ii) Acute gout iii) Muscular skeletal disorder, dysmenorrhoea	i: 275mg bd ii: Initial: 825mg followed by 275mg every 8 hrs as necessary iii. Initial: 550mg followed by 275 every 6-8 hrs as necessary.	A (SRQ GENERAL)

No.	Generic Name	MDC	Indications	Dosage	Category
555.	Neomycin 0.5% Cream	D06AX0425 6G1001XX	Infections of the skin due to susceptible organisms	Apply sparingly to affected area up to 3 times daily (For short term use, 1 – 2 weeks)	B
556.	Neostigmine Methylsulphate 2.5 mg/ml Injection	N07AA0118 3P3002XX	i) Symptomatic treatment of myasthenia gravis where oral therapy is impractical ii) Reversal of the effects of non-depolarizing neuromuscular blockade iii) The management of post-operative distension, paralytic ileus and urinary retention, where mechanical obstruction has been out-ruled	i) ADULT: 1 - 2.5 mg at suitable intervals by SC, IM or IV. Usual total daily dose 5 - 20 mg. CHILD: 0.1 mg IM. Titrated in the range of 0.05 mg - 0.25 mg. NEONATE: 50 - 250 mcg every 4 hours ii) By IV injection over 1 minute, 50 - 70 mcg/kg (maximum 5 mg and 2.5 mg for children) after or with atropine sulphate 0.6 - 1.2 mg iii) Adults: SC or IM 0.5 - 2.5 mg. Children: SC or IM 0.125 mg – 1 mg	B
557.	Nepafenac 0.1% ophthalmic solution	S01BC1000 0D2001XXX	Reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients.	One drop 3 times/day beginning 1 day prior to cataract surgery, continued on the day of surgery and up to 60 days of the postoperative period as directed by the clinician. An additional drop should be administered 30 to 120 minutes prior to surgery.	A* (SRQ OPHTH)
558.	Nifedipine 10 mg Tablet	C08CA0500 0T1001XX	Hypertension	Initial dose of 10 mg twice daily. Usual range 10 – 30 mg 3 times daily. Maximum: 120 - 180 mg per day. Elderly: Dose reduction may be necessary.	B
559.	Nimodipine 30 mg Tablet	C08CA0600 0T1001XX	Prophylaxis & treatment of ischaemic neurological deficits caused by cerebral vasospasm following subarachnoid haemorrhage of aneurysmal origin	360 mg daily in divided doses for 7 days	A* (UKK SURG)
560.	Nitrofurantoin 100 mg Tablet	J01XE01000 T1002XX	Uncomplicated lower urinary tract Infections	Acute uncomplicated urinary tract infections Adult: 50 -100 mg 4 times daily for 7 days. Dual-release preparation: 100 mg bid. Child: >3 mth and older children: 3 mg/kg daily in 4 divided doses. Prophylaxis of uncomplicated urinary tract infections Adult: 50 -100 mg at bedtime. Child: >3 mth and older children: 1 mg/kg once daily.	B
561.	Noradrenaline Acid Tartrate (Norepinephrine Bitartrate) 1 mg/ml Injection	C01CA0312 3P3001XX	i) For blood pressure control in certain acute hypotensive states (e.g.pheochromocytomectomy, sympathectomy, poliomyelitis, spinal anesthesia, myocardial infarction, septicemia, blood transfusion, and drug reactions). ii) As an adjunct in the treatment of cardiac arrest and profound hypotension	Infuse and titrate to desired pressure response. Range: 0.05 - 0.5 mcg/kg/minute	A (SRQ GENERAL)

No.	Generic Name	MDC	Indications	Dosage	Category
562.	Norethisterone 0.35 mg Tablet	G03AC0100 OT1001XX	Contraception	1 tablet daily starting on the first day of the menstrual bleeding	C+ (SRQ O&G)
563.	Nystatin 100,000 units / ml Suspension	A07AA0200 OL8001XX	Prevention and treatment of candidiasis of the skin and mucous membranes, protection against candida overgrowth during antimicrobial /corticosteroid therapy and as selective decontamination regimens	Treatment: Adult & Children: 100,000 to 600,000 units 6 hourly Infant: 100,000 – 200,000 units 6 hourly Neonates: 100,000 units 8 hourly Prophylaxis: Adult: 1,000,000 units daily Neonates and Infants: 100,000 units 2-3 times a day Children: 250,000 – 500,000 units 2-3 times a day	B
564.	Octreotide 0.1 mg / ml Injection	H01CB0212 2P3001XX	i) Acromegaly treatment in patients in whom surgery or radiotherapy is inappropriate or ineffective-based on level of growth hormone and high IGF-1 and residual pituitary tumor ii) Relief of symptoms associated with functional gastro-entero-pancreatic (GEP) endocrine tumors: • Carcinoid tumors with features of the carcinoid syndrome. • VIPomas, Glucagonomas • Gastrinomas/Zollinger-Ellison syndrome • Insulinomas • GRFomas. iii) Prevention of complications following pancreatic surgery iv) Emergency management of bleeding gastro-esophageal varices in patients with cirrhosis	i) Initially 0.05-0.1mg SC every 8 or 12 hours. Optimal daily dose is 0.3mg, not to exceed maximum dose of 1.5mg/day. ii) Initially 0.05 mg once or twice daily, gradually increase to 0.1-0.2mg 3 times daily. Higher doses may be required in exceptional circumstances. iii) 0.1 mg 3 times daily for 7 consecutive days, starting on the day of operation, at least 1 hour before laparotomy iv) ADULT: 50mcg bolus, followed by continuous infusion of 25-50mcg/hour for 2-5 days. CHILD: IV 1-5 mcg/kg/hour The dosing is individualized according to product insert / protocol	A
565.	Ofloxacin 0.3 % Otic Solution	S02AA0000 OD1001XX	i) Acute otitis media with tympanostomy tubes ii) Chronic suppurative otitis media with perforated tympanic membranes and iii) Otitis externa	CHILD: 1 - 12 years: 5 drops twice daily for 10 days. ADULT and CHILD over 12 years: 6 - 10 drops twice daily and remain in the ear about 10 minutes	A/KK (SRQ ENT)
566.	Ofloxacin 100 mg Tablet	J01MA0100 OT1001XX	i) As second-line treatment of leprosy ii) As second-line treatment for tuberculosis and multidrug resistant tuberculosis (MDR-TB) iii) Sequential therapy for UTI and Pyelonephritis	i) 400 mg/day ii) 400 mg twice daily iii) 200 mg twice daily	A (SRQ GENERAL)

No.	Generic Name	MDC	Indications	Dosage	Category
567.	Olanzapine 5mg Disintegrating Tablet	N05AH03-000-T40-01-XXX	i) Acute and maintenance treatment of schizophrenia and other psychoses where positive and or negative symptoms are prominent ii) Short-term use for acute mania episodes associated with Bipolar 1 disorder iii) Prevention of recurrence of manic, mixed or depressive episodes in Bipolar I Disorder. Prescribing Restrictions Consultant/specialists for specific indications only, including Geriatricians	i) 5 - 10 mg once daily, increase to 10 mg once daily within 5 - 7 days, adjust by 5 - 10 mg/day at 1 week intervals, maximum 20 mg/day ii) 10 - 15 mg once daily, increase by 5 mg/day at intervals of not less than 24 hours. Maintenance 5 - 20 mg/day; maximum 20 mg/day iii) Starting dose is 10mg/day, daily dosage may subsequently be adjusted on the basis of individual clinical status within the range 5-20 mg/day	A* (SRQ PSY)
568.	Olanzapine 10 mg Disintegrating Tablet	N05AH03-000-T40-02-XXX	i) Acute and maintenance treatment of schizophrenia and other psychoses where positive and or negative symptoms are prominent ii) Short-term use for acute mania episodes associated with Bipolar 1 disorder iii) Prevention of recurrence of manic, mixed or depressive episodes in Bipolar I Disorder. Prescribing Restrictions Consultant/specialists for specific indications only, including Geriatricians	i) 5 - 10 mg once daily, increase to 10 mg once daily within 5 - 7 days, adjust by 5 - 10 mg/day at 1 week intervals, maximum 20 mg/day ii) 10 - 15 mg once daily, increase by 5 mg/day at intervals of not less than 24 hours. Maintenance 5 - 20 mg/day; maximum 20 mg/day iii) Starting dose is 10mg/day, daily dosage may subsequently be adjusted on the basis of individual clinical status within the range 5-20 mg/day	A* (SRQ PSY)
569.	Olanzapine 5 mg Tablet	N05AH03-000-T10-01-XXX	i) Acute and maintenance treatment of schizophrenia and other psychoses where positive and or negative symptoms are prominent ii) Short-term use for acute mania episodes associated with Bipolar 1 disorder iii) Prevention of recurrence of manic, mixed or depressive episodes in Bipolar I Disorder.	i) 5 - 10 mg once daily, increase to 10 mg once daily within 5 - 7 days, adjust by 5 - 10 mg/day at 1 week intervals, maximum 20 mg/day ii) 10 - 15 mg once daily, increase by 5 mg/day at intervals of not less than 24 hours. Maintenance 5 - 20 mg/day; maximum 20 mg/day iii) Starting dose is 10mg/day, daily dosage may subsequently be adjusted on the basis of individual clinical status within the range 5-20 mg/day	B (SRQ PSY)

No.	Generic Name	MDC	Indications	Dosage	Category
570.	Olanzapine 10 mg Tablet	N05AH03-000-T10-02-XXX	i) Acute and maintenance treatment of schizophrenia and other psychoses where positive and or negative symptoms are prominent ii) Short-term use for acute mania episodes associated with Bipolar 1 disorder iii) Prevention of recurrence of manic, mixed or depressive episodes in Bipolar I Disorder.	i) 5 - 10 mg once daily, increase to 10 mg once daily within 5 - 7 days, adjust by 5 - 10 mg/day at 1 week intervals, maximum 20 mg/day ii) 10 - 15 mg once daily, increase by 5 mg/day at intervals of not less than 24 hours. Maintenance 5 - 20 mg/day; maximum 20 mg/day iii) Starting dose is 10mg/day, daily dosage may subsequently be adjusted on the basis of individual clinical status within the range 5-20 mg/day	B (SRQ PSY)
571.	Olopatadine HCl ophthalmic solution 0.2 %	S01GX0911 0D2002XX	Temporary prevention of ocular itching due to allergic conjunctivitis	One drop in each affected eye once a day	A* (SRQ OPHTH)
572.	Omeprazole 20 mg Capsule	A02BC0100 0C1002XX	i) Reflux oesophagitis ii) For eradication of Helicobacter pylori infection iii) Benign peptic ulcer not responding to conventional therapy iv) Zollinger-Ellison Syndrome	i) 20 - 80 mg 1 - 2 times daily up to 8 - 12 weeks ii) 20 mg twice daily in combination with any of the 2 antibiotics (clarithromycin 500 mg twice daily, amoxicillin 1 g twice daily or metronidazole 400 mg twice daily) for 1 - 2 weeks iii) 20 mg once daily for 4 - 6 weeks iv) ADULT: 20 - 120 mg once daily adjusted according to the patient's response. CHILD 0.4 - 0.8 mg/kg/day	A/KK (SRQ ENT) (SRQ PAED) (SRQ SURG)
573.	Omeprazole 40mg Injection	A02BC0100 0P4001XX	i) Reflux oesophagitis, eradication of H. Pylori infection, benign peptic ulcer not responding to conventional therapy, Zollinger-Ellison Syndrome ii) Endoscopically confirmed peptic ulcer	i) 40 mg IV once daily when oral therapy is inappropriate ii) 40- 160 mg by IV in single or divided doses	A* (SRQ GENERAL)
574.	Ondansetron 2 mg / ml Injection	A04AA0111 0P3001XX	i) Prevention of nausea and vomiting induced by chemotherapy and radiotherapy ii) Postoperative nausea and vomiting	i) 8 mg given by IV infusion over 15 minutes or by IM immediately before treatment followed by 8 mg orally every 12 hours for up to 5 days. CHILD 5 mg/m2 body surface IV over 15 minutes immediately before chemotherapy followed by 4 mg orally every 12 hours for up to 5 days ii)Prevention : 4 mg given by IV at induction of anaesthesia. CHILD over 2 years, 100 mcg/kg (max 4mg) by slow IV before, during or after induction of anaesthesia. Treatment of postoperative: 4 mg by IM or slow. CHILD over 2 years 100 mcg/kg (maximum 4 mg) by slow IV	A (SRQ ANAES)

No.	Generic Name	MDC	Indications	Dosage	Category
575.	Oral Rehydration Salt	A07CA0090 5F2101XX	Replacement of fluid and electrolytes loss in diarrhoea	Dissolve 1 sachet in 200 or 250mL of water according to product insert. The amount to give depends on hydration status. ADULT: 200-400mL (1 - 2 sachets) for every loose motion / diarrhoea / vomiting CHILD (2 yrs & above): 100-200mL (1 sachet) for every loose motion / diarrhoea / vomiting. In severe dehydration 100ml/kg for 3-4 hours. INFANT (up to 2 yrs): 1 - 1.5 times their usual feed volume (50-100mL) each diarrhoea/vomiting Dose is according to product insert and dependent on the product / brand used as well as patient comorbidities e.g. heart failure and chronic kidney disease.	C
576.	Orphenadrine 100 mg Tablet	M03BC0111 0T1001XX	Painful muscle spasm	100mg BD. In severe cases, doses may increase to 300mg in any 24-hour period.	A (SRQ GENERAL)
577.	Oseltamivir 75mg capsule	J05AH02000 C1001XX	i) For treatment of patients with suspected or confirmed influenza and severe disease (requiring hospitalization or evidence of lower respiratory tract infection). ii) For treatment of patients with suspected or confirmed influenza and with co-morbidity and associated with increased risk of influenza complications. Not to be used as prophylaxis.	Recommended dose in adults and adolescents $\geq$ 13 years of age and body weight >40 kg is 75mg twice daily for 5 days. Dosing adjustment for renal impaired patient, follow manufacturer's recommendations in product insert.	A/KK (SRQ MED)
578.	Oseltamivir 60 mg / 5 ml oral suspension	J05AH02000 L8001XX	i) For treatment of patients with suspected or confirmed influenza and severe disease (requiring hospitalization or evidence of lower respiratory tract infection). ii) For treatment of patients with suspected or confirmed influenza and with co-morbidity and associated with increased risk of influenza complications. Not to be used as prophylaxis.	Children $\geq$ 1 year (for 5 days): a) ≤ 15 kg: 30mg twice daily b) >15 kg to 23kg: 45mg twice daily c) >23 kg to 40kg: 60mg twice daily Children with body weight more than 40kg who are able to swallow capsule is recommended to be dosed as adults.	A/KK (SRQ ANAES) (SRQ PAED)

No.	Generic Name	MDC	Indications	Dosage	Category
579.	Oxybutynin Chloride 5 mg Tablet	G04BD0411 OT1001XX	For the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (ie urgency, frequency, urinary leakage, urge incontinence, dysuria)	ADULT: Initially 5 mg 2 - 3 times daily increased if necessary to maximum 5 mg 4 times daily. ELDERLY: Initially 2.5 - 3 mg twice daily, increased to 5 mg twice daily according to response and tolerance. CHILD over 5 years, neurogenic bladder instability: 2.5 - 3 mg twice daily increased to 5 mg twice daily to maximum 3 times daily	A* (UKK PAED) (UKK REHAB)
580.	Oxycodone HCl 5 mg Immediate Release Capsules	N02AA05-110-C10-01-XXX	i) Management of moderate to severe chronic cancer pain non-responsive to morphine in accordance with WHO step-wise ladder of chronic pain management ii) As a step-down analgesic drug in post-operative procedures iii) As a second line treatment of chronic non-cancer pain when treatments with adjuvant analgesics and non-pharmacological approach fail Prescribing Restrictions: <u>Indication (iii)</u> Initiated by Pain, Palliative Specialists and geriatricians only Precautions Geriatric patients: Caution and proper monitoring is warranted. Opioid related adverse effects may be more prominent in this population therefore should be monitored regularly and addressed if occurred	Initially 5 mg every 4 to 6 hours, increased if necessary according to severity of pain, usual max. 400 mg daily, but some patients may require higher doses	A* (SRQ ANAES) (SRQ Palliative)

No.	Generic Name	MDC	Indications	Dosage	Category
581.	Oxycodone Hydrochloride 10mg Controlled Release Tablet	N02AA05-110-T53-01-XXX	i) Management of moderate to severe chronic cancer pain non-responsive to morphine in accordance with WHO step-wise ladder of chronic pain management ii) As a second line treatment of chronic non-cancer pain when treatments with adjuvant analgesics and non-pharmacological approach failed Prescribing Restrictions: <u>Indication (ii)</u> Initiated by Pain, Palliative Specialists or geriatricians only	Adults, elderly and children over 12 years: Usual starting dose for opioid-naïve patients or patients presenting with moderate to severe pain uncontrolled by weaker opioids (especially if they are receiving concurrent sedatives, muscle relaxants or other CNS medicines) is 10mg 12 hourly. The dose should then be carefully titrated with longitudinal patient monitoring, assessing whether the pain is opioid responsive and providing the patient significant pain relief. Patients with renal or hepatic impairment: The recommended adult starting dose should be reduced by 1/3 to 1/2, and each patient should be titrated to adequate pain control according to their clinical situation.	A* (SRQ ANAES) (SRQ Palliative)
582.	Oxycodone HCl 10mg Immediate Release Capsules	N02AA05-110-C10-02-XXX	i) Management of moderate to severe chronic cancer pain non-responsive to morphine in accordance with WHO step-wise ladder of chronic pain management ii) As a step-down analgesic drug in post-operative procedures iii) As a second line treatment of chronic non-cancer pain when treatments with adjuvant analgesics and non-pharmacological approach failed Pres. Restrictions: <u>Indication (iii)</u>: Initiated by Pain, Palliative Specialists and Geriatricians only	Initially 5 mg every 4 to 6 hours, increased if necessary according to severity of pain. Usual max. 400 mg daily, but some patients may require higher doses	A* (SRQ Palliative)

No.	Generic Name	MDC	Indications	Dosage	Category
583.	Oxycodone Hydrochloride 20mg Controlled Release Tablet	N02AA05-110-T53-02-XXX	i) Management of moderate to severe chronic cancer pain non-responsive to morphine in accordance with WHO step-wise ladder of chronic pain management. ii) As a second line treatment of chronic non-cancer pain when treatments with adjuvant analgesics and non-pharmacological approach failed Pres. Restrictions: Indication (ii): Initiated by Pain, Palliative Specialists or Geriatricians only	Adults, elderly and children over 12 years: Usual starting dose for opioid-naïve patients or patients presenting with moderate to severe pain uncontrolled by weaker opioids (especially if they are receiving concurrent sedatives, muscle relaxants or other CNS medicines): 10mg 12 hourly. The dose should then be carefully titrated with longitudinal patient monitoring, assessing whether the pain is opioid responsive and providing the patient significant pain relief. Patients with renal or hepatic impairment: The recommended adult starting dose should be reduced by 1/3 to 1/2, and each patient should be titrated to adequate pain control according to their clinical situation.	A* (SRQ Palliative)
584.	Oxymetazoline HCl 0.025 % (Paediatric) Nasal Drops	R01AA0511 0D6001XX	Acute colds, paranasal sinusitis and otitis media	1 - 2 drops twice daily in each nostril for child more than 1 year	A/KK (SRQ ENT)
585.	Oxymetazoline HCl 0.05 % (Adult) Nasal Drops	R01AA0511 0D6002XX	Acute colds, paranasal sinusitis and otitis media	1 - 2 drops twice daily in each nostril	A/KK (SRQ ENT)
586.	Oxytocin 10 units / ml Injection	H01BB0200 0P3001XX	i) Induction of labour ii) Inadequate uterine effort iii) Management of third stage of labour iv) Post-partum haemorrhage	i & ii) Initiate at 2 milliunits/min, may be increased by 4 milliunits/min gradually at 30 minute intervals. Dose may be decreased once a contraction pattern similar to normal labour is achieved and labor has progressed to 5 - 6 cm dilation. Maximum dose of oxytocin for multiparae - 16 milliunits/min and nulliparae-32 milliunits/min. iii) IV/IM: 5 -10 units iv) IV : 5-10 units followed by IV infusion at 10 units/hour The dosing is individualized	B
587.	Oxytocin 5 units & Ergometrine Maleate 0.5 mg / ml Injection	G02AC0190 0P3001XX	i) Prevention and treatment of postpartum haemorrhage associated with uterine atony. ii) Active management of third stage of labour	i) 1 ml IM, may be repeated after 2 hours. Should not exceed 3 ml within 24 hours ii) For routine management of third stage of labour, 1 ml IM following delivery of the anterior shoulder or immediately after delivery of the child	C+

No.	Generic Name	MDC	Indications	Dosage	Category
588.	Paliperidone 3 mg Extended Released Tablet	N05AX1300 OT5001XX	Second or third line treatment of schizophrenia	ADULT 6 mg once daily in the morning, adjusted if necessary; usual range 3 -12 mg daily. Renal impairment (creatinine clearance between 10-50 mL/min) 3 mg once daily. Avoid if creatinine clearance less than 10mL/min	A* (SRQ PSY)
589.	Paliperidone 6 mg Extended Released Tablet	N05AX1300 OT5002XX	Second or third line treatment of schizophrenia	ADULT 6 mg once daily in the morning, adjusted if necessary; usual range 3 -12 mg daily. Renal impairment (creatinine clearance between 10-50 mL/min) 3 mg once daily. Avoid if creatinine clearance less than 10mL/min	A* (SRQ PSY)
590.	Paliperidone 100 mg Prolonged Release Injection	N05AX1300 OP2004XX	Second or third line treatment of acute and maintenance treatment of schizophrenia in adults	Initiation: Deltoid IM 150 mg eq on Day1, followed by deltoid IM 100 mg eq on one week later. Maintenance: Monthly dose of 75 mg eq (this can be increased or decreased based on individual patient?s tolerability and/or efficacy). These monthly maintenance dose can be administered in either the deltoid or gluteal muscle	A* (SRQ PSY)
591.	Paliperidone 150 mg Prolonged Release Injection	N05AX1300 OP2004XX	Second or third line treatment of acute and maintenance treatment of schizophrenia in adults	Initiation: Deltoid IM 150 mg eq on Day1, followed by deltoid IM 100 mg eq on one week later. Maintenance: Monthly dose of 75 mg eq (this can be increased or decreased based on individual patient?s tolerability and/or efficacy). These monthly maintenance dose can be administered in either the deltoid or gluteal muscle	A* (SRQ PSY)
592.	Paliperidone 525mg/ 2.625ml Prolonged-Release for Intramuscular Injection	N05AX13- 126-P20- 04-001	For the maintenance treatment of schizophrenia in adult patients who have been adequately treated with the 1-month paliperidone palmitate injectable product for at least four months.	Apply 3.5 as a dose multiplier to the previous 1-month injection dose, and administer every 3 months	A* (SRQ PSY)
593.	Pamidronate Disodium 30 mg Injection	M05BA0352 OP3001XX	Hypercalcaemia of malignancy (tumour - induced hypercalcaemia)	Dose depends on the initial serum calcium levels. Doses range from a single infusion of 30 - 90 mg	A* (SRQ MED) (SRQ SURG) (SRQ ORTHO) (UKK PAED-Off Label Use)
594.	Pancreatin 150 mg Capsule (equivalent to amylase 8000 units, lipase 10,000 units and protease 600 units)	A09AA0200 OC1001XX	Treatment of pancreatic exocrine insufficiency	Initially 1 - 2 capsules with each meal. May increase to 5 - 15 capsules daily Dosing is individualised and according to product insert/protocol	A/KK (SRQ PAED)
595.	Pantoprazole 40 mg Injection	A02BC0200 OP3001XX	Bleeding peptic ulcer and acute stress ulceration	40 mg twice daily until oral administration can be resumed. CHILD not recommended	A/KK (SRQ GENERAL)

No.	Generic Name	MDC	Indications	Dosage	Category
596.	Pantoprazole 40 mg Tablet	A02BC0200 OT1001XX	i) Helicobacter pylori eradication ii) Peptic ulcer disease iii) Erosive and non-erosive reflux oesophagitis (GERD and NERD) iv) Zollinger-Ellison Syndrome v) Prevention of NSAID induced gastropathy	i) 40 mg twice daily in combination with any of the 2 antibiotics (Clarithromycin 500 mg twice daily, Amoxicillin 1 g twice daily or Metronidazole 400 mg twice daily) for 1-2 weeks ii) 40 mg daily for 2 - 4 weeks iii) 20 - 40 mg daily on morning for 4 weeks iv) Initially 80 mg daily, dose can be titrated up or down as needed. v) 20 mg daily. CHILD not recommended	B
597.	Paracetamol 10mg/ml Solution for IV Infusion	N02BE0100 OP3101XX	Mild to moderate pain and pyrexia	Body Weight (BW) ≤ 10kg: 7.5mg/kg, max: 30mg/kg >10kg to ≤ 33kg: 15mg/kg, max 60mg/kg not exceeding 2g >33kg to ≤ 50kg: 15mg/kg, max 60mg/kg not exceeding 3g >50kg (with risk of hepatotoxicity): 1g, max 3g BW >50kg (without risk of hepatotoxicity): 1g, max 4g OR as in the product leaflet	A (SRQ GENERAL)
598.	Paracetamol 125 mg Suppository	N02BE0100 OS2002XX	Symptomatic relief of fever and post operative pain whom cannot tolerate oral preparations.	ADULT & CHILDREN more than 12 years old: 500mg - 1g every 4-6 hours CHILD 6 - 12 years : 250 - 500 mg; 1 - 5 years : 125 - 250 mg; 3 - 11 months : 80 mg inserted every 4 - 6 hours if necessary, maximum 4 doses in 24 hours. INFANTS under 3 months should not be given Paracetamol unless advised by doctor; a dose of 10 mg/kg (5 mg/kg if jaundiced) is suitable.	C+
599.	Paracetamol 250 mg Suppository	N02BE0100 OS2001XX	Symptomatic relief of fever and post operative pain whom cannot tolerate oral preparations.	ADULT & CHILDREN more than 12 years old: 500mg - 1g every 4-6 hours CHILD 6 - 12 years : 250 - 500 mg; 1 - 5 years : 125 - 250 mg; 3 - 11 months : 80 mg inserted every 4 - 6 hours if necessary, maximum 4 doses in 24 hours. INFANTS under 3 months should not be given Paracetamol unless advised by doctor; a dose of 10 mg/kg (5 mg/kg if jaundiced) is suitable.	B
600.	Paracetamol 250 mg/5 ml Syrup	N02BE0100 OL8002XX	Mild to moderate pain and pyrexia	CHILD: 6 - 12 years: 250 - 500 mg per dose. Repeat every 4 - 6 hours when necessary. Maximum of 4 doses in 24 hours	C+
601.	Paracetamol 500mg Tablet	N02BE0100 OT1001XX	Mild to moderate pain and pyrexia	ADULT: 500 - 1000 mg every 4 - 6 hours, maximum of 4 g daily	C+

No.	Generic Name	MDC	Indications	Dosage	Category
602.	Paraffin Mole Alba (White Soft Paraffin)	D02AC0000 0G5001XX	Xerosis and ichthyosis	Apply to the affected area	C
603.	Paraffin Mole Flava	D02AC0000 0G5002XX	Xerosis and ichthyosis	Apply to the affected area	C
604.	Parecoxib Sodium 40 mg Injection	M01AH0452 0P3001XX	Management of post operative pain in the immediate post operative setting only	40 mg followed by 20 or 40 mg every 6 to 12 hours, as required, not exceeding daily dosage of 80 mg. There is limited clinical experience with parecoxib treatment beyond three days. Reduce the initial dose by 50% in elderly less than 50 kg, with a maximum daily dosage of 40 mg.	A* (SRQ A&E) (SRQ ANAES) (SRQ SURG) (SRQ ORTHO)
605.	Penicillamine 0.25 g Capsule	M01CC0100 0C1001XX	i) Treatment of severe lead poisoning, it is used as adjunctive treatment following initial treatment with another chelating agent. May also be used as sole therapy in the treatment of asymptomatic patients with moderately elevated blood concentrations ii) Wilson's Disease: to aid in elimination of copper ions	i) Heavy metal poisoning: 900mg-1800mg daily. Duration of treatment is dictated by the urinary heavy metal excretion. Simultaneous oral vitamin B6 replacement with at least 40mg daily is essential ii) Wilson's disease: 0.25g - 1.5g daily on an incremental basis. Maximal daily dose: 2g. Maintenance dose: 0.75g - 1g daily	A (UKK A&E)
606.	Pentoxifylline 400 mg Tablet	C04AD0300 0T1001XX	Peripheral vascular disease	400 mg 2 - 3 times daily	A/KK
607.	Perindopril 4 mg Tablet	C09AA0400 0T1001XX	i) Hypertension ii) Stable coronary artery disease iii) Heart failure	i) & ii) Initial: 4mg once daily Max. 8mg daily iii) Initial: 2mg once daily Maintenance: 4mg once daily Dosing is individualised and according to product insert / protocol.	B
608.	Peritoneal Dialysis Solution (1.5 % Dextrose)	B05DB0090 8H2001XX	For chronic renal disease requiring dialysis and for acute renal failure	Dose depending on clinical cases	B (SRQ PAED)
609.	Permethrin 1 % w/v Lotion	P03AC0400 0L6002XX	For topical treatment of head lice.	Apply lotion onto clean towel dried hair ensuring every strand comes in contact with lotion for at least 10 minutes. Rinse completely. Re-apply after 10 days to ensure total recovery.	B
610.	Permethrin 5 % w/v Lotion	P03AC0400 0L6001XX	Treatment of scabies	Two applications needed one week apart. Apply thoroughly to all body parts from neck down. Leave overnight for 8 - 14 hours. Washed off. Reapply after one week. Not recommended for children less than 2 months of age.	A/KK (SRQ PAED) (SRQ A&E)

No.	Generic Name	MDC	Indications	Dosage	Category
611.	Perphenazine 4mg Tablet	N05AB03-000-T10-01-XXX	i) Treatment of psychotic disorders ii) Used in the treatment of behavioural disorders in adults, in the aged and in children	ADULT: Initially 4 mg 3 times daily adjusted according to response, maximum 24 mg daily. ELDERLY: 1/4 to 1/2 adult dose. CHILD: The lower range of the adult dosage may be used in children over 12. It should start with the smallest dose e.g 2mg, then titrate accordingly.	B (SRQ PSY)
612.	Pethidine HCl 50 mg / ml Injection	N02AB0211 0P3001XX	For relief of moderate to severe pain (medical and surgical), preanaesthetic medication and obstetrical analgesia	ADULT: 0.5 - 2 mg/kg SC or IM every 3 - 4 hours if necessary. CHILD: by IM 0.5 - 2 mg/kg. Up to 1 year : 1- 2 mg/kg weight IM, 1 - 5 years : 12.5 - 25 mg IM, 6 - 12 years: 25 - 50 mg IM	B
613.	Phenobarbitone 30 mg Tablet	N03AA0200 0T1002XX	Epilepsy	ADULT: 60 - 180 mg daily on. CHILD: Up to 8 mg/kg daily	B
614.	Phenobarbitone Sodium 200 mg / ml Injection	N03AA02-520-P30-01-XXX	All forms of epilepsy except absence seizures.	ADULT: 10 mg/kg IV at a rate of not faster than 100 mg/minute. Initial maximum dose does not exceeding 1 gm. Daily maintenance of 1 - 4 mg/kg/day. CHILD: 3-5mg per kg body weight as a single dose by intramuscular injection. Dosing is according to product insert.	B (UKK CFLN)
615.	Phenoxymethyl Penicillin 125 mg Tablet	J01CE02500 T1001XX	i) Treatment or prophylaxis of infections caused by susceptible organisms ii) Prophylactic, rheumatic fever	i) ADULT: 500 - 750 mg 6 hourly.CHILD; up to 1 year: 62.5 mg, 1 - 5 years: 125 mg, 6 - 12 years: 250 mg 6 hourly ii) ADULT: 125 - 250 mg twice daily. CHILD: 25 - 50 mg/kg in divided doses every 6 - 8 hours. Maximum: 3 g/day	C
616.	Phenoxymethyl Penicillin 125 mg / 5 ml Syrup	J01CE02500 F2101XX	Treatment or prophylaxis of infections caused by susceptible organisms	CHILD: Up to 1 year: 62.5 mg 6 hourly; 1 - 5 years: 125 mg 6 hourly; 6 - 12 years: 250 mg 6 hourly	C
617.	Phenylephrine HCl 2.5 % Eye Drops	S01FB0111 0D2001XX	For pupillary dilation in uveitis, for refraction without cyclopegic. For fundoscopy and other diagnostic procedures	Mydriasis and vasoconstriction: 1 drop of 2.5% or 10% solution, repeated in one hour if necessary. Chronic mydriasis: 1 drop of a 2.5% or 10% solution 2 - 3 times a day. Uveitis with posterior synechiae (treatment) or synechiae, posterior (prophylaxis): 1 drop of a 2.5% or 10% solution, repeated in one hour if necessary, not to exceed three times a day. Treatment may be continued the following day, if necessary	B

No.	Generic Name	MDC	Indications	Dosage	Category
618.	Phenytoin Sodium 30 mg Capsule	N03AB0252 OC1001XX	Control of tonic-clonic (grand mal) and psychomotor seizures	ADULT Initial: 300mg daily in 3 equally divided doses Maintenance: 300-400 daily in 3-4 equally divided doses Max. dose: 600mg daily CHILD Initial: 5mg/kg/day in 2-3 equally divided doses Maintenance: 4-8mg/kg/day Max. dose: 300mg daily Dosing is according to product insert	B
619.	Phenytoin Sodium 100 mg Capsule	N03AB0252 OC1002XX	Control of tonic-clonic (grand mal) and psychomotor seizures	ADULT Initial: 300mg daily in 3 equally divided doses Maintenance: 300-400 daily in 3-4 equally divided doses Max. dose: 600mg daily CHILD Initial: 5mg/kg/day in 2-3 equally divided doses Maintenance: 4-8mg/kg/day Max. dose: 300mg daily Dosing is according to product insert	B
620.	Phenytoin Sodium 50mg /ml Injection	N03AB0252 OP3001XX	i) Control of status epilepticus of the tonic-clonic (grand mal) type ii) Prevention and treatment of seizures occurring during or following neurosurgery.	i) ADULT Loading: 10-15mg/kg slow IV (max. 50mg per minute) Maintenance: 100mg orally or IV every 6-8 hours NEONATE & CHILD Loading: 15-20mg/kg IV slow IV (max. 1-3mg/kg/minute) ii) 100-200mg deep IM at approximately 4 hour intervals during surgery and continued postoperative. Dosing is individualised and according to product insert / protocol.	B
621.	Phenytoin Sodium 125mg /5ml Suspension	N03AB0252 OL8001XX	Control of tonic-clonic (grand mal) and psychomotor seizures	ADULT: Initial: 125mg 2-3 times daily. Max. dose: 625mg daily CHILD: Initial: 5mg/kg/day in 2-3 divided doses Maintenance: 4-8 mg/kg/day in equally divided doses Max. dose: 300mg daily	B (SRQ PAED) (SRQ ANAES)
622.	Pilocarpine 2 % Eye Drops	S01EB0111 OD2002XX	Miotics in chronic open-angle glaucoma	1 drop 1 - 4 times a day	B

No.	Generic Name	MDC	Indications	Dosage	Category
623.	Piperacillin 4 g & Tazobactam 500 mg Injection	J01CR05961 P3001XX	Febrile neutropenia, lower respiratory tract infection and severe sepsis	Adult and children more than 12 years: 4.5g 6 hourly, for neutropenia adult and children more than 50kg: 4.5g 6 hourly. Children less than 50kg: 90mg/kg 6 hourly	A* (SRQ GENERAL)
624.	Piracetam 1.2 g Tablet	N06BX0300 OT1001XX	Mild cognitive impairment, post concussional head syndrome, head injury disorder, chronic vertigo and myoclonus	Initially 7.2 g daily in 2 - 3 divided doses, increased according to response by 4.8 g daily every 3 - 4 days to maximum of 20 g daily. CHILD under 16 years not recommended	A* (SRQ GENERAL)
625.	Piribedil 50 mg Tablet	N04BC0800 OT5001XX	Parkinson disease	As monotherapy: 150 - 250 mg as 3 - 5 divided doses daily. As combination with L-dopa therapy: 50 - 150 mg daily (50 mg per 250 mg of L-dopa)	A* (SRQ MED)
626.	Pizotifen 0.5 mg Tablet	N02CX0125 3T1001XX	Prophylactic treatment of vascular headache	Starting with 0.5mg daily, the dosage should be progressively increased. The average maintenance dosage is 1.5mg daily in divided doses or as a single dose at night. Max dose: 4.5 mg/day and 3 mg/dose. Child: >2 yr: Up to 1.5 mg daily in divided doses. Max dose: 1 mg/dose.	B
627.	Pneumococcal Vaccine (Polyvalent) (Pneumo 23)	J07AL01- 000-P30-03- XXX	Prevention of pneumococcal infections in high risk subjects from the age of 2 years including patient with a history of splenectomy or scheduled splenectomy	Primary injection: 1 single injection (0.5 ml) only. Booster: Must not be given within 5 years except in very high risk patient who received the vaccine while under immunosuppressive treatment	A (SRQ GENERAL)
628.	Polycitra Syrup	A12BA0295 5L9001XX	For treatment of calcium and uric acid stones	The usual dose of potassium citrate is 30 - 60 mEq/day orally in 3 or 4 doses with meals or within 30 minutes after meals. ADULT: 15 ml 3 times daily well diluted with water. CHILD 5-15 ml 3 times daily, after meals and at bedtime.	C
629.	Polyethylene Glycol / Macrogol 4000 Powder	A06AD1500 OF2101XX	Bowel cleansing prior to colonoscopy, radiological examination or colonic surgery. Suitable for patients with heart failure or renal failure	1 sachet dissolved in 1 L of water and to be consumed within 1 hour. Usual dose: 3-4 L of oral solution are required. When morning surgery is planned, the oral solution is given in the late afternoon the day prior. If surgery is scheduled in afternoon, the oral solution should be given on the same day for ingestion to be completed three hours before surgery	A (SRQ GENERAL)

No.	Generic Name	MDC	Indications	Dosage	Category
630.	Polymyxin B Sulphate 10,000 U, Neomycin Sulphate 5 mg and Hydrocortisone 10 mg Ear Drops	S02CA0399 1D1001XX	Treatment of bacterial infection and inflammation of the external auditory meatus	3-4 drops 3 – 4 times daily. Dosing is individualised and according to product insert/protocol	B (SRQ ENT)
631.	Potassium Chloride 1 g / 10 ml Injection	B05XA0110 0P3001XX	For the correction of severe hypokalaemia and when sufficient potassium cannot be taken by mouth	By slow IV infusion depending on the deficit or the daily maintenance requirements. 1 g diluted in 500 ml normal saline or glucose and given slowly over 2 - 3 hours	B
632.	Potassium Chloride 1 g / 10 ml Mixture	A12BA0110 0L2101XX	Potassium depletion	1 g once or twice daily until serum potassium is restored	C
633.	Potassium Chloride 600 mg SR Tablet	A12BA0110 0T5001XX	For the treatment and specific prevention of hypokalaemia	ADULT: 2 - 3 tablets daily. Severe deficiency: 9 - 12 tablets daily or according to the needs of the patient	B
634.	Potassium Citrate 3 g / 10 ml and Citric Acid Mixture	A12BA0295 5L2101XX	For systemic or urinary alkalinization	ADULT: 10-20 ml 3 times daily, well diluted with water. CHILD up to 1 year: 2.5 ml 3 times daily; 1 - 5 years: 5 ml 3 times daily; 6 - 12 years: 10 ml 3 times daily. To be taken well diluted with water, after meals and at bedtime.	C
635.	Potassium Dihydrogen Phosphate Injection 1.36 g / 10ml	B05XA0617 0P3001XX	For treatment of hypophosphataemia	Up to 10mmol phosphate administered over 12 hours	A (SRQ GENERAL)
636.	Potassium Permanganate 1:10,000 Solution	D08AX0636 2L9901XX	Cleansing and deodorising suppurative eczematous reactions and wounds	As soaks or wet dressing 1-3 times daily or as required	C+
637.	Povidone Iodine 10 % (equivalent to 1% iodine) Solution	D08AG0200 0L9902XX	Skin operation prior to surgery, in cleansing open wounds, as an antiseptic for operative wounds infections	To be applied undiluted in pre-operative skin disinfection and general antisepsis	B

No.	Generic Name	MDC	Indications	Dosage	Category
638.	Pralidoxime 25 mg/ml Injection	V03AB0400 OP3002XX	Antidote in the treatment of organophosphorus insecticide poisoning and in the control of overdosage by anticholinergic drugs used in the treatment of myasthenia gravis	Adult: Used in combination with atropine. Admin atropine via IM/IV inj and repeat as needed until patient shows signs of atropine toxicity. Maintain atropinisation for at least 48 hr. As soon as the effects of atropine are observed, 1-2 g of pralidoxime (chloride, iodide or mesilate) may be given via IM/IV inj. Repeat dose after 1 hr, then every 8-12 hr, if necessary. In severe poisoning, continuous infusion of 200-500 mg/hr may be given, titrated according to response. Alternatively, pralidoxime chloride may be given at an initial dose of 30 mg/kg via IV infusion over 20 minutes or IV inj over 5 minutes, followed by IV infusion at 8 mg/kg/hr. Max: 12 g/24 hr. Child: As mesilate: 20-60 mg/kg. Renal impairment: Dose adjustment may be required.	B (SRQ GENERAL)
639.	Prazosin HCl 1 mg Tablet	C02CA0111 OT1001XX	Hypertension	Initially 0.5 mg 2 - 3 times daily, the initial dose on retiring to bed at night; increased to 1 mg 2 - 3 times daily after 3 - 7 days: further increased if necessary to maximum 20 mg daily	B
640.	Prazosin HCl 2 mg Tablet	C02CA0111 OT1002XX	Hypertension	Initially 0.5 mg 2 - 3 times daily, the initial dose on retiring to bed at night; increased to 1 mg 2 - 3 times daily after 3 - 7 days: further increased if necessary to maximum 20 mg daily	B
641.	Prazosin HCl 5 mg Tablet	C02CA0111 OT1003XX	Hypertension	Initially 0.5 mg 2 - 3 times daily, the initial dose on retiring to bed at night; increased to 1 mg 2 - 3 times daily after 3 - 7 days: further increased if necessary to maximum 20 mg daily	B
642.	Prednisolone 2.5 mg/5 ml Syrup	H02AB0600 OL9002XX	i) Replacement therapy for primary and secondary adrenocortical insufficiency ii) Adrenogenital syndrome iii) Other therapy	i) 5 - 25 mg daily in divided doses ii) 10 - 20 mg/m ² body surface daily in divided doses iii) ADULT: 5 - 60 mg daily. CHILD: 0.5 - 2 mg/kg/day in divided doses every 6 - 8 hours or as a single daily	B

No.	Generic Name	MDC	Indications	Dosage	Category
643.	Prednisolone 5 mg Tablet	H02AB0600 0T1001XX	i) Replacement therapy for primary and secondary adrenocortical insufficiency ii) Adrenogenital syndrome iii) Other therapy	i) 5 - 25 mg daily in divided doses ii) 10 – 20 mg/m ² body surface daily in divided doses iii) ADULT: 5 - 60 mg daily. CHILD: 0.5 - 2 mg/kg/day in divided doses every 6 – 8 hours or as a single daily	B
644.	Pregabalin 50 mg capsule	N03AX16-000-C10-03-XXX	Neuropathic pain ii. Fibromyalgia iii. Epilepsy	The dose range is 150 to 600 mg per day given in either two or three divided doses. Dosing is according to Product Insert	A* (SRQ ANAES)
645.	Pregabalin 75 mg Capsule	N03AX1600 0C1001XX	i) Neuropathic pain ii) Fibromyalgia iii) Epilepsy Prescribing restrictions: Consultant/specialists for specific indications only, including geriatricians	The dose range is 150 to 600 mg per day given in either two or three divided doses. Dosing is according to Product Insert	A* (SRQ ANAES) (SRQ ORTHO) (SRQ REHAB)
646.	Pregabalin 150 mg Capsules	N03AX1600 0C1002XX	i) Neuropathic pain ii) Fibromyalgia iii) Epilepsy Prescribing restrictions: Consultant/specialists for specific indications only, including geriatricians	The dose range is 150 to 600 mg per day given in either two or three divided doses. Dosing is according to Product Insert.	A* (SRQ ANAES) (SRQ REHAB) (SRQ Palliative)
647.	Primaquine 7.5 mg Base Tablet	P01BA0316 2T1001XX	i) Treatment of malaria ii) Prophylaxis together with a schizonticide such as chloroquine	0.5mg/kg/day up to 30mg daily	B
648.	Prochlorperazine Maleate 5 mg Tablet	N05AB0425 3T1002XX	i) Severe nausea and vomiting ii) Vertigo/labyrinthine disorders	Nausea and vomiting Adult: As maleate or mesilate: 20 mg, further doses are given if needed. Recommended buccal dose: As maleate: 3-6 mg bid. Vertigo Adult: As maleate or mesilate: 15-30 mg daily, given in divided doses. May reduce gradually to 5-10 mg daily. Recommended buccal dose: 3-6 mg bid. May be taken with or without food.	B
649.	Prochlorperazine Mesylate 12.5 mg / ml Injection	N05AB0425 3P3001XX	i) Severe nausea and vomiting ii) Vertigo/labyrinthine disorders	Deep IM injection, 12.5 mg repeated if necessary after 6 hours and then followed by an oral dose. Not recommended in children	B

No.	Generic Name	MDC	Indications	Dosage	Category
650.	Procyclidine HCl 5 mg/ ml Injection	N04AA0411 OP3001XX	i) All forms of Parkinson's disease (idiopathic paralysis agitans), post-encephalitis and arteriosclerosis ii) To control troublesome extrapyramidal symptoms induced by neuroleptic drugs including pseudo-parkinsonism, acute dystonic reactions and akathisia	i) Initial dose 2.5mg TDS, increasing by 2.5-5mg/day at intervals of 2 or 3 days until the optimum clinical response is achieved. Usual maintenance dose: 15-30mg/day. Max: 60mg/day ii) Initial dose 2.5mg TDS, increasing by 2.5mg daily until symptoms are relieved. Usual maintenance dose: 10-30mg/day. IV Emergency: 5-10 mg. IM Emergency: 5-10 mg as a single dose, may repeat after 20 mins if needed. Max: 20 mg/day.	B (SRQ GENERAL)
651.	Prolase Tablet	M09AB0000 OT1001XX	Oedema and inflammation in conjunction with other physical or chemotherapeutic measures	2 tablet 4 times daily for the first day, then 1 tablet 4 times daily for at least 5 days.	B
652.	Promethazine HCl 25 mg/ ml Injection	R06AD0211 OP3001XX	i) Allergic conditions ii) Treatment and prevention of vomiting including: - motion sickness - drug induced nausea - prevention and control of nausea and vomiting associated with certain types of anaesthesia and surgery	i) Allergic Conditions Adult and adolescent dose: 25mg intramuscular or intravenous. May be repeated within 2 hours if required. Children 2 years and older: intramuscularly- 0.125mg/kg body weight every 4 to 6 hours OR 0.5mg/kg bodyweight at bedtime as needed OR 6.25-12.5mg three times a day as needed OR 25mg at bedtime as needed. ii. Treatment and prevention of vomiting: - Motion Sickness Adult and adolescent dose: 25mg twice a day as needed. Children: 0.5mg/kg every 12 hours as needed OR 10 - 25mg twice a day as needed. - Anti Emetic Therapy Adult and adolescent dose: 25mg initially and then 10 -25mg every 4 - 6 hours as needed. Children: 0.25-0.5mg/kg every 4 to 6 hours as needed OR 10 - 25mg every 4 to 6 hours as needed. Dosing is individualised and according to product insert/protocol	B
653.	Promethazine HCl 5 mg/ 5 ml Syrup	R06AD0211 OL9001XX	Allergic conditions	CHILD 2 - 5 years: 5 - 15 mg daily 5 - 10 years: 10 - 25 mg daily	B

No.	Generic Name	MDC	Indications	Dosage	Category
654.	Proparacaine HCl 0.5% Ophthalmic Drops	S01HA0411 0D2001XX	Topical anaesthesia in ophthalmic procedures	Deep anaesthesia: 1 or 2 drops in the (eyes) every 5 to 10 minutes for 3 to 5 doses. For minor surgical procedures: instill 1 to 2 drops every 5 to 10 minutes for 1 to 3 doses. Tonometry and/or tonography procedure: 1 to 2 drops in each eye before procedure.	B (SRQ GENERAL)
655.	Propofol 10mg/ml (1%) Injection	N01AX1000 0P9901XX	Induction & maintenance of general anaesthesia. Sedation of ventilated ICU patients	Adult: Induction: 20- 40 mg by injection or infusion every 10 sec. Usual dose: 1.5-2.5 mg/kg. Maintenance: 4-12 mg/kg/hr or intermittent bolus inj of 20-50 mg. Child: >8 yr: Induction dose of 2.5 mg/kg. Maintenance dose: 9-15 mg/kg/hr by IV infusion or intermittent bolus inj. Elderly: Including neurosurgical and debilitated patients: Infuse at a rate of 20 mg every 10 sec. Maintenance: 3-6 mg/kg/hr. Usual dose needed: 1-1.5 mg/kg. Duration of use : Can be administered for a maximum period of 7 days. Sedation: 0.3 - 4 mg/kg/hour up to 3 days	A* (SRQ A&E) (SRQ ANAES)
656.	Propranolol HCl 1 mg/ml Injection	C07AA0511 0P3001XX	Arrhythmias and thyrotoxicosis crisis	Slow IV injection in a dose of 1 mg over 1 minute, repeated if necessary every 2 minutes until a maximum of 10 mg has been given in conscious patients and 5 mg in patients under anaesthesia. CHILD: 25 - 50 mcg/kg slow IV with appropriate monitoring	A (SRQ GENERAL)

No.	Generic Name	MDC	Indications	Dosage	Category
657.	Propranolol HCl 10 mg Tablet	C07AA0511 OT1001XX	i) Hypertension ii) Angina pectoris iii) Myocardial infarct iv) Cardiac arrhythmias v) Migraine prophylaxis vi) Hyperthyroidism vii) Hypertrophic obstructive cardiomyopathy	i) Initial: 40-80 mg twice daily Maintenance: 160-320 mg daily. Max. 640 mg daily ii) Initial: 40 mg 2-3 times daily Maintenance: 120-240 mg daily Max. 480mg daily iii) Initial (within 5-21 days of MI): 40 mg 4 times daily for 2-3 days Maintenance: 80 mg twice daily iv) 10-40 mg 3-4 times daily Max. 240 mg/day. v) Initial: 40 mg 2-3 times Maintenance: 80-160 mg daily Max. 240 mg/day. vi) 10-40 mg 3-4 times daily. Max. 240 mg/day. vii) 10-40 mg 3-4 times daily Dosing is individualised and according to product insert / protocol.	B

No.	Generic Name	MDC	Indications	Dosage	Category
658.	Propranolol HCl 40mg Tablet	C07AA0511 OT1002XX	i) Hypertension ii) Angina pectoris iii) Myocardial infarct iv) Cardiac arrhythmias v) Migraine prophylaxis vi) Hyperthyroidism vii) Hypertrophic obstructive cardiomyopathy viii) Portal hypertension	i) Initial: 40-80 mg twice daily Maintenance: 160-320 mg daily. Max. 640 mg daily ii) Initial: 40 mg 2-3 times daily Maintenance: 120-240 mg daily Max. 480mg daily iii) Initial (within 5-21 days of MI): 40 mg 4 times daily for 2-3 days Maintenance: 80 mg twice daily iv) 10 - 40 mg 3 - 4 times daily. Max. 240 mg/day. v) Initial: 40 mg 2-3 times. Maintenance: 80-160 mg daily. Max. 240 mg/day. vi) 10-40 mg 3-4 times daily. Max. 240 mg/day. vii) 10-40 mg 3-4 times daily viii) Initial: 40 mg twice daily Maintenance: 40-80mg 3 times daily Max. 320mg daily Dosing is individualised and according to product insert / protocol.	B
659.	Propylthiouracil 50mg Tablet	H03BA0200 OT1001XX	Hyperthyroidism	ADULT Initially 300-450mg in 8 hourly intervals (can be given up to 600-900mg/daily) until symptoms are controlled in 1-2 months. Maintenance 50-150mg daily for at least 12-18 months. CHILDREN 6-10 years: 50-150mg. CHILDREN > 10 years: 150-300mg daily. All doses are to be given in 3 divided doses daily. Taken with food.	B

No.	Generic Name	MDC	Indications	Dosage	Category
660.	Protamine Sulphate 10 mg / ml Injection	V03AB1418 3P3001XX	Heparin overdose and following cardiac or arterial surgery or dialysis procedures when required to neutralize the effects of heparin administered during extracorporeal circulation	5 ml slow IV injected over 10 minutes. If administered within 15 minutes of heparin dose, 1 mg will neutralise approximately 100 units of heparin. If longer time has elapsed, less protamine is required. Not more than 50 mg should be injected at any one time. The dose is dependent on the amount and type of heparin to be neutralised, its route of administration and the time elapsed since it was last given and blood coagulation studies.	B
661.	Pyrazinamide 500 mg Tablet	J04AK01000 T1001XX	Tuberculosis	Adult: 20-40mg/kg daily (max 1500mg) or 50mg/kg biweekly (max 2000mg). Children: 20-30mg/kg daily or 30-40mg/kg thrice weekly.	B
662.	Pyridostigmine Bromide 60 mg Tablet	N07AA0232 OT1001XX	Myasthenia gravis	ADULT: 30 - 120 mg at suitable intervals throughout the day, total daily dose 0.3 - 1.2 g. CHILD up to 6 years initially 30 mg, 6 - 12 years initially 60 mg, usual total daily dose 30 - 360 mg	B
663.	Pyridoxine HCl 10 mg Tablet	A11HA0211 OT1001XX	i) Pyridoxine-dependent convulsions in infant ii) Sideroblastic anaemia iii) B6-deficient anaemia in adult iv) Prophylaxis to peripheral neuritis in isoniazid therapy v) Nausea and vomiting of pregnancy and irradiation sickness	i) INFANT 4 mg/kg daily for short periods ii) 100 - 400mg daily in divided doses iii) ADULT 20 - 50 mg up to 3 times daily iv) Prophylaxis 10 mg daily, therapeutic 50 mg 3 times daily v) 20 - 100 mg daily	B
664.	Quetiapine Fumarate 50mg Extended Release Tablet	N05AH0413 8T5001XX	i) Schizophrenia ii) Moderate to severe manic episodes in bipolar disorder iii) Major depressive episodes in bipolar disorder Prescribing Restrictions Consultant/specialists for specific indications only, including Geriatricians and Neurologists	i) & ii) 300 mg once daily on Day 1 then 600 mg on Day 2. Maintenance dose: 400 to 800 mg once daily. Maximum dose: 800 mg daily. iii) 50 mg on Day 1, 100 mg on Day 2, 200 mg on Day 3 and 300 mg on Day 4. Recommended daily dose is 300 mg. May be titrated up to 600 mg daily. In elderly or hepatic impairment: Start with 50mg/ day, may be increased in increments of 50mg /day to an effective dose.	A* (SRQ PSY)

No.	Generic Name	MDC	Indications	Dosage	Category
665.	Quetiapine Fumarate 100 mg Immediate Release Tablet	N05AH0413 8T1002XX	i) Schizophrenia ii) Short term treatment of acute manic episodes associated with bipolar I disorder, either monotherapy or adjunct to lithium or divalproex iii) Treatment of depressive episodes associated with bipolar disorder Prescribing Restrictions Consultant/specialists for specific indications only, including Geriatricians and Neurologists	i) Initial titration schedule over 4 days: 25 mg twice daily on Day 1, increase in steps of 25 - 50 mg 2 to 3 times daily on Days 2 and 3 to reach target dose of 300 - 400 mg daily by Day 4, given in 2 - 3 divided doses. Institute further dose adjustments, if indicated, at intervals of 2 days or more, in steps of 25 - 50 mg twice daily ii) 100 mg (Day 1), 200 mg (Day 2), 300 mg (Day 3) & 400 mg (Day 4). Further dosage adjustments up to 800 mg/day by Day 6 should be in increments of not more than 200 mg/day. Adjust dose within the range of 200 - 800 mg/day depending on clinical response and tolerability of the patient. Usual effective dose range: 400 - 800 mg/day iii) 50 mg ORALLY once a day on Day 1, then 100 mg once daily on Day 2, then 200 mg once daily on Day 3, then 300 mg once daily on Day 4 (all doses given at bedtime); patients requiring higher doses should receive 400 mg on Day 5, increased to 600 mg on Day 8 (week 1)	A* (SRQ PSY)
666.	Quetiapine Fumarate 200 mg Extended Release Tablet	N05AH0413 8T5002XX	i) Schizophrenia ii) Moderate to severe manic episodes in bipolar disorder iii) Major depressive episodes in bipolar disorder Prescribing Restrictions Consultant/specialists for specific indications only, including Geriatricians and Neurologists	i) & ii) 300 mg once daily on Day 1 then 600 mg on Day 2. Maintenance dose: 400 to 800 mg once daily. Maximum dose: 800 mg daily iii) 50 mg on Day 1, 100 mg on Day 2, 200 mg on Day 3 and 300 mg on Day 4. Recommended daily dose is 300 mg. May be titrated up to 600 mg daily. In elderly or hepatic impairment: Start with 50mg/ day, may be increased in increments of 50mg /day to an effective dose.	A* (SRQ PSY)

No.	Generic Name	MDC	Indications	Dosage	Category
667.	Quetiapine Fumarate 200 mg Immediate Release Tablet	N05AH0413 8T1004XX	i) Schizophrenia ii) Short term treatment of acute manic episodes associated with bipolar I disorder, either monotherapy or adjunct to lithium or divalproex iii) Treatment of depressive episodes associated with bipolar disorder Prescribing Restrictions Consultant/specialists for specific indications only, including Geriatricians and Neurologists	i) Initial titration schedule over 4 days: 25 mg twice daily on Day 1, increase in steps of 25 - 50 mg 2 to 3 times daily on Days 2 and 3 to reach target dose of 300 - 400 mg daily by Day 4, given in 2 - 3 divided doses. Institute further dose adjustments, if indicated, at intervals of 2 days or more, in steps of 25 - 50 mg twice daily ii) 100 mg (Day 1), 200 mg (Day 2), 300 mg (Day 3) & 400 mg (Day 4). Further dosage adjustments up to 800 mg/day by Day 6 should be in increments of not more than 200 mg/day. Adjust dose within the range of 200 - 800 mg/day depending on clinical response and tolerability of the patient. Usual effective dose range: 400 - 800 mg/day iii) 50 mg ORALLY once a day on Day 1, then 100 mg once daily on Day 2, then 200 mg once daily on Day 3, then 300 mg once daily on Day 4 (all doses given at bedtime); patients requiring higher doses should receive 400 mg on Day 5, increased to 600 mg on Day 8 (week 1)	A* (SRQ PSY)
668.	Quetiapine Fumarate 300mg Extended Release Tablet	N05AH0413 8T5003XX	i) Schizophrenia ii) Moderate to severe manic episodes in bipolar disorder iii) Major depressive episodes in bipolar disorder Prescribing Restrictions Consultant/specialists for specific indications only, including Geriatricians and Neurologists	i) & ii) 300 mg once daily on Day 1 and 600 mg on Day 2. Maintenance dose: 400 - 800 mg once daily. Maximum dose: 800 mg daily iii) 50 mg on Day 1, 100 mg on Day 2, 200 mg on Day 3 and 300 mg on Day 4. Recommended daily dose is 300 mg. May be titrated up to 600 mg daily	A* (SRQ PSY)
669.	Quetiapine Fumarate 400 mg Extended Release Tablet	N05AH0413 8T5004XX	i) Schizophrenia ii) Moderate to severe manic episodes in bipolar disorder iii) Major depressive episodes in bipolar disorder Prescribing Restrictions <i>Consultant/specialists for specific indications only, including Geriatricians and Neurologists</i>	i) & ii) 300 mg once daily on Day 1 and 600 mg on Day 2. Maintenance dose: 400 - 800 mg once daily. Maximum dose: 800 mg daily iii) 50 mg on Day 1, 100 mg on Day 2, 200 mg on Day 3 and 300 mg on Day 4. Recommended daily dose is 300 mg. May be titrated up to 600 mg daily	A* (SRQ PSY)

No.	Generic Name	MDC	Indications	Dosage	Category
670.	Rabies Vaccine Injection	J07BG01000 P4001XX	Pre-exposure and post-exposure vaccination against rabies	1ml by IM. Dosing is according to product insert based on patient's needs (pre and post exposure).	B
671.	Raloxifene HCl 60 mg Tablet	G03XC0111 OT1001XX	i. Treatment and prevention of osteoporosis in postmenopausal women. ii. Risk reduction of invasive breast cancer in postmenopausal women with osteoporosis.	1 tablet daily	A* (SRQ O&G) (SRQ ORTHO)
672.	Raltegravir 400 mg Tablet	J05AX08500 T1001XX	Raltegravir combination with other antiretroviral agents is indicated for the treatment of HIV-1 infection in patients who are contraindicated to boosted Protease Inhibitor or who are intolerant to boosted Protease Inhibitor.	400mg administered orally, twice daily with or without food, to be given combination with other antiretroviral agent.	A* (SRQ MED)
673.	Ramipril 5 mg Tablet	C09AA0500 OT1002XX	i) Hypertension ii) Congestive heart failure iii) Reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in high-risk patients iv) Prevention of progressive renal impairment in patients with persistent proteinuria	i) Initial: 2.5mg once daily Maintenance: 2.5-5mg once daily Max. 10mg daily in 1-2 divided doses ii) Initial: 1.25mg once daily Maintenance: 10mg in 2 divided doses iii) Initial: 2.5mg twice daily Maintenance: 5mg twice daily Max: 10mg daily iv) Initial: 1.25mg once daily Maintenance: 5mg once daily Dosing is individualised and according to product insert / protocol.	A (SRQ MED)
674.	Ranitidine 25 mg/ml Injection	A02BA0211 OP3001XX	i) Benign gastric/ duodenal ulceration, reflux oesophagitis, Zollinger Ellison Syndrome ii) Stress ulcer prophylaxis in post-operative and high risk patients	i) ADULT: Slow IV injection of 50 mg diluted to 20 ml and given over at least 2 minutes. May be repeated every 6-8 hours or IV infusion at rate of 25 mg/hour for 2 hours, may be repeated at 6-8 hours intervals or IM. CHILD: 1 mg/kg/dose 6-8 hourly. ii) Initial slow IV injection of 50 mg, then continuous infusion of 125-250 mcg/kg/hour	B

No.	Generic Name	MDC	Indications	Dosage	Category
675.	Remifentanyl 5 mg Injection	N01AH0611 OP4001XX	i) As an analgesic agent for use during induction and/or maintenance of general anaesthesia during surgical procedures including cardiac surgery. ii) Continuation of analgesia into the immediate post-operative period under close supervision, during transition to longer acting analgesia. iii) Provision of analgesia and sedation in mechanically ventilated intensive care patients.	For IV use only. ADULT: Induction: Bolus infusion: 1µg/kg over 30-60 seconds; Continuous infusion: 0.5-1µg/kg/min; Maintenance: Continuous infusion: 0.025 to 2 µg/kg/min. CHILD (1-12 years of age): Induction: Insufficient data; Neonates: IV infusion 0.4-1.0 mcg/kg/minute depending on the anaesthetic method and adjust according to patient response, supplemental IV inj of 1 mcg/kg dose may be given. 1-12 yr: initially 0.1-1 mcg/kg by IV inj over at least 30 seconds (excluded if not needed), followed by IV infusion 0.05-1.3 mcg/kg/minute depending on the anaesthetic method and adjust according to patient response, supplemental IV bolus inj may be admin during infusion. 12-18 yr: 0.1-1 mcg/kg IV inj over at least 30 seconds (excluded if not needed), followed by IV infusion of 0.05-2 mcg/kg/minute depending on anaesthetic method and adjust according to patient response, supplemental IV bolus inj may be admin during infusion.	A* (SRQ ANAES)
676.	Rifampicin 150 mg Capsule	J04AB02000 C1001XX	i) Tuberculosis ii) Leprosy iii) Prophylaxis for meningococcal meningitis iv) Staphylococcus biofilm related prosthetic joint infection or any biofilm sensitive to rifampicin in combination therapy with another antibiotic	i) ADULT: 450 - 600 mg as a single morning dose. CHILD: 10 - 20 mg/kg body weight daily in 1 - 2 doses. Directly observed therapy (DOT): 10 mg/kg twice weekly or 3 times/week. Maximum: 600 mg ii) ADULT: 600 mg/day CHILD: 10mg/kg iii) ADULT: 600 mg twice daily for 2 days CHILD: 10mg/kg twice daily for 2 days INFANT: 5mg/kg twice daily for 2 days iv) ADULT: 600mg OD CHILD: 10-20mg/kg/day in 1-2 divided doses Dosing is individualised and according to product insert/protocol.	B

No.	Generic Name	MDC	Indications	Dosage	Category
677.	Rifampicin 150 mg, Isoniazid 75 mg, Pyrazinamide 400 mg & Ethambutol HCl 275 mg Tablet	J04AM0600 OT1001XX	Treatment of both pulmonary and extrapulmonary tuberculosis, in the intensive treatment phase	ADULT: 30-37kg: 2 tablets daily, 38-54kg: 3 tablets daily, 55-70kg: 4 tablets daily, more than 70kg: 5 tablets daily	B
678.	Rifampicin 300 mg Capsule	J04AB02000 C1002XX	i) Tuberculosis ii) Leprosy iii) Prophylaxis for meningococcal meningitis iv) Staphylococcus biofilm related prosthetic joint infection or any biofilm sensitive to rifampicin in combination therapy with another antibiotic	i) ADULT: 450 - 600 mg as a single morning dose. CHILD: 10 - 20 mg/kg body weight daily in 1 - 2 doses. Directly observed therapy (DOT): 10 mg/kg twice weekly or 3 times/week. Maximum: 600 mg ii) ADULT: 600 mg/day CHILD: 10mg/kg iii) ADULT: 600 mg twice daily for 2 days CHILD: 10mg/kg twice daily for 2 days INFANT: 5mg/kg twice daily for 2 days iv) ADULT: 600mg OD CHILD: 10-20mg/kg/day in 1-2 divided doses Dosing is individualised and according to product insert/protocol.	B
679.	Rifampicin, Dapsone & Clofazimine Tablet	J04AM0296 1T9901XX	For the treatment of leprosy and tuberculosis	Rifampicin: 600 mg once monthly, Dapsone: 100 mg daily, Clofazimine: 300 mg once monthly and 50 mg daily (or 100 mg on alternate days)	B
680.	Risperidone 1 mg Tablet	N05AX0800 OT1001XX	i) Schizophrenia, including first episode psychosis, acute schizophrenic exacerbations, chronic schizophrenia and other psychotic conditions Short-term symptomatic treatment (up to 6 weeks) of persistent aggression in conduct disorder in children from the age of 5 years and adolescents with subaverage intellectual functioning or mental retardation.	i) Schizophrenia ADULT: Initial dose :2mg/day Maintenance dose : 4 to 6mg. Max 16mg/day CHILD : Not recommended ELDERLY: Initial dose : 0.5mg twice daily Maintenance : 1 to 2mg twice daily ii) Conduct disorder CHILD & ADOLESCENTS, 5-18 years ≥50kg: Initial- 0.5mg once daily Optimum dose : 1mg once daily <50kg: Initial – 0.25mg once daily Optimum dose : 0.5mg once daily Dosing should be individualized according to product insert	B

No.	Generic Name	MDC	Indications	Dosage	Category
681.	Risperidone 2 mg Tablet	N05AX0800 OT1002XX	ii) Schizophrenia	ADULT: Initial dose :2mg/day Maintenance dose : 4 to 6mg. Max 16mg/day CHILD : Not recommended ELDERLY: Initial dose : 0.5mg twice daily Maintenance : 1 to 2mg twice daily Dosing should be individualized according to product insert	B
682.	Rivaroxaban 20 mg Tablet	B01AX06000 T1003XX	i)Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as Congestive heart failure (CHF), hypertension, age ≥ 75 yrs, diabetes mellitus, prior stroke or transient ischaemic attack. ii) Treatment of deep vein thrombosis (DVT), and prevention of recurrent DVT and pulmonary embolism (PE) following an acute DVT in adults. iii) Treatment of Pulmonary Embolism (PE), and prevention of recurrent DVT and pulmonary embolism (PE) following an acute PE in adults.	i)20mg once daily or 15mg once daily (for patients with moderate renal impairment (creatinine clearance 30-49 ml/min) ii) & iii) 15mg BD for 21 days, followed by 20mg OD.	A* (SRQ MED)
683.	Rivastigmine 1.5 mg Capsule	N06DA0312 3C1001XX	For psychiatrists and neurologists only. Mild to moderately severe dementia associated with Alzheimer's or Parkinson's disease	Initial dose 1.5 mg 2 times daily, may increase by 1.5 mg 2 times daily every 2 weeks to maximum of 6 mg 2 times daily. If treatment is interrupted for several days, should be reinitiated at the lowest daily dose	A* (SRQ PSY)
684.	Rivastigmine 3 mg Capsule	N06DA0312 3C1002XX	For psychiatrists and neurologists only. Mild to moderately severe dementia associated with Alzheimer's or Parkinson's disease	Initial dose 1.5 mg 2 times daily, may increase by 1.5 mg 2 times daily every 2 weeks to maximum of 6 mg 2 times daily. If treatment is interrupted for several days, should be reinitiated at the lowest daily dose	A* (SRQ PSY)
685.	Rivastigmine 9.5 mg/24 hr Transdermal Patch	N06DA0312 3M7002XX	Mild to moderately severe dementia associated with Alzheimer's or Parkinson's disease	Initial: 4.6mg/24hr once daily Maintenance: 9.5mg/24hr once daily after a minimum of 4 weeks and then 13.3mg/24hr if tolerated Dosing is individualised and according to product insert.	A* (SRQ PSY)

No.	Generic Name	MDC	Indications	Dosage	Category
686.	Rocuronium Bromide 10 mg/ ml Injection	M03AC0932 OP3001XX	As an adjunct to general anaesthesia to facilitate endotracheal intubation, to provide skeletal muscle relaxation during surgery and to facilitate mechanical ventilation in adults, children and infants from one month of age.	Adult: Initial: 0.6mg/kg. Higher doses of 1 mg/kg may be used for intubation during rapid sequence induction of anaesthesia. Maintenance: 0.15mg/kg (may reduce to 0.075-0.1 mg/kg if inhalational anaesthesia is used) or by infusion at a rate of 0.3-0.6mg/kg/hr (0.3-0.4mg/kg/hr if inhalational anaesthesia is used). Doses should be based on ideal body weight for obese patients weighing >30% above the ideal body weight. Child: Infants and children >1 mth: Initially: 0.6mg/kg. Maintenance: 0.15mg/kg or by infusion at a rate of 0.3-0.6mg/kg/hr, maintenance doses may be required more frequently than in adult patients. Elderly/patients with hepatic and/or biliary tract disease and/or renal impairment: Initially: 0.6mg/kg. Maintenance: 0.075-0.1 mg/kg or by infusion at a rate of 0.3-0.4mg/kg/hr.	A* (SRQ A&E) (SRQ ANAES) (SRQ PAED)
687.	Ropinirole HCl 1 mg Tablet	N04BCO411 OT1002XX	i) Treatment of idiopathic Parkinson's disease. It may be used as monotherapy or in combination with levodopa ii) Treatment of restless leg syndrome	i) 0.25 mg 3 times daily gradually increasing till adequate response obtained up to a maximum of 24 mg/day. Most patients need 3-9 mg/day ii) Initial: 0.25mg ON for 2 days then increased if tolerated to 0.5mg ON. Further dose increment of 0.5mg/week can be made until optimal response is achieved	A* (SRQ MED)
688.	Ropivacaine HCl 2 mg/ ml Injection	N01BB0911 OP3001XX	i) Surgical anaesthesia including obstetrics ii) Acute pain management	Dose adjusted according to patient physical status and nature of procedure. i) Lumbar epidural: 15-25 ml of 7.5 mg/ml solution; Caesarean section, 15-20 ml of 7.5 mg/ml solution in incremental doses (max. total dose 150 mg). ii) lumbar epidural: 10-20 ml of 2mg/ml solution followed by 10-15 ml of 2 mg/ml solution at interval at of least 30 minutes. Labour pain 6-10 ml/hour of 2 mg/ml solution	A* (SRQ ANAES)

No.	Generic Name	MDC	Indications	Dosage	Category
689.	Ropivacaine HCl 7.5 mg/ml Injection	N01BB0911 OP3002XX	i) Surgical anaesthesia including obstetrics ii) Acute pain management	Dose adjusted according to patient physical status and nature of procedure. i) Lumbar epidural: 15-25 ml of 7.5 mg/ml solution; Caesarean section, 15-20 ml of 7.5 mg/ml solution in incremental doses (max. total dose 150 mg). ii) lumbar epidural: 10-20 ml of 2mg/ml solution followed by 10-15 ml of 2 mg/ml solution at interval at of least 30 minutes. Labour pain 6-10 ml/hour of 2mg/ml solution	A* (SRQ ANAES)
690.	Rosuvastatin 10mg Tablet	C10AA0739 OT1002XX	Dyslipidaemia not responsive to atorvastatin 40mg or equivalent doses of other statins	Initially 5-10 mg once daily (5mg in patients with pre-disposing factors to myopathy), increased if necessary at intervals of at least 4 weeks to 20 mg once daily, increased after further 4 weeks to 40 mg daily ONLY in severe hypercholesterolemia with high cardiovascular risk. Patient of Asian origin, patients on concomitant ciclosporin/fibrate and patients with risk factors for myopathy/rhabdomyolysis (including personal/family history of muscular disorders/toxicity), the maximum dose should be 20 mg daily	A/KK (SRQ MED)
691.	Rosuvastatin 20mg Tablet	C10AA0739 OT1003XX	Dyslipidaemia not responsive to atorvastatin 40 mg or equivalent doses of other statins	Initially 5-10 mg once daily (5mg in patients with pre-disposing factors to myopathy), increased if necessary at intervals of at least 4 weeks to 20 mg once daily, increased after further 4 weeks to 40 mg daily ONLY in severe hypercholesterolemia with high cardiovascular risk. Patient of Asian origin, patients on concomitant ciclosporin/fibrate and patients with risk factors for myopathy/rhabdomyolysis (including personal/family history of muscular disorders/toxicity), the maximum dose should be 20 mg daily	A/KK (SRQ MED)
692.	Salbutamol 0.5 % Inhalation Solution	R03AC0218 3A3001XX	Indicated for the relief of bronchospasm in patients with reversible obstructive airway disease and acute bronchospasm.	2.5 to 5mg (0.5ml – 1ml), repeat according to response and tolerability. Dosing is individualised and according to product insert/protocol.	B

No.	Generic Name	MDC	Indications	Dosage	Category
693.	Salbutamol 0.5 mg/ml Injection	R03CC0218 3P3001XX	i. Asthma and other conditions associated with reversible airways obstruction ii. For prevention of uncomplicated premature labour	i. 500 mcg by SC/IM injection 4 hourly or 250 mcg by slow IV. If required, by IV infusion, initially 5 mcg/min adjusted according to response and heart rate, usually in the range 3 - 20 mcg/min ii. Infusions containing 5 mg in 500ml (10 mcg/ml) at the rate of 10 - 45 mcg/min increased at intervals of 10 minutes until evidence of patient response as shown by reduction of strength, frequency or duration of contractions; maintain rate for 1 hour after contractions have stopped, then gradually reduce by 50% every 6 hours	A (SRQ GENERAL)
694.	Salbutamol 100 mcg/dose Inhalation	R03AC0218 3A1001XX	Asthma and other conditions associated with reversible airways obstruction	ADULT : 100 - 200 mcg up to 3 - 4 times daily. CHILD : 100 mcg increased to 200 mcg if necessary	B
695.	Salbutamol 2 mg/5 ml Syrup	R03CC0218 3L9001XX	Asthma and other conditions associated with reversible airways obstruction	CHILD 2 - 6 years : 1 - 2 mg 3 - 4 times daily, 6 - 12 years : 2 mg 3 - 4 times daily	B
696.	Salicylazosulphapyridine (Sulfasalazine) 500 mg Tablet	A07EC0100 0T1001XX	i) Treatment of inflammatory bowel disease of ulcerative colitis and Crohn's disease ii) Rheumatoid arthritis	i) ADULT, acute attack 1-2 g 4 times daily until remission occurs (if necessary corticosteroids may also be given), reducing to a maintenance dose of 500 mg 4 times daily, CHILD over 2 years, acute attack 40-60 mg/kg daily, maintenance dose 20-30 mg/kg daily ii) ADULT, initially; 0.5-1 g/day, increase weekly to maintenance dose of 2 g/day in 2 divided doses, maximum 3 g/day. CHILD over 6 years, juvenile rheumatoid arthritis: 30-50 mg/kg/day in 2 divided doses up to a maximum of 2 g/day	A/KK
697.	Salicylic Acid 2% Ointment	D01AE1200 0G5001XX	Seborrhoeic dermatitis, scalp, psoriasis and hyperkeratotic skin disorders	Apply sparingly to the affected area 2-3 times daily	C
698.	Salmeterol 25 mcg and Fluticasone Propionate 125 mcg Inhalation	R03AK0698 9A2102XX	Regular treatment of reversible obstructive airways diseases including asthma	ADULT and CHILD more than 12 years: 1 - 2 puff twice daily. CHILD over 4 years: 1 puff twice daily	A* (SRQ PAED)

No.	Generic Name	MDC	Indications	Dosage	Category
699.	Salmeterol 50 mcg and Fluticasone Propionate 250 mcg Inhalation	R03AK0698 9A2101XX	Prescriber Category A* : i) Treatment of COPD patients with a blood eosinophil count of 300 cells/microliter and more ii) Treatment of COPD patients with blood eosinophil count of 100 cells/microliter and more with history of repeated exacerbation despite regular treatment with long-acting bronchodilators. Prescriber Category A/KK: - Regular treatment of reversible obstructive airways diseases including asthma.	ADULT and CHILD more than 12 years : 1 puff twice daily.	A/KK, A* (SRQ MED)
700.	Salmeterol 50 mcg and Fluticasone Propionate 500 mcg Inhalation	R03AK0698 9A2106XX	Prescriber Category A* : i) Treatment of COPD patients with a blood eosinophil count of 300 cells/microliter and more ii) Treatment of COPD patients with blood eosinophil count of 100 cells/microliter and more with history of repeated exacerbation despite regular treatment with long-acting bronchodilators. Prescriber Category A/KK: - Regular treatment of reversible obstructive airways diseases including asthma.	ADULT and CHILD more than 12 years : 1 puff twice daily.	A/KK, A* (SRQ MED)
701.	Selegiline HCl 5 mg Tablet	N04BD0111 0T1001XX	Only for treatment of late stage Parkinsonism with on and off phenomenon	5 mg twice daily at breakfast and lunch. Maximum 10 mg/day	A* (SRQ MED)
702.	Selenium Sulphide 2.5 % Shampoo	D11AC0318 0L5201XX	Dandruff, seborrheic dermatitis of scalp	Apply onto wet hair, lather and leave on scalp for 3 minutes. Rinse. Repeat treatment. Rinse thoroughly. Use twice weekly at first, then as necessary as directed by the physician.	A/KK (SRQ GENERAL)
703.	Sertraline HCl 50 mg Tablet	N06AB06-110-T10-01-XXX	i) Major depression, obsessive-compulsive disorder (OCD), panic disorder ii) Social anxiety disorder (social phobia)	i) Depression, obsessive-compulsive disorder: 50 mg/day, may increase in steps of 50mg at weekly interval, max: 200 mg/day. Panic disorder: Initially 25 mg/day. After 1 week, increase dose to 50 mg/day. All dose changes should be made at intervals of more than 1 week, max: 200 mg/day ii) Therapy should be initiated at 25 mg/day. After one week, the dose should be increased to 50 mg once daily. Patients not responding to a 50 mg dose may benefit from dose increases. Dose changes should be made at intervals of at least one week, up to a maximum of 200 mg/day.	B

No.	Generic Name	MDC	Indications	Dosage	Category
704.	Sevoflurane Liquid	N01AB0800 0L5001XX	To be used only for i) induction and ii) maintenance of anaesthesia	i) Adult: Given via a calibrated vaporiser: Up to 5% v/v with oxygen or a mixture of oxygen and nitrous oxide. Child: Given via a calibrated vaporiser: Up to 7% v/v. ii) Adult: 0.5-3% v/v with or without nitrous oxide. Child: 0.5-3% v/v with or without nitrous oxide.	A* (SRQ ANAES)
705.	Silver Sulfadiazine 1% Cream	D06BA0119 9G1001XX	Prevention and treatment of infections in severe burns, leg ulcers where infections may prevent healing and for the prophylaxis of infections in skin grafting	Burns: Apply 3 mm thick layer twice daily with sterile applicator. Leg ulcer: apply at least 3 times a week	B
706.	Simvastatin 40 mg Tablet	C10AA0100 0T1003XX	i) Hypercholesterolaemia ii) Prevention of cardiovascular disease	i) & ii) 10 - 40 mg once daily. Maximum: 80 mg daily	B
707.	Sodium Bicarbonate 5% w/v Ear Drops	S02DC0013 1D1001XX	To soften the impacted ear wax	2-3 drops 3-4 times daily	C
708.	Sodium Bicarbonate 8.4% (1 mmol/ml) Injection	B05XA0213 1P3002XX	(i) For acceleration of excretion in drug intoxication (where excretion of the drug into the urine is accelerated by elevated urine pH) For metabolic acidosis secondary to underlying diseases	According to the needs of the patient. In severe shock due to cardiac arrest: 50 ml by IV	B
709.	Sodium Bicarbonate and Magnesium Carbonate Compound Mixture (Carminative Mixt)	A02AH0091 2L2101XX	(ii) Heartburn, for rapid relief of dyspepsia	ADULT 10-20 ml 3 times daily	C
710.	Sodium Bicarbonate, Citric Acid, Sodium Citrate and Tartaric Acid - 4 g per sachet	B05CB1095 5M4001XX	For relieving of discomfort in mild urinary tract infection, symptomatic relief of dysuria to enhance the action to certain antibiotics especially some sulpho-namides. In gout: urinary alkalinizers to prevent crystallisation of urates	4 - 8 g (1 - 2 sachets) dissolved in a glass of cold water 4 times daily as prescribed	B
711.	Sodium Biphosphate 16%, Sodium Phosphate 6% Rectal Solution	A06AG0116 2G2001XX	Bowel cleansing before colonic surgery, colonoscopy or radiological examination to ensure the bowel is free of solid contents. It is not to be used for treatment of constipation	ADULT 133 ml (1 bottle) administered rectally. CHILD more than 2 years half the adult dose (66.6ml)	A (SRQ SURG)
712.	Sodium Chloride 0.18% with Dextrose 10% Injection	B05XA0390 4P6001XX	For replenishing fluid and energy and for restoring or maintaining the concentration of sodium and chloride ions	According to the needs of the patient	B
713.	Sodium Chloride 0.45% Injection	B05XA0310 0P6001XX	For replenishing fluid and for restoring / maintaining the concentration of sodium and chloride ions	100 - 1000 ml by IV or according to the needs of the patient	B
714.	Sodium Chloride 0.45% with Dextrose 5% Injection	B05XA0390 4P6005XX	For replenishing fluid and energy and for restoring or maintaining the concentration of sodium and chloride ions	According to the needs of the patient	B

No.	Generic Name	MDC	Indications	Dosage	Category
715.	Sodium Chloride 0.45 % with Dextrose 10 % Injection	B05XA0390 4P6002XX	For replenishing fluid and energy and for restoring or maintaining the concentration of sodium and chloride ions	According to the needs of the patient	B
716.	Sodium Chloride 0.9 % Injection	B05XA0310 0P6002XX	For replenishing fluid and for restoring / maintaining the concentration of sodium and chloride ions	100 - 1000 ml by IV or according to the needs of the patient	C+
717.	Sodium Chloride 0.9 % Injection	B05XA0310 0P6002XX	For replenishing fluid and for restoring / maintaining the concentration of sodium and chloride ions	100 - 1000 ml by IV or according to the needs of the patient	C+
718.	Sodium Chloride 0.9 % Injection (10ml)	B05XA0310 0P6002XX	For replenishing fluid and for restoring / maintaining the concentration of sodium and chloride ions	100 - 1000 ml by IV or according to the needs of the patient	C+ (SRQ PAED) (SRQ ANAES)
719.	Sodium Chloride 0.9 % with Dextrose 5 % Injection	B05XA0390 4P6003XX	For replenishing fluid and energy and for restoring or maintaining the concentration of sodium and chloride ions	According to the needs of the patient	C+
720.	Sodium Chloride 3 % Injection	B05XA0310 0P9901XX	Acute dilutional hyponatraemia	According to the needs of the patient	B
721.	Sodium Citrate 0.3M Solution	B05CB0213 6L9901XX	Prophylaxis for aspiration pneumonitis (use as an oral solution)	Dose depending on clinical cases. Usually, 30 ml given 10- 60 minutes before anaesthesia prior to elective cesarean surgery is an effective antacid	B
722.	Sodium Citrate, Citric Acid Mixture 3 g / 10 ml (Shohl solution)	B05CB0213 6L2101XX	Citrates and citric acid solutions are used to correct the acidosis of certain renal tubular disorders to treat metabolic acidosis for long-term urine alkalinization for prevention and treatment of uric acid and calcium kidney stones and as nonparticulate neutralizing buffers	ADULT 10 - 20 ml. CHILD up to 1 year 2.5 ml tds; 1-5 year 5 ml tds; 6-12 years 10 ml tds. To be taken well diluted with water	B
723.	Sodium Cromoglycate 2 % Eye Drops	S01GX0152 0D2001XX	Prevention and treatment of allergic conjunctivitis including seasonal and perennial allergic conjunctivitis and vernal keratoconjunctivitis	1 or 2 drops 4 times daily	A/KK (SRQ OPHTH)
724.	Sodium Dichloroisocyanurate Tablet	V07AV0000 0T1001XX	Low and medium level disinfectant	50 - 10,000 ppm av chlorine	C
725.	Sodium glycerophosphate for addition into infusion solution, 20ml vial	B05XA1417 1P3001XX	Indicated in adult patients and infants as a supplement in intravenous nutrition to meet the requirement of phosphate.	Adults: The recommended dosage is individual. The recommended daily dosage of phosphate during intravenous nutrition would normally be 10-20mmol. This can be met by using 10-20ml of sodium glycerophosphate to the infusion solution or to the admixture for which compatibility has been proved. Infants: The recommended dosage is individual. The recommended dose for infants and neonates is 1.0-1.5 mmol/kg bodyweight/day.	A (SRQ GENERAL)
726.	Sodium Fusidate 2 % Ointment	D06AX0152 0G5001XX	Skin infections caused by staphylococci, streptococci, corynebacterium minutissimum and other sodium fusidate-sensitive organisms	Apply to affected area 2 – 3 times daily	A (SRQ GENERAL)

No.	Generic Name	MDC	Indications	Dosage	Category
727.	Sodium Fusidate 250 mg Tablet	J01XC01520 T1001XX	Treatment of infections caused by susceptible organisms especially Staphylococcal infections including Methicillin Resistant Staphylococcus aureus (MRSA)	ADULT: 500 mg 3 times daily, skin and soft tissue infection: 250 - 500 mg twice daily	A* (SRQ GENERAL)
728.	Sodium Tetradecyl Sulphate 3% Injection	C05BB0418 3P3002XX	Sclerotherapy of oesophageal varices, haemorrhoids and varicose veins	0.5-2 mL into the submucosal layer at the base of the oesophageal varix or the haemorrhoid; several injections may be given at different sites, max. total injected 10-15 mL of 1% per treatment	A* (UKK DENTAL)
729.	Sodium Valproate 200 mg Tablet	N03AG0152 OT1001XX	i) Epilepsy ii) Treatment and prevention of mania associated with bipolar disorders (Off-label indication with one-off UKK approval: Neuropathic pain; aggression and associated impulsivity)	i. Epilepsy: ADULT: Initially 600 mg/day in 2 - 3 divided doses, dose may be increased by 200 mg at 3-day intervals to max 2.5 g/day. Usual maintenance dose: 1-2 g/day (20-30 mg/kg/day). CHILD: - More than 20 kg. Initially 400 mg/day with spaced increases until control is achieved (usually 20-30 mg/kg/day), dose may be increased to 35 mg/kg/day. - Less than 20 kg 20 mg/kg/day, in severe cases the dose may be increased provided plasma concentration can be monitored. ii. Treatment and prevention of mania associated with bipolar disorders: ADULT: The recommended initial dose is 1000mg/day. The dose should be increased as rapidly as possible to achieve the lowest therapeutic dose, which produces the desired clinical effects. The recommended maintenance dosage for the treatment of bipolar disorder is between 1000mg and 2000mg daily. In exceptional cases, the dose may be increased to not more than 3000mg daily.	B

No.	Generic Name	MDC	Indications	Dosage	Category
730.	Sodium Valproate 200 mg/5 ml Syrup	N03AG0152 OL9001XX	i) Treatment of generalized or partial epilepsy. ii) Treatment and prevention of mania associated with bipolar disorder	i. Epilepsy: ADULT: Initially 600 mg/day in 2 - 3 divided doses, dose may be increased by 200 mg at 3-day intervals to max 2.5 g/day. Usual maintenance dose: 1-2 g/day (20-30 mg/kg/day). CHILD: - More than 20 kg. Initially 400 mg/day with spaced increases until control is achieved (usually 20-30 mg/kg/day), dose may be increased to 35 mg/kg/day. - Less than 20 kg 20 mg/kg/day, in severe cases the dose may be increased provided plasma concentration can be monitored. ii. Treatment and prevention of mania associated with bipolar disorders: ADULT: The recommended initial dose is 1000mg/day. The dose should be increased as rapidly as possible to achieve the lowest therapeutic dose, which produces the desired clinical effects. The recommended maintenance dosage for the treatment of bipolar disorder is between 1000mg and 2000mg daily. In exceptional cases, the dose may be increased to not more than 3000mg daily.	B
731.	Sodium Valproate 400 mg Injection	N03AG0152 OP4001XX	Status epilepticus	ADULT and CHILD above 10 years: 10 to 15 mg/kg/day IV, may increase 5 to 10 mg/kg/week to achieve optimal clinical response (Maximum 60 mg/kg/day or less with a therapeutic range of 50 to 100 mcg/mL)	B (SRQ MED)
732.	Solifenacin Succinate 5 mg Tablet	G04BD0800 OT1001XX	Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with overactive bladder syndrome.	5 mg od. Dose can be increased to 10 mg if necessary.	A* (SRQ REHAB)
733.	Spirolactone 25 mg Tablet	C03DA0100 OT1001XX	Oedema and ascites in cirrhosis of the liver, congestive heart failure	ADULT: 100-200 mg daily in divided doses. Increase to 400 mg if required. CHILD: initially 3 mg/kg daily in divided doses	B

No.	Generic Name	MDC	Indications	Dosage	Category
734.	Streptokinase 1,500,000 IU Injection	B01AD0100 0P4001XX	Acute myocardial infarction, acute pulmonary embolism (Off-label indication with one-off UKK approval: Fibrinolysis in pleural empyema, complicated parapneumonic effusion)	Myocardial infarction: 1,500,000 units over 30 - 60 minutes. Pulmonary embolism: 250,000 units by IV infusion over 30 minutes, then 100,000 units every hour for up to 12-72 hours with monitoring of clotting factors	A* (SRQ GENERAL)
735.	Streptomycin Sulphate 1 g Injection	J01GA01183 P4001XX	i) Tuberculosis ii) Brucellosis iii) Bacterial endocarditis	15 mg/kg daily (Max: 1 g daily). Dosing is according to product insert.	B
736.	Sugammadex 100 mg/ml Injection	V03AB3500 0P3001XX	Indicated for reversal of neuromuscular blockade induced by rocuronium and vecuronium in selective patient group: obese, elderly, underlying cardiovascular disease. For pediatric population, sugammadex is recommended for routine reversal	2 mg/kg sugammadex is recommended, if spontaneous recovery has occurred up to at least the reappearance of second twitch tension of the train of four (T2). 4 mg/kg sugammadex is recommended if recovery has reached at least 1- 2 post-tetanic counts (PTC). For immediate reversal following administration of rocuronium a dose of 16 mg/kg sugammadex is recommended	A* (SRQ ANAES)
737.	Sulphamethoxazole 200 mg & Trimethoprim 40 mg / 5 ml Suspension	J01EE01961 L8001XX	Infections caused by susceptible Pathogens	Mild to moderate infections: more than 2months: 8 – 12 mg Trimethoprim/kg/day divided every 12hours. Serious Infections: 15- 20 mg Trimethoprim /kg/day divided every 6hours.	B
738.	Sulphamethoxazole 400mg & Trimethoprim 80mg Injection	J01EE01961 P3001XX	i) Severe or complicated infections when oral therapy is not feasible ii) Treatment and prophylaxis of pneumocystis carinii pneumonia (PCP) in immunocompromised patients	i) ADULT: 960 mg twice daily increased to 1.44 g twice daily in severe infections. CHILD: 36 mg/kg daily in 2 divided doses increased to 54 mg/kg/day in severe infections ii) Treatment: ADULT & CHILD over 4 weeks: 120 mg/kg/day PO/IV infusion in 2 - 4 divided doses for 14 days. Prophylaxis: ADULT: 960 mg once daily or 960 mg on alternate days (3 times a week) or 960 mg twice daily on alternate days (3 times a week). CHILD 6 weeks - 5 months: 120 mg twice daily on 3 consecutive days or 7 days per week; 6 months - 5 years: 240 mg; 6 - 12 years: 480 mg	A (UKK CFLN) (SRQ GENERAL)

No.	Generic Name	MDC	Indications	Dosage	Category
739.	Sulphamethoxazole 400 mg & Trimethoprim 80mg Tablet	J01EE01961 T1001XX	i) Severe or complicated infections due to susceptible infection ii) Treatment and prophylaxis of pneumocystis carinii pneumonia (PCP) in immunocompromised patients	i) ADULT: 1 - 3 tablets twice daily ii) Treatment: ADULT & CHILD over 4 weeks: 120 mg/kg/day in 2 - 4 divided doses for 14 days. Prophylaxis: ADULT: 960 mg once daily or 960 mg on alternate days (3 times a week) or 960 mg twice daily on alternate days (3 times a week). CHILD; 6 weeks - 5 months: 120 mg twice daily on 3 consecutive days or 7 days per week; 6 months - 5 years: 240 mg; 6 - 12 years: 480 mg	B
740.	Sulpiride 200 mg Tablet	N05AL0100 OT1001XX	Acute and chronic psychotic disorders	200-1000mg daily	B
741.	Sumatriptan 50 mg Tablet	N02CC0100 OT1001XX	Treatment of acute migraine attacks	50 mg per attack and not > 300 mg daily	A/KK (SRQ MED)
742.	Suxamethonium 50 mg/ml Injection	M03AB0110 OP3001XX	As an adjunct to general anaesthesia to facilitate endotracheal intubation, to provide skeletal muscle relaxation during surgery and to facilitate mechanical ventilation	Intravenous: Muscle relaxant in general anaesthesia Adult: As chloride: single dose of 0.3-1.1 mg/kg injected; supplementary doses of 50-100% of the initial dose may be given at 5-10 min intervals. Max dose (repeated IV injection or continuous infusion): 500 mg/hr Child: As chloride: <1 yr: 2 mg/kg; 1-12 yr: 1 mg/kg. Intramuscular: Muscle relaxant in general anaesthesia Adult: As chloride: 3-4 mg/kg. Max total dose: 150 mg Child: As chloride: <1 yr: Up to 4-5 mg/kg; ≥1 yr: Up to 4 mg/kg. Max dose: 150 mg.	B
743.	Tacrolimus 0.5 mg Capsule	L04AD0200 OC1003XX	i) Primary immunosuppression in liver and kidney allograft recipients. ii) Liver and kidney allograft rejection resistant to conventional immunosuppressive agents. It is recommended to be used concomitantly with adrenal corticosteroids. Because of the risk of anaphylaxis. Injection should be reserved for patients unable to take capsules only.	0.1-0.2 mg/kg/day for liver transplantation and at 0.15-0.3 mg/kg/day for kidney transplantation administered as 2 divided doses.	A* (SRQ MED)

No.	Generic Name	MDC	Indications	Dosage	Category
744.	Tacrolimus 1 mg Capsule	L04AD0200 OC1001XX	i) Primary immunosuppression in liver and kidney allograft recipients. ii) Liver and kidney allograft rejection resistant to conventional immunosuppressive agents. It is recommended to be used concomitantly with adrenal corticosteroids. Because of the risk of anaphylaxis. Injection should be reserved for patients unable to take capsules only.	0.1-0.2 mg/kg/day for liver transplantation and at 0.15-0.3 mg/kg/day for kidney transplantation administered as 2 divided doses.	A* (SRQ MED)
745.	Tamsulosin HCl 400 mcg Extended Release Tablet	G04CA0211 OT5001XX	Second line treatment of functional symptoms of benign prostatic hyperplasia (BPH) in patients who do not tolerate first line drugs or when first line drugs are inappropriate or contraindicated Pres. Restrictions: Consultant/specialists for specific indications only, including Geriatricians	400 mcg once daily	A* (SRQ SURG)
746.	Tamoxifen Citrate 20 mg Tablet	L02BA01136 T1001XX	Breast cancer	20 mg in 1-2 divided doses. Max: 40 mg/day	A
747.	Tenecteplase 10,000 unit (50 mg) Injection	B01AD1100 OP4001XX	Acute myocardial infarction where streptokinase is contraindicated due to previous streptokinase induced antibodies. [Indicated when antibodies was given more than 5 days and less than 12 months]	Less than 60 kg: 30 mg, 60 - 69 kg: 35 mg, 70 - 79 kg: 40 mg; 80 -90 kg: 45 mg, 90 kg or above: 50 mg. Administer single IV bolus over 5-10 seconds	A* (SRQ A&E)
748.	Tenofovir Disoproxil Fumarate 300mg Tablet	J05AF07138 T1001XX	i) Treatment of HIV-1 infected adults in combination with other antiretroviral agents. ii) Use as first line monotherapy for chronic hepatitis B or as a rescue therapy for patients with drug resistance hepatitis B virus (according to resistant profile or treatment guidelines).	300mg once daily. Renal Dose Adjustment: 300mg every 48 hours (30-49ml/min); 300mg every 72 hours (10-29ml/min); 300mg every 7 days after dialysis (Hemodialysis)	A* (SRQ MED)
749.	Tenofovir Disoproxil Fumarate 300 mg & Emtricitabine 200mg Tablet	J05AR03964 T1001XX	Treatment of HIV-1 infection in adults in combination with other antiretroviral agents (such as non-nucleoside reverse transcriptase inhibitors or protease inhibitors).	1 tablet once daily.	A/KK (SRQ MED) (SRQ PAED)
750.	Terazosin HCl 2 mg Tablet	G04CA0311 OT1002XX	i) Treatment of Benign Prostatic Hyperplasia ii) Hypertension	i) Initial dose: 1mg at bedtime Maintenance dose: 5-10mg once daily ii) Initial dose: 1mg at bedtime Maintenance dose: 1-5mg once daily Max: 20-40mg/day	A/KK (SRQ SURG)

No.	Generic Name	MDC	Indications	Dosage	Category
751.	Terazosin HCl 5 mg Tablet	G04CA0311 OT1003XX	i) Treatment of Benign Prostatic Hyperplasia ii) Hypertension	i) Initial dose: 1mg at bedtime Maintenance dose: 5-10mg once daily ii) Initial dose: 1mg at bedtime Maintenance dose: 1-5mg once daily Max: 20-40mg/day	A/KK (SRQ SURG)
752.	Testosterone 250 mg/ml Injection	G03BA0300 OP3001XX	i. In male: Testosterone replacement therapy for male hypogonadism, when testosterone deficiency has been confirmed by clinical features and biochemical test. ii. In female: Additive therapy in cases of advanced breast cancer in postmenopausal women.	By IM only. Hypogonadism 250 mg every 2-3 weeks. To maintain an adequate androgenic effect 250 mg every 3-6 weeks. Potency disorders 250 mg every 4 weeks. Male climacteric disorders: 250 mg every 3-4 weeks. Repeated 6-8 weeks courses at 2-3 months interval	A* (UKK CFLN) (SRQ MED)
753.	Tetanus Immunoglobulin Human 250 Unit/Vial Injection	J06BB02000 P3001XX	Passive immunization against tetanus	Prophylaxis of tetanus: IM 250 units. Treatment of tetanus: IM 30 - 300 units/kg	B
754.	Tetanus Toxoid Vaccine Injection	J07AM0100 OP3001XX	Immunization against tetanus infection	0.5 mL by IM. Dosing is according to product insert.	C+
755.	Thalidomide 50 mg Capsule	L04AX02000 C1001XX	Treatment of multiple myeloma	50 mg to 200 mg daily	A* (SRQ GENERAL)
756.	Theophylline 125 mg Tablet	R03DA0400 OT1001XX	Reversible airways obstruction, acute severe asthma	ADULT: 125 mg 3 - 4 times daily after food, increased to 250 mg if required. CHILD: 1 - 15 years: 5 mg/kg/dose (up to 600 mg/ day) every 3 - 4 times daily	B
757.	Theophylline 250 mg Long Acting Tablet	R03DA0400 OT5001XX	Reversible airways obstruction and acute severe asthma	ADULT: 250 mg 2 times daily. CHILD under 12 years : Up to 10 mg/kg body weight 2 times daily	B
758.	Thiamine HCl 100 mg/ml Injection	A11DA0111 OP3001XX	i) For the prevention or treatment of Vitamin B1 deficiency syndromes including beri-beri and peripheral neuritis associated with pellagra ii) Wernicke-Korsakoff Syndrome	i) Mild to chronic deficiency: 10-25 mg daily. Severe deficiency: 200 -300 mg daily ii) 500 mg every 8 hours for 2 days, followed by 100 mg 2 times daily until patient can take oral dose	B (UKK A&E) (UKK ANAES)
759.	Thiamine Mononitrate 10 mg Tablet	A11DA0122 1T1002XX	Prevention and treatment of thiamine deficiency state	Mild chronic deficiency: 5mg to 30mg daily Severe deficiency: up to 300mg daily	C
760.	Thiopental Sodium 500 mg Injection	N05CA1952 OP3001XX	i) General anaesthesia, induction ii) Anticonvulsant for cases resistant to conventional anticonvulsants in the ICU	i) ADULT: For induction 200 - 400 mg. For repeat injection 3 - 5 mg/kg over 10 - 15 seconds until desired depth of anaesthesia is obtained. Not FDA approved for use in pediatric patients ii) 75 - 125 mg IV single dose; for local-anaesthetic induced convulsion: 125 - 250 mg IV over 10 minutes	B

No.	Generic Name	MDC	Indications	Dosage	Category
761.	Tibolone 2.5 mg Tablet	G03CX0100 0T1001XX	i. Treatment of complaints resulting from the natural or surgical menopause & in cases at high risk for breast carcinomas where general hormone replacement therapy is contraindicated ii. Prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis.	2.5 mg daily	A* (SRQ O&G)
762.	Timolol 0.5 % Eye Drops	S01ED0125 3D2002XX	Elevated intraocular pressure, chronic open angle glaucoma	One drop in the affected eye(s) twice daily or as directed by physician	A
763.	Timolol 0.5 % Eye Drops (Preservative free)	S01ED0125 3D2002XX	Elevated intraocular pressure, chronic open angle glaucoma	One drop in the affected eye(s) twice daily or as directed by physician	A (SRQ OPHTH)
764.	Tiotropium 2.5mcg / puff solution for inhalation	R03BB0432 0A3001XX	i) Maintenance bronchodilator treatment to relieve symptoms of patients with chronic obstructive pulmonary disease (COPD). ii) As add-on maintenance bronchodilator treatment in adult patients (18 years and older) with asthma who are currently treated with the maintenance combination of inhaled corticosteroids ($\geq 800\mu\text{g}$ budesonide/day or equivalent) and long-acting β_2 -agonist and who experienced one or more severe exacerbations in the previous year. Prescribing restriction: For indication (i): The diagnosis of COPD should be confirmed by spirometry.	5 mcg (2 puff) once daily, at the same time of the day	A/KK (SRQ MED) (SRQ PAED)
765.	Tiotropium 2.5mcg and Olodaterol 2.5mcg per actuation, inhalation	R03AL06- 989-A10- 01-XXX	As a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). Pres. Restrictions: Patients without inhaler coordination problem (Only applies to Primary Care settings)	2 puffs once daily, at the same time of the day.	A/KK (SRQ MED)

No.	Generic Name	MDC	Indications	Dosage	Category
766.	Tocilizumab 20 mg/ml Injection	L04AC07-000-P30-01-001	Indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients: i) with inadequate respond or intolerance to conventional disease- modifying antirheumatic drugs (DMARDS) ii) who has failed antitumour necrosis factors (antiTNFs) iii) where TNF is contraindicated (patients with history of pulmonary tuberculosis [PTB]) It also can be used as monotherapy or with combination with methotrexate (MTX) and/ or other DMARDS.	Recommended dose for rheumatoid arthritis of tocilizumab for adult patients is 8mg/kg given once every 4 weeks as a single-drip IV infusion over 1 hour. It should be diluted to 100 ml by a healthcare professional with sterile 0.9% w/v sodium chloride solution over 1 hour. For patients whose body weight is more than 100kg, doses exceeding 800mg per infusion are not recommended	A* (SRQ PAED)
767.	Tolterodine Tartrate ER 4 mg Capsule	G04BD0712 3C2002XX	Treatment of overactive bladder with symptoms of urinary, frequency or urge incontinence	4 mg once daily. May decrease to 2 mg once daily depending on response and tolerability	A* (SRQ O&G) (SRQ REHAB) (SRQ SURG)
768.	Topiramate 25 mg Tablet	N03AX1100 0T1001XX	As adjunctive therapy for adults and children (2 years and above) with: i) partial onset seizures and generalized tonic-clonic seizures ii) seizures associated with Lennox Gastaut syndrome.	ADULT: Usual daily dose: 200-400 mg/day. CHILD: Daily doses up to 30mg/kg/day Dosing is according to product insert.	A* (SRQ PAED)
769.	Topiramate 50 mg Tablet	N03AX1100 0T1002XX	As adjunctive therapy for adults and children (2 years and above) with: i) partial onset seizures and generalized tonic-clonic seizures ii) seizures associated with Lennox Gastaut syndrome.	ADULT: Usual daily dose: 200-400 mg/day. CHILD: Daily doses up to 30mg/kg/day Dosing is according to product insert.	A* (SRQ MED) (SRQ PAED)
770.	Topiramate 100 mg Tablet	N03AX1100 0T1003XX	As adjunctive therapy for adults and children (2 years and above) with: i) partial onset seizures and generalized tonic-clonic seizures ii) seizures associated with Lennox Gastaut syndrome.	ADULT: Usual daily dose: 200-400 mg/day. CHILD: Daily doses up to 30mg/kg/day Dosing is according to product insert.	A* (SRQ PAED) (SRQ PSY)
771.	Trace Elements and Electrolytes Solution (Adult)	B05XA3090 5P3001XX	Only to be used to cover daily loss of electrolyte and trace elements for patient on parenteral nutrition	10 ml added to 500-1000 ml solution, given by IV infusion	A* (SRQ GENERAL)
772.	Trace Elements and Electrolytes (Paediatric) Solution	B05XA3090 5P3002XX	Only to be used to cover daily loss of electrolyte and trace elements for patient on parenteral nutrition	According to the needs of the patient. INFANT and CHILD weighing 15 kg or less: Basal requirements of the included trace elements are covered by 1 ml/kg/day to a maximum dose of 15 ml. CHILD weighing 15 kg or more, a daily dose of 15 ml, should meet basic trace element requirements. However, for patients weighing more than 40 kg the adult preparation trace element should be used	A* (SRQ GENERAL)

No.	Generic Name	MDC	Indications	Dosage	Category
773.	Tramadol HCl 50 mg Capsule	N02AX0211 0C1001XX	Moderate to severe acute or chronic pain (eg. Post-operative pain, chronic cancer pain and analgesia/pain relief for patients with impaired renal function)	ADULT: 50 mg initially, can take another 50mg after 30 - 60 min if pain not relieved. Max 400 mg daily. CHILD: 1 mg/kg/dose repeated every 6 hours (Max: 2 mg/kg/dose and 100 mg/dose)	A/KK (SRQ GENERAL)
774.	Tramadol HCl 50 mg/ml Injection	N02AX0211 0P3001XX	Moderate to severe acute or chronic pain (eg. Post-operative pain, chronic cancer pain and analgesia/pain relief for patients with impaired renal function)	ADULT: IV/IM/SC 50 – 100 mg. (IV inj over 2-3 min or IV infusion). Initially 100 mg then 50 - 100 mg every 4 - 6 hours. Max: 400 mg daily. CHILD (1 year and above): 1 – 2 mg/kg/dose	A (SRQ GENERAL)
775.	Tranexamic Acid 100 mg/ml Injection	B02AA0200 0P3001XX	Haemorrhage associated with excessive fibrinolysis	ADULT: Slow IV 0.5-1 g (10 - 15 mg/kg) 3 times daily. Continuous infusion at a rate of 25 - 50 mg/kg daily. CHILD: slow IV 10 mg/kg/day 2-3 times daily	B
776.	Tranexamic Acid 250 mg Capsule	B02AA0200 0C1001XX	Haemorrhage associated with excessive fibrinolysis	ADULT: 1-1.5 g (15-25 mg/kg) 2-4 times daily. CHILD: 25 mg/kg/day 2-3 times daily. Menorrhagia (initiated when menstruation has started), 1 g 3 times daily for up to 4 days; maximum 4 g daily	B
777.	Triamcinolone Acetonide 0.1 % Oral Paste	A01AC0135 1G3101XX	As an adjunctive treatment and for the temporary relief of symptoms associated with inflammatory or ulcerative lesions of oral mucosa resulting from trauma.	Apply thin film to affected areas 2 to 3 times daily	B
778.	Triamcinolone Acetonide 40 mg/ml Injection	H02AB0835 1P3002XX	Allergies, dermatoses, rheumatoid arthritis and inflammatory ophthalmic diseases (Off-label indication with one-off UKK approval: Radicular pain)	40-80 mg deep into the gluteal muscle	A/KK (SRQ GENERAL)
779.	Trifluoperazine HCl 5 mg Tablet	N05AB0611 0T1001XX	i) Schizophrenia, other psychotic disorder ii) Treatment of behavioural disorders in adults and in children	ADULT: Initially 5 mg twice daily, increase by 5 mg after 1 week, then at 3-day intervals. Maximum 40 mg/day. CHILD up to 12 years: Initially up to 5 mg daily in divided doses adjusted to response, age and body weight. Elderly reduce initial dose by at least half.	B
780.	Trimetazidine 20 mg Tablet	C01EB1511 0T1001XX	Prophylactic treatment of episodes of angina pectoris	20 mg 3 times daily	B
781.	Triprolidine HCl 2.5 mg and Pseudoephedrine HCl 60 mg Tablet	R01BA5298 8T1002XX	Decongestion of the upper respiratory tract in common cold, hay fever, allergic and vasomotor rhinitis and aerotitis	ADULT 2.5 mg every 4 - 6 hours; max dose 10 mg/day. CHILD (syrup) 6 – 12 years : 1.25 mg every 4 - 6 hours; max dose 5 mg/day 4 - 6 years : 0.938 mg every 4 - 6 hours; max dose 3.744 mg/day 2 - 4 years : 0.625 mg every 4 - 6 hours; max dose 2.5 mg/day	B

No.	Generic Name	MDC	Indications	Dosage	Category
782.	Triptorelin 3.75 mg Injection	L02AE04000 P2001XX	i) Treatment of confirmed central precocious puberty (preterm sexual development) in girls under 9 years, boys under 10 years of age ii) Genital and extragenital endometriosis (stage I to stage IV). Treatment should not be administered for more than 6 months. It is not recommended to start a second treatment course with triptorelin or another GnRH analogue.	1 intramuscular injection every 4 weeks. The treatment must be started in the first 5 days of the menstrual cycle. The duration of treatment depends on the initial severity of the endometriosis and the changes observed in the clinical features. In principle, the treatment should be administered for at least 4 months and for at most 6 months. It is not recommended to start a second treatment course with triptorelin or another GnRH analogue.	A (SRQ O&G)
783.	Tropicamide 1% Eye Drops	S01FA06000 D2002XX	Topical use to produce cycloplegic refraction for diagnostic purposes	1 - 2 drops several times a day	A/KK (SRQ OPHTH)
784.	Tuberculin PPD Injection	V04CF0100 OP3001XX	For routine Mantoux (tuberculin sensitivity) test	10 units is injected Intradermally	B
785.	Typhoid Vaccine Injection	J07AP02000 P3001XX	Active immunization against typhoid fever in adult and child more than 2 years	0.5 ml single IM injection into the deltoid or vastus lateralis, may immunize again with 0.5 ml IM every 3 years if needed.	B
786.	Ursodeoxycholic Acid 250 mg Capsule	A05AA0200 OC1001XX	Cholestatic liver diseases (eg. primary biliary cholangitis, primary cholangitis etc.)	10-15 mg/kg daily in 2 to 3 divided doses Dosing is individualised based on body weight and according to product insert/protocol	A (SRQ MED) (SRQ PAED) (SRQ SURG)
787.	Valproic Acid and Sodium Valproate (ER) 500 mg Tablet	N03AG0152 OT5001XX	i) In the treatment of generalized or partial epilepsy, particularly with the following patterns of seizures: absence, myoclonic, tonic-clonic, atonic-mixed as well as, for partial epilepsy: simple or complex seizures, secondary generalized seizures, specific syndrome (West, Lennox-Gastaut). ii) Treatment and prevention of mania associated with bipolar disorders.	i) Adults: Dosage should start at 500mg daily increasing by 200mg at three-day intervals until control is achieved. This is generally within the dosage range 1000mg to 2000 mg per day. Children: >20KG: 500mg/day (irrespective of weight) with spaced increases until control is achieved. ii) Initial dose of 1000mg/day, to be increase rapidly as possible to achieve lowest therapeutic dose, which produce desired clinical effects. Recommend initial dose is 1000mg & 2000mg daily. Max dose 3000 mg daily.	B (SRQ PSY)

No.	Generic Name	MDC	Indications	Dosage	Category
788.	Valsartan 80 mg Tablet	C09CA0300 OT1001XX	Patients intolerant to ACE inhibitors in: i) Heart failure ii) Post myocardial infarction iii) Hypertension	i) Initial: 40mg twice daily. Titrate up to highest tolerated dose. Max: 320mg daily in divided doses ii) Initial: 20mg twice daily Titrate up to 160mg over next few weeks. Max: 160mg twice daily iii) 80mg or 160mg once daily Max: 320mg daily Dosing is individualised and according to package insert / protocol.	A/KK (SRQ MED)
789.	Valsartan 160 mg Tablet	C09CA0300 OT1002XX	Patients intolerant to ACE inhibitors in: i) Heart failure ii) Post myocardial infarction iii) Hypertension	i) Initial: 40mg twice daily. Titrate up to highest tolerated dose. Max: 320mg daily in divided doses ii) Initial: 20mg twice daily Titrate up to 160mg over next few weeks. Max: 160mg twice daily iii) 80mg or 160mg once daily Max: 320mg daily Dosing is individualised and according to package insert / protocol.	A/KK (SRQ MED)
790.	Vancomycin HCl 500 mg Injection	J01XA01110 P4001XX	i) Treatment of infections due to susceptible gram-positive organisms which cannot be treated with other agents (eg. MRSA and Enterococcus sp.) ii) Treatment of severe staphylococcal infections in patients who cannot receive or who have failed to respond to the penicillins and cephalosporins.	Slow IV infusion. ADULT: 15-20mg/kg q 8-12 hours, not to exceed 2gm per dose. NEONATE up to 1 week, 15 mg/kg initially, then 10 mg/kg every 12 hours. INFANT 1 - 4 weeks, 15 mg/kg initially then 10 mg/kg every 8 hours. CHILD over 1 month, 10 mg/kg every 6 hours	A* (SRQ GENERAL)
791.	Vasopressin 20 units / ml Injection	H01BA0100 OP3001XX	i) Pituitary diabetes insipidus ii) Oesophageal variceal bleeding (Off-label indication with one-off UKK approval: 1) Septic shock; 2) ventricular fibrillation; 3) asystole/pulseless electrical activity)	i) 5 - 20 units SC or IM every 4 hours ii) 20 units in 100 - 200 ml 5% dextrose saline over 15 minutes as infusion which may be repeated after at intervals of 1 - 2 hours. Maximum: 4 doses	A (SRQ ANAES) (SRQ A&E) (SRQ O&G)
792.	Verapamil HCl 2.5 mg / ml Injection	C08DA0111 OP3001XX	Supraventricular tachycardia	Initially 5-10mg given by slow IV over at least 2 minutes. The dose can be repeated 10mg 30 minutes after the first dose if the initial response is not adequate.	A/KK (SRQ GENERAL) (UKK CFLN)

No.	Generic Name	MDC	Indications	Dosage	Category
793.	Verapamil HCl 40 mg Tablet	C08DA01- 110-T10- 01-XXX	i) Supraventricular tachyarrhythmias (SVT) prophylaxis ii) Angina iii) Hypertension	i) SVT: 120-480mg in divided doses. ii) Angina: 80mg 3 times daily iii) Hypertension: 40 - 80 mg 3-4 times daily. In oral long term therapy, max: 480 mg daily.	B
794.	Vildagliptin 50 mg Tablet	A10BH0200 OT1001XX	FUKKM restriction: As add- on therapy for patient who failed therapy and/or contraindicated/unable to tolerate metformin and/or sulphonylurea. i) As second line therapy in type 2 diabetes patients inadequately controlled on maximal tolerated dose of metformin monotherapy and high risk of hypoglycaemia. ii) As second line therapy in type 2 diabetes patients inadequately controlled on maximal tolerated dose of sulphonylurea and intolerant/contraindicated for metformin therapy. iii) As third line therapy in type 2 diabetes patients inadequately controlled with dual OAD combination therapy with sulphonylurea and metformin iv) As a monotherapy in type 2 diabetes mellitus patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. v) An adjunct to diet and exercise to improve glycaemic control in patients with type 2 diabetes mellitus: As a dual therapy in combination with insulin in patients with insufficient glycaemic control. Insulin dose and regimen should be optimized before addition of vildagliptin.	ADULT over 18 years: 50mg bd when combine with metformin, 50 mg od when combine with sulphonylurea	A/KK (SRQ MED)
795.	Vincristine Sulphate 1 mg / ml Injection	L01CA0218 3P3001XX	i) Solid tumours ii) Gestational trophoblastic disease iii) Lymphoma iv) Multiplemyeloma v) Acute lymphoblastic leukemia	ADULT: 1.4 mg/m2 injection CHILD: 1 mg/m2 to 2 mg/m2 weekly (0.05 mg/kg for infants less than 10kg) Dosing is according to product insert/protocol	A (SRQ ONCO)
796.	Vitamin B Complex Tablet (Vit B1, B3, B6, B12)	A11EA0090 1T1001XX	Prophylaxis and treatment of vitamin B deficiency	1-2 tablets daily	C+

No.	Generic Name	MDC	Indications	Dosage	Category
797.	Vitamin K1 1 mg / ml Injection (Phytomenadione)	B02BA0100 OP3001XX	Vitamin K deficiency in neonates	Prophylaxis of vitamin K deficiency bleeding in neonates Child: Neonate: 0.5-1 mg, given as a single dose via IM inj. Alternatively, 2 mg may be given orally, followed by a 2nd dose of 2 mg after 4-7 days. Intravenous Vitamin K deficiency bleeding in neonates Child: Infant: 1 mg by IV/IM/SC inj, further doses may be given if necessary.	C+
798.	Vitamin K1 10mg / ml Injection (Phytomenadione)	B02BA0100 OP3002XX	Haemorrhage associated with hypoprothrombinaemia caused by overdose of anticoagulants	0.5 - 20 mg by very slow IV at a rate not exceeding 1 mg per minute	B
799.	Vortioxetine 10 mg tablet	N06AX26-330-T32-01-XXX	Treatment of major depressive episodes in adults. Prescribing Restrictions Consultant/specialists for specific indications only, including Geriatricians and Neurologists	10mg once daily in adults less than 65 years of age. Depending on the individual patient response, the dose may be increased to a maximum of 20mg vortioxetine once daily or decreased to a minimum of 5mg vortioxetine once daily. After the depressive symptoms resolve, treatment for at least 6 months is recommended for consolidation of the anti-depressive response.	A* (SRQ PSY)
800.	Warfarin Sodium 1 mg Tablet	B01AA0352 OT1001XX	Treatment and prophylaxis of thromboembolic disorders	Initially 2 to 5mg per day. Maintenance dose 2-10mg daily according to the INR Dosing is individualised based on patient's INR and according product insert/protocol/ guideline.	B
801.	Warfarin Sodium 2 mg Tablet	B01AA0352 OT1002XX	Treatment and prophylaxis of thromboembolic disorders	Initially 2 to 5mg per day. Maintenance dose 2-10mg daily according to the INR Dosing is individualised based on patient's INR and according product insert/protocol/ guideline.	B
802.	Warfarin Sodium 5 mg Tablet	B01AA0352 OT1004XX	Treatment and prophylaxis of thromboembolic disorders	Initially 2 to 5mg per day. Maintenance dose 2-10mg daily according to the INR Dosing is individualised based on patient's INR and according product insert/protocol/ guideline.	B
803.	Water for Injection	V07AB0000 OP3001XX	As a diluent and vehicle for the administration of medications	According to the needs of the patient	C+

No.	Generic Name	MDC	Indications	Dosage	Category
804.	Zidovudine 1 % Injection	J05AF01000 P3001XX	To reduce the rate of maternal-foetal transmission of HIV in: i) HIV-positive pregnant women over 14 weeks of gestation ii) Their newborn infants	i) Prophylaxis of maternal-foetal HIV transmission during labour and delivery Adult: Loading dose: 2 mg/kg, followed by continuous infusion of 1 mg/kg/hr until umbilical cord is clamped. If caesarean section is planned, start the IV infusion 4 hr before the operation. Renal and Hepatic impairment: Dose reduction may be needed. HIV infection (to be discuss: not in indication) Adult: 1-2 mg/kg every 4 hr, given as 2-4 mg/ml infusion over 1 hr. Child: As continuous infusion: 20 mg/m2/hr. Alternatively, as intermittent infusion: 120 mg/m2 every 6 hr. Renal impairment: Haemodialysis or peritoneal dialysis: 1 mg/kg every 6-8 hr. ii) Prophylaxis of HIV infection in neonates Child: Neonates: 1.5 mg/kg every 6 hr. Start treatment within 12 hr after birth and continue for 1st 6 wk of life. Dose to be given via IV infusion over 30 minutes. Renal impairment: Dose adjustment may be needed.	A (SRQ O&G)
805.	Zidovudine 10 mg/ml Syrup	J05AF01000 L9001XX	i) Management of patients with asymptomatic and symptomatic (early or advanced) HIV infections with CD4 cell counts less than 500cu. mm ii) Neonatal prophylaxis	i) HIV infection Adult: 600 mg daily in divided doses, in combination with other antiretroviral agents. Child: 6 wk - 12 yr: 160 mg/m2 every 8 hr. Max: 200 mg every 8 hr. May be used in combination with other anti-retrovirals. Renal and Hepatic impairment: Dose reduction may be needed. ii) Prophylaxis of HIV infection in neonates Child: Neonates: 2 mg/kg every 6 hr for 1st 6 wk of life, starting within 12 hr after birth. Renal and hepatic impairment: Dose adjustment may be needed.	A* (SRQ PAED)
806.	Zidovudine 300 mg & Lamivudine 150 mg Tablet	J05AR01964 T1001XX	HIV infection in combination with at least one other antiretroviral drug	ADULT and CHILD over 12 years: 1 tablet twice daily	A/KK (SRQ MED) (SRQ PAED)
807.	Zinc Oxide Ointment	D02AB0024 OG5001XX	Skin protective in various skin conditions such as nappy rash and eczema	Apply 3 times daily or as Required	C

No.	Generic Name	MDC	Indications	Dosage	Category
808.	Zinc oxide, benzyl benzoate and balsam peru suppository (Anusol)	C05AX0493 1S1001XX	For relief of pruritus, burning and soreness in patients with haemorrhoids and perianal conditions	Insert 1 suppository night and morning after bowel movements; do not use for longer than 7 days OR please refer to the product insert.	C
809.	Zoledronic acid 4mg Injection	M05BA0800 0P3001XX	i) Treatment of hypercalcaemia of malignancy ii) Prevention of skeletal related events (SREs) in patients with multiple myeloma involving multiple bone lesions iii) Prevention of skeletal related events (SREs) for metastatic cancers of solid tumours	i) 4mg single dose ii) 4mg every 3-4 weeks iii) 4mg reconstituted and should be given as a 15- minute IV infusion every 12 weeks (as advised in MaHTAS 2018 Report)	A* (SRQ GENERAL)
810.	Zolpidem Tartrate 10 mg Tablet	N05CF0212 3T1001XX	For treatment of insomnia	ADULT: 10mg daily at bedtime ELDERLY OR DEBILITATED SUBJECTS: 5mg daily at bed time Max. dose: 10mg daily	A (SRQ PSY)
811.	Zuclopenthixol 20 mg /ml Drops	N05AF0500 0D5001XX	i) Acute schizophrenia and other acute psychoses, including agitation ii) Chronic schizophrenia and other chronic psychoses iii) Mania	i) & iii) 10-50mg daily Max. dose: 100-150mg daily in 2-3 divided doses ii) 20-40mg daily	A* (SRQ PSY)
812.	Zuclopenthixol Acetate 50mg /ml Injection	N05AF0512 2P3001XX	Initial treatment of acute psychoses, including mania, and exacerbations of chronic psychoses in patients not responding to available standard drugs	50-150mg IM repeated if necessary, preferably within a time interval of 2-3 days. Additional injection may be needed 24-48 hours following the first injection	A* (SRQ PSY)
813.	Zuclopenthixol Decanoate 200 mg /ml Injection	N05AF0513 5P2001XX	Maintenance treatment of schizophrenia and other psychoses, especially with symptoms such as hallucinations, delusions and thought disturbances along with agitation, restlessness, hostility and aggressiveness in patients not responding to available standard drugs	By deep IM injection test dose 100 mg followed after 7 - 28 days by 100 – 200 mg or more followed by 200 - 400 mg at intervals of 2 - 4 weeks adjusted according to response. Max 600 mg weekly. Child not recommended	B (SRQ PSY)

Hospital Formulary (UKK Items Applied by HDOK) Hospital Duchess of Kent, Sandakan

No.	Generic Name	Department	Indication	Remarks
1.	Acetylcysteine 600mg Tablet	REHAB (patient)	Reduce the thickness of secretions	Not in FUKKM
2.	Atomoxetine HCl 10mg Cap	PSY (stock)	As per FUKKM	Import permit
3.	Atomoxetine HCl 25mg Cap	PSY (stock)	As per FUKKM	Import permit
4.	Atomoxetine HCl 40mg Cap	PSY (stock)	As per FUKKM	Import permit
5.	Baclofen 5mg / ml Oral Suspension	STANDARD (Stock)	Spasticity of the skeletal muscle in children	Import permit
6.	Barium Sulphate Suspension	RADIO (stock)	For x-ray examination of the alimentary tract;oesophagus, colon, stomach and duodenum.	Import permit
7.	Carnoy's Solution	DENTAL (stock)	Treatment of keratocystic odontogenic tumours	Import permit; Not in FUKKM
8.	Clofazimine 100mg Cap	SRQ MED (patient)	Treatment for drug-resistant tuberculosis (Off-label)	Patient basis; Off-label use (Pengecualian UKK)
9.	Cyclophosphamide 50 mg Tablet	MED (stock)	As per FUKKM	Import permit
10.	Dapsone 100 mg Tablet	MED (stock)	Pemphigus vulgaris, PCP prophylaxis	Import permit; Off label FUKKM & PBKD
11.	Dantrolene Sodium 20 mg Inj	ANAES (stock)	For the treatment of malignant hyperthermia	Pengecualian UKK
12.	Diazoxide 100 mg Capsule / Tablet	PAED (stock)	Persistent hypoglycaemia secondary to hyperinsulinaemia	Import permit; Not in FUKKM
13.	Digoxin Immune Fab 40 mg Injection	A&E (stock)	Digitalis toxicity	Import permit; Not in FUKKM
14.	Eltrombopag 25 mg Tablet	MED (patient)	Severe aplastic anemia	Off-label FUKKM
15.	Etomidate 20mg / 10ml Inj	A&E (stock)	General anaesthesia hemodynamically unstable patient	Import permit
16.	Fluticasone Propionate 50mcg / dose Inhaler	PAED (patient)	Chronic Lungs Disease in Infant	Not in FUKKM
17.	Flucytosine 500 mg Tablet	MED (stock)	Only for the treatment of fungal meningitis	Import permit
18.	Frusemide 10mg / ml oral solution	PAED (stock)	Oedema	Import permit
19.	Glyceryl Trinitrate 5 mg / 24 hr Transdermal Patch	PAED (stock)	Treatment of ischemia problem in paediatric patients	Not in FUKKM
20.	Human Normal Globulin Inj (3 g)	ANAES (stock)	Myasthenia Gravis	Off label FUKKM & PBKD
21.	Hydroxocobalamin 5g Inj	A&E(stock)	Cyanide poisoning	Pengecualian UKK
22.	Idarucizumab 2.5g / 50ml Injection	A&E (stock)	Dabigatran poisoning	Not in FUKKM
23.	Iodine and Potassium Iodide Solution	STANDARD (Stock)	Pre-operative treatment of thyrotoxicosis & Thyrotoxicosis crisis	Import permit
24.	Isoprenaline HCl 2 mg / ml Injection	SRQ GENERAL	As per FUKKM	Stock basis; Import permit

No.	Generic Name	Department	Indication	Remarks
25.	Irbesartan 150mg Tablet	MED (patient-pesara)	Hypertension	Not in FUKKM
26.	Letrozole 2.5 mg Tablet	O&G (patient)	Ovarian Canceer	Off label FUKKM & PBKD
27.	Levamisole 50 mg Tablet	PAED (patient)	Steroid resistant nephrotic syndrome	Import permit; Not in FUKKM
28.	Levofloxacin 500mg Tab	SRQ MED (patient)	Treatment of drug resistant tuberculosis (Off-label)	Patient-basis; Off-label use
29.	L-Carnitine 500mg / 10ml Oral Solution	PAED (patient)	Propionic acidemia	Patient-basis; Not in FUKKM
30.	Medroxyprogesterone Acetate 100 mg Tablet	O&G (patient)	Focal atypical hyperplasia not responding to low dose medroxyprogesterone acetate	Patient-basis: Import permit
31.	Melatonin 3mg Capsule	PAED (patient)	Sleeping Disorder	Import permit; Not in FUKKM
32.	Memantine HCl 10mg Tab	REHAB (patient)	Post-Stroke Aphasia	Off label FUKKM & PBKD
33.	Mercaptopurine 50mg Tab	Standard (stock)	As per FUKKM	Import permit
34.	Metolazone 2.5mg Tab	MED (stock)	Steroid-resistant nephrotic syndrome	Import permit
35.	Milrinone 1 mg / ml Injection	PAED (stock)	Inotropic support in paediatrics and neonates in septic shock and cardiogenic shock not responding to available inotropes (off-label PBKD)	Not in FUKKM; Off label PBKD
36.	Misoprostol 200 mcg Tablet	O&G (stock)	Induce abortion/Termination of pregnancy	Import permit; Not in FUKKM
37.	Mycophenolate Mofetil 500 mg Tab	MED (stock)	Myasthenia Gravis	Off label FUKKM & PBKD
38.	Nimodipine 30 mg Tablet	SURG (stock)	Prophylaxis & treatment of ischaemic neurological deficits caused by cerebral vasospasm following subarachnoid haemorrhage of aneurysmal origin	Import permit
39.	Nortriptyline HCl 10mg Tablet	ANAES (patient)	Pain Management	Import permit; Not in FUKKM
40.	Neuropolyvalent Snake Antivenom	A&E (stock)	Neuropolyvalent for cases of snake envenomation	Pengecualian UKK
41.	Oxybutynin Chloride 5 mg Tablet	PAED (patient) REHAB (patient)	As per FUKKM	Import permit
42.	Pamidronate Disodium 30 mg Inj	PAED (patient)	Prophylaxis Steroid induced osteoporosis	Off Label FUKKM & PBKD
43.	Penicillamine 250mg Capsule	A&E (stock)	Heavy Metal Poisoning	Import permit
44.	Phenylephrine HCl 10 mg / ml Injection	ANAES (stock)	For treatment of hypotension during anaesthesia	Import permit; Not in FUKKM
45.	Physostigmine 2mg / 5ml Injection	A&E (stock)	Anticholinergic Toxicity/Poisoning	Import permit; Not in FUKKM
46.	Primidone 250 mg Tablet	MED (patient)	Essential Tremor	Import permit; Not in FUKKM
47.	Purified King Cobra Antivenom 8mg / 10ml Inj	A&E (stock)	Antidote for king cobra envenomation (life threatening condition)	Pengecualian UKK
48.	Pyrimethamine 25mg Tab	MED (stock)	Toxoplasmosis	Import permit; Not in FUKKM

No.	Generic Name	Department	Indication	Remarks
49.	Pyridoxine 100mg /2ml Injection	A&E (stock)	For the indication of isoniazid poisoning, ethylene glycol poisoning, tetramine poisoning, gyromitrin poisoning, ginkgo biloba seed toxicity	Import permit; Not in FUKKM
50.	Remdesivir 100mg Inj (Veklury)	PAED (stock)	For treatment of covid-19 in paediatric patients who are hospitalized or not hospitalized	Not in FUKKM
51.	Risperidone 1 mg Tablet	PAED (patient)	Tourette's Syndrome	Off Label FUKKM & PBKD
52.	Sildenafil Citrate 50 mg Tablet	ANAES /MED/ PAED (stock)	Pulmonary hypertension	Not in FUKKM; Off Label PBKD
53.	Sildenafil Citrate 50 mg Tablet	Rehab	Erectile Dysfunction	Not in FUKKM;
54.	Sirolimus 1mg Tablet	PAED (patient)	Kaposiform Hemangioma Endothelioma	Not in FUKKM; Off Label PBKD
55.	Sirolimus 1mg / ml Oral Solution	PAED (patient)	Kaposiform Hemangioma Endothelioma	Import permit; Not in FUKKM, Off Label
56.	Sodium Tetradecyl Sulphate 3% Injection	DENTAL (stock)	As per FUKKM	Import permit
57.	Tamoxifen 20mg Tablet	MED (patient)	Sclerosing Peritonitis	Off label FUKKM & PBKD
58.	Teriparatide 250mcg / ml Injection	ORTHO (patient-pesara)	Osteoporosis	Not in FUKKM
59.	Thiamine HCl 100 mg / ml Injection	A&E (stock)	Alcohol withdrawal syndrome	Import permit; Off label FUKKM & PBKD
60.	Thiamine HCl 100 mg / ml Injection	ANAES (stock)	Severe sepsis/ septic shock	Import permit; Off label FUKKM & PBKD
61.	Urokinase 60,000 IU Injection	MED (stock)	Clotted arterio-venous shunts	Import permit; Not in FUKKM
62.	Urokinase 60,000 IU Injection	PAED (stock)	Thoracic empyema	Import permit; Not in FUKKM
63.	Vitamin D Cholecalciferol 1000 IU Tab	MED (patient) PAED (patient)	Vitamin D deficiency	Not in FUKKM
64.	Venetoclax 100 mg Tablet	MED-Hemato (patient)	Acute myeloid leukemia (AML)	Not in FUKKM
65.	Zinc Gluconate 50mg (Elemental Zinc 7 mg) Tablet	PAED (patient)	Malnutrition due to zinc deficiency	Not in FUKKM

Hospital Formulary (UKK Items Applied by others) Hospital Duchess of Kent, Sandakan

No.	Generic Name	Department	Indication	Remarks
1.	Acyclovir 3% Eye Ointment	SRQ OPHTH	As per FUKKM	Stock basis; Import permit (UKK CFLN)
2.	Antirabies Immunoglobulin (equine) 300 IU/ ml injection (upon request in HQE)	Standard	As per FUKKM	Stock basis; Import permit (UKK CFLN)

No.	Generic Name	Department	Indication	Remarks
3.	Box Jellyfish 20000 IU Antivenom	SRQ A&E	Treatment of patient who exhibit manifestations of jellyfish envenomation	Stock basis; Not in FUKKM; Import permit (UKK CFLN)
4.	Caffeine Anhydrous USP 500g Powder	SRQ PAED	For apnea of prematurity	Stock basis; Not in FUKKM; Import permit (Hospital Lahad Datu)
5.	Chloral Hydrate 500 mg / 5 ml Suspension	Standard	As per FUKKM	Stock basis; Import permit (UKK CFLN)
6.	Chloroquine Phosphate 250 mg Tablet	Standard	As per FUKKM	Stock basis; Import permit (UKK CFLN)
7.	Diphtheria Antitoxin 100,000 IU Injection	Standard	As per FUKKM	Stock basis; Import permit (UKK CFLN)
8.	Fludrocortisone Acetate 0.1 mg Tablet	SRQ MED SRQ PAED	As per FUKKM	Stock basis; Import permit (UKK CFLN)
9.	Green Pit Viper Antivenom 7mg / 10ml Inj	SRQ A&E	Treatment of patients who exhibit manifestations of systemic envenomation following a bite by Green Pit Viper	Stock basis; Not in FUKKM; Import permit (UKK CFLN)
10.	Isoprenaline HCl 0.2 mg / ml Injection	SRQ GENERAL	As per FUKKM	Stock basis; Import permit (UKK CFLN)
11.	Neuropolyvalent Snake Antivenom Inj	SRQ A&E	Treatment of patients who exhibit neurological manifestations of snake envenomation	Stock basis; Not in FUKKM; Import permit (UKK CFLN)
12.	Phenobarbital 200 mg / ml Inj	Standard	As per FUKKM	Stock basis; Import permit (UKK CFLN)
13.	Rifampicin 75mg, Isoniazid 50mg & Pyrazinamide 150mg Dispersible Tablet (FDC3)	PAED (stock)	Tuberculosis in children	Import permit; Not in FUKKM (UKK CFLN)
14.	Rifampicin 75mg & Isoniazid 50mg Dispersible Tablet (FDC2)	PAED (stock)	Tuberculosis in children	Import permit; Not in FUKKM (UKK CFLN)
15.	Sulphamethoxazole 40 mg & Trimethoprim 80 mg Injection	SRQ GENERAL	As per FUKKM	Stock basis; Import permit (UKK CFLN)
16.	Testosterone Enanthate 250 mg Injection	SRQ MED	As per FUKKM	Stock basis; Import permit (UKK CFLN)
17.	Verapamil 5 mg / 2ml Injection	SRQ GENERAL	As per FUKKM	Stock basis; Import permit (UKK CFLN)
18.	Vitamin A 50,000 IU Capsule	SRQ PAED	Children with measles malnutrition and serious infection	Stock basis; Not in FUKKM; Import permit (UKK CFLN)

**Hospital Formulary (Galenic) Hospital Duchess of Kent, Sandakan
INTERNAL PREPARATION**

NO	GENERIC NAME (INTERNAL PREPARATION)
1.	Acetazolamide 25 mg/mL Oral Suspension
2.	Allopurinol 20 mg/mL Oral Suspension
3.	Amiodarone 40 mg/mL Oral Suspension
4.	Amlodipine 1 mg/mL Oral Suspension
5.	Baclofen 5 mg/mL Suspension
6.	Benzhexol 0.4 mg/mL Oral Liquid
7.	Caffeine Citrate 20mg/ml Syrup
8.	Calcitriol 0.25mcg/ml Syrup
9.	Calcium Carbonate 200mg/ml Syrup
10.	Captopril 1 mg/mL Syrup
11.	Carbidopa 1.25 mg + Levodopa 5 mg/mL Oral Suspension
12.	Carvedilol 1.67 mg/mL Oral Suspension
13.	Ciprofloxacin 50mg/ml Syrup
14.	Clobazam 1mg/ml Syrup
15.	Chloroform Water Double Strength (0.5% v/v) BP
16.	Concentrated Peppermint Emulsion BP
17.	Clonazepam 0.1 mg/mL Oral Suspension
18.	Clopidogrel 5 mg/mL Oral Suspension
19.	Clozapine 20 mg/mL Oral Suspension
20.	Cyclophosphamide 10mg/ml Oral Solution
21.	Dexamethasone 1 mg/mL Syrup
22.	Diazepam 1 mg/mL Syrup
23.	Diazoxide 10 mg/mL Oral Suspension
24.	Diltiazem 12mg/ml Syrup
25.	Enalapril 1 mg/mL Oral Suspension
26.	Ethambutol 100 mg/mL Oral Suspension
27.	Ferric Ammonium Citrate 400 mg/5 mL Mixture
28.	Fluconazole 1 mg/mL Suspension
29.	Folic Acid 5mg/5ml Syrup
30.	Gabapentin 100 mg/mL Oral Suspension
31.	Glycopyrrolate 0.1 mg/mL Syrup
32.	Hydrochlorothiazide 5 mg/mL Oral Suspension
33.	Hydrocortisone 1 mg/mL Oral Suspension
34.	Hydroxychloroquine 25 mg/mL Syrup
35.	Indomethacin 5 mg/mL Syrup
36.	Iodine 5% and Potassium Iodide 10% Solution (Lugol's Solution)
37.	Isoniazid 40 mg/mL Syrup

NO	GENERIC NAME (INTERNAL PREPARATION)
38.	Itraconazole 20mg/mL Syrup
39.	Labetalol 10 mg/mL Syrup
40.	Lamotrigine 5 mg/mL Syrup
41.	Lemon spirit BP
42.	Lemon syrup BP
43.	Liquid Paraffin (oral)
44.	Lorazepam 0.4 mg/mL Syrup
45.	Magnesium Sulphate Mixture (Mistura Alba) 2 g/5 ml (2.2 mmol/ml)
46.	Metoprolol 10 mg/mL Oral Suspension
47.	Methylcellulose 1% (0.01g/ml) Suspending Liquid
48.	Morphine HCl 10 mg/5mL Aqueous
49.	Morphine HCl 10 mg/5ml Syrup (XTEMP)
50.	Nifedipine 4 mg/mL Oral Suspension
51.	Nitrofurantoin 10mg/ml Syrup
52.	Omeprazole 2 mg/mL Oral Suspension
53.	Pantoprazole 2 mg/mL Solution
54.	Phenobarbitone 10 mg/mL Oral Suspension
55.	Phytomenadione (Vitamin K1) 1 mg/mL Liquid
56.	Potassium Chloride 500 mg/5 mL Mixture
57.	Potassium Citrate 110 mg + Sodium Citrate 100 mg + Citric Acid 68 mg/ml Syrup (Polycitra)
58.	Propranolol 5 mg/mL Oral Suspension
59.	Propylthiouracil 5mg/ml Syrup
60.	Pyrazinamide 100 mg/mL Oral Suspension
61.	Pyridostigmine 5mg/ml Syrup
62.	Reconstituted Oral Rehydration Salt for Severely Malnourished Children (ReSoMal)
63.	Rifampicin 50 mg/mL Syrup
64.	Sildenafil 2.5 mg/mL Oral Suspension
65.	Sodium Bicarbonate 84 mg/mL (8.4%) Oral Solution
66.	Sodium Chloride 1 g/5 mL (3.42 mmol/mL) (20%) Oral Solution
67.	Sodium Citrate 0.3M Solution
68.	Sodium Citrate, Citric Acid Mixture 3 g/10 ml (Shohl's Solution)
69.	Sodium Phosphate 1.2 g/10 mL (10 mmol/10 mL) Oral Liquid
70.	Spironolactone 2.5 mg/mL Oral Suspension
71.	Tacrolimus 0.5 mg/mL Oral Suspension
72.	Topiramate 6mg/ml Syrup
73.	Thiamine 20mg/ml Syrup
74.	Tramadol 5 mg/mL Oral Suspension
75.	Ursodeoxycholic 50 mg/mL Oral Suspension

**Hospital Formulary (Galenical) Hospital Duchess of Kent, Sandakan
EXTERNAL PREPARATION**

NO	GENERIC NAME (EXTERNAL PREPARATION)
1.	Alcohol 50% Solution Alcohol 70% Solution Alcohol 80% Solution
2.	Alkaline Nasal Douche
3.	Benzyl Benzoate 12.5% Lotion (PAED)
4.	Chlorhexidine 1 in 200 (0.5%) In Alcohol 70%
5.	Chlorhexidine 1 in 2000 (0.05%) in Aqueous Solution
6.	Coal Tar 1% Ointment Coal Tar 2% Ointment Coal Tar 3% Ointment Coal Tar 6% Ointment
7.	Glycerin Ear/Nasal Drops
8.	Ichthammol Glycerin 10% w/v Ear Drops
9.	Potassium Permanganate 5% Solution
10.	Sodium Bicarbonate 5% Ear Drops
11.	Sodium Bicarbonate 2% Mouthwash
12.	Sulphur 6% in Calamine Lotion

MISCELLANEOUS

NO	GENERIC NAME	REMARKS
1.	Acetic Acid 5% v/v Solution in Aqueous	Bottle of 1000ml
2.	Cetrimide 2% Lotion	Bottle of 125 ml
3.	Chlorhexidine gluconate 1% Cream	Bottle of 1000 ml
4.	Chlorhexidine Gluconate 2% in Alcohol 70% Solution	Bottle of 60 ml
5.	Chlorhexidine Gluconate 0.2% Mouthwash	Bottle of 80ml
6.	Chlorhexidine Gluconate 4% Solution	Bottle of 1000 ml and Prepack as 120 ml
7.	Formalin 10% Buffered Solution	Bottle of 2500 ml & 3800 ml
8.	Glycerin	Bottle of 5 Litres and Prepack as 120ml
9.	Hydrogen Peroxide 10 Volume (3%) Solution	Bottle of 1000ml
10.	Hydrogen Peroxide 20 Volume (6%) Solution	Bottle of 500ml
11.	Silver Nitrate Crystal	Pack of 100 g
12.	Soda Lime Granules BP/USP	Pack of 5000g
13.	Sodium Dichloroisocyanurate Tablet	Pack of 100 tab
14.	Menthol Crystal BP/USP	Prepack in pack of 15g (available in FKP and Galenikal)

SENARAI NAMA DAGANGAN UBAT YANG DILULUSKAN UNTUK KEGUNAAN DI HDOK

NO	BRAND NAME	GENERIC NAME
1.	Actifed	Triprolidine HCl 2.5 mg and Pseudoephedrine HCl 60 mg Tablet
2.	Actrapid	Insulin Recombinant Synthetic Human Short Acting 100IU/ml Penfill and Refill
3.	Akurit-4	Rifampicin 150 mg, Isoniazid 75 mg, Pyrazinamide 400 mg & Ethambutol HCl 275 mg Tablet
4.	Bactrim	Sulphamethoxazole 400 mg & Trimethoprim 80 mg Injection Sulphamethoxazole 200 mg & Trimethoprim 40 mg/5 ml Suspension Sulphamethoxazole 400 mg & Trimethoprim 80 mg Tablet
5.	Betnesol-N	Betamethasone Disodium Phosphate & Neomycin Sulphate Eye Drops
6.	Berodual	Ipratropium Bromide 20mcg and Fenoterol 50mcg/dose Inhaler
7.	Cardiprin	Acetylsalicylic Acid 100 mg, Glycine 45 mg Tablet
8.	Cerumol	Ear Wax Softener
9.	Clarinase	Loratadine 5 mg & Pseudoephedrine Sulphate 120 mg Tablet
10.	Combivent	Ipratropium Bromide 0.5 mg and Salbutamol 2.5 mg per UDV Ipratropium Bromide 20 mcg and Salbutamol base 100 mcg / dose inhalation
11.	Combivir	Zidovudine 300 mg & Lamivudine 150 mg Tablet
12.	Co-Amoxiclav	Amoxicillin 500mg and Clavulanate 125mg Tablet Amoxicillin 1g & Clavulanate 200mg Injection
13.	Cyclogyl	Cyclopentolate 1% Eye Drops
14.	Cyclomydril	Cyclopentolate 0.2% with Phenylephrine 1% Eye Drops
15.	Daflon	Diosmin 450mg and Hesperidin 50mg Tablet
16.	Duolin	Ipratropium Bromide 0.5 mg and Salbutamol 2.5 mg per UDV Ipratropium Bromide 20 mcg and Salbutamol base 100 mcg / dose inhalation
17.	Eprex	Erythropoietin Human Recombinant 2000 IU Injection (alfa)
18.	Essential	Essential Phospholipids, nicotinamide, cyanocobalamine, tocopheryl, pyridoxine, thiamine, riboflavin capsule
19.	Exforge	Amlodipine 10 mg & Valsartan 160 mg Tablet
20.	FEIBA	Factor VIII Inhibitor By passing Activity Injection
21.	Fleet	Monobasic Sodium Phosphate 48%, Dibasic Sodium Phosphate 18%
22.	Fortrans	Polyethylene Glycol/Macrogol 4000 Powder
23.	Fosamax	Alendronate Sodium 70 mg Tablet
24.	Foster	Beclomethasone dipropionate 100mcg and formoterol fumarate dihydrate 6mcg pressurized inhalation solution
25.	Genteal	Artificial tears/eye lubricant ophthalmic gel
26.	Iberet	Ferrous controlled release 525 mg, Vitamin B1, Vitamin B2, Vitamin B6, Vitamin B12, Vitamin C, Niacinamide, Calcium Pantothenate, Folic Acid 800 mcg Tablet
27.	Insulatard	Insulin Recombinant Synthetic Human, Intermediate acting 100IU/ml Penfill and Refill
28.	Isordil	Isosorbide Dinitrate 10 mg Tablet
29.	Kalimate	Calcium Polystyrene Sulphonate Powder
30.	KY Jelly	Hydroxyethyl Cellulose Jelly
31.	Lomotil	Diphenoxylate with Atropine Sulphate Tablet
32.	Madopar HBS	Levodopa 100 mg, Benserazide 25mg HBS capsule
33.	Madopar	Levodopa 200 mg, Benserazide 50mg Tablet

NO	BRAND NAME	GENERIC NAME
34.	Maxitrol	Dexamethasone and Neomycin Sulphate and Polymyxin B Eye Ointment Dexamethasone and Neomycin Sulphate and Polymyxin B Sulphate Ophthalmic Suspension
35.	Mixtard	Insulin Recombinant Synthetic Human, pre-mixed 100 IU/ml Penfill and Refill
36.	Novomix	Insulin Aspart 30% and Protaminated Insulin Aspart 70% 100 U/ml Injection
37.	Novoseven	Factor VIIa (Recombinant) eptacog alfa (activated) 50 KIU (1 mg) Injection
38.	Oxycodone IR	Oxycodone HCl 5 mg Immediate Release Capsules
39.	Oxycodone SR / Oxycontin	Oxycodone HCl 10 mg Controlled Release Tablet
40.	Parentrovite	Multivitamin Injection: Amp 1 – Vit B1, B2, B6; Amp 2 – Vit B3, Panthenol, Vit C.
41.	Penicillin V	Phenoxymethyl Penicillin 125 mg Tablet Phenoxymethyl Penicillin 125 mg/5 ml Syrup
42.	Piriton	Chlorpheniramine Maleate 10 mg/ml Injection Chlorpheniramine Maleate 2 mg/5 ml Syrup Chlorpheniramine Maleate 4 mg Tablet
43.	Recormon	Erythropoietin Human Recombinant 2000IU Injection (Beta)
44.	Regulon	Desogestrel 150 mcg & Ethinylestradiol 30 mcg Tablet
45.	Riamet	Artemether 20 mg & Lumefantrine 120 mg
46.	Seretide	Salmeterol 25 mcg and Fluticasone Propionate 125 mcg Inhalation Salmeterol 50 mcg and Fluticasone Propionate 250 mcg Inhalation Salmeterol 50 mcg and Fluticasone Propionate 500 mcg Inhalation
47.	Shohl's Solution	Sodium Citrate, Citric Acid Mixture 3 g/10 ml
48.	Sinemet	Levodopa 100 mg and Carbidopa 25 mg Tablet Levodopa 250 mg and Carbidopa 25 mg Tablet
49.	Slow K	Potassium Chloride 600mg SR Tablet
50.	Solu wax	Ear Wax Softener
51.	Spiolto Respimat	Tiotropium 2.5mcg and Olodaterol 2.5mcg per actuation, inhalation
52.	Sulperazone	Cefoperazone Sodium 500 mg & Sulbactam Sodium 500 mg Injection
53.	Survanta	Beractant Intratracheal Suspension (200 mg phospholipids in 8 ml vial)
54.	Symbicort	Budesonide 160 mcg and Formoterol 4.5 mcg Inhalation
55.	Tazocin	Piperacillin 4 g & Tazobactam 500 mg Injection
56.	Timo-Comod	Timolol Maleate 0.5% Eye Drops
57.	Ural	Sodium Bicarbonate, Citric Acid, Sodium Citrate and Tartaric Acid - 4 g per sachet
58.	Ultibro	Indacaterol Maleate 110mcg & Glycopyrronium Bromide 50mcg inhalation powder hard capsules

Amendments on HDOK Drug Formulary 02/2023

No.	Generic name	Amendments	Remarks
1.	Amino Acids, Glucose and Lipid with Electrolytes Injection (SMOFKabiven, Peripheral, 1.5 L)	Added	SRQ SURG (as per pre-JKUT & JKUT 02.23)
2.	Acetylcysteine 600mg Tablet	Added	SRQ REHAB (as per pre-JKUT & JKUT 02.23)
3.	Beclomethasone dipropionate 100mcg and formoterol fumarate dihydrate 6mcg pressurized inhalation solution (Foster)	Added	SRQ MED (as per pre-JKUT & JKUT 02.23)
4.	Ceftriaxone 0.5g Injection	Amended	Change in the prescriber category from A to A/KK
5.	Cefazolin Sodium 1 g Injection	Added	SRQ PAED & SRQ O&G (as per pre-JKUT & JKUT 02.23)
6.	Ceftazidime 2g/Avibactam 0.5g Injection	Added	Listed in FUKKM per Pindaan FUKKM Bil 02.2023
7.	Cisatracurium Besylate 2 mg/ml Injection	Removed	SRQ ANAES (as per pre-JKUT & JKUT 02.23)
8.	Dapagliflozin 10mg Tablet	Added	SRQ MED (as per pre-JKUT & JKUT 02.23)
9.	Desmopressin 60mcg Sublingual Tablet	Added	SRQ MED & PAED (as per pre-JKUT & JKUT 02.23)
10.	Desvenlafaxine Succinate 50 mg Extended Release Tablet Nervous System	Added	SRQ PSY (as per pre-JKUT & JKUT 02.23)
11.	Enoxaparin Sodium 40mg & 60mg Injection	Amended	Streamlined dosages as per pindaan FUKKM Bil 02.2023
12.	Fentanyl 12mcg/h Transdermal Patch	Added	SRQ Palliative (as per pre-JKUT & JKUT 02.23)
13.	Fentanyl 25 mcg/h Transdermal Patch	Added	SRQ Palliative (as per pre-JKUT & JKUT 02.23)
14.	Gabapentin 100 mg Tablet	Added	SRQ REHAB (as per pre-JKUT & JKUT 02.23)
15.	Gabapentin 100 mg Tablet	Added	SRQ Palliative (as per pre-JKUT & JKUT 02.23)
16.	Glycine 1.5% Irrigation Solution	Added	SRQ SURG (as per pre-JKUT & JKUT 02.23)
17.	Human Normal Globulin Injection (IVIG)	Amended	Streamlined indication and dosage as per pindaan FUKKM Bil 02.2023
18.	Ketoprofen 30 mg Transdermal Plaster	Added	SRQ Palliative (as per pre-JKUT & JKUT 02.23)
19.	Lignocaine (Lidocaine) 2% Viscous Solution	Added	SRQ Palliative (as per pre-JKUT & JKUT 02.23)
20.	Medroxyprogesterone Acetate 100 mg Tablet	Added	SRQ O&G (as per pre-JKUT & JKUT 02.23)
21.	Mesalazine 500mg MR Tablet	Amended	Streamlined dosages as per pindaan FUKKM Bil 02.2023
22.	Morphine Sulphate 10mg Prolonged Release Tablet	Added	SRQ Palliative (as per pre-JKUT & JKUT 02.23)
23.	Morphine Sulphate 30mg Prolonged Release Tablet	Added	SRQ Palliative (as per pre-JKUT & JKUT 02.23)
24.	Oral Rehydration Salts	Amended	Streamlined dosages as per pindaan FUKKM Bil 02.2023
25.	Oxycodone HCl 10mg Immediate Release Capsules	Added	SRQ Palliative (as per pre-JKUT & JKUT 02.23)
26.	Oxycodone HCl 5mg Immediate Release Capsules	Added	SRQ Palliative (as per pre-JKUT & JKUT 02.23)
27.	Oxycodone Hydrochloride 10mg Controlled Release Tablet	Added	SRQ Palliative (as per pre-JKUT & JKUT 02.23)
28.	Oxycodone Hydrochloride 20mg Controlled Release Tablet	Added	SRQ Palliative (as per pre-JKUT & JKUT 02.23)
29.	Peritoneal Dialysis Solution (1.5% Dextrose)	Added	SRQ PAED (as per pre-JKUT & JKUT 02.23)
30.	Primaquine 7.5mg base Tablet	Amended	Streamlined dosages as per pindaan FUKKM Bil 01.23

No.	Generic name	Amendments	Remarks
31.	Pregabalin 150 mg Capsules	Added	SRQ Palliative (as per pre-JKUT & JKUT 02.23)
32.	Tetanus Toxoid Vaccine Injection	Amended	Streamlined generic name as per pindaan FUKKM Bil 01.23
33.	Tamsulosin HCl 400 mcg Extended Release Tablet	Added	SRQ SURG (as per pre-JKUT & JKUT 02.23)
34.	Rosuvastatin 20mg Tablet	Added	SRQ MED (as per pre-JKUT & JKUT 02.23)
35.	Sodium Dichloroisocyanurate Tablet	Amended	Streamlined generic name as per pindaan FUKKM Bil 03.22
36.	Sodium glycerophosphate for addition into infusion solution, 20ml vial	Added	SRQ GENERAL (as per pre-JKUT & JKUT 02.23)
37.	Tiotropium 2.5mcg and Olodaterol 2.5mcg per actuation, inhalation (Spiolto Respimat)	Added	SRQ MED (as per pre-JKUT & JKUT 02.23)
38.	Vasopressin 20 units/ml Injection	Added	SRQ O&G (as per pre-JKUT & JKUT 02.23)

Amendments on UKK List (applied by HDOK)

No.	Generic name	Amendments	Remarks
1.	Atomoxetine HCl 10mg Cap	Added	UKK PSY (as per JKUT 02.23)
2.	Atomoxetine HCl 25mg Cap	Added	UKK PSY (as per JKUT 02.23)
3.	Atomoxetine HCl 40mg Cap	Added	UKK PSY (as per JKUT 02.23)
4.	Baclofen 5mg/ml Oral Suspension	Added	UKK STANDARD (as per JKUT 02.23)
5.	Cholecalciferol (Vitamin D3) 1000 IU Cap	Added	UKK PAED (as per PAED pre-jkut 02.23 & JKUT 02.23)
6.	L-Carnitine 500mg/10ml Oral Solution	Added	UKK PAED (as per PAED pre-jkut 02.23 & JKUT 02.23)
7.	Mercaptopurine 50mg Tab	Added	UKK STANDARD (as per JKUT 02.23)
8.	Iodine and Potassium Iodide Solution (Lugol's Solution)	Added	UKK STANDARD (as per JKUT 02.23)
9.	Oxybutynin Chloride 5mg Tablet	Added	UKK REHAB (as per REHAB pre-Jkut 02.23 & JKUT 02.23)
10.	Pamidronate Disodium 90mg Inj	Removed	UKK MED (as per MED pre-jkut 02.23 & JKUT 02.23)
11.	Risperidone 1 mg Tablet	Added	UKK PAED (as per PAED pre-Jkut 02.23 & JKUT 02.23)
12.	Venetoclax 100mg Tablet	Added	UKK MED (as per MED pre-Jkut 02.23 & JKUT 02.23)

List of Medicines With Porcine Origins in Hospital Duchess of Kent, Sandakan

No.	Generic Name	Brand Name	Source
1.	Enoxaparin Sodium 40mg/0.4mL Inj	Clexane, Sanofi	Porcine origin
2.	Enoxaparin Sodium 60mg/0.6mL Inj	Clexane, Sanofi	Porcine origin
3.	Factor IX, Factor II, Factor VII & factor X in combination 500IU/vial Inj	Octaplex, Octapharma	Contains substance of porcine source
4.	Pancreatin 150mg Cap	Creon, Abbott	Contains porcine pancreatin formulated as enteric-coated (acid-resistant) minimicrospheres within gelatine capsules

List of Medicines With Bovine Origins in Hospital Duchess of Kent, Sandakan

No.	Generic Name	Brand Name	Source
1.	Ampicillin Sodium + Sulbactam Sodium 375mg Tab	Unasyn, Pfizer	Excipient: Lactose hydrate (bovine milk) and magnesium stearate (tallow oil)
2.	Calcitriol 0.25mcg Cap	Osteocap, Mega Lifesciences	Source of capsule: Gelatin (Bovine)
3.	Ciclosporin 25mg Cap Microemulsion	Sandimmun Neoral®, Novartis	Source of capsule: Gelatin (Bovine)
4.	Ciclosporin 100mg Cap Microemulsion	Sandimmun Neoral®, Novartis	Source of capsule: Gelatin (Bovine)
5.	Cloxacillin Sodium 500mg Capsule	Cloxacap 500, Hovid	Source of capsule: Gelatin (Bovine)
6.	Clindamycin HCl 300mg Cap	Tidact®, Y.S.P	Source of capsule: Gelatin (Bovine)
7.	Dexamethasone 4mg Tab	Vextasone 4mg Tablet. Y.S.P. Industries (M)	Bovine
8.	Doxycycline 100mg Cap	Doxycycline, Pharmaniaga	Source of capsule shell: Gelatin (Bovine)
9.	Dutasteride 0.5m Cap	Avodart, GlaxoSmithKline	Source of capsule: Gelatin (Bovine)
10.	Duloxetine 30mg Cap	Cymbalta, Lilly Del	Source of capsule: Gelatin (Bovine)
11.	Essential Phospholipids, nicotinamide, cyanocobalamine, tocopheryl, pyridoxine, thiamine, riboflavine capsuleCap	Livovid, Hovid	Source of capsule: Gelatin (Bovine)
12.	Fluconazole 100mg Cap	Fluconazole, Pharmaniaga	Source of capsule: Gelatin (Bovine)
13.	Gabapentin 300mg Cap	Gabapin, Intas Pharmaceuticals Ltd	Source of capsule shell : Bovine
14.	Gemfibrozil 300mg Cap	Gemfibrozil, Pharmaniaga	Source of capsule shell : Bovine
15.	Hydrocortisone 10mg Tab	Hydrocortison Orion, Orion Pharma	Lactose (Calf rennet)
16.	Hydroxyurea 500mg Cap	DHNP Hydroxyurea Daehan New Pharma	Source of capsule: Bovine
17.	Indomethacin 25mg Cap	Indecin, Dynapharm	Source of capsule: Gelatin (Bovine)
18.	Itraconazole 100mg Cap	Itrazol, Noripharma	Source of capsule: Gelatin (Bovine)
19.	Itraconazole 100mg Cap	Inox, Hovid	Source of capsule: Gelatin (Bovine)
20.	Levodopa 100mg + Benserazide 25mg HBS Cap	Madopar Roche HBS Capsule	Contains materials of bovine origin
21.	Methotrexate 2.5mg Tab	PFZ, Methotrexate, Excella GmbH & Co	Excipient of bovine origin: Lactose Monohydrate
22.	Mycophenolate Mofetil 250mg Cap	Cellcept, Roche	Contains materials of bovine origin
23.	Mycophenolate Mofetil 250mg Cap	Mycofit 250, Intas Pharmaceuticals	Source of capsule shell: Bovine
24.	Mycophenolate Mofetil 500mg Cap	Cellcept, Roche	Source of capsule shell: Gelatin (Bovine)
25.	Omeprazole 20mg Cap	Ometac 20 Capsules, Noripharma	Source of capsule: Gelatin (Bovine)
26.	Oxycodone HCl 5mg Immediate Released Cap	Oxynorm, Mundipharma, UK	Source of capsule shell: Gelatin (Bovine)
27.	Phenytoin Sodium 30mg Cap	Dilantin, Pfizer	Source of capsule: Gelatin (Bovine)
28.	Phenytoin Sodium 100mg Cap	Dilantin, Pfizer	Source of capsule: Gelatin (Bovine)
29.	Pregabalin 50mg Cap	Novugab Pregabalin,	Source of capsule: Gelatin (Bovine)
30.	Pregabalin 75mg Cap	Novugab Pregabalin,	Source of capsule: Gelatin (Bovine)
31.	Pregabalin 150mg Cap	Novugab Pregabalin,	Source of capsule: Gelatin (Bovine)
32.	Rifampicin 150mg Cap	Rifampicin, Royce Pharma Mfg.Sdn.Bhd	Source of capsule: Gelatin (Bovine)
33.	Rifampicin 300mg Cap	Rifampicin, Royce Pharma Mfg.Sdn.Bhd	Source of capsule: Gelatin (Bovine)

34.	Rivastigmine 1.5mg Cap	Rivadem, Torrent	Source of capsule: Gelatin (Bovine)
35.	Rivastigmine 3mg Cap	Rivadem, Torrent	Source of capsule: Gelatin (Bovine)
36.	Tacrolimus 0.5mg Cap	Prograf, Astellas Ireland Co.	Source of capsule: Gelatin (Bovine)
37.	Tacrolimus 1mg Cap	Prograf, Astellas Ireland Co.	Source of capsule: Gelatin (Bovine)
38.	Tramadol HCl 50mg Cap	Acugesic, Duopharma	Source of hard capsule: Gelatin (Bovine)
39.	Heparin Sodium Inj (50U)	Heparinol, Ain Medicare	Bovine
40.	Heparin Sodium Inj (1000U/ml & 5000U/ml)	Heparinol, Ain Medicare	Bovine
41.	Heparin Sodium 5000U/ml	Unihepa, Duopharma(M) Sdn.Bhd	Contains bovine mucosa
42.	Modified Fluid Gelatin 4% Injection	Infusol SG, Ain Medicare	Succinylated gelatin (Bovine)

List of Medicines With Other Animal Origins in Hospital Duchess of Kent, Sandakan

No.	Generic Name	Brand Name	Source
1.	Antivene Serum (Sea Snake) 1000 units Injection	Sea Snake Antivenin, Seqirus Pty Ltd	Plasma protein of equine (horse) origin.
2.	Antivene Serum Cobra Injection	Cobra Antivenin, Queen Saovabha, Thailand	Purified equine (horse) immunoglobulin
3.	Antivene King Cobra 0.8mg/mL Injection	King Cobra Antivenin, Queen Saovabha, Thailand	Purified equine (horse) immunoglobulin
4.	Antivene Green Pit Viper 0.7mg/mL Injection	Green Pit Viper 0.7mg/mL Antivenin, Queen Saovabha, Thailand	Purified equine (horse) immunoglobulin
5.	Conjugated Oestrogen 0.625mg Tab	Premarin, Pfizer, Ireland.	Active ingredient derived from pregnant mare's urine
6.	Denosumab in 1.0 mL solution (60 mg/mL) Pre-filled syringe (subcutaneous injection)	Prolio, Amgen	Human monoclonal IgG2 antibody produced in a mammalian cell line (Chinese hamster ovary cells) by recombinant DNA technology
7.	Idarucizumab 2.5g/50ml solution for Injection	Praxbind, Boehringer Ingelheim	Produced by recombinant DNA technology in Chinese Hamster Ovary cells
8.	Amino Acids, Glucose and Lipid with Electrolytes Injection (Kabiven, Peripheral, 1.5L)	Kabiven® Peripheral 1.5L Infusion Bag, Fresenius Kabi	Egg phospholipids
9.	Amino Acids, Glucose and Lipid with Electrolytes Injection (SMOFKabiven, Central, 1.5L)	SmofKabiven Emulsion for Infusion, Fresenius Kabi	Contains egg phospholipids and fish oil
10.	Fat Emulsion 20% for IV Infusion (Intralipid)	Intralipid 20%, Fresenius Kabi	Purified egg phospholipids,
11.	Propofol 1% (10mg/mL)	Propofol –Lipuro 1% (10mg/ml), B.Braun Melsungen AG	Excipients: contain egg lecithin
12.	Hydrocortisone 10mg Tab	Hydrocortison Orion, Orion Pharma	Contains fish gelatin
13.	Levothyroxine Sodium 50mcg & 100mcg Tablet	Euthyrox, Merck	Fish oil gelatin
14.	Factor VIIa (Recombinant) Eptacog Alfa (Activated) 50 KIU (1mg) Inj	NovoSeven, Novo Nordisk	Baby hamster kidney cells (BHK Cells) by recombinant DNA technology.
15.	Rabies Human Diploid Cell Vaccine Inj	Verorab, Sanofi Pasteur	Inactivated rabies virus strain produced in VERO cells.

HOSPITAL ANTI INFECTIVES FORMULARY

A1) ANTIBIOTIC (INJECTION)

- 1) Amikacin 125 mg/ml Injection
- 2) Amikacin 250 mg/ml Injection
- 3) Amoxicillin 1g & Clavulanate 200mg Injection
- 4) Ampicillin Sodium 500mg Injection
- 5) Ampicillin Sodium 1g & Sulbactam Sodium 500mg Injection
- 6) Azithromycin 500mg Injection
- 7) Benzathine Penicillin 2.4 MIU (1.8 g) Injection
- 8) Benzylpenicillin 1 mega unit (600mg) Injection
- 9) Benzylpenicillin 5 mega unit (3g) Injection
- 10) Cefazolin 1g Injection
- 11) Cefepime 1g Injection
- 12) Cefoperazone Sodium 1g Injection
- 13) Cefoperazone Sodium 500mg & Sulbactam Sodium 500mg Injection
- 14) Cefotaxime 500mg Injection
- 15) Cefotaxime 1g Injection
- 16) Ceftazidime 2g Injection
- 17) Ceftazidime 2g / Avibactam 0.5g Injection
- 18) Ceftriaxone 250mg Injection
- 19) Ceftriaxone 1g Injection
- 20) Cefuroxime Sodium 750mg Injection
- 21) Cefuroxime Sodium 1.5g Injection
- 22) Ciprofloxacin 200mg/100ml Injection
- 23) Clindamycin Phosphate 150mg/ml Injection
- 24) Cloxacillin Sodium 250mg Injection
- 25) Cloxacillin Sodium 500mg Injection
- 26) Colistimethate Sodium (Polymyxin E) 1 million IU per vial Injection
- 27) Erythromycin Lactobionate 500mg Injection
- 28) Gentamicin Sulphate 40mg/ml Injection
- 29) Imipenem 500 mg and Cilastatin 500mg Injection
- 30) Kanamycin 1g Injection
- 31) Meropenem 500mg Injection
- 32) Meropenem 1g Injection
- 33) Metronidazole 500mg/100ml Injection
- 34) Piperacillin 4g & Tazobactam 500mg Injection
- 35) Streptomycin Sulphate 1g Injection
- 36) Sulphamethoxazole 400mg & Trimethoprim 80mg Injection
- 37) Vancomycin HCl 500mg Injection

A2) ANTIBIOTIC (ORAL - CAPSULE/TABLET)

- 1) Amoxicillin 500mg Capsule
- 2) Amoxicillin 500mg & Clavulanate 125mg Tablet
- 3) Ampicillin Sodium & Sulbactam Sodium 375mg Tablet
- 4) Azithromycin 250mg Tablet
- 5) Cefuroxime Axetil 125mg Tablet
- 6) Cephalexin Monohydrate 250mg Capsule
- 7) Ciprofloxacin 250mg Tablet

- 8) Clarithromycin 250mg Tablet
- 9) Clindamycin HCl 300mg Capsule
- 10) Clofazimine 100mg Capsule
- 11) Cloxacillin 500mg Capsule
- 12) Dapsone 100mg Capsule
- 13) Doxycycline 100mg Capsule
- 14) Erythromycin Ethylsuccinate 400mg Tablet
- 15) Ethambutol HCl 400mg Tablet
- 16) Ethionamide 250mg Tablet
- 17) Isoniazid 100 mg Tablet
- 18) Isoniazid 400 mg Tablet
- 19) Levofloxacin 500mg Tablet
- 20) Metronidazole 200mg Tablet
- 21) Nitrofurantoin 100mg Tablet
- 22) Ofloxacin 100mg Tablet
- 23) Pyrazinamide 500mg Tablet
- 24) Phenoxymethyl Penicillin 125mg Tablet
- 25) Rifampicin 150 mg Capsule
- 26) Rifampicin 300 mg Capsule
- 27) Rifampicin 150mg, Isoniazid 75mg, Pyrazinamide 400mg & Ethambutol 275 mg Tablet
- 28) Rifampicin, Dapsone & Clofazimine Tablet
- 29) Rifampicin 75mg, Isoniazid 50mg & Pyrazinamide 150mg Dispersible Tablet (FDC3)
- 30) Rifampicin 75mg & Isoniazid 50mg Dispersible Tablet (FDC2)
- 31) Sodium Fusidate 250mg Tablet
- 32) Sulphamethoxazole 400mg & Trimethoprim 80mg Tablet

A3) ANTIBIOTIC (ORAL - SOLUTION)

- 1) Amoxicillin Trihydrate 125mg/5ml Syrup
- 2) Amoxicillin & Clavulanate 228mg/5ml
- 3) Ampicillin Trihydrate 125mg/5 ml Suspension
- 4) Ampicillin Sodium & Sulbactam Sodium 250 mg/5ml Suspension
- 5) Azithromycin 200mg/5 ml Granules
- 6) Cefuroxime Axetil 125mg/5ml Syrup
- 7) Cephalexin Monohydrate 125mg/5ml Syrup
- 8) Ciprofloxacin 50mg/ml Syrup
- 9) Cloxacillin 125mg/5ml Syrup
- 10) Erythromycin Ethylsuccinate 200 mg/5 ml Suspension
- 11) Ethambutol 100mg/ml Oral Suspension
- 12) Isoniazid 40mg/ml Syrup
- 13) Metronidazole 200mg/5ml Syrup
- 14) Nitrofurantoin 10mg/ml Syrup
- 15) Phenoxymethyl Penicillin 125mg/5ml Syrup
- 16) Pyrazinamide 100mg/ml Oral Suspension
- 17) Rifampicin 50mg/ml Syrup
- 18) Sulphamethoxazole 200mg & Trimethoprim 40mg/5ml Suspension

A4) ANTIBIOTIC (LOCAL APPLICATION)

- 1) Betamethasone Disodium Phosphate and Neomycin Sulphate 0.5% Ear/Eye Drops
- 2) Chloramphenicol 0.5% Eye Drops
- 3) Chloramphenicol 1% Eye Ointment
- 4) Chloramphenicol 5% w/v Ear Drops
- 5) Ciprofloxacin HCl 0.3% Ophthalmic Solution
- 6) Dexamethasone and Neomycin Sulphate and Polymyxin B Eye Ointment
- 7) Dexamethasone and Neomycin Sulphate and Polymyxin B Sulphate Ophthalmic Suspension
- 8) Fusidic Acid 1% Eye drops
- 9) Gentamicin 0.1% Cream
- 10) Gentamicin 0.3% Eye Drops
- 11) Gentamicin 0.3% Eye Ointment
- 12) Moxifloxacin 0.5% Ophthalmic Solution
- 13) Mupirocin 2% Ointment
- 14) Neomycin 0.5% Cream
- 15) Ofloxacin 0.3% Otic Solution
- 16) Polymyxin B Sulphate 10,000 U, Neomycin Sulphate 5 mg & Hydrocortisone 10mg Ear Drops
- 17) Silver Sulfadiazine 1% Cream
- 18) Sodium Fusidate 2% Ointment

B1) ANTIFUNGAL (INJECTION)

- 1) Amphotericin B 50mg Injection
- 2) Anidulafungin 100mg Injection
- 3) Fluconazole 100mg/50ml Injection

B2) ANTIFUNGAL (ORAL - CAPSULE/TABLET)

- 1) Fluconazole 50mg Capsule
- 2) Fluconazole 100mg Capsule
- 3) Griseofulvin (Ultramicrosize 125 mg = 250 mg Microsize) Tablet
- 4) Itraconazole 100mg Capsule

B3) ANTIFUNGAL (ORAL - SOLUTION)

- 1) Fluconazole 1mg/ml Suspension
- 2) Nystatin 100,000 units/ml Suspension

B4) ANTIFUNGAL (LOCAL APPLICATION)

- 1) Benzoic Acid Compound Ointment
- 2) Clotrimazole 1% Cream
- 3) Clotrimazole 1% Ear Drop
- 4) Clotrimazole 500mg Vaginal Tablet
- 5) Ketoconazole 2% Shampoo
- 6) Miconazole 2% Cream

C1) ANTIMALARIAL (INJECTION)

- 1) Artesunate 60mg Injection

C2) ANTIMALARIAL (ORAL - CAPSULE/TABLET)

- 1) Artemether 20 mg + Lumefantrine 120mg Tablet
- 2) Chloroquine Phosphate 250 mg Tablet (150 mg Chloroquine base)
- 3) Primaquine 7.5 mg Base Tablet

D1) ANTIPARASITIC (ORAL - CAPSULE/TABLET)

- 1) Albendazole 200mg Tablet
- 2) Pyrimethamine 25mg Tablet

D2) ANTIPARASITIC (ORAL - SOLUTION)

- 1) Albendazole 200mg/5ml Suspension

D3) ANTIPARASITIC (LOCAL APPLICATION)

- 1) Benzyl Benzoate 12.5% Emulsion (Children)
- 2) Benzyl Benzoate 25% Emulsion (Adult)
- 3) Permethrin 1% w/v Lotion
- 4) Permethrin 5% w/v Lotion

E1) ANTIRETROVIRAL (INJECTION)

- 1) Zidovudine 200mg Injection

E2) ANTIRETROVIRAL (ORAL - CAPSULE/TABLET)

- 1) Dolutegravir 50mg Tablet
- 2) Efavirenz 200mg Capsule/Tablet
- 3) Efavirenz 600mg Tablet
- 4) Lopinavir 200mg and Ritonavir 50mg Tablet
- 1) Raltegravir 400mg Tablet
- 2) Tenofovir Disoproxil Fumarate 300mg & Emtricitabine 200mg Tablet
- 3) Zidovudine 300mg & Lamivudine 150mg Tablet

E3) ANTIRETROVIRAL (ORAL - SOLUTION)

- 1) Lamivudine 10mg/ml Oral Solution
- 2) Lopinavir 80mg/Ritonavir 20mg (per ml) Oral Solution
- 3) Nevirapine 50mg/5ml Oral Suspension
- 4) Zidovudine 10 mg/ml Syrup

F) ANTIVENOM (INJECTION)

- 1) Antivenene Cobra Injection
- 2) Antivenene Serum (Sea snake) 1000 units Injection
- 3) Box Jellyfish 20000 IU Antivenom
- 4) Green Pit Viper Antivenom 7mg/10ml Injection
- 5) Neuropolyvalent Snake Antivenom Injection

G1) ANTIVIRAL (INJECTION)

- 1) Acyclovir 250mg Injection
- 2) Remdesivir 100mg Injection

G2) ANTIVIRAL (ORAL - CAPSULE/TABLET)

- 4) Acyclovir 200mg Tablet
- 5) Acyclovir 800mg Tablet
- 6) Entecavir 500mg Tablet
- 7) Oseltamivir 75mg Capsule
- 8) Tenofovir Disoproxil Fumarate 300mg Tablet

G3) ANTIVIRAL (ORAL - SOLUTION)

- 1) Oseltamivir 60mg/5 ml oral suspension

G4) ANTIVIRAL (LOCAL APPLICATION)

- 1) Acyclovir 3% Eye Ointment

H) VACCINES (INJECTION)

- 1) Antirabies Immunoglobulin (equine) 300 IU/ml injection
- 2) BCG Vaccine Freeze-Dried Injection
- 3) Diphtheria antitoxin 100,000 IU Injection
- 4) Haemophilus Influenza Type B Conjugate Vaccine Injection
- 5) Hepatitis B Immunoglobulin (Human) Injection
- 6) Hepatitis B 10mcg HbsAg Vaccine (Paediatric)
- 7) Hepatitis B 20mcg HbsAg Vaccine (Adult)
- 8) Meningococcal A,C,Y,W-135 Vaccine Injection
- 9) Pneumococcal Vaccine (Polyvalent) (Pneumo 23)
- 10) Rabies Vaccine Injection
- 11) Tetanus Immunoglobulin Human 250 Unit/Vial Injection
- 12) Tetanus Toxoid Injection
- 13) Typhoid Vaccine Injection

I) OTHERS : ANTISEPTICS & DISINFECTANTS

- 1) Acetic Acid 5% v/v Solution in Aqueous
- 2) Acriflavine 0.1% Lotion
- 3) Alcohol 50% Solution
- 4) Alcohol 70% Solution
- 5) Alcohol 80% Solution
- 6) Alcohol 80% + Hydrogen Peroxide + Glycerol Handrub Solution
- 7) Cetrimide 2% Lotion
- 8) Chlorhexidine 1 in 200 (0.5%) In Alcohol 70%
- 9) Chlorhexidine 1 in 2000 (0.05%) in Aqueous Solution
- 10) Chlorhexidine Gluconate 0.2% Mouthwash
- 11) Chlorhexidine Gluconate 1% cream
- 12) Chlorhexidine Gluconate 2% in Alcohol 70% Solution
- 13) Chlorhexidine Gluconate 4% Scrub
- 14) Chlorhexidine Gluconate 5% Solution
- 15) Glutaraldehyde Solution 2%
- 16) Hydrogen Peroxide 5 volume (1.5%) mouthwash
- 17) Hydrogen Peroxide 10 Volume (3%) Solution
- 18) Hydrogen Peroxide 20 Volume (6%) Solution
- 19) Povidone Iodine 10% (equivalent to 1% iodine) Solution
- 20) Sodium Dichloroisocyanurate Tablet

List of Standard, Conditional and Restricted Antibiotics

STANDARD	
Antibiotics that can be prescribed by any category of prescriber	
1. Ampicillin Sodium 500mg Injection 2. Benzathine Penicillin 2.4 MIU (1.8 g) Injection 3. Benzylpenicillin 1 mega unit (600mg) Injection 4. Benzylpenicillin 5 mega unit (3g) Injection 5. Cloxacillin Sodium 250mg Injection 6. Cloxacillin Sodium 500mg Injection 7. Gentamicin Sulphate 40mg/ml Injection 8. Streptomycin Sulphate 1g Injection 9. Amoxicillin 500mg Capsule 10. Cephalexin Monohydrate 250mg Capsule 11. Clofazimine 100mg Capsule 12. Cloxacillin 500mg Capsule 13. Dapsone 100mg Capsule 14. Doxycycline 100mg Capsule 15. Erythromycin Ethylsuccinate 400mg Tablet 16. Ethambutol HCl 400mg Tablet 17. Isoniazid 100 mg Tablet 18. Isoniazid 400 mg Tablet 19. Metronidazole 200mg Tablet 20. Nitrofurantoin 100mg Tablet 21. Pyrazinamide 500mg Tablet 22. Phenoxymethyl Penicillin 125mg Tablet 23. Rifampicin 150 mg Capsule 24. Rifampicin 300 mg Capsule 25. Rifampicin 150mg, Isoniazid 75mg, Pyrazinamide 400mg & Ethambutol 275 mg Tablet	26. Rifampicin, Dapsone & Clofazimine Tablet 27. Rifampicin 75mg, Isoniazid 50mg & Pyrazinamide 150mg Dispersible Tablet (FDC3) 28. Rifampicin 75mg & Isoniazid 50mg Dispersible Tablet (FDC2) 29. Sulphamethoxazole 400mg & Trimethoprim 80mg Tablet 30. Amoxicillin Trihydrate 125mg/5ml Syrup 31. Ampicillin Trihydrate 125mg/5 ml Suspension 32. Ampicillin Sodium & Sulbactam Sodium 250 mg/5ml Suspension 33. Cephalexin Monohydrate 125mg/5ml Syrup 34. Cloxacillin 125mg/5ml Syrup 35. Erythromycin Ethylsuccinate 200 mg/5 ml Suspension 36. Ethambutol 100mg/ml Oral Suspension 37. Isoniazid 50mg/ml Syrup 38. Metronidazole 200mg/5ml Syrup 39. Nitrofurantoin 10mg/ml Syrup 40. Phenoxymethyl Penicillin 125mg/5ml Syrup 41. Pyrazinamide 100mg/ml Oral Suspension 42. Rifampicin 50mg/ml Syrup 43. Sulphamethoxazole 200mg & Trimethoprim 40mg/5ml Suspension

CONDITIONAL

Antibiotics that require specialist's authorization (A*, A, A/KK)

- | | |
|---|---|
| 1. Amikacin 125 mg/ml Injection | 21. Amoxicillin 500mg & Clavulanate 125mg Tablet |
| 2. Amikacin 250 mg/ml Injection | 22. Ampicillin Sodium & Sulbactam Sodium 375mg Tablet |
| 3. Amoxicillin 1g & Clavulanate 200mg Injection | 23. Azithromycin 250mg Tablet |
| 4. Ampicillin Sodium 1g & Sulbactam Sodium 500mg Injection | 24. Cefuroxime Axetil 125mg Tablet |
| 5. Azithromycin 500mg Injection | 25. Ciprofloxacin 250mg Tablet |
| 6. Cefazolin 1g Injection | 26. Clarithromycin 250mg Tablet |
| 7. Cefoperazone Sodium 1g Injection | 27. Clindamycin HCl 300mg Capsule |
| 8. Cefoperazone Sodium 500mg & Sulbactam Sodium 500mg Injection | 28. Ethionamide 250mg Tablet |
| 9. Cefotaxime 500mg Injection | 29. Levofloxacin 500mg Tablet |
| 10. Cefotaxime 1g Injection | 30. Ofloxacin 100mg Tablet |
| 11. Ceftazidime 2g / Avibactam 0.5g Injection | 31. Sodium Fusidate 250mg Tablet |
| 12. Ceftriaxone 250mg Injection | 32. Amoxicillin & Clavulanate 228mg/5ml |
| 13. Ceftriaxone 1g Injection | 33. Azithromycin 200mg/5 ml Granules |
| 14. Cefuroxime Sodium 750mg Injection | 34. Cefuroxime Axetil 125mg/5ml Syrup |
| 15. Cefuroxime Sodium 1.5g Injection | 35. Ciprofloxacin 50mg/ml Syrup |
| 16. Erythromycin Lactobionate 500mg Injection | |
| 17. Clindamycin Phosphate 150mg/ml Injection | |
| 18. Kanamycin 1g Injection | |
| 19. Metronidazole 500mg/100ml Injection | |
| 20. Sulphamethoxazole 400mg & Trimethoprim 80mg Injection | |

List of Abbreviations in Hospital Duchess of Kent, Sandakan

(Frequency)

No.	Abbreviations	Meaning
1.	3x/week	Three times a week
2.	4x/week	Four times a week
3.	5x/week	Five times a week (—————)
4.	BD	Two times a day
5.	BD / PRN	Two times a day or when needed
6.	CONT	Continuous
7.	EOD	Every Alternate day (start on _____)
8.	EOD / PRN	Every Alternate day or when needed
9.	Fri-Wed Weekly	Every Friday-Wednesday
10.	HS (at bedtime)	At bedtime
11.	NA	Not Applicable
12.	OD	Once daily
13.	OD HD	Once daily on hemodialysis day
14.	OD nHD	Once daily on nonhemodialysis day
15.	OD / PRN	Every day or when needed
16.	OM	Every morning
17.	OM HD	Every morning on hemodialysis day
18.	OM nHD/non-HD	Every morning on non-hemodialysis day
19.	OM / PRN	Every morning or when needed
20.	ON	(at) night
21.	ON HD	At night on hemodialysis day
22.	ON nHD/non-HD	At night on non-hemodialysis day
23.	ON / PRN	Every night or when needed
24.	Once	Single dose
25.	Once a month	Once a month
26.	PM	In the evening
27.	PRN	When required
28.	Q1H or OH	Every 1 hour OH (omni hora)
29.	Q1H / PRN OH / PRN	Every 1 hour or when needed
30.	Q12H	Every 12 hours
31.	Q12H / PRN	Every 12 hours or when needed
32.	Q24H	Every 24 hours
33.	Q24H / PRN	Every 24 hours or when needed
34.	Q2H	Every 2 hours
35.	Q2H / PRN	Every 2 hours or when needed
36.	Q4H	Every 4 hours
37.	Q4H / PRN	Every 4 hours or when needed
38.	Q6H	Every 6 hours
39.	Q6H / PRN	Every 6 hours or when needed
40.	Q8H	Every 8 hours
41.	Q8H / PRN	Every 8 hours or when needed
42.	QID	Four times a day
43.	QID / PRN	Four times a day or when needed
44.	Sat-Thur Weekly	Every Saturday-Thursday
45.	STAT	Immediately
46.	TDS	Three times a day
47.	TDS on Fri, Sat, Sun	Three times a day every Friday, Saturday, Sunday
48.	TDS on Mon, Wed, Fri, Sat	Three times a day every Monday, Wednesday, Friday, Saturday
49.	TDS / PRN	Three times a day or when needed
50.	Thur-Tue Weekly	Every Thursday-Tuesday
51.	Wed-Mon Weekly	Every Wednesday-Monday

List of Abbreviations in Hospital Duchess of Kent, Sandakan

(Administration Route)

No.	Abbreviation	Meaning
1.	BATH	Bath
2.	LE	Left eye
3.	RE	Right eye
4.	BE	In both eyes
5.	B/L	Bilateral
6.	ID	Intradermal
7.	IM	Intramuscular
8.	INH	Inhalation
9.	INVT	Intravitreal
10.	IP	Intraperitoneal
11.	IT	Intrathecal
12.	IU	Intrauterine
13.	IV	Intravenous
14.	IVB	Intravenous bolus
15.	IVSB	Intravenous slow bolus
16.	IVI	Intravenous Infusion
17.	LA	Apply on affected area
18.	NEB	Nebuliser
19.	NG	Nasogastric
20.	PO	By mouth/ orally
21.	PR	Per rectum
22.	PV	Per vagina
23.	SC	Subcutaneous
24.	SUBL or S/L	Sublingual

List of Abbreviations in Hospital Duchess of Kent, Sandakan

(Dosage Form)

No.	Abbreviation	Meaning
1.	Amp	Ampule
2.	Cap or C.	Capsule
3.	Cart	Cartridge
4.	Crm	Cream
5.	Drop	Liquid Drop
6.	Emuls	Emulsion
7.	Inj	Injection
8.	Liq	Liquid
9.	Lot	Lotion
10.	Mist	Mixture
11.	Oint	Ointment
12.	Opth	Ophthalmic
13.	Soln	Solution
14.	Supp	Suppository
15.	Susp	Suspension
16.	Syr	Syrup
17.	Tab or T.	Tablet
18.	Vial	Vial
19.	Occ	Eye Ointment
20.	Gutt	Eye Drops